PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C12N 15/12, C07K 14/435, C12N 5/10, A01K 67/027, 67/033, A61K 38/17, A01H 5/00, C07K 16/18, C12N 5/26, C12Q 1/02

A2

(11) International Publication Number: **WO 96/38555**

(43) International Publication Date: 5 December 1996 (05.12.96)

(21) International Application Number: PCT/EP96/02311

(22) International Filing Date: 31 May 1996 (31.05.96)

(30) Priority Data:
9510944.3 31 May 1995 (31.05.95) GB

(71)(72) Applicants and Inventors: BOGAERT, Thierry [BE/BE]; Voorstraat 36 bus 11, B-8500 Kortrijk (BE). STRINGHAM, Eve [CA/CA]; 9326-133 A Street, Surrey, British Columbia V3V 5R5 (CA). VANDEKERCKHOVE, Joel [BE/BE]; Rode Beukendreef 27, B-Loppem (BE).

(74) Agent: BALDOCK, Sharon, Claire; Boult Wade Tennant, 27 Furnival Street, London EC4A 1PQ (GB).

(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
Without international search report and to be republished upon receipt of that report.

(54) Title: PROCESSES FOR THE IDENTIFICATION OF COMPOUNDS WHICH CONTROL CELL BEHAVIOUR, THE COMPOUNDS IDENTIFIED AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THE CONTROL OF CELL BEHAVIOUR

(57) Abstract

UNC-53 protein of C. elegans or its functional equivalent is identified as a signal transducer/integrator involved in controlling the rate and directionality of cell migration and/or cell shape. Nucleic acid sequences encoding UNC-53 protein or its functional equivalent, such as genomic or cDNA are used to transfect C. elegans or mammalian cell lines useful for identifying inhibitors or enhancers of the UNC-53 protein. Any of the inhibitors or enhancers identified or the UNC-53 protein itself or sequences encoding UNC-53 protein can be used in the preparation of medicament for treatment of neurological conditions such as Alzheimer's or Huntingdon's disease, peripheral neuropathies for inhibition of metastasis.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	**GB**	United Kingdom	**MW**	Malawi
AT	Austria	**GE**	Georgia	**MX**	Mexico
AU	Australia	**GN**	Guinea	**NE**	Niger
BB	Barbados	**GR**	Greece	**NL**	Netherlands
BE	Belgium	**HU**	Hungary	**NO**	Norway
BF	Burkina Faso	**IE**	Ireland	**NZ**	New Zealand
BG	Bulgaria	**IT**	Italy	**PL**	Poland
BJ	Benin	**JP**	Japan	**PT**	Portugal
BR	Brazil	**KE**	Kenya	**RO**	Romania
BY	Belarus	**KG**	Kyrgystan	**RU**	Russian Federation
CA	Canada	**KP**	Democratic People's Republic of Korea	**SD**	Sudan
CF	Central African Republic			**SE**	Sweden
CG	Congo	**KR**	Republic of Korea	**SG**	Singapore
CH	Switzerland	**KZ**	Kazakhstan	**SI**	Slovenia
CI	Côte d'Ivoire	**LI**	Liechtenstein	**SK**	Slovakia
CM	Cameroon	**LK**	Sri Lanka	**SN**	Senegal
CN	China	**LR**	Liberia	**SZ**	Swaziland
CS	Czechoslovakia	**LT**	Lithuania	**TD**	Chad
CZ	Czech Republic	**LU**	Luxembourg	**TG**	Togo
DE	Germany	**LV**	Latvia	**TJ**	Tajikistan
DK	Denmark	**MC**	Monaco	**TT**	Trinidad and Tobago
EE	Estonia	**MD**	Republic of Moldova	**UA**	Ukraine
ES	Spain	**MG**	Madagascar	**UG**	Uganda
FI	Finland	**ML**	Mali	**US**	United States of America
FR	France	**MN**	Mongolia	**UZ**	Uzbekistan
GA	Gabon	**MR**	Mauritania	**VN**	Viet Nam

PROCESSES FOR THE IDENTIFICATION OF COMPOUNDS WHICH CONTROL CELL BEHAVIOUR, THE COMPOUNDS IDENTIFIED AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THE CONTROL OF CELL BEHAVIOUR

The present invention relates to processes for the identification of compounds which inhibit or enhance the rate and direction of cell migration or the control of cell shape, the compounds identified and pharmaceutical formulations containing such compounds together with their use in the regulation of cell behaviour. The invention also relates to an UNC-53 protein encoded by nucleic acid in the cells of the nematode worm C. elegans and cDNA sequences encoding an UNC-53 protein or functional equivalents thereof.

The control of cell motility, cell shape and the outgrowth of axones or other cell outgrowths is an essential feature in the morphogenesis and function of both unicellular and multicellular organisms. The control of this process is disturbed in a variety of disease states in which for example the Receptor Tyrosine Kinase (RTK) signal transduction pathways or the like or their downstream intra-cellular pathways (which are shared with other extra-cellular receptors, including cell adhesion molecules like N-CAMS and integrins) are overstimulated.

Some cell surface proteins and extracellular molecules controlling the directionality and potential of cell migration have been identified. However the processes in which these proteins or molecules are involved to effect cell migration, shape or rate of cell differentiation are not understood.

It is generally considered that a long-range migration of a cell process (which may also be known as a growth cone spike) is a stepwise event, whereby prior to and after each extension there is the

formation of a structure at the leading edge of the cell which senses signals in the environment instructing the cell to either stabilize a cell process extending in a preferred direction, or to cause a cell process lamellipodium to extend a process in a given direction. Localized stabilization of the actin cytoskeleton, is a general cell biological process underlying this choice of directional extension.

A gene from the free-living nematode Caenorhabditis elegans, designated "unc-53" has been previously identified and cloned (Abstract, International C. elegans meeting; June 1-5 1991, Madison, Wisconsin, 58, Bogaert and Goh). However, to date no known biological function has been attributed to the unc-53 gene or its corresponding UNC-53 protein.

The present inventors have surprisingly identified, through biochemical, genetic, phenotypic and transgenic evidence which is presented herewith, UNC-53 as a signal transducer or signal integrator controlling the rate and directionality of cell migration, and/or cell shape. Key experiments leading to this conclusion were the molecular identification of its domain structure, its biochemical interaction with GRB-2, actin cytoskeleton sequence information and the presence of a potential signal integrating domain in the UNC-53 protein.

An additional key observation is that increased UNC-53 protein activity is proportional to increased cell process extension in the correct direction of cell migration. Reduction of UNC-53 function has previously been shown to lead to a reduction of cell process extension, identifying it as a general component required for cell migration. However, it had not been identified as a component whose level of

activity has a determining role in the specification of the quantum and directionality of migration.

The work of the present inventors suggests that UNC-53 plays a central role in quantitatively transducing extracellular signals to the machinery controlling directional cell migration.

The importance of UNC-53 in a variety of cell types in C. elegans has been demonstrated. The gene encodes a signal transduction molecule that transduces a signal from a Receptor Tyrosine Kinase such as for example via the adaptor protein SEM-5/GRB-2, to the machinery controlling directional growth cone extension or stabilization. The UNC-53 protein does this in a highly dosage-dependent fashion whereby reduction of protein activity such as reduction in expression of protein or in the reduction in its activity leads to proportional reduction of cell process extension (cell migration). This is believed to be either by regulated cross-linking of the actin cytoskeleton or by transferring the received signal downstream within the transduction pathway. Higher than wild type UNC-53 expression leads to higher than wild type growth cone extension in the anterior-posterior axis. Both the observed SEM-5/GRB-2 binding to UNC-53 and the predicted ATP/GTP-ase activity of UNC-53 demonstrate a signal transduction role for UNC-53 involved in cell process or growth cone guidance.

UNC-53 is a protein working at the intracellular level. It is so far believed to be the only intracellular protein identified which is involved in the control of directionality and rate of cell migration in response to a specific signal and which integrates different directional signals in defining direction of migration.

Based on the present inventors accumulated

knowledge of the unc-53 gene function in C. elegans it is understood that inhibitors or enhancers of the unc-53 gene or the UNC-53 protein will affect the cell motility including (metastasis) via an RTK pathway or the like, or may lead to changes in the shape of the cells (which has been demonstrated in C. elegans body muscle). Applications for such inhibitors and/or enhancers are envisaged in a wide variety of pathologies in which the RTK pathways play a central role, including oncogenesis, psoriasis, cell migration (metastasis), neuronal regeneration/degeneration and immunological disorders among others.

The identification of the biochemical function of the unc-53 gene (and UNC-53 pathway) in the RTK signal transduction pathway is novel and unexpected. No biological function has previously been linked to the unc-53 gene or UNC-53 protein, nor has any homology with any other nucleic acid sequence or gene been recognised.

An analysis of the predicted protein sequence of UNC-53 from the gene sequence thereof has revealed the following:

(a) an N-terminal domain with homology to cortical actin binding proteins of the α-actinin and β-spectrin families (designated ABPII in Figure 11). Alignment of UNC-53 with the α-actinin and β-spectrin family of proteins is shown in Fig. 15.).

(b) two putative actin binding sites of the LKK class (ABS1 and ABS2).

(c) two polyproline rich sequences similar to the SH3 binding domains of the SOS family of signal transduction molecules (SH3 binding site) (Fig. 16).

(d) a putative ATP/GTP nucleotide binding site having some of the additional features of the GTP

binding domain of RAS-like proteins (Dynamin, NBD).

(e) besides the N-terminal region of the protein, which is similar to actin binding proteins, the predicted protein sequence of UNC-53 identified two putative actin binding sites. The first borders on the 3′ end of the region of α-actinin/β-spectrin homology and the second lies in the 3′ end of the cDNA sequence. This suggests that UNC-53 could potentially bind two actin molecules and via actin cross linking, could stabilize a particular cell process to promote directional extension.

In addition, genetic evidence shows that alleles of unc-53 enhance the sex myoblast migration defect of sem-5 mutants. Sem-5 represents the C. elegans homologue of GRB2, the function of these proteins being assigned/attributed to their SH2 and SH3 domains (Clark et al., (1992) Nature 356, 340-344; Stern et al., (1993), Molec. Biol. Cell, 4, 1175-1188). The current model regarding sem-5 function in the migration of sex myoblasts is that sem-5 transduces a signal received at the cell surface by egl-15, a receptor kinase of the fibroblast growth factor family. Together, the genetic and molecular data suggest a role for UNC-53 in both signal transduction and actin binding. We have been able to demonstrate how UNC-53 might act to direct both growth cone rate and directionality. By binding directly to the actin cytoskeleton, UNC-53 may stabilize and cross-link actin molecules (assuming a two actin binding site model) to promote directional growth cone extension. Alternatively, by binding actin, UNC-53 may convey a signal to the cytoskeleton and then via an ATP/GTPase activity transduce the signal to downstream targets. To test these models, biochemical experiments were

conducted to determine if any of the sequence similarities observed repres nted functional domains (see examples 2 to 5). Transgenic analysis as described in examples 6 to 8 support this proposed model.

As described above, the unc-53 gene from C. elegans has been previously identified. However, cDNA sequences substantially corresponding to unc-53 genomic exon sequences of C. elegans or fragments or derivatives thereof have never been previously disclosed. The present inventors have advantageously identified two unc-53 cDNA clones which have been designated as the 7A and 8A clones. The two clones differ in the number of Adenosine(A) residues (7 or 8) in a poly A stretch of the 3′ coding region. Therefore, the two clones have different reading frames in the carboxyterminal coding region.

Therefore according to one aspect of the present invention there is provided a cDNA encoding an UNC-53 protein of C. elegans or a functional equivalent derivative or bioprecursor of said protein which cDNA comprises at least from nucleotide position 431 to nucleotide position 4647 or alternatively to the 3′ poly-A region of the sequence shown in Figure 1. More preferably the cDNA comprises at least from nucleotide position 64 to nucleotide position 4647 or to the 3′ poly-A region of the sequence as shown in Figure 1. This cDNA is comprised in the 8A clone having 8A residues in a poly A stretch of the 3′ coding region as shown in Figure 1.

In an alternative embodiment of this aspect of the invention the cDNA comprises at least from nucleotide position 431 to nucleotide position 4812 or alternatively to the 3′ poly-A region of the sequence shown in Figure 2 and more preferably at least from position 64 to nucleotide position 4812 or the 3′

poly-A region of the sequence shown in Figure 2. This cDNA according to the invention compris s the 7A clone, having only 7 Adenine residues in the poly A stretch of the 3′ coding region as shown in the nucleotide sequence of Figure 2 page 8. Each of the cDNA clones according to the invention, may be included in an expression vector which vector may itself be used to transform or transfect a host cell which may be bacterial, animal or plant in origin. Thus, advantageously, once the cDNA corresponding to the unc-53 genome is synthesised using for example reverse transcriptase or the like, a range of cells, tissues or organisms may be transfected following incorporation of the selected cDNA clone into an appropriate expression vector.

The present invention therefore, also further comprises a transgenic cell, tissue or organism comprising a transgene capable of expressing UNC-53 protein of C. elegans or a functional equivalent, fragment, derivative or bioprecursor thereof. The term "transgene capable of expressing UNC-53 protein" as used herein means a suitable nucleic acid sequence which leads to the expression of an UNC-53 protein having the same function and/or activity. The transgene may include for example genomic nucleic acid isolated from C. elegans or synthetic nucleic acid or alternatively any of the cDNA clones as described above.

The term "transgenic organism, tissue or cell" as used herein means any suitable organism and/or part of an organism, tissue or cell that contains exogenous nucleic acid either stably integrated in the genome or in an extra chromosomal state.

Preferably, the transgenic cell comprises either a C. elegans cell, an N4 neuroblastoma cell or an MCF-7 breast carcinoma cell. The transgenic organism may

be C. elegans itself, or alternatively may be an insect, a non-human animal or a plant. Preferably the unc-53 transgene comprises the unc-53 gene or a functional fragment thereof. The term "functional fragment" as used herein should be taken to mean a fragment of an UNC-53 gene which encodes an UNC-53 protein or a functional equivalent or bioprecursor of the protein. For example the gene may comprise deletions or mutations but may still encode a functional UNC-53 protein.

Reference to "tissue or tissue culture" for the purpose of the present invention should be taken to mean such a mutant cell which has been grown in such a culture. Further provided by the present invention is a mutant C. elegans organism which comprises an induced mutation, such as a point mutation in the wild-type unc-53 gene and which mutation affects the regulation of cell motility or shape or the direction of cell migration. Such mutations may be introduced using changes in the cDNA corresponding to qualitative, quantitative direct and indirect changes in the genomic make up.

The term "mutant organism" used herein means any suitable organism that contains genetic information which has been induced to mutate and is thus altered from the wild-type. Therefore naturally occurring mutations in the wild-type organism are not within the scope of this term.

The present invention further comprises an UNC-53 protein or a functional equivalent or fragment thereof, which protein may be encoded by a cDNA according to the invention, and which protein has the amino acid sequence shown in Figure 4 from amino acid position 135 to amino acid position 1528; this corresponds to the 8A clone. More preferably the UNC-53 protein, when encoded by a cDNA according to the

invention, comprises the amino acid s quence shown in Figure 4. In another aspect of the invention the protein comprises an UNC-53 protein or a functional equivalent, fragment or bioprecursor of the protein which comprises the sequence of from amino acid position 135 to amino acid position 1583 of the amino acid sequence shown in Figure 6. Preferably, the UNC-53 protein when encoded by a cDNA in accordance with the invention has the amino acid sequence shown in Figure 6.

The UNC-53 protein of C. elegans or a functional equivalent, fragment or bioprecursor of the UNC-53 protein, may advantageously be used as a medicament to promote neuronal regeneration, revascularisation or wound healing or the treatment of chronic neuro-degenerative disorders or acute traumatic injuries. Similarly, the UNC-53 protein produced by the transgenic cells, tissue or organisms according to the invention may also be used in the preparation of a medicament for treatment of the conditions as described above.

Furthermore, in an alternative embodiment of the invention the nucleic acid sequence itself encoding an UNC-53 protein of C. elegans or a functional equivalent, fragment or bioprecursor of the protein may also be used as a medicament or, alternatively in the preparation of a medicament, to promote neuronal regeneration, vascularisation or wound healing or for treatment of chronic neuro-degenerative diseases or acute traumatic injuries. Typically neurological conditions which may be treated by either an UNC-53 protein or a functional equivalent thereof, or a nucleic acid according to the invention, comprise peripheral nerve regeneration after trauma; recovery of function of the spinal cord after spinal cord trauma or peripheral neuropathies. Similarly neuro-

d generation diseases which may be treated include Alzheimers disease or Huntingdons disease. Acute traumatic injuries such as stroke, head trauma or haemorrhages may also advantageously be treated.

The nucleic acid sequence according to the invention may comprise a cDNA sequence according to the invention as described above or alternatively may be genomic DNA derived from C. elegans.

The UNC-53 protein of C. elegans, or a functional equivalent, fragment or bioprecursor of said protein may be incorporated into a pharmaceutically acceptable composition together with a suitable carrier, diluent or an excipient therefor. The pharmaceutical composition may advantageously comprise, additionally or alternatively to the UNC-53 protein according to the invention, the nucleic acid sequence according to the invention as defined above.

The present invention also provides for a method of determining whether a compound is an inhibitor or an enhancer of the regulation of cell shape or motility or the direction of cell migration in a transgenic cell, tissue or organism according to the invention as described herein. The method preferably comprises contacting the compound with a transgenic cell, tissue or organism according to the invention as described above, and screening for a phenotypic change in the cell, tissue or organism. Preferably the compound comprises an inhibitor or enhancer of a protein of the signal transduction pathway of the cell, tissue or organism of which UNC-53 is a component or is an inhibitor or enhancer of a parallel or redundant signal transduction pathway. Such enhancers or inhibitors are defined by particular phenotypic changes in the transgenic cell, tissue or organism, for example changes in cell shape or mobility or the direction of cell migration.

Preferably th compound is an inhibitor or an enhancer of the activity of UNC-53 protein of C. elegans or a functional equivalent, derivative or bioprecursor thereof, which protein is expressed in the transgenic cell, tissue or organism as defined herein.

Preferably the phenotypic change to be screened comprises a change in cell shape or a change in cell motility. Where a transgenic cell is used in accordance with one embodiment of the method of the invention, an N4 neuroblastoma cell may be used and in such an embodiment the phenotypic change to be screened may be the length of neurite growth or changes in filipodia outgrowth or alternatively changes in ruffling behaviour or cell adhesion. In an alternative embodiment of the method of the invention, the transgenic cell may comprise an MCF-7 breast carcinoma cell. Typically in such an embodiment the phenotypic change to be screened comprises the extent of phagokinesis. The method according to the invention, may also utilise a mutant cell or mutant organism according to the invention as described above, where the mutant cell is capable of growing in tissue culture and either of which cell or organism has a mutation in the wild-type unc-53 gene.

In accordance with the present invention, a "phenotypic change", may be any phenotype resulting from changes at any suitable point in the life cycle of the cell, tissue or organism defined above, which change can be attributed to the expression of the transgene such as for example, growth, viability, morphology, behaviour, movement, cell migration or cell process or growth cone extension of cells and includes changes in body shape, locomotion, chemotaxis, mating behaviour or the like. The phenotypic change may preferably be monitored directly by visual inspection or alternatively by for example

measuring indicators of viability including endogenous or transgenically introduced histochemical markers or other reporter genes, such as for example ß-galactosidase.

A compound which is identifiable by the method according to the invention as described above, as an enhancer of the regulation of cell shape or motility or the direction of cell migration in C. elegans may be used as a medicament, or alternatively in the preparation of a medicament, for promoting neuronal regeneration, revascularisation or wound healing, or for treatment of chronic neuro-degenerative diseases or acute traumatic injuries. Examples of promoting neuronal regeneration include for example peripheral nerve regeneration after trauma and spinal cord trauma.

Where a compound is identified in accordance with the method described above as being an inhibitor of the regulation of cell shape, the compound may be used as a medicament, or in the preparation of a medicament, for substantially alleviating spread of disease inducing cells, such as in spread of cancers, or the like in metastasis. Advantageously, any of the compounds which may have been identified as an inhibitor or an enhancer in accordance with the method as described above, may also be included in a pharmaceutically acceptable formulation comprising the respective compound and an acceptable carrier, diluent or excipient therefor.

The particular mechanism of action of a compound identified as either an inhibitor or an enhancer of the cell motility or direction of cell migration is not limiting preferably the compound acts as an inhibitor or enhancer of a signal transduction pathway downstream. The compound may also act on parallel pathway or on the UNC-53 protein of C. elegans. For

example, the method of action of the compound may include direct interaction with UNC-53 protein, interaction with processes for regulating phosphorylation of UNC-53 or for processes regulating activity of an unc-53 gene or for processes for post-transcriptional or post-translational modification or the like.

Preferably the compound is identified by the method according to the invention as an inhibitor or an enhancer, by utilising differences of phenotype of the cell, tissue or organism, which are visible to the eye. Alternatively indicators of viability including endogenous or transgenically introduced histochemical markers or a reporter gene may be used.

According to a further aspect of the invention there is also provided a transgenic cell or tissue culture which has been constructed to comprise a promoter sequence of an unc-53 gene of C. elegans or a functional fragment thereof, fused to a nucleic acid sequence encoding a reporter molecule. Preferably, the reporter sequence encoding the reporter molecule encodes for a detectable protein, for example one which may be monitored by eye inspection such as antibiotic resistance, ß-galactosidase or a molecule detectable by spectrophotometric, spectrofluorometric, luminescent or radioactive assays. Preferably the reporter molecule is green fluorescent protein (GFP), which advantageously allows inhibition or enhancement of the UNC-53 protein according to the invention to be monitored visually.

The present invention also provides a method of determining whether a compound is an inhibitor or an enhancer of transcription of a an unc-53 gene in C. elegans, or a functional fragment thereof, which method comprises the steps of:

(a) contacting said compound with a transgenic

cell according to the further aspect of the invention as described above,

(b) monitoring the reporter molecule and comparing results obtained from this monitoring step with a control comprising a transgenic cell having the promoter sequence of an unc-53 gene, or a functional fragment thereof and the reporter molecule, in the absence of the compound.

In one embodiment of the method according to the invention the reporter molecule may comprise messenger RNA. Alternatively the reporter molecule may be green fluorescent protein (GFP).

A compound identified as an inhibitor or enhancer of transcription of the unc-53 gene or a fragment thereof may also be used as a medicament, or in the preparation of a medicament, for promoting neuronal regeneration, revascularisation or wound healing, or for treatment of chronic neuro-degenerative diseases or acute traumatic injuries. Furthermore, such compounds may be included in a pharmaceutical formulation including a carrier, diluent or excipient therefor.

The present invention also provides a kit for determining whether a compound is an enhancer or an inhibitor of the regulation of cell motility or shape or the direction of cell migration, which kit comprises at least a plurality of transgenic or mutant cells according to the invention as described above and a plurality of wild-type cells of the same cell type or cell line or tissue culture.

Also provided by the present invention is a kit for determining whether a compound is an inhibitor or an enhancer of transcription of an unc-53 gene of C. elegans or a functional fragment thereof, which comprises at least a plurality of transgenic cells as described above and means for monitoring the reporter

molecule.

For the purposes of the present invention, the term "unc-53 gene or a functional fragment thereof" includes the nucleic acid sequence shown in Figure 1 or a fragment thereof, including the differentially spliced isoforms and transcriptional start of the unc-53 gene sequence and which sequence encodes an UNC-53 protein or a functional equivalent, derivative, fragment or bioprecursor of the protein.

The present invention also provides an oligonucleotide probe which comprises the carboxy-terminal 1.5 kb of the coding nucleic acid sequence shown in Figure 1 or a fragment thereof comprising not less than 15 base pairs. In addition, the present invention provides a further oligonucleotide probe comprising a nucleic acid sequence encoding the amino acid sequence as numbered 1 to 10 and 14 to 133, 487 to 495, 537 to 545, 1032 to 1037, 1097 to 1116 or 1300 to 1307, as shown in Figure 3 or a fragment thereof comprising between 18 and 24 base pairs. The oligonucleotide probes described above may also be advantageously be labelled for detection.

The present invention also provides methods of identifying C. elegans genes or fragments thereof, which encode proteins which are active in the signal transduction pathway of which UNC-53 is a component and which are homologues of UNC-53. A preferred method comprises hybridizing to a C. elegans cDNA library an oligonucleotide probe according to the invention as described above, under appropriate conditions or stringency in order to identify genes having statistically significant homology with the cDNA clones of any one of the cDNA sequences according to the invention described above.

Furthermore, there is also provided by the present invention a method of identifying a protein

which is active in the signal transduction pathway of a cell. According to this aspect of the invention, the method comprises;

(a) contacting an extract of said cell with an antibody to the UNC-53 protein or a functional equivalent, fragment or bioprecursor thereof,

(b) identifying the antibody/UNC-53 complex, and

(c) analysing the complex to identify any protein bound to the UNC-53 protein other than the antibody.

The UNC-53 protein, therefore may bind regions of other proteins involved in the signal transduction pathway. It is also possible to sequentially identify a whole range of proteins involved in the signal transduction pathway. This aspect of the invention, further comprises a method of identifying a further protein or proteins which are active in the signal transduction pathway of a cell which method comprises:

(a) forming an antibody to the identified protein bound to the UNC-53 protein in the method as described above,

(b) contacting a cell extract of C. elegans with the antibody,

(c) identifying the antibody/protein complex,

(d) analysing the complex to identify any further protein bound to the first protein other than the antibody, and

(e) optionally repeating steps (a) to (d) to identify further proteins in the pathway.

According to this aspect of the present invention, the antibody, which is preferably a monoclonal antibody, such as for example monoclonal antibody designated as 16-48-2, starts the process by binding to the UNC-53 protein or a functional equivalent thereof in the signal transduction pathway. Any other proteins found complexed to the bound

antibody or UNC-53 protein can then be used to identify further interacting proteins involved in the pathway.

It may also be possible to identify proteins involved in the signal transduction of a cell by using UNC-53 protein of C. elegans. According to this aspect of the invention the method comprises:

(a) contacting an extract of the cell with the UNC-53 protein of C. elegans or a functional equivalent, fragment or bioprecursor of said UNC-53 protein

(b) identifying the UNC-53 protein/protein complex and

(c) analysing the complex to identify any protein bound to the UNC-53 protein other than another UNC-53 protein

This method can also advantageously be used to identify further proteins in a signal transduction pathway of a cell by contacting an extract of the cell used as described above, with any protein identified from step (c) above not being an UNC-53 protein and repeating steps (b) and (c).

Other methods which may be used for identifying proteins in a signal transduction pathway of a cell may comprise for example a western blot overlay method which method is well known to those skilled in the art. Cell extracts are run on SDS-gels to separate out protein and subsequently blotted onto a nylon membrane. These membranes may then be incubated, for example in a medium containing UNC-53 with a biotin label thereon and any protein conjugates visualised

with a streptavidin-alkaline phosphatase conjugated antibody.

The present invention also advantageously provides a process for the preparation of binding antibodies which recognise proteins or fragments thereof involved in the rate and direction of cell migration or the control of cell shape, for the above methods. Preferably the antibody is monoclonal antibody and more preferably monoclonal antibody 16-48-2.

The monoclonal antibody for binding to UNC-53 (or its functional equivalent) may be prepared by known techniques as described by Kohler R. and Milstein C., (1975) Nature 256, 495 to 497.

Another method which may be used to identify proteins involved in the signal transduction pathway involves investigating protein-protein interactions using the two-hybrid vector method. This method, which is well known to those skilled in the art, utilises the properties of the GAL4 protein in yeast. GAL4 is a transcriptional activator of galactose metabolism in yeast and has a separate domain for binding to activators upstream of the galactose metabolising genes as well as a protein binding domain. Nucleotide vectors may be constructed, one of which comprises the nucleotide residues encoding the DNA binding domain of GAL4. These binding domain residues may be fused to a known protein encoding sequence, such as for example unc-53. The other vector comprises the residues encoding the protein binding domain of GAL4. These residues are fused to residues encoding a test protein, preferably from the signal transduction pathway of C. elegans. Any interaction between the UNC-53 protein and the protein to be tested leads to transcriptional activation of a

reporter molecule in a GAL-4 transcription deficient yeast cell into which the vectors have been transformed. Preferably, a reporter molecule such as ß-galactosidase is activated upon restoration of transcription of the yeast galactose metabolism genes. This method enables any interactions between proteins involved in the signal transduction pathway to be investigated.

Any proteins identified in the signal transduction pathway of the cell, which may be for example a mammalian cell, may also be included in a pharmaceutical composition together with a carrier, diluent or excipient therefor.

The present invention also provides a process for producing an UNC-53 protein of C. elegans or a functional equivalent, fragment, or derivative of the protein, which process comprises culturing the cells transformed or transfected with a cDNA expression vector having any of the cDNA sequences according to the invention as described above, and recovering the expressed UNC-53 protein. The cell may advantageously be a bacterial, animal, insect or plant cell.

A particularly preferred process for producing UNC-53 protein comprises using insect cells. Accordingly, the invention provides a process for producing an UNC-53 protein of C. elegans or a functional equivalent, fragment, derivative or bioprecursor of the UNC-53 protein, which process comprises culturing an insect cell transfected with a recombinant Baculovirus vector, said vector comprising a nucleotide vector encoding the UNC-53 protein or a functional equivalent, fragment or bioprecursor thereof downstream of the Baculovirus polyhedrin promoter and recovering the expressed UNC-53 protein. Advantageously, this method produces large amounts of protein for recovery. The insect cell may be from for

example Spodoptera frugiperda or Drosophila Melanogester.

In accordance with the present invention, a defined nucleic acid sequence includes not only the identical nucleic acid but also any minor base variations from the natural nucleic acid sequence including in particular, substitutions in bases which result in a synonymous codon (a different codon specifying the same amino acid), due to the degenerate code in conservative amino acid substitution. The term "nucleic acid sequence" also includes the complimentary sequence to any single stranded sequence given which includes the definition above regarding base variations.

Furthermore, a defined protein, polypeptide or amino acid sequence according to the invention, includes not only the identical amino acid sequence but also minor amino acid variations from the natural amino acid sequence including conservative amino acid replacements (a replacement by an amino acid that is related in its side chains). Also included are amino acid sequences which vary from the natural amino acid but result in a polypeptide which is immunologically identical or similar to the polypeptide encoded by the naturally occurring sequence. Such polypeptides may be encoded by a corresponding nucleic acid sequence.

The invention may be more clearly understood from the following description with reference to the accompanying drawings and photographs, in which

Fig. 1 shows one strand of the C. elegans unc-53 mRNA translated into DNA (U to T) (5073 bases) which corresponds to the 8A clone variant encoding the corresponding 8A protein shown in Figure 3. Designations "TB" are positions onto which SL1 transplices have been identified at the 5′ end of the sequence. Different mRNAs which differ in their 5′

end therefore exist. Potential start methionines are double underlined (M). Restriction endonuclease sites are indicated. A region of 8 sequential A bases at positions 4594 to 4601 is underlined. This region differs from the corresponding region of the known sequence in the database (F45E10.1) by having 8 rather than 7 A'denine (A) bases resulting in a frame shift (see Fig 15) and corresponds to the 7A form of the protein. The nucleic acid sequence from the database is also included in the nucleic acid sequences of the present application for reference only.

Fig. 2 shows a comparison of the sequences of the 7A and 8A clones of Figure 1.

Fig. 3 shows the predicted C. elegans amino acid UNC-53 sequence corresponding to the nucleic acid sequence of the 8A clone shown numbered from 1 to 1528. Again, potential start methionines are double underlined (M). Designations "tb" are regions for PCR clones to identify PCR products. Other regions of interest are identified. The region indicated as S4 is part of a lambda clone - 16.8 kb of the UNC-53 nucleic acid. This sequence, when translated is part only of the UNC-53 protein. Yet, injection of this part gives transformation rescue in organisms, i.e. providing additional evidence for the existence of shorter forms of the protein.

Fig. 4 shows the predicted C. elegans amino acid sequences of Figure 3 in the three letter code for indicating amino acids.

Fig. 5 shows the predicted C. elegans amino acid sequence UNC-53 sequence corresponding to the nucleic acid sequence of the 7A clone of Figure 2 shown numbered from 1 to 1583.

Fig. 6 shows the amino acid sequence of Figure 5 in the corresponding three letter code format for indicating amino acids.

Fig. 7 shows sequences of low compl xity of the amino acid sequence of the corresponding nucleic acid sequence of the 8A clone of Fig. 3 identified with the filter and SEG algorithms of the BLAST sequence homology package. Regions of low complexity are indicated by "X" for the first copy of the sequence and by underlined amino acids for the second copy.

Fig. 8 shows, schematically, the known branches of the highly conserved Receptor Tyrosine Kinase/GRB2 signal transduction pathway including UNC-53.

Fig. 9 shows, schematically, the differences in cells with increased and decreased UNC-53 expression from the wild type.

Fig. 10 is a graph of the effect of anterior-posterior signal strength on growth cone extension rate of C. elegans organisms, with increased and decreased UNC-53 expression from the wild type. This graph translates the observation that UNC-53 acts in a dosage-dependent way to direct the rate of extension in the anterior/posterior axis into a model. The signal received e.g. (egl-15) is an RTK mediated signal which is postulated to be received by UNC-53 and which results in extension in the anterior/posterior axis. The graph shows an allelic series of organisms with a graded reduction in extension from increased UNC-53 expression down through wild type to a reduced UNC-53 expression. The prediction is thus: for the same level of RTK mediated signal the increased/decreased growth in the anterior/posterior axis depends on the level of expression of UNC-53 in any organism. The graph also reflects the prediction that for organisms with a particular level of UNC-53 overexpression there is no requirement for a signal before growth cone extension occurs. This extension is likely to be in a random direction or influenced by alternative factors.

Fig. 11 shows constructs of unc-53 nucleic acid including identified functional domains .

Fig. 12 shows 5′ amino terminus of the cDNA encoding from the first methionine amino acid through the actin binding protein homology domain (amino acids 1-133 from Fig. 1) and oligonucleotides designated oligo BG01, BG02 and BG03 (amplification strategies of amino terminus of the unc-53 cDNA). Combinations of oligo BG02 with either oligo BG02 or BG03 were used to amplify the 5′ terminus of the cDNA from the first methionine through the actin binding protein homology domain (amino acids 1-133). All of the oligonucleotides are underlined and sequences identical to the cDNA are shown in upper-case. In addition to unc-53 sequence, oligo BG02 contains a stop codon and the recognition sequence for BamHI endonuclease. Oligo BG01 has engineered EcoRI and NdeI recognition sites for inclusion in bacterial expression vectors. Both constructs remove the 5′ untranslated region of unc-53 and oligo BG03 contains a NotI cleavage site. Oligo BG03 has an improved ribosome binding site similar to mammalian ribosome binding sites. Use of BG03 in PCR thus results in constructs optimised for mammalian expression.

Figure 13 shows, schematically, constructs of the plasmids pTB109, pTB110, pTB111 and pTB112.

Fig. 14(a) shows a summary of transcript starts at the 5′ end of the unc-53 gene. Different identified transcript starts and corresponding in-frame ATG-codons are marked. Tab2 is the oligo from within cDNA M5 which was used in RT PCR experiment to identify/isolate the 5′ ends of different UNC-53 mRNAs.

Figure 14(b) shows the location of the different transcript starts on the genomic DNA and the position of the S4 Lambda clone with respect to genomic DNA.

Figure 14(c) shows the sequence near the 5′ and 3′ ends of the lambda S4 clone, identifying its composition corresponding to the 5′ and at position 2260 of comid COGHIO and the 3′ end of F45R10 at position 3287.

Fig. 15 shows the alignment of UNC-53 protein with the carboxytermini of the α-actinin and β-spectrin family (QY is UNC-53).

Fig 16 shows the predicted actin binding sites of UNC-53. The comparison shows internal LKK repeats.

Fig. 17 shows the alignment of the candidate SH3 binding sites in UNC-53 with known SH3 sites of other named proteins. Proteins at positions 4 and 7 are critical for binding into SH3 pockets.

Fig. 18 shows the alignment of the predicted amino acid sequences from F45E10.1 (available in public database) with UNC-53. The different identified amino acid is shown at position 1186. The frameshift which results in the different amino acid sequence from position 1513 is a result of the different number of adenine bases in the nucleic acid sequence (see Fig. 1).

Fig. 19 is a series of photographs of C. elegans embryos (strain TB4Ex25 (Table 1) [UNC-53-UNC-54 construct]). The photographs show increased outgrowth in the anterior-posterior axis of body wall cells in the C. elegans embryos which overexpress UNC-53 (immunofluorescence with UNC-53 mab 16-48-2) Individual photographs are as follows:

A: early embryo comma stage
B: 1.5 fold stage embryo
C: 3 fold stage embryo, first plane of focus
D: 3 fold stage embryo, second plane of focus
E: 3 fold stage, mosaic animal, 3-cells in a quadrant giving expression.

This demonstrates that immunofluorescence

provides a measure of the expression in the transgenic lines of UNC-53.

Fig. 20A is a photograph of C. elegans embryo containing DNA construct pTB110 (strain TBAIn76(table 1)). Shown is expression of UNC-53 following heat shock.

Fig. 20B and C are photographs of C. elegans embryos containing DNA construct pTB111 (strain TB1Ex6 (table 1)). Shown is transgenic expression of UNC-53 in mechano-sensory neurons.

Fig. 21 shows photographs of the following:

A: A wild-type UNC-53 L1 larva of genotype 4-25 (strain TB4Ex25) as in photographs 19B, C and D.

B: L1 larva of 4-25 with morphological defects associated with muscle abnormalities.

C: Lethal phenotype of 4-25.

D: L1 larva of 4-25 showing misshapen animal and muscle cells with increased extensions. Also shows constipation problems associated with abnormal muscle pattern.

E: L1 larva of the heat-shock line TBAIn76 (table 1) exhibiting morphological abnormalities following heat shock and recovery.

F: L1 larva of line TBAIn76 (table 1) showing morphological defects in the pharynx.

All Figs. 19, 20 and 21 are Normarski optics of live embryos.

Fig. 22 is a map of plasmid pTB110 (tables 1 and 2) a heat shock promoter fusion, indicating restriction endonuclease sites.

Fig. 23 is a map of plasmid pTB112 (tables 1 and 2) a muscle specific UNC-54 fusion, indicating restriction endonuclease sites.

Fig. 24 is a map of plasmid pTB54 (the 8A clone variant) (tables 1 and 2). In the construction of this plasmid the complete unc-53 cDNA (tb3M5) of the

8A variant, including 5′ and 3′ UTRs was cloned as a NotI-ApaI fragment into th mammalian expression vector pcDNA3 (Invitrogen).

Figure 25 is a map of plasmid pTB72 (the construct encoding the 7A clone variant of UNC-53 cDNA of Figure 2.

Figure 26 is nucleotide sequence of the plasmid map of Figure 25.

Figure 27 is a map of plasmid pTB73.

Figure 28 is a nucleotide sequence of plasmid pTB73 of Figure 27.

Figure 29 is a map of plasmid pCB50.

Figure 30 is a nucleotide sequence of plasmid pCB50 of Figure 29.

Figure 31 is a map of plasmid pCB51.

Figure 32 is a nucleotide sequence of the plasmid pCB51 of Figure 31.

Figure 33 is a map of plasmid ppCB55.

Figure 34 is a nucleotide sequence of plasmid pCB55 of Figure 33.

Figure 35A illustrates a flowchart of the actin co-sedimentation assay. Soluble UNC53 protein was incubated with monomeric G-actin in a buffer containing ATP. Polymerization of G-actin to F-actin was induced by increasing the salt concentration to 100 mM, F-actin protein complexes were collected by centrifugation and analyzed by SDS-PAGE and fluorography.

Figure 35(B) illustrates the concentration series of the actin co-sedimentation assay. The full length UNC-53 encoding cDNA (pTB72) was transcribed and translated *in vitro* and co-sedimented with F-actin at a starting G-actin concentrations ranging from 0 to 250 mg/ml. See methods for details. S=supernatant after airfuging. P=pellet after airfuging.

Figure 35(C) illustrates both the full length

(pTB72) and amino terminal deleted UNC53 (pTB73) protein co-sediment with F-actin. Starting G-actin concentration was 500 mg/ml. S=supernatant, P=pellet, R= starting *in vitro* reaction.

Figure 36(A) is a flowchart of a SEM-5 binding experiment. The truncated UNC53 cDNA (pTB50) was transcribed and translated *in vitro* and incubated with SEM5-GST sepharose or GST sepharose. After four washes, the remaining proteins bound to the matrix were analyzed by SDS-PAGE and fluorography.

Figure 36(B) illustrates an immunoprecipitation experiment of radioactively labelled UNC53 proteins from the TnT pTB50 reaction shows that monoclonal antibody 16-48-2 recognizes both the native (=SDS lanes) and denatured (+SDS) protein products *in vitro*. c=control reaction without anti-UNC53 monoclonal antibody 16-48-2. ab=reaction with monoclonal antibody 16-48-2. See methods for details.

Figure 36(C) illustrates the results of SEM-5-GST binding experiments outlined in (a). *In vitro* translated UNC53 protein were analyzed by SDS-PAGE and fluorography. See methods for details. sup=supernatant

Figure 36(D) illustrates a western blot overlay experiment of UNC-53 (construct pTB61) expressed in bacterial cells. Cell lysates were denatured in Laemmli buffer and the proteins separated by 5-25% gradient SDS-PAGE. The arrowhead indicates the presence of full length UNC-53 in the induced bacterial lysate. Additional gels were blotted to nylon membrane, incubated with biotinylated GST or biotinylated GST-GRB2 protein and bound protein complexes subsequently detected with a streptavidin-alkaline phosphatase conjugated antibody. See methods for details. U=uninduced bacterial cell lysate, I=induced bacterial cell lysate.

Figure 37 is a series of photographs of C. elegans which illustrates overexpression of UNC-53 in body muscle cells results in over-extension along the longitudinal axis. Transgenic C. elegans embryos carrying the construct pTB113 were analyzed for UNC-53 activity by immunohistochemistry with the 16-48-2 antibody. Starting from the photograph (a) of the top left panel of Figure 37.

(A) and (B) illustrate ectopic growth cone spikes (indicated by the arrowheads) are observed early in myogenesis in the comma stage embryo. (C) and (D) illustrate over-extension of muscle cells in the head region of a three fold embryo during outgrowth. (E) illustrates over-extension is clearly observed along the anterior-posterior axis (indicated by the arrowheads) of a late 3 fold embryo.

Figure 38 is a map of plasmid ptb113.

Figure 39 is a nucleotide sequence of the plasmid ptb113 of Figure 38.

Figure 40 illustrates neurite tree length and fraction positive cells enhancement in a transfected cell C9 compared to wild-type cells C0. Black bars indicate fraction positive cells whereas hatched bars indicate neurite tree length cells, as described in example 8.

Figure 41 illustrates the results obtained following application of compound (I-(IH-pyrrol-2-ylmethyl)-2-piperidinone) to N4 transfected cells. The dark coloured bars indicate fraction positive C0 clones whereas the hatched bars of the chart indicate fraction positive C9 clones.

The following sequence listings are referred to in the specification.

Sequence ID No 1: is a nucleic acid sequence

corresponding to the 7A nucleic acid sequence variant of Figure 2.

Sequence 1D No 2: is a nucleic acid sequence corresponding to the 8A nucleic acid sequence variant of figure 1.

Sequence 1D No 3: is an amino acid sequence corresponding to the amino acid sequence of the 8A variant of figure 3.

Sequence 1D No 4: is an amino acid sequence corresponding to the amino acid sequence of the 7A variant of figure 2.

Sequence 1D No 5: is an amino acid corresponding to the amino acid sequence shown in figure 7.

Sequence 1D No 6: is a nucleic acid sequence of the oligo BGO3 sequence of figure 12.

Sequence 1D No 7: nucleic acid sequence of the oligo BG01 sequence of figure 12.

Sequence 1D No 8: is a nucleic acid sequence of the oligo BG02 sequence of figure 12.

Sequence 1D No 9: is an amino acid sequence corresponding to the amino acid UNC-53(a) sequence shown in figure 17.

Sequence ID No 10: is an amino acid sequence corresponding to amino acid sequence of sequence (b) of UNC-53 shown in figure 17.

Sequence ID No 11: is an amino acid sequence

corresponding to the sequence (c) of an SOS shown in figure 17.

Sequence ID No 12: is an amino acid sequence corresponding to the sequence (d) of an SOS shown in figure 17.

Sequence ID No 13: is an amino acid sequence corresponding to the sequence (d) of an SOS shown in figure 17.

Sequence ID No 14: is an amino acid sequence corresponding to the sequence (f) of SOS 1359 shown in figure 17.

Sequence ID No 15: is an amino acid sequence corresponding to the sequence (g) of SOS 1377 shown in figure 17.

Sequence ID No 16: is an amino acid sequence corresponding to the sequence (h) of Dynamin shown in figure 17.

Sequence ID No 17: is an amino acid sequence corresponding to the sequence (i) of dynamin shown in figure 17.

Sequence ID No 18: is an amino acid sequence corresponding to the sequence (j) of PI3K p85 shown in figure 17.

Sequence ID No 19: is an amino acid sequence corresponding to the sequence (k) of P13k p85 shown in figure 17.

Sequence ID NO 20: is an amino acid sequence

corresponding to the sequence (l) of AFAP-110 shown in figure 17.

Sequence No 21: is an amino acid sequence corresponding to the sequence (m) of AFAP-110 shown in figure 17.

Sequence No 22: is an amino acid sequence corresponding to the sequence (n) of 3BP-1 shown in figure 17.

Sequence ID No 23: is an amino acid sequence corresponding to the sequence (o) of 3BP-1 shown in figure 17.

Sequence ID No 24: is an amino acid sequence which corresponds to the amino acid sequence from positions 106 to 133 of UNC-53 shown in figure 16.

Sequence ID No 25: is an amino acid sequence which corresponds to the amino acid sequence from positions 1093 to 1120 of UNC-53 shown in figure 16.

Sequence ID No 26: is a nucleotide sequence corresponding to the nucleotide sequence of ptB72 shown in figure 26.

Sequence ID No 27: is a nucleotide sequence corresponding to the nucleotide sequence of ptB73 shown in figure 28.

Sequence ID No 28: is a nucleotide sequence corresponding to the nucleotide sequence of pCB50 shown in figure 30.

Sequence ID No 29: is a nucleotide sequence

corresponding to the nucleotide sequence of pCB51 shown in figur 32.

Sequence ID No 30: is a nucleotide sequence corresponding to the sequence of pCB55 shown in figure 34.

Sequence ID No 31: is a nucleotide sequence corresponding to the nucleotide sequence of ptb113 shown in figure 39.

Sequence ID No 32: is an amino acid sequence corresponding to the amino acid sequence as numbered from amino acid 1 to 110 of the sequence figure 3.

Sequence ID No 33: is an amino acid sequence corresponding to the sequence as numbered from amino acid sequence 114 to 133 of the sequence of figure 3.

Sequence ID No 34: is an amino acid sequence corresponding to the sequence as numbered from amino acid sequence 487 to 495 of the sequence of figure 3.

Sequence ID No 35: is an amino acid sequence corresponding to the sequence as numbered from amino acid sequence 537 to 545 of the sequence of figure 3.

Sequence ID No 36: is an amino acid sequence corresponding to the sequence as numbered from amino acid sequence 1032 to 1037 of the sequence of figure 3.

Sequence ID No 37: is an amino acid sequence corresponding to the sequence as numbered from amino acid sequence 1097 to 1116 of the sequence of figure 3.

Sequence ID No 38: is an amino acid sequenc ecorresponding to the sequence as number d from amino acid sequence 1300 to 1307 of the sequence shown in figure 3.

Sequence ID No 39: is an amino acid sequence corresponding to the amino acid sequence (a) of ∝-actinin (aact) shown in figure 15.

Sequence ID No 40: is an amino acid sequence corresponding to the amino acid sequence (b) of unc-53 shown in figure 15.

Sequence ID No 41: is an amino acid sequence corresponding to the amino acid sequence (c) of β-spectrin (spectrin) shown in figure 15.

Sequence ID No 42: is an amino acid sequence corresponding to the amino acid sequence (d) of ∝actinin (aact) shown in figure 15.

Sequence ID No 43: is an amino acid sequence corresponding to the amino acid sequence (e) of UNC-53 shown in figure 15.

Sequence ID No 44: is a amino acid sequence corresponding to the amino acid sequence (f) of β-spectrin (spectrin) shown in figure 15.

Sequence ID No 45: is an amino acid sequence corresponding to the amino acid sequence (g) of ∝-actinin shown in figure 15.

Sequence ID No 46: is an amino acid sequence corresponding to the amino acid sequence (h) of UNC-53 shown in figure 15.

Sequence ID No 47: is an amino acid sequence corresponding to th amino acid sequence (I) of β-spectrin shown in figure 15.

Sequence ID No 48: is a nucleotide sequence corresponding to the nucleotide sequence of S4 lambda clone shown in figure 14(c).

The inventors have established a set of processes particularly in C. elegans to select for inhibitors or enhancers of UNC-53. This screen is based on transgenic or mutant organisms or cells in which we have introduced a nucleic acid sequence encoding UNC-53 under the control of a specific promoter. In these organisms UNC-53 is over-stimulated as judged by increased extension of growth cones of muscle cells which over-express UNC-53 in C. elegans. This leads to a range of phenotypes in both embryonic and postembryonic development(from death to defective morphology and motility). These phenotypes can be scored with simple means at high throughput. Similar results can be obtained with heat shock specific lines. The basis of our test for inhibitors of the UNC-53 signal transduction pathway is reversal of this phenotype to an improved state of health.

We have constructed transgenic strains of C. elegans which over-express UNC-53 in body muscle. This results in increased extension of muscle cells and embryonic lethality (17 to 80% of transgenic organisms depending on the line used). These strains are used to directly screen for drugs which interfere with unc-53 genes, UNC-53 protein activity or any regulatory factor thereof to thereby suppress the background lethality.

Another process which may be used for selecting

inhibitors or enhancers of UNC-53 uses a constitutively active unc-53. This is achieved by mutating the nucleotide binding domain such that GTP or ATP is always bound or by covalently attaching SEM-5. In this strategy, transgenics (tissue cultured cell lines, or organisms such as nematodes) are generated which maintain unc-53 in a higher endogenous level of activity. Over-extension and subsequent lethality results in a greater proportion than that observed in the UNC-54/UNC-53 wild type lines. By screening for survivors after drug treatment, this assay specifically identifies inhibitors of downstream components in the signal transduction pathway.

Another process utilises an UNC-53 promoter. In this approach, an UNC-53 promoter is fused to a nucleic acid sequence encoding a reporter molecule, for example green fluorescent protein (GFP). Cells will glow when trans-acting factors bind to the promoter to activate transcription. By screening for cells which do not fluoresce, molecules which inhibit transcription of UNC-53 are identified.

The processes for selecting inhibitors and/or enhancers according to the invention are preferably carried out on whole animals. This can be done using a C. elegans system. The advantages of these tests include:

(1) The screening in a whole animal assay. C. elegans is a complex multicellular organism with a full nervous system, digestive system, etc. Its anatomy and development has been described in extreme detail. It is one of the best-characterised higher organisms at the genetic, molecular, developmental and cell biological level. Any observed changes to phenotype can be checked against this database.

(2) To study effects on rate and directionality of cell migration and the change of cell shape it is

important to leave the cells under study in a setting where they are surrounded by the in vivo interacting tissues, cells and substrates for cell migration etc. This can be done using whole C. elegans subjects. A situation has been created where the given pathway is over-stimulated leading to an easily scorable phenotype which can be reverted in any assay or process.

(3) The endpoint of the screen is the substantially increased health of the organism. This permits the exclusion of non-specific and toxic compounds.

(4) A complete and specific inhibition of UNC-53 in the transgenics will lead at the worst to the phenotype of an UNC-53 reduction or loss of function mutant which we have described, can recognise and have shown not to be essential for viability.

(5) The test can be adapted to make full use of the advantages of the C. elegans model system such as the possibility to conduct the test chronically over several generations and the possibility to conduct the test in different genetic backgrounds, e.g. RTK constitutive or defective.

(6) C. elegans exhibits a complex set of wild type, drug- and mutation-induced phenotypes such as changes in body shape, subtle changes in locomotion, mating behaviour, chemotaxis, pharyngeal pumping, egg laying behaviour, which can be used as part of a phenotype analysis or screen.

The results of C. elegans research described herein has provided important breakthroughs in biomedical research fields such as programmed cell death, neuronal guidance, the Receptor Tyrosine Kinase/RAS signal transduction pathway, integrin/cell adhesion receptor signalling, etc.,

The biochemical association of UNC-53 in the RTK signal transduction pathway enables identification of

genes or of biochemical pathways which are targets for pharmacologically or pharmaceutically active compounds and the development of high throughput and mode of action specific drug screens using wild type, mutant and transgenic animal strains including, in particular, C. elegans.

Thus pharmacological manipulation of the UNC-53 pathway is now possible on the following rationale:

We have scientific arguments to expect C. elegans UNC-53 to interact in vivo with the other components of RTK signal transduction pathways based on:

(1) The observation that C. elegans SEM-5 and GRB-2 are mutually exchangeable in vivo, combined with our observed in vitro binding of both GRB-2 and SEM-5 to UNC-53. Thus, C. elegans UNC-53 will be able to interact with the activated GRB-2/RTK receptor in mammalian cells.

(2) UNC-53 interacts with the rabbit actin-cytoskeleton

Expression of C. elegans UNC-53 in mammalian cell lines represents a shortcut to develop pharmacological assays and screens to target this pathway. We have shown that over-expression of the C. elegans UNC-53 in C. elegans myoblasts leads to over-extension of these cells in the anterior/posterior axis of the embryo and ultimate disorganisation of the muscle cell and myofilament pattern. (Over)-expression of C. elegans UNC-53 in a human cell line leads to a detectable change in phenotype, in particular increased motility of cells, increased outgrowth of neurons and morphological changes in the elongation and cytoskeletal morphology of differentiating myotubes.

The C. elegans unc-53 Open Reading Frame (ORF) (with and without optimised Kozak consensus sequence) of both 7A and 8A clone variants has been cloned between the CMV major intermediate early

promoter/enhancer and bovine growth hormone polyA signal sequence of xpression vector pcDNA3 (Invitrogen). This vector is designed for high level stable and transient expression in most mammalian cells.

The following additional considerations require mention:

(1) Genetic analysis of reduction in UNC-53 function and ectopic expression experiments suggest that UNC-53 acts in a highly dosage-dependent manner. As is the case for RAS, increased expression may lead to lowering the threshold of RTK-signal required for a given response or may remove the requirement for an activating signal to obtain a phenotype response (Fig 10). In addition UNC-53 is an unusually low abundance protein in wild type C. elegans. It is therefore likely to be necessary or useful to control the temporal and quantitative expression of UNC-53 in the proposed assay conditions in all organisms or cells to be assayed. The already available or a further optimised expression cassette is then cloned in expression vectors with IPTG- inducible or tetracycline-repressible promoters. It is realised that both the Lac and Tet expression systems are leaky. Additional other repressible/inducible expression systems (e.g. Mx promoter) or weak mammalian promoters might be preferred.

(2) Over-expression of the endocytosis controlling protein dynamin leads to phenotypes which are not associated with dynamin function in the cell but which are thought to be due to sequestration of the GRB-2 pool in the cell (GRB-2 is an adaptor for a variety of signal transduction pathways). Such sequestration is unlikely to lead to "positive effects" on the activity of the cell such as is observed in the presently described assay system (increased cell process

xtension or motility), see Fig 19. Based on the homology between UNC-53 and GTP-binding, we can also predict specific mutations in the nucleotide-binding pocket or the predicted effector region which should lead to loss of function. Sequence analysis of unc-53 alleles is instructive in determining which amino acids of UNC-53 are essential for function, e.g. as exemplified by the indication that an allele (n152) which has a differential effect on anterior versus posterior guidance has a deletion in a region of differential splicing. The differential splices of the C. elegans unc-53 gene encode different variants of the protein which independently affect posterior or anterior migration and/or cell specificity. One predicted exon in C. elegans unc-53 is indicated in Fig 1. It is conceivable that of two variants of the same protein one is inhibited or enhanced by a particular compound whereas the other is not (or to a lesser degree). Such a compound could then be used to control direction of migration or cell specificity by selective inhibition or enhancement.

(3) To develop pharmacological screens for inhibitors of a biochemical pathway a "gain of function" phenotype has been invented which can be expected to revert to wild type in the presence of specific inhibitors. Overexpression of UNC-53 in C. elegans myoblasts already leads to lethal subviable muscle phenotypes which can be easily scored with high throughput or a scorable heat shock inducible phenotype (Fig 21). They may form the basis for a pharmacological screen for inhibitors. A similar screen is obtained for over-expressing UNC-53 in mammalian cells. An alternative strategy is based on the homology to GTP binding proteins, RAS and dynamin and NTPases. We can introduce amino-acid changes in the nucleotide binding pocket which are

predicted/expected to lead to a constitutively activated or inactivated UNC-53. Similar chang s ar based on homologies with SOS, dynamin or ATP/GTP binding proteins from homology tables.

(4) Correct expression of UNC-53 in each cell line may be assessed by immunofluorescence and western blot analysis with the monoclonal antibody (mab) designated as 16-48-2.

The inventors have thus expressed and stably integrate the expression constructs in the neuronal, myoblast and 3T3 cell lines.

These cell lines are primarily used to:

- Assess the effect of UNC-53 expression on the morphology, motility, metastatic potential and growth cone extension of the cell lines.
- Produce protein and mRNA
- Screen for pharmacological compounds inhibiting observed UNC-53 mediated phenotypes
- Analyse signal transduction pathways associated with UNC-53 activation (for example, phosphorylation,)
- Immunofluorescence studies with mab 16-48-2 to assess changes in subcellular localisation following growth factor treatment.

Thus, the present invention provides for the identification of compounds which inhibit or enhance the UNC-53 signal transduction pathway. Such compounds can be used in the control of cell directional migration, motility and differentiation. These compounds are useful in the treatment of oncogenesis, psoriasis, neuronal degeneration and cell migration (metastasis).

The present invention also provides the ability to identify nucleic acid sequences and proteins which are involved in the UNC-53 pathway in C. elegans. Such nucleic acid sequences and proteins may be UNC-53 equivalents, members of an UNC-53 pathway or may be

nucleic acid sequences or proteins which interact in the UNC-53 pathway, for example as demonstrated by th GRB-2/SEM-5 proteins. This knowledge of the UNC-53 pathway in C. elegans can be established as can factors which influence the functioning of the pathway, for example, factors/ proteins which feed into the pathway or are of a parallel pathway which at least, in vitro, compensates for steps in an UNC-53 pathway.

The identification of other components in the UNC-53 signal transduction pathway:

(1) help to determine the interaction of UNC-53 with known signal transduction pathways (RAC-, RHO-, cdc42-RAS-pathway exchange factors, downstream or regulating kinases)

(2) identify the new interacting proteins which may constitute additional potential pharmacological targets.

(3) may assign functions to the more than 1000 amino acids of UNC-53 which have no homology to known proteins.

Accordingly, proteins which cross-react with anti-C. elegans UNC-53 protein antibodies can be isolated. The basic experiment protocol for purifying antigen-antibody complexes is described in Example 11. This system can also be used to identify factors which interact with proteins which bind to anti-UNC-53 C. elegans antibodies.

The following tissue sources may be used for immuno-precipitation:

(1) Mammalian cells which exhibit a phenotype after transfection with unc-53 indicating that it interacts with vertebrate components of its signal transduction pathway.

(2) UNC-53 protein may be too low abundance to make affinity purification from wild type C. elegans

feasible. The inventors have affinity-purified UNC-53 from already constructed transgenic C. elegans lines which express UNC-53 under control of the hsp-16 promoter and/or the myosin promoter. These experiments in C. elegans are justified because with the vast amount of sequence information (genomic and cDNA) available, one has a good chance of identifying the corresponding genes in the databases with a minimum of peptide sequence.

Several types of proteins may be expected to co-purify with UNC-53, including GRB-2 and other proteins with SH3 domains of the Grb2 class or phosphorylation sites, RTK-receptors, subunits of an UNC-53 homo-heterodimer complex, downstream regulating kinases or proteins from the microfilament cytoskeleton.

This co-immuno-precipitation approach can also be used to dissect the order of events in this signal transduction pathway. For example: UNC-53 immuno-purified after stimulation of mammalian cell-lines with growth factors and pharmacological agents can also be assayed with respect to its state of phosphorylation, or complex formation with interacting proteins.

Proteins interacting with specific UNC-53 domains are identified using a yeast two-hybrid system, whereby two sets of hybrid proteins are used to assay for functional restoration of the GAL4 transcriptional activator: the first consisting of a GAL4 activation domain/UNC-53 structural domain of unknown function, the second derived from a cDNA library cloned into an expression vector to generate a library of hybrid proteins containing a GAL4 DNA binding domain. The yeast two-hybrid system is well know in the art.

A set of unc-53-fusion constructs can be constructed, including a fusion to

(1) the full length protein,

(2) the carboxyterminal domain (from second actin binding domain to th ATP/GTP binding domain),
(3) The aminoterminus (predicted cortical localisation domain up to the SH3 binding sites),
(4) a variety of overlapping constructs within the central domain of 1000 amino acids to which no function can as yet be assigned.

These are tested in yeast to exclude those which lead to activation of the reporter gene in the absence of the cDNA-activator fusion. cDNA libraries were transformed into these reporter strains and positive clones identified. (In this strategy, screening of multiple libraries requires very little effort (transformation followed by plating on selective and indicator medium)).

A preferred cDNA library is from cell lines in which a phenotypic change is observed following UNC-53 expression such as mouse N4 neuroblastoma cells or MCF-7 breast carcinoma cells. The yeast two hybrid system can identify interacting proteins or "sections" of nucleic acid which may not be translated in vivo but which may inhibit UNC-53.

Candidate positives are tested for the fusion-protein dependence of the reporter gene activation. The cDNA insert in remaining positive clones is sequenced. The obtained sequence is screened through the databases, which provides, especially in the case of C. elegans clones, significant extra sequence.

Another system also exists for the identification of proteins which bind or modify UNC-53. An UNC-53 protein is bound by conventional techniques to a column. A sample to be tested is then passed over the column. This sample may be fractions from cells from C.elegans, mammals or any other organism. These sample fractions may have been incubated with ^{32}ATP. In this course the "reaction" of the labelled fraction

with UNC-53 can be determined. If the UNC-53 on the column becomes ^{32}P phosphorylated then this indicat s that the sample fraction contains an UNC-53 modifying protein. Alternatively a constituent of the sample may bind to the UNC-53 and remain bound therewith on the column. The retention of any fraction of the sample on the column and the identification of the fraction can easily be determined by techniques known in the art.

Example 9 describes the identification of sensitive, dependant or resistant mutations as direct tools for the development of screens for compounds with similar or antagonistic activities. Both resistant and sensitising mutations may have a phenotype in the absence of the compound and no or a different phenotype in the presence of the compound. This permits the introduction of action-specificity in the screens.

High throughput screens are a basic feature of C. elegans genetic methodology. Non-complementation screens for new alleles in a locus require setting up of up to 8000 separate worm populations starting from one hand-picked individual each. This is done in 24 well plates or small Petri-plates. These are subsequently (after 1 or 2 generations) visually screened for a complex behavioural phenotype. For pharmacological screens where populations can be started from multiple individuals pipetted from a pool of synchronised eggs, high throughput screens can also be developed. If the endpoint of the assay can be scored in liquid, populations can be set up in microtitreplates. If the end-point is linked to a reporter gene (e.g. β-galactosidase activity) ELISA type colour-metric assays can be used to score the end-point. C. elegans can also be introduced into soils, exposed to compounds and subsequently recovered

and assayed. Such endpoints are used in the heat-shock assay developed by Stressgen (Stringham & Candido (1994), Environ. Toxicology and Chemistry, 13(8), 1211-1220).

Gain of function mutants of C. elegans or transgenic C. elegans in which a pathway of interest has been over- or constitutively activated, causing a dominant phenotype which can be used to develop specific screens for inhibitors.

Transgenic lines expressing UNC-53 ectopically under the C. elegans heat-shock (hsp-16) promoter, and body wall muscle (unc-54) promoter have been constructed. These lines lead to dominant phenotypes in development and are used directly to screen a spectrum of compounds. Where necessary or deemed useful endogenous C. elegans genes can be replaced by or complemented with human signal transduction pathways.

DEPOSITED CELL LINES AND PLASMIDS

STRAIN NAME	DATE OF DEPOSIT	LMBP ACCESSION NUMBER
pTB54 Plasmid	22 MAY 1995	3296
pTB112 Plasmid	22 MAY 1995	3295
pTB72	22 MAY 1996	3486
TB4EX25 Cell Line	22 MAY 1995	1384 CB
TBAIn76 Cell Line	22 MAY 1995	1385 CB
HYBRIDOMA Cell Line	22 MAY 1995	1383 CB
MCF-7 TRANSFECTED BREAST CARCINOMA		

CELL LINE	24 MAY 1996	1550 CB
TRANSFECTED N4 NEUROBLASTOMA CELL LINE	24 MAY 1996	1549 CB
WILD TYPE MCF-7 BREAST CARCINOMA CELL LINE	24 MAY 1996	1551 CB

The above plasmids and cell-lines were deposited at the Belgian Coordinated Collections of Micro organisms (BCCM) at Laboratorium voor Moleculaire Biologie - Plasmidencollective (LMBP) B-9000, Ghent, Belgium, in accordance with the provisions of the Budapest Treaty of 28 April 1977.

The present invention will now be described with reference to the following Examples.

Examples

Example 1 - Molecular Characterisation of unc-53 gene in C. elegans

Screen for muscle pattern mutants :

C. elegans has two sets of muscles which are suitable to study this problem, the body wall muscles and the sex muscles. The sex muscles are a set of 16 muscle cells (4 muscle types) in the hermaphrodite and 41 cells in the male (10 muscle types) with distinct attachments points on the hypodermis and gonads. The sex muscles develop postembryonically and are not required for viability. The body wall muscles are arranged longitudinally (roughly 2 cells abreast) into four quadrants. At birth there are 81 cells. In postembryonic development, extra muscles interdigitate with these bringing the total number of body wall

muscles in the hermaphrodite to 95. Head, neck and body muscles can be distinguished within these rows on the basis of their innervation and patterning within the rows.

We have screened 4800 haploid genomes using Nomarski and polarized microscopy for mutants with specific attachment or pattern defects in a subset of the male sex muscles but with wild type body wall muscle pattern and myofilament organization, wild type movement and wild type male bursa anatomy (a sensitive indicator of wild type morphogenesis). Amongst the 21 identified mutants we selected for further study those with specific phenotypes in both the male and hermaphrodite sex muscles. As these muscles lie in different regions of the animals this was thought to reduce the chance that the male tail phenotype is a pleiotropic consequence of changes in regional identity of the tail or defects in male tail hypodermal lineage or morphogenesis.

Muscle phenotype of e2432.

Mutant e2432 was isolated on the basis of its phenotype in the male spicule retractor muscles, a pair of bilaterally symmetrical muscles which attach anteriorly to the body wall and posteriorly to the base of the spicules. The spicule retractors of mutant e2432 are shorter than wild type. Their attachment to the spicules is wild type, but their attachment point to the body wall is shifted posteriorly. The spicule protractors sometimes extend processes onto the attachment point of the spicule retractors on the hypodermis, suggesting the defect is not in these attachment points, but rather in the extension of the muscles towards that point. The diagonal muscles are in most specimens wild type but they are occasionally not parallel to one another or are have a dorsal

attachment point that is mor ventrally positioned than in wild tye. e2432 males have a nicely shap d fan with the normal pattern of rays, suggesting that the sex muscle defect is not pleiotropic due to defects in the hypodermis.

e2432 hermaphrodites have a reduced ability to lay eggs which is variable from animal to animal. This is due to a muscle pattern defect in the vulval sex muscles. The uterine muscles, 8 muscle cells which circle the hermaphrodite uterus, are wild type in e2432. The vulval muscles are a set of 4 pairs of cells arranged symmetrically in a cross-pattern around the vulval slit. Each pair consists of one vm1 and one vm2 muscle cell. The vm2 muscles attach to the junction between uterus and vulva and extend anteriorly to attach to the hypodermis in between two muscle cells of the ventral body wall muscle quadrant. In e2432 these muscles are shorter than in wild type small. In e2432 they can only be visualized by laser confocal microscopy (after FITC-phalloidin staining of the myofilaments). This showed that they attached to the uterus as in wild type, but that their attachment to the body wall is ectopic (in a random position lateral of the vulva, usually on the ventral edge of the muscle row). In e2432 vm2 myofilaments are oriented more dorsoventrally than in wild type (where their orientation is essentially in the longitudinal axis of the animal). This phenotype is not due to a defect in the attachment point on the epidermis to which these cells should attach in wild type, since we frequently observe that the vm1 sex muscles make an apparently wild type attachment to this unoccupied attachment point.

In wild type hermaphrodites, the vm1 muscle cells attach close to the junction between epidermis and vulva and in the adult extend dorsally and anteriorly

(under an angle of 45-50 degrees with respect of the vulval slit) to attach to the hypodermis at the dorsal edge of the ventral body wall muscle quadrants. In e2432 the attachment of the vm1 muscles to the vulva is wild type. With their other end they attach, like wild type vm1 cells, along the dorsal of the edge of the ventral body wall muscles. However the angle between the vulval slit and the myofilaments of the vm1 sex muscles is reduced (less than 45 degrees) so that their dorsal attachment point is closer to the vulva than in wild type. The forces acting on the vulva can be separated in an antero-posterior and a dorsal vector. In e2432, the antero-posterior vector of both the vm1 and vm2 muscle is significantly reduced, leading to a reduced ability to open the vulva upon contraction. Studies in which vulval muscles were ablated individually or in groups suggested that 2 vulval muscle cells of wild type orientation are sufficient for wild type function.

Adult C. elegans hermaphrodites have 95 body wall muscle cells arranged longitudinally (roughly 2 cells abreast) into four quadrants. In wild type cells these cells are spindle shaped.

e2432 adults have body wall muscles with a wild type muscle cell and myofilament pattern, except that cells with interdigitating tips occur more frequently than in wild type. Like the unc-53 phenotype in the male and hermaphrodite sex muscles, this body wall muscle defect, which can also be observed in other guidance and attachment mutants like unc-6 and mups, can also be attributed to a reduced ability to extend "growth cones" otherwise referred to as cell processes in the anterior-posterior axis of the animal.

Position on the genetic map :

e2432 was mapped to the left arm of chromosome II

and was found not to complement unc-53(e404). The unc-53 locus was originally identified by Brenner (1974), Genetics, 77, 71-94 as one of the uncoordinated mutants but has received only sporadic attention in general phenotypic surveys of the UNC-collection (Hedgecock et al (1987), Development, 100, 365-382 and Siddiqui (1990), Neurosci. Res. (Suppl) 13, 171-190, in a genome wide screen for egg laying defective mutants (Trent and Horvitz (1983), Genetics, 104, 619-647) and using e2432 as a tool to study the effect of body shape on the pattern of neuronal processes (Hekimi and Kershaw (1993), J. Neuroscience, 13(10) 4254-4271). We initiated a detailed genetic and phenotypic analysis of this locus using the existing available alleles which various colleagues isolated in different screens : The canonical unc-53 allele e404, a strong UNC was isolated by Sydney Brenner. Alleles n152, n166 and n1199 have been obtained in screens for egg laying defective mutants. Alleles NJ234 and NJ222 were isolated by Ed Hedgecock in a screen defective in excretory canal outgrowth. As these screens were aimed at isolating viable fertile alleles, we isolated additional alleles by pre-complementation screens designed to yield loss of function alleles irrespective of their phenotype. e2432/mnDf90 hermaphrodites are egl, weak unc's with a slightly stronger phenotype than e2432. Matings were set up on 3 cm petri dishes between 2 to 3 unc-53(e2432) sqt-1(sc13) /+ males and 2 e2431ts or dpy-6(e14) hermaphrodites mutagenized with EMS in the L4 stage (Brenner, 1974) , Genetics, 77 71-94. The F1 egl, unc-53 like hermaphrodites, which may be unc-53(e2432) sqt-1(sc13)/unc-53(new) were cloned on petri dishes and their offspring examined for the segregation of new unc-53 alleles. In two screens, two unc-53 alleles, 5 and 8 were isolated in an estimated 13000

F1 offspring, giving an approx. mutation rate 1/3250 mutagenized chromosomes. Sqt-1(sc13), an allele of sqt-1 that confers a roller phenotype was included because it is closely linked to unc-53 (0.2 m.u.) and marks the original allele e2432. e2431ts, an X-linked ts larval lethal with a mup phenotype was included to eliminate F1 hermaphrodites arising from selfing and F1 males which can mate. In the second screen dpy-6(e14) was included to prevent F1 males from mating with F1 hermaphrodites.

All unc-53 alleles used in this study fail to complement to e2432. Complementation was tested by mating unc-53(e2432) sqt-1(sc13)/+ males to hermaphrodites of the respective alleles. The male sex muscle phenotype described above for e2432 was found to be the only 100% penetrant phenotype in the unc-53 locus (see below) and was the primary phenotype used in complementation tests. Each of these alleles was also complemented to mnDf90 by mating unc-4 mnDf90/mnC1 males to unc-53 homozygotes and temporary unc-53/unc-4 mnDf90 lines were established to evaluate the phenotype. The male and hermaphrodite phenotypes of all alleles over deficiency is identical or slightly, but not substantially stronger than that of the homozygous lines (which is not unusual for a large deficiency).

S. Brenner mapped unc-53 to 2.9 +/- 0.7 map units from dpy-10 (chromosome II). We refined this map position by mapping unc-53 with respect to different deficiencies in the region and doing three factor crosses between unc-4 and sqt-1, a 1.5 map unit interval. Unc-53(e2432)/+ males were mated in unc-4 sqt-1 hermaphrodites. Non-rolling F1 offspring were cloned on petriplates and their broods screened for the segregation of unc-53(e2432). Unc-4 non sqt-1 and sqt-1 non unc-4 hermaphrodites were picked from those

plates and cloned on petriplates. 6 out of 42 sqt-1 non unc-4 recombinants segregated unc-53 and 3 out of 18 unc-4 non sqt-1 recombinants did not segregate unc-53. This yields a relative position of unc-4 / 51 / unc-53 / 9 / sqt-1. Or a calculated map position for unc-53 on chromosome II, 0.23 map units left of sqt-1.

Unc-53(e2432) was mapped relative to three deficiencies in the region mnDf90 mnDf87 and mnDf77 by mating e2432/+ males to unc-4 Dfx/mnC1 hermaphrodites and scoring for males and hermaphrodites with the unc-53 phenotype in the F1. The experiment was also performed by mating unc-4 mnDfx/mnC1 males to homozygous unc-53. mnDf87 and mnDf90 do not complement unc-53 while mnDf77 complements unc-53. Ooc-3, the only other gene on the genetic map in the region, was found to complement unc-53 in identical crosses between e2432 and unc-4 ooc-3/mnC1. Further mapping of unc-53 relative to RFLPs between wt strains in the region and the molecular cloning confirmed the map position of unc-53 (see below).

Molecular characterization :

We started cloning the unc-53 locus because the study and interpretation of the unc-53 phenotype and the different mutants in the locus would be greatly facilitated by having information on and probes for the unc-53 mRNA and gene product.

At the time we initiated cloning of unc-53, a contig extending between unc-4 and sqt-1 (approx. 1500 kb) had been identified by A. Coulson and J. Sulston (*C. elegans* genome project LMB Cambridge), with no clone markers in between. To correlate the genetic map with the physical map in this region we positioned cosmids of this contig relative to the deficiencies mnDf77, mnD87 and mnDf90 by comparing band intensities of Southern blots of mnDfx/mnC1 strains probed with

cosmids throughout the region. Cosmid KO2F7 is deleted in mnDf90 but not deleted in mnDf87 an mnDf77 thus identifying a leftmost location for unc-53. Cosmids W10G4, TO8D11 and F33G3 are in the unc-53 region (not deleted in mnDf77 but deleted in mnDf87 and mnDf90). Cosmid KO4H9 is deleted in mnDf77 and identifies a rightmost location for the gene. The distance between KO2F7 and KO4H9 is approx. 10 cosmids.

To narrow down the position of unc-53 further we looked for restriction fragment length polymorphisms between wild type strains in this interval and identified N2/RC301 RFLPs in cosmids W10G4, F40F8 and F22G3. We mapped these using three factor crosses with the strains unc-53 sqt-1/RC301 and unc-4 unc-53/RC301. We mapped F22G3 and F40F8 between unc-53 and sqt-1 at the following relative distances :
unc-4 / 9 / W10G4 / 2 / unc-53 / 1 / F40F8 / 1 / F22G3 / sqt-1.

These data localize unc-53 in an interval of approx. 80kb in which more than 15 differently overlapping cosmids are available. Pools of cosmids were injected in unc-53(n152) gonads together with the rol-6 selectable marker. Transient roller lines were established and scored for rescue of the unc-53 phenotype. Cosmid T28D2 was found to rescue the backward movement egg laying phenotypes of allele n152 .

A genomic library of N2 in lambda 2001 was screened with T28D2 and flanking overlapping cosmids. These were assayed in pools and individually for transformation rescue. Lambda clone, S4 carrying a sixteen kb insert was shown to give some rescue activity. Using restriction fragments of S4 as a probe, cDNA clones M5 (3.8 kb) and M18 (1-2 kb) were

isolated from a Lamda MGU1 cDNA library. Both M18 and M5 contain an identical 3'-end as judged by restriction fragment analysis. Partial sequence analysis showed that M18 is shorter version of M5. Insert M5 was sequenced on both strands and was found not to be a poly-A tail at its 3'-end but appears not to full length at its 5'-end.

To find the 5' end of the unc-53 transcript we did nested PCR on L2 stage random primed cDNA, between antisense oligos tab2 and tab (43 bp away from the 5' end of cDNA M5) and an oligo to the SL1 trans-spliced leader sequence. This sequence is transspliced to the 5'-end of most C. elegans mRNAs. This yielded at least 6 classes of PCR-fragments which have been subcloned and sequenced. All contain the 43 bp between oligo tab2 and the 5' end of cDNA M5 (bp1281 to 1338). The longest PCR fragment (TB3) extends the sequence of cDNA M5 with 1280 bp. When added to the length of the cDNA M5, this unc-53 transcript which we constructed in vitro and named tb3-M5 would then be 5073 bp long (including some poly-A tail) and have a 1528 AA open reading frame. Recently a 5 kb cDNA, was identified in an embryonic cDNA library which has the TB3-5'-end (including part of the SL1), and the same 3'-end as M5, suggesting that TB3-M5 occurs in vivo. Similar PCR reactions in which the SL1 oligo was replaced by an SL2 transplice oligo gave no reaction products. Preliminary Northern blot analysis identifies a major 5.0 kb transcript and at least 2 smaller transcripts that are expressed in L2, L4 and adult worms. It needs to be examined whether the unc-53 5' ends reported here are made in vivo and encode different proteins or whether they represent PCR noise. The smaller PCR-fragments TB1b, TB16, TB1, TB6b and TB22 are "nested deletions" of clone TB3 with SL1's at their 5' end. The sequence of each is identical in the

regions of overlap. The shorter SL1 transspliced transcripts contain ATGs downstream of the SL1 addition sites at positions 466, 988 and 1324. Comparison to the sequence of genomic clones confirmed that the SL1s are spliced onto intron exon boundaries. However not all intron-exon boundaries receive SL1, suggesting that there is some specificity to this differential trans-splicing.

Recently the C. elegans sequencing consortium has sequenced cosmids F45E10. We mapped cDNA tb3-M5 onto these cosmids and found that unc-53 is an unusually large locus. It has 23 exons spread over more than 31 kb of genomic DNA.

The lambda clone S4 that rescues does not contain the first 430 bp of the unc-53 transcript. This suggests that the ORF between positions 63 and 430 is not essential for transformation rescue. This rescue may derive from expression of transcripts TB6b or TB22 or from "non-specific" initiation of transcription on the extrachromosomal arrays.

Additional confirmation that M5 was derived from the unc-53 transcription unit is provided by the observation that allele n152 has a 300 bp deletion, disrupting the sequence of cDNA M5 and leading to a large (possibly complete) reduction of UNC-53 protein in n152 embryos stained in immunofluorescence with an anti-unc-53 antibody (16-48-2). In addition, allele e2432 was found to carry a 3-4 kb insertion in this transcription unit.

Sequence homology :

Antibody staining :

The NdeI-EcoRI fragment of cDNA M5, the 47 kd fragment of UNC-53 encoded by the NdeI-EcoRI (position 3187 to 4458 (tb-M5 fig 3) protein sequence

fig 2) was subcloned in the T7 expression vector prk172 (yielding vector TB66 and xpressed in E. coli. Inclusion bodies containing recombinant protein were purified, by processes known in the art solubilized in 8 M Urea and the recombinant protein purified over a DEAE column equilibrated in 8M urea. Purified protein was mixed with complete Freund's adjuvant and injected in a rabbit and 4 Lou rats. This was followed six weeks later by bi-weekly boosts with antigen mixed with incomplete adjuvant. All sera are active in western blotting at titers of 1:30,000 on Western blots of the 47 kd unc-53 fragment expressed in E.coli. With this western blotting assay, a rat-mouse hybridoma cell line was prepared producing a monoclonal antibody to UNC-53. Mab 16-48-2 has the following properties :

- protein G-binding
- binding activity on western blots of
(1) the 47 kd UNC-53 fragment expressed in E. coli, (pTB66)
(2) the 57 kd carboxyterminal fragment of UNC-53 expressed in E. coli (construct pTB65.)
(3) the full length TB3-M5 UNC-53 expressed in E. coli (construct pTB61) and mammalian cells (COS-cells; constructs pTB54 and 56).
- immunoprecipitation of native and SDS denatured full length TB3-M5 UNC-53 construct pTB50 expressed in vitro-transcription translation reactions in reticulocyte lysates.
- immuno-histochemistry in wild-type C. elegans fixed with methanol, acetone or paraformaldehyde and transgenic C. elegans expressing UNC-53 tb3-m5 pTB110, 111 or 112 in epidermis, neurones, gut and muscle.

Mab 16-48-2 fail to detect antigen of the correct size on Western blots of total worm proteins or worm proteins fractioned by progressive extraction with

deterg nts, urea and SDS.

Excretory canal phenotype :

The excretory canal of C. elegans is a large H-shaped cell. It's cell body is positioned ventrally at the level of the pharyngeal bulb and send out two processes dorsally. At the level of the lateral epidermis (seam) each of these bifurcates and extends anteriorly and posteriorly over the seam cells, until they extend over most of the whole body length. It has been reported that in unc-53 the posterior process of the excretory cell does not extend up to the V6/T seam-cell boundary (E. Hedgecock et al., (1987), Development, 100 365-382).

We have done an extensive characterization of this phenotype in all alleles listed, either by direct in vivo Nomarski microscopy or UL6 rol6d marked unc-53 strains which express LacZ in the epidermis and excretory cell (Hope(1991) Development 113(2) 399-408). In wild type the excretory cell processes are straight. In unc-53 the canal is often meandering from left to right over the seam before it arrests prematurely, as if it has lost directional cues in its migration. It never leaves the lateral epidermis seam. Both the anterior and posteriorward processes are affected.

In weak unc-53 alleles the posterior excretory canal processes arrest anywhere between the vulval region and the V6/T boundary. We noticed that in even the strongest alleles or in unc-53/Df heterozygotes the canal arrests unusually frequently at or close to the vulva and never substantially before the vulva . We therefore set out to test whether the gonad dependent attractive signal which attracts the sex myoblasts to the gonad also might attract the excretory canal in an unc-53 independent manner to the

vulval region. If this is the case we would expect that in a strong unc-53 mutant n152 in which the 2 somatic gonad cells (the source of the signal) have been ablated, the excretory canal migration would be fully arrested. As a control we ablated one germ cell and one somatic gonad cell (Z1 and Z2 or Z2 and Z4). Embryos were ablated in the comma to 2 fold stage and the position of the excretory canal scored double blind in hatched embryos. At the time of ablation, the canal may already have started growing out. At hatching, the endpoint of our experiment, the growth cone of the posterior canal process has reached just beyond the gonad. Although these are technically difficult laser ablations, the results show a substantial difference in excretory canal outgrowth between embryo with an ablated somatic gonad and control ablated embryos. In the experimental series the canal usually arrested a significant distance from the gonad or any other potentially damaged cells, suggesting the loss of a long range signal as described for the SM myoblast migration (Thomas et al (1990) and Stern (1991)). In the control series the excretory canal usually extended as far as unablated n152 and into region of the partially ablated gonad. This indicates that the premature arrest observed in the experimental series was not due to encountering a damaged region.

A gonad dependent and independent pathway were found to act redundantly in the posteriorard migration of the sex myoblasts. The data suggest that in wild type the migration of excretory cell growth cones is also guided by a gonad dependent and a gonad independent cue. In both cases the gonad dependent cue acts towards the gonad, but from opposite directions. However the gonad independent signal act anteriorward on the SM myoblasts and posteriorward on

the posterior excretory cell growth cones. Since single mutants in both the gonad dependent pathway (sem-5) and independent pathway (unc-53) have no excretory cell phenotype these pathways may be redundant in the trajectory up to the gonad. An analogous redundancy has been observed for the sex myoblast migration. In the trajectory between gonad and tail the gonad independent pathway acts in different directions on the SM cells versus the excretory cell. In the excretory cell it acts in both anteriorward and posteriorward migration. A simple explanation which is elaborated in detail below is that unc-53 (like sem-5) may act downstream of a variety of receptors interpreting different cues.

The previously described interaction between the gonad and the sex myoblasts was rationalizable as an interaction between cells due to become part of the same organ. The interaction between the excretory cell and the gonad we report here suggests that the gonad may have a more general role as organizer cell migrations in the embryo. We wish to point out that the described dependent and independent pathways are formal genetic concepts. It is for example possible that in unc-53 embryos or unc-53 embryos in which the gonad dependent pathway has been genetically or laser ablated, as yet to be identified, pathway defining growth cones are misplaced leading indirectly to defective sex myoblast, neuronal (PLM, see below) or excretory canal migration. The observed highly restricted expression of unc-53 is an additional indication of this possibility.

Sex muscle phenotype :

All unc-53 alleles exhibit the sex muscle phenotype described for e2432. We quantified phenotype

in eight alleles :

Young adults grown at 20°C were mounted for polarized light or Nomarski microscopy on 2% agarose pads containing 0.2% phenoxypropanol as described in Sulston and Horvitz (1977) Dev. Biol. 56,110-156 . The vm1 sex muscles were examined under polarized light with a 40x objective and a Brace Kohler compensator and photographed. In addition, adults were fixed, incubated with fitc-coupled phalloidin and mounted for fluorescence microscopy as described in Goh and Bogaert (1991) Dev. Biol. 56, 110-156. The angle between the longitudinal axis of the animal and the central bundle of myofilaments of the anterior and posterior vm1 was measured from the negatives with a protractor. As the vulva is a transverse slit at a right angle to the cylindrical body axis, the angle between the vm1 and the vulval slit can be measured independently of which side of the animal faces the observer.

Neuronal phenotype :

Unc-53 animals move poorly backwards when prodded but has good forward movement (Brenner (1974) Genetics 77 71-94). Various aspects of the neuronal phenotype of unc-53 has been reported in general phenotypic surveys of the UNC-collection (Brenner (1974) Genetics 77 71-94). : The posterior branch of the PDE neuron can be abnormal (Hedgecock et al. (1987) Development 100 365-382) and the mechanosensory PLMR & PLML neurons can have commissures into the ventral cord at a position much posterior than in the wild-type. There are also frequently multiple ventralward PLM commissures evenly spaced along the posterior half of the body (Siddiqui (1990) Neurosci. Res. (Suppl) 13 171-190), Hedgecock et al., (1987) Development 100 365-382).

Examples 2 to 5 - Biochemical Analysis of UNC-53

Example 2 - Immunoprecipitations of ^{35}S labelled unc-53 gene products.

The rat anti-UNC-53 monoclonal antibody, 16-48-2 (obtained from the hybridoma LMBP Accession no. 1383CB) elicited against a 47 kD fragment of the 3' end of UNC-53 from C. elegans was used to immunoprecipitate UNC-53 proteins. In this experiment, the full length unc-53 construct pTB50 (Fig. 11) was transcribed and translated in vitro in rabbit reticulocyte lysates. The resulting radioactively labelled ^{35}S unc-53 gene products were incubated with the monoclonal antibody under both denaturing (using SDS)and non-denaturing conditions, then incubated with protein G sepharose. The bound products were analysed by SDS-PAGE and fluorography. Monoclonal antibody 16-48-2 recognised both native and SDS denatured radioactive UNC-53 products verifying that the protein translated in vitro was bona fide UNC-53. This result shows that immuno-precipitation is a useful tool in schemes to purify native protein and to identify UNC-53 protein complexes in biochemical experiments.

Example 3 - Actin sedimentation assays (8A variant).

Besides the N-terminal region of the protein which is similar to actin binding proteins, the predicted protein sequence of UNC-53 identified two putative actin binding sites. The first borders on the 3' end of the region of α-actinin/β-spectrin homology and the second lies in the 3' end of the cDNA sequence. This suggests that UNC-53 could potentially

bind two actin molecules and via actin cross-linking, stabilise a particular growth cone spike to promote directional extension. Alternatively, the two actin binding sites may serve to anchor UNC-53 (and its shorter gene products) to the microfilament cytoskeleton to then transduce a signal via the NTPase domain to the downstream pathway.

To test the two site model, full length and truncated versions of UNC-53 (pTB50 and pTB52) were transcribed and translated in rabbit reticulocyte lysates for 90 minutes following standard protocols (Promega). To remove insoluble components, the reactions were airfuged for 1 hour at 100,000 x g and the supernatant containing ^{35}S labelled UNC-53 products introduced in actin co-sedimentation assays according to the method of Vancompernolle et al. (1992), EMBO J. 11, 4739-4746. In this procedure, radioactively labelled UNC-53 was incubated with monomeric G-actin in G buffer (2 mM Tris pH 7.5, 0.2 mM $CaCl_2$ 0.5 mM β-mercaptoethanol, 0.2 mM ATP) for one hour at room temperature. The salt concentration was then increased with F buffer (1 M KCl, 10 mM $MgCl_2$) to a final concentration of 100 mM to promote polymerisation of G-actin to F-actin. After an additional one hour incubation, polymerised F-actin/protein complexes were pelleted at 100,000 x g in an airfuge, washed with G buffer, resuspended in Laemmli buffer and separated by denaturing SDS-PAGE. The presence of actin in the pellets was confirmed by Coomasie staining while radioactively labelled UNC-53 products were detected by fluorography. Both the full length UNC-53 protein, pTB50, and the truncated construct, pTB52 translated in vitro in rabbit reticulocyte lysates cosedimented with F-actin at starting G-actin concentrations of 50-100 μg/ml. This suggests that UNC-53 binds to microfilament

cytoskel ton. Moreover, deletion of the first putative actin binding site (pTB52) did not eliminate actin binding.

Example 4 - UNC53 interacts with F-actin cytoskeleton (7A and 8A variant)

Analysis of the predicted protein sequence of UNC-53 identified two putative actin binding sites of the LKK class. The first borders the 3' end of the region of α-actinin/ß-spectrin homolgy in the amino terminus of the protein while the second lies in the 3' end of the protein sequence upstream of the putative nucleotide binding domain. A single UNC-53 monomer could thus potentially bind and crosslink two actin molecules.

To test whether UNC-53 associates with the actin cytoskeleton, a 7A (pTB72) and 8A version (pTB73) of unc-53 (Figures 25 and 27 respectively) were transcribed and translated in rabbit reticulocyte lysates and the ^{35}S labelled products introduced into F-actin co-sedimentation assays (Figure 35a). The full length UNC-53 protein (pTB72) translated *in vitro* cosedimented with F-actin at starting G-actin concentrations of 100 mg/ml (Figure 35b) suggesting that UNC-53 interacts with F-actin. By 250 mg/ml, all of the UNC53 protein co-sedimented with the F-actin pellet. In contrast, no UNC53 was present in the pellet of the control reaction without actin. Thus, sedimentation was purely actin dependent. This result also indicated that the *in vitro* UNC-53 protein remained soluble even after the salt concentration was raised.

Deletion of the first putative actin binding site

in pTB73 did not eliminate actin binding since the larger pTB73 products, including the largest fragment co-sedimented with F-actin under the identical set of conditions (Figure 35b). However, since the rabbit reticulocyte lysates contain numerous proteins, it is possible that the interaction of UNC-53 with actin may not be direct but rather mediated through another associated protein.

Several smaller radiolabelled protein fragments in the TnT reactions were observed in addition to the predicted protein products. Immunoprecipitation experiments confirmed that these products were UNC53 derived. Most likely they result from additional translational starts at internal methionines, since the identical set of smaller products was observed from reaction to reaction; or from premature termination and proteolytic degradation. Many of these smaller fragments also co-sedimented with F-actin. Since the second predicted actin binding site is within the 3' end of the molecule, truncated proteins that are the result of internal starts would be expected to have this site and to bind actin.

EXPERIMENTAL PROCEDURES:

Construction of UNC53 plasmids.

The complete unc53 cDNA was cloned as a 5.1 kb NotI-ApaI cassette in the mammalian expression vector pCDNA3 (Invitrogen) to generate plasmid pTB72, the 7A clone variant. To optimize translational initiation at the first methionine, a mammalian KOZAK consensus sequence was engineered upstream of the start methionine by PCR amplification of DNA coding for the first 139 amino acids of the amino terminus with the

oligonucleotides BG03 (5'-ataagaatgcggccgccgccatgacgacgtcaaatgtagaattgata-3') and BG02 (5'-cgcggatcctcaaaccgcgggtggcataatggatg-3'). BG03 contains the mammalian KOZAK consensus sequence in addition to a NotI restriction site. pTB73 is a deletion of the first 408 base pairs of the unc53 cDNA contained in the vector Bluescript II-KS. This construction removes the first two methionines of the unc53 cDNA sequence such that the first possible start methionine in pTB73 is at amino acid position 165 in the cDNA sequence. In all these constructs, (pTB72, pTB73 and pTB50) the unc53 cDNA is inserted into the multiple cloning site such that the T7 promoter is immediately upstream of the 5' end of the cDNA sequence.

The first 139 amino acids of the UNC53 cDNA were amplified by PCR with oligonucleotides BG01 (5'ggaattccaaccatatgacgacgtcaaatgtagaattgaata-3') and BG02 (5'-cgcggatcctcaaaccgcgggtggcataatggatg-3') to generate a convenient NdeI cloning site immediately upstream of the start methionine. This amplification was cloned as an NdeI-BamHI fragment into the prokaryotic expression vector pRK172 (Godedert M. and Jakes R. (1990), EMBO J. Vol. 9, pp 4225-4230 and McLeod M *et al*, 1987 EMBO. J. Vol 6, pp 729-736) to generate construct pTB57. pTB61 contains the PCR derived amino terminus of pTB57 in addition to the 3' end of pTB50. Thus pTB61 contains the identical unc53 8A variant cDNA as in pTB50, but as an NdeI-NcoI fragment in the vector pRK172 for prokaryotic expression.

In vitro transcription/ translation reactions

The UNC53 cDNA constructs pTB72, pTB73 or pTB50 were transcribed and translated for 90' at 30°C in a cell free T7 polymerase expression system in rabbit reticulocyte lysates following the company's protocols (ProMega). Prior to further manipulations, the reactions were centrifuged for 1 hour at 100,000 x g to remove insoluble components. In all subsequent experiments, the supernatant containing the soluble fraction of ^{35}S labelled UNC-53 products was utilized.

Actin co-sedimentation assays

Soluble radioactively labelled ^{35}S-Met-UNC53 products were introduced in actin co-sedimentation assays according to the method of Vancompernolle et al. (1992). In this procedure, radioactively labelled UNC-53 was incubated with monomeric G-actin in G buffer (2 mM Tris-pH 7.5, 0.2 mM CaCl2, 0.5 mM b-mercaptoethanol, 0.2 mM ATP) for one hour at room temperature and then the salt concentration increased with F buffer (1 M KCl, 10 mM MgCl2) to a final concentration of 100 mM to promote polymerization of G-actin to F-actin. After an additional one hour incubation, polymerized F-actin/protein complexes were pelleted at 100,000 x g in an airfuge (Beckman), washed with G buffer, resuspended in Laemmli buffer and separated by denaturing SDS-PAGE. The presence of actin in the pellets was confirmed by Coomasie staining while radioactively labelled UNC-53 products were detected by fluorography. Briefly, after destaining, gels were soaked in 45 % methanol, 7.5 % acetic acid (vol/vol) for 30 minutes, followed by 30 min. in dimethyl sulfoxide (DMSO), and 1 hour in 10 % PPO dissolved in DMSO (wt/vol). The scintillant was precipitated by rehydrating the gels with four five

minute water washes. After drying, gels were exposed to Xray film (Hyperfilm-Amersham).

Immunoprecipitations

To confirm that the radioactively labelled proteins translated *in vitro* were of UNC53 origin, an anti-rat monoclonal antibody, 16-48-2, elicited against a 47 kD fragment of the 3' end of UNC-53 was used to immunoprecipitate UNC-53 proteins. In this experiment, the unc-53 construct pTB50 was transcribed and translated *in vitro* in rabbit reticulocyte lysates. The resulting radioactively labelled ^{35}S UNC-53 gene products were incubated with the monoclonal antibody under both denaturing (0.4% SDS, 2.0% Triton X-100) and non-denaturing conditions for 1 hour at room temperature, then incubated with protein G sepharose for 2 hours at room temperature, the beads washed 3 times with PBS and the bound products analyzed by SDS-PAGE and fluorography. Monoclonal antibody 16-48-2 recognized both native and denatured radioactive UNC-53 products. As a control, a reaction without monoclonal antibody 16-48-2 was treated identically.

Example 5 - Interaction of UNC-53 with SEM-5/GRB-2

The observation that certain alleles of UNC-53 enhance the sex myoblast migration defect of sem-5 mutants is difficult to interpret. While the genetics suggests that UNC-53 and SEM-5 cooperate to regulate sex myoblast migration, it is unclear whether this is the result of a direct molecular interaction. To answer this question, two types of biochemical experiments were used to determine if UNC-53

physically interacts with SEM-5. In the first experiment, radioactively labelled ^{35}S UNC-53, synthesised in reticulocyte lysates, was incubated with SEM-5/GST (glutathione-S-transferase) fusion protein bound to glutathione resin or with GST protein bound to glutathione resin. After incubation, the beads were washed and the bound proteins analysed by SDS-PAGE and fluorography. This demonstrated that UNC-53 made in vitro specifically bound to the SEM-5/GST fusion protein resin. The GST fusion proteins have been previously described. Purification of GST-fusion proteins was facilitated by using a commercially available kit (Pharmacia). All purification methods followed the manufacturer's protocols.

To further characterise the nature of the interaction with SEM-5, a second experiment utilised Western blot overlays. UNC-53 fusion proteins were expressed in E.coli and the denatured protein lysates separated by SDS-PAGE and blotted to Immobilon-P nylon membrane (Milipore). Blots were incubated with biotin labelled SEM-5/GST, GRB-2/GST or GST protein, washed and bound multi-protein biotinylated complexes detected by probing with an avidin-alkaline phosphatase conjugate. The results from this experiment demonstrated that SEM-5 and its mammalian homologue GRB2 can interact with UNC-53 in vitro. Binding was observed in induced cell lysates only and probing with the UNC-53 monoclonal antibody 16-48-2 detected the identical sets of products. In addition, only the full length UNC-53 fusion, pTB61 (Fig. 7), which contained the SH3 binding sites gave a positive result (pTB52 was not tested) No signal was detectable for either of the SH3 binding site minus fusion proteins, pTB57 (Fig. 11) or pTB65 (Fig. 11). This provides supportive evidence that the polyproline

repeats of the UNC-53 directly bind to the SH3 domains of SEM-5. Moreov r, these results show that a SEM-5 or GRB-2/GST glutathione resin may be used in schemes to affinity purify native UNC-53 from tissue culture cells or nematodes or other organism extracts.

Detailed Methodology

Radioactively labelled ^{35}S UNC-53 synthesized in reticulocyte lysates was incubated with SEM-5/GST (glutathione-S-transferase) fusion protein bound to glutathione resin or with GST protein alone bound to glutathione resin for one hour at 20°C. After incubation, the beads were washed four times with Phosphate Buffered Saline (PBS)/Triton X-100 (0.2%) and the bound proteins analyzed by SDS-PAGE and fluorography. The SEM5 and GRB2 GST fusions have been previously described (Lowenstein et al., 1992; Stern et al., 1993). Purification of GST-fusion proteins was facilitated using a commercially available kit (Pharmacia). All purification methods followed the company protocols.

Western blot overlays

Approximately 500-1000 mg each of purified GRB2-GST protein or GST protein were biotin labelled by the following procedure. After overnight dialysis in PBS at 4°C, 1 M Hepes, pH7.4, was added to a final concentration of 100 mM and 50-100 mg of biotinylation reagent, dissolved in dimethyl sulfoxide, and the mixture incubated at 20°C for 90 minutes. The biotinylation reaction was stopped by the addition of 1 M Tris, pH7.4 to a final concentration of 100 mM and the labelled proteins stored on ice.

The UNC-53 construct pTB61 was expressed in *E. coli* strain BL21 (DE3), and the denatured protein

lysate separated by SDS-PAGE and electroblotted to Immobilon-P nylon membrane (Millipore). Membranes were blocked with 1 % skim milk powder in TBS-T (20 mM Tris, pH7.6; 0.14 M NaCl; 0.1% Tween-20) for 1 hour at 37°C. Subsequently, membranes were incubated in equimolar amounts of either biotin labelled GRB-2/GST or biotin labelled GST protein for 1 hour at 20°C, washed 4 x with TBS-T and bound multi-protein biotinylated complexes detected by probing for 1 hour at 20°C with an avidin-alkaline phosphatase conjugate (dilution 1:5000). Biotinylated protein conjugate complexes were visualized with a chromogenic solution containing bromochloroindolyl phosphate (BCIP)/nitro blue tetrazolium (NBT) in 100 mM Tris(pH 9.5), 100 mM NaCl, 5 mM $MgCl_2$.Development was terminated with 10 mM Tris (pH8.0), 1 mM EDTA.

Example 6 - Transgenic Analysis

To further our understanding of the function of unc-53 we developed an in vivo assay to test gene fusions generated in vitro. Nematode expression vectors containing the full length unc-53 cDNA, TB3M5, downstream of various tissue specific and inducible promoters were constructed.

The mec-7 promoter of pTB112 (Fig. 7) confers tissue specific expression to the mechanosensory neurons, the unc-54 promoter of pTB111 (Fig. 7) confers tissue specific expression to body wall muscle and the hsp16-41 promoter of pTB109 (Fig. 7) confers and pTB110 (Fig. 7) confers heat inducible expression to somatic cells. pTB109 is a transcriptional fusion containing only the hsp16-41 gene promoter and has been shown to confer high levels of inducible expression in embryos. pTB110 contains a larger

portion of the hsp16-41/2 intergenic region in addition to a synthetic intron. This plasmid is expected to be highly inducible in embryos and post-embryonic stages in most somatic cell types.

Oocytes of both wild type (N2) and unc-53(n152) hermaphrodites were microinjected according to the method of Fire (1986), EMBO J., 5, 2673-2680. Coinjection of the unc-53 fusion with a selection plasmid, pRF4, a dominant marker of rol-6, allowed identification of transgenic animals by their right rolling phenotype (Mello et al, (1991), EMBO J., 10, 3959-3970. In C. elegans, the injected DNA does not integrate into the genome but rather forms extrachromosomal arrays which are heritable at a frequency ranging from 20-95% (Stinchcomb et al, (1985), Mol. Cell. Biol., 5, 3483-3496; Fire et al, (1990), Gene, 93, 189-198; Mello et al, (1991), EMBO J., 10, 3959-3970. Transgenic extrachromosomal lines were considered stable after the rolling phenotype had passed through four generations. Some transgenic HS-unc-53 strains were mutagenised with 3550 rads of γ rays emanating from a ^{60}Co source which produces breaks in the chromosomes allowing for insertion of the extrachromosomal array. Stable integrants were identified by screening for homozygous rolling F3 broods. The names and genotypes of all transgenic strains are listed in Table 1 with details of the unc-53 fusions (constructs/vectors) listed in Table 2:

Table 1 - Extend in other constructs

STRAIN NAME	PARENTAL STRAIN	unc53 FUSION	SELECTION	lacZ MARKER
TB3In54	n152	pTB109	pRF4	UL6
TBAIn8	N2	pTB110	pRF4	pPCZ1

TBAIn61	N2	pTB110	pRF4	pPCZ1
TBAIn69	N2	pTB110	pRF4	pPCZ1
TBAIn76 Accession No 1385CB (See Fig 17A)	N2	pTB110	pRF4	pPCZ1
TBAIn90	N2	pTB110	pRF4	pPCZ1
TBAIn210	N2	pTB110	pRF4	pPCZ1
TBAIn222	N2	pTB110	pRF4	pPCZ1
TBAIn306	N2	pTB110	pRF4	pPCZ1
TBAIn327	N2	pTB110	pRF4	pPCZ1
TBBIn3	N2	pTB110	pRF4	pPCZ1
TBBIn267	N2	pTB110	pRF4	pPCZ1
TB1Ex10	n152	pTB112	pRF4	none
TB1Ex23	n152	pTB112	pRF4	none
TB1Ex8	N2	pTB112	pRF4	none
TB1Ex16	N2	pTB112	pRF4	none
TB2Ex1	N2	pTB112	pRF4	none
TB2Ex37	N2	pTB112	pRF4	none
TB3Ex10	N2	pTB112	pRF4	none
TB3Ex12	N2	pTB112	pRF4	none
TB3Ex20	N2	pTB112	pRF4	none
TB3Ex37	N2	pTB112	pRF4	none
TB4Ex14	N2	pTB112	pRF4	none
TB4Ex18	N2	pTB112	pRF4	none
TB4Ex22	N2	pTB112	pRF4	none
TB4Ex25 Accession No LMBP 1384CB (See Fig 16)	N2	pTB112	pRF4	none
TB1Ex3	n152	pTB111	pRF4	none

TB1Ex6 (See Fig 17B, C)	n152	pTB111	pRF4	non
TB1Ex11	n152	pTB111	pRF4	none

Notes for Table 1:
Ex-extrachromosomal
In-integrated
pTB109, pTB110-Heat shock unc-53 fusions
pTB111-mec-7 fusion
pTB112-unc-54 fusion
pRF4-rol-6 (su1006) (Mello et al, (1991), EMBO J., 5, 3959-3970)
UL6-excretory canal promoter lacZ fusion
pPCZ1-Hsp16-48/1 lacZ fusion (Stringham et al, (1992) Molec.Biol.Cell 3, 221-233)

Table 2

Full length cDNA tb3M5 (still has SL1 and 5' UTR)

pTB50 (NotI-ApaI fragment in Bluescript II-KS, for in vitro transcription)
pTB51 (NotI-ApaI fragment in Bluescript II-SK, for in vitro transcription)
pTB54 (NotI-ApaI fragment in pCDNA3, for mammalian expression)
(Deposited as accession no. LMBP3296)
pTB109 (NotI-ApaI fragment in hsp16-pucBM21, for in vivo expression)
pTB67 (NotI-Apa fragment in pGEM5 +)

PCR1 of amino terminus of cDNA
(*PCR using oligos BG01 and BG02)
pTB57 (NdeI-BamHI fragment in pRK172, for E. coli expression)
pTB58 (NdeI-NcoI fragment in pGEM5)

pTB63 (SacI-NcoI fragment in pRSETA, for E. coli expression)

pTB64 (BamHI fragment in pBluescriptII-KS)

Full length cDNA utilizing PCR1 amino terminus

pTB61 (NdeI-NcoI fragment in pRK172, for E. coli expression)

pTB110 (XbaI-KpnI fragment in pPD49.83, for in vivo expression)

pTB111 (XbaI-KpnI fragment in pPD52.102, for in vivo expression)

pTB112 (XbaI-KpnI fragment in pPD30.38, for in vivo expression)
(Deposited as accession no. LMBP3295)

PCR2 of amino terminus of cDNA
(*PCR using oligos BG03 and BG01)

pTB59 (NotI-BamHI fragment in pBluescript II-KS)

pTB60 (NotI-XhoI fragment in pCDNA3, for mammalian expression)

Full length cDNA utilizing PCR2 amino terminus

pTB55 (NotI-EaeI fragment in pBluescriptII-KS)

pTB56 (NotI-ApaI fragment in pCDNA3, for mammalian expression)

Other constructs

pTB52 (SacII deletion of amino terminus of pTB50)

pTB53 (SacII deletion of amino terminus of pTB51)

pTB62 (SmaI fragment of pTB52 in pGEX2T, for prokaryotic expression)

pTB65 (NdeI-NcoI fragment of 3′ terminus in pRK172, for prokaryotic expression)

pTB66 (NdeI-EcoRI fragment of 3′ terminus in pRK172, for prokaryotic expression, MAB 16-48-2)

Initially, the phenotype of each transgenic line was characterised by inspection with a dissecting microscope and/or Nomarski optics. Transgenic strains were directly analysed for expression of unc-53 by immunohistochemistry. Briefly, embryos were adhered to polylysine coated slides and permeabilised by a combination of freeze fracturing and immersion in cold methanol and acetone (3-4 minutes each). Embryos were rehydrated through an acetone/distilled water series and then incubated for 30 minutes at room temperature in TBS-Tween (0.1%). The anti-UNC-53 monoclonal 16-48-2 anti-sera was applied undiluted and the slides incubated at 4°C overnight. The embryos were washed three times with TBS-T and then incubated in a secondary rhodamine like (Cy3-M)conjugated antibody for 1 hour at 37°C. After 3-4 washed in TBS-T the slides were mounted for fluorescence microscopy in 2% propylgallate, 80% glycerol-pH 8.0.

Characterisation of transgenic strains carrying pTB112

UNC-53 was over-expressed in the muscle of wild type animals (pTB112 in N2). Each extrachromosomal pTB112/N2 line consisted of wild type and rolling animals as expected, but in addition, several mutant phenotypes were observed at low frequency. These animals varied considerably in phenotype and included embryos which arrested at the two fold stage, larvae which hatched but died soon afterward, animals with extra protrusions on the epidermis and animals with a truncated posterior end. This phenotype is consistent with that of the mup or mua classes of muscle mutants in which the positioning and/or integrity of muscle attachments to the hypodermis has been disrupted. Most of these animals were either inviable or sterile. The progeny of the viable mutants contained the same

frequency of rollers, wild type and mutants as did the prog ny of rolling individuals. Since th extrachromosomal array may be lost at each cell division, every animal is a mosaic. The healthy rollers may have lost the transgene from most muscle cells and may represent weak phenotypes whereas the 2 fold arrests represent the situation where the array has been lost from few muscle cells. Nomarski and polarised light microscopy of the severe larval lethals showed that the muscle cells were disorganised and over-extended.

Detailed analysis of the underlying defect in embryonic development that leads to this terminal phenotype were performed with immunofluorescence microscopy (Fig 21).

Since the unc-54 gene encodes the myosin heavy chain, we expected that this promoter would be active in body muscle descendants from the comma stage onwards. In the unc-54 - unc-53 strains, signal was indeed localised to the body muscle cells in comma and later stages as predicted. The immunofluorescence was localised to the cytoplasm of the cell bodies and was particularly intense at the tips of the extending processes. Increased process length was observed very early in muscle development (comma to 1.5 fold stage) and increased up to the three fold stage. No other abnormalities in shape or muscle myofilament pattern were observed in the anterior-posterior axis of the animal. Two and three fold embryos which were stained with the monoclonal antibody NE8(4c6.3) (Goh and Bogaert,(1991), Dev. Biol. 56, 110-156) appeared to have a relatively wild type myofilament structure. As these animals are mosaic, it may be possible that severe cases die in late morphogenesis and those which survive through embryogenesis to adulthood can tolerate a few distorted muscle cells.

pTB111 transgenic lines

Immunostains indicates that the transgene is expressed efficiently in the mechanosensory neurons of a transgenic extrachromosomal line carrying the pTB111 transgene in an unc-53 (n152) genetic background (Fig 20).

pTB109 and pTB110 lines

Twelve integrated lines derived from three separate mutageneses of extrachromosomal lines have been isolated. TB3In54 carries the pTB109 fusion in addition to pRF4. Nine TBA strains were isolated after mutagenesis of an extrachromosomal strain, HSA. There are two strains (TBB) derived from mutagenesis of the extrachromosomal strain HS B. Both TBA and TBB strains contain the transgenes pTB110, pPCZ1 and pRF4. Inclusion of the HS-lacZ plasmid, pPCZ1 (Stringham et al, (1992), Molec.Bio.Cell 3, 221-233) allows one to monitor the strength of the heat shock induction by assaying for β-galactosidase activity.

Immunostains of embryos freeze fractured after a two hour heat shock showed that the signal was most prominent in the pharynx, gut and neurons. Surprisingly, the signal had a speckled appearance. This may be a feature of heat shock. Heat shock proteins may sequester UNC-53 to "chaperone" it during stress. Alternatively, UNC-53 may be targeted for degradation. In one experiment, embryos were heat shocked for two hours, allowed to recover overnight and then freeze fractured the next morning. While levels were reduced, there was a little residual UNC-53 signal in the gut cells. Thus, about 16 hours later most the protein has gone.

Level of heat shock and recovery times are

therefore important factors in the mutant rescue experiments and th preferred assay system described in example 10. In addition, experiments suggest that heat shock induction in liquid culture versus agar plates or dry incubators versus water baths need careful calibration.

After a strong three hour heat shock, a high percentage of animals were not able to recover from the stress. Embryos which were not subjected to a double shock (2-two hour heat shocks at 33°C separated by a two-hour recovery) hatch out as malformed worms reminiscent of the muscle overexpression lines (Fig 21). The heat shock promoter used is especially active in the pharynx. Consistent with this, a strong pharyngeal morphogenetic phenotype was observed (Fig 21). Pharyngeal phenotypes are easy to score and quantify (feeding rate, dye uptake, LacZ lines staining the pharynx) by anyone skilled in the C. elegans field and may form a preferred embodiment of the assay.

Example 7

Over-expression of UNC-53 results in directional over-extension : Assay with 7A variant.

In wild type *C. elegans*, body muscle cells are normally spindle shaped while in UNC53 mutants, a number of these cells have a reduced process which results in a fork shaped tip. This phenotype is consistent with the general reduction of extension observed in many growth cone types along the longitudinal axis of the animal in unc-53 mutants. Recalling the extremely limited pattern of UNC53 expression in embryogenesis detected by immunostaining with monoclonal antibody 16-48-2;no UNC53 activity was

discernable in wild type body muscle cells during outgrowth suggesting that the levels of UNC53 activity required for this extension may be extremely low.

We overexpressed unc-53 in the muscle of wild type animals by expressing the full length cDNA under the control of the unc-54 myosin heavy chain promoter in the fusion pTB113. Plasmid pTB113 is a translational fusion containing the 7A variant unc-53 cDNA sequence as an XbaI-KpnI fragment starting from the first methionine and including the unc-53 cDNA poly adenylation tail under control of the myosin heavy chain unc-54 promoter of the nematode expression vector pPD30.38 available on Internet web site ftp archive: ciwl, ciwemb.edu. Plasmid pTB114 contains the identical cDNA fragment under control of the hsp16-41 *-2* promoter (Jones et al.,1995, Dev. Biol. VOL. 171, PAGES 60-72) which confers heat inducible expression to somatic cells, in the expression vector pPD 49.83 (Fire, pers. comm.) The amino terminus of the UNC53 cDNA is identical to the PCR amplification with BG01 and BG02 of pTB57. Thus, both pTB113 and pTB114 are in frame translational fusions devoid of the SL1 leader sequence and upstream untranslated region of the cDNA.

Each transgenic mosaic line (3 were examined) consisted of wild type and rolling animals as expected, but in addition, several mutant phenotypes were observed at a low frequency. These animals varied considerably in phenotype and included, embryos which arrested at the two fold stage, larvae which hatched but died soon afterwards, animals with extra protrusions on the epidermis and animals with a truncated posterior end. Most of these latter animals

were either inviable or sterile. The progeny of the viable mutants contained the same frequency of rollers, wild type and mutants as did the progeny of rolling individuals. Since the extrachromosomal array may be lost at each cell division, every animal is a mosaic. The healthy rollers may have lost the transgene from most muscle cells and may represent weak phenotypes whereas the 2 fold arrests represent the situation where the array has been retained in most muscle cells. The truncated posterior end may be the result of lethality in the D lineage due to mosaicism. Nomarski and polarized light microscopy of the severe larval lethals showed that the muscle cells were disorganized and over-extended in the longitudinal axis. In some cases the muscle cells appeared detached from the hypodermis. As these animals are mosaic, it may be possible that severe cases die early in morphogenesis whereas those which survive through embryogenesis to adulthood can tolerate a few distorted muscle cells.

In transgenic pTB113 strains, UNC53 expression, as detected by immunostaining with monoclonal antibody 16-48-2, was localized to the body muscle cells in comma and later stages as predicted for the UNC-53 promoter (myosin heavy chain). The pattern of immunofluoresence with the anti UNC-53 antibody was localized to the cytoplasm of the cell bodies and was particularly intense at the tips of the extending processes and in the cytoskeleton, when compared to phalloidin staining which specifically stains the actin cytoskeleton. The identical pattern of sub-cellular localization, in the cytoplasm and cytoskeleton, was also observed in the intestinal

cells of pTB114 transgenic embryos expressing UNC-53 ectopically after heat shock.

In addition, the growth cone processes appeared to be overextended specifically in the anterior-posterior axis of the animal. To verify this, the length of body muscle cells over-expressing the UNC53 cDNA in the pTB113 strains were measured and compared to the length of wild-type muscle growth cones expressing an unc-54 promoter-GFP (green fluorescent protein) fusion, pPD49.83 (available on Internet Web Ste Ftp archive: ciwl. ciwemb.edu. The GFP reporter allowed visualization of the entire cell body and boundaries of the muscle cells in wild-type animals. We estimated that the processes of the pTB113 expressing cells were roughly 1½ times the length of pPD49.83 expressing wild type cells.

The lethality in the transgenic progeny of the three pTB113 strains examined ranged from 32% to 78%. Thus a significant proportion of the transformed mosaic progeny did not survive morphogenesis. In contrast, no lethality was observed in the pPD93.48 (unc-54-GFP) control strains. The lethality observed in the pTB113 lines is likely the consequence of overextension of muscle cells during embryogenesis because (a) both pTB113 and pPD93.48 utilize the identical promoter and should be expressed in the same cells at the same point in development, and (b) rol-6 selection was used to identify transformants for both constructs.

Example 8

Transient and stable transfection of UNC-53 in N4 neuroblastoma cells.

pTB72 and a plasmid expressing LacZ under the CMV promoter were transfect d transiently with the Ca-phosphate method in N4 neuroblastoma cells.

N4 cells and their stably transfected counterparts were grown in Minimum Essential Medium (MEM)-REGA 3 (GIBCO BRL) supplemented with 10% Foetal Calf Serum, 1% L-Glutamine, 2% Sodium Bicarbonate, 200 units/ml penicilline and 200 μg/ml Streptomycine, in a humidified atmosphere of 90% air and 10% CO_2 at 37ºC. Transfections were performed by the Lipofectamine method (GIBCO BRL). 18 to 24 hrs before transfection cells were seeded in complete growth medium at a density of $7x10^5$ per well in a six well tissue culture plate, and incubated at 37º C in a CO_2 incubator. For each transfection the following solutions were prepared.:

SolA = 4 μg of DNA diluted in 200 ul of Optimem (GIBCO BRL)

SolB = 12 ul of Lipofectamine reagent diluted in 200 ul of Optimem (GIBCO BRL)

Solutions A and B were combined, gently mixed and incubated at room temperature for 30 minutes. For each transfection 0.6 ml of Optimem was added to the lipid-DNA complex to reach the final volume of 1 ml. This mixture was then added onto the cells (which had been previously rinsed once with 2 ml of Optimem). The cells were incubated in the transfection mixture for 5 hrs at 37C in a CO2 incubator. At the beginning of the sixth hour from transfection, 1 ml of complete growth medium supplemented with 20% of Foetal calf serum was added to the transfected cells. The cells were incubated for 18 hrs at 37C in a CO2 incubator. 24 hrs following the beginning of transfection the supernatans was replaced with fresh growth medium. 72hrs post transfection cell cultures from each well were harvested, diluted 1:24 and distributed over 24

well plates with the growth medium containing 500, 750 ug/ml or 1mg/ml of geneticin (G418, GIBCO BRL). After ~12 days from the start of selection, single clones were picked and allowed to grow in the absence of selection. Of 27 initial clones, 7 were lost while expanding the clones because of their slow growth rate and the apparent general toxicity of caused by the transfected construct. Clone 9 was selected for further analysis.

Functional assay for neurite extension in N4 neuroblastoma

Step (1): Quantitative determination of neuronal morphology, i.e. length of neurites and fraction of positive cells is performed fully automatically. As an example we studied the degree of morphological differentiation in the wild-type N4 cells to a stably transfected C9 clone.

Step (2): Quantitative neuronal morphology

Morphological changes of neurones were quantitated as described in GEERTS et al (1992 Restorative Neurology and Neuroscience 4: 21-32 and Katsuhito *et al* Neurodegeration, 2: 173-181). Briefly, at appropriate times, glutaraldehyde was applied to cell cultures. No washing steps were performed. This ensured that the morphology of the cells at that time point was frozen. The cells were observed in transmitted light mode on an Axiovert microscope, equipped with a Marzhauser scanning stage driven by an Indy workstation (Silicon graphics). Images were captured using a MC5 video camera (HCS). About 3000 cells were detected in 64 neatly aligned images, forming a 8x8 square matrix of images. The exact alignment of the images ensured that neurites

could b followed from one image field to the next. The analysis software automatically detected cell bodies and neurites and saved cell body size and length of each individual neurite on a file. Different parameters were subsequently calculated. The neurite length per cell was calculated on freely lying cells (not within a cluster). The fraction positive cells is the fraction of cells having at least one neurite with a length exceeding twice the cell body diameter. Figure 40 clearly shows that clone C9 increases both neurite length (free length) and fraction of positive cells, compared to wild-type N4 cells clone.

Example 9

Transient and stable transfection of UNC-53 in MCF-7 breast carcinoma cells.

pTB72 and a plasmid expressing Lac Z under the CMV promoter where transfected transiently with the Ca-phosphate method in MCF-7 breast carcinoma cells.

MCF7 cells and their stably transfected counterparts were grown in Dulbecco's Modified Eagle's Medium (DMEM, GIBCO BRL) supplemented with 10% foetal Calf Serum, 1% L-Glutamine, 1% of a 5mg/ml stock of Gentamicine and 1% of a 100mM stock of Sodium Pyruvate in an humidified atmosphere of 90% air and 10% CO2 at 37 C. Construct pTB72 was transfected by the Calcium-phosphate method (ref): 18-24hrs before transfection. cells were seeded at a density of $3x10^5$ in a six well tissue culture plate with complete growth medium. Two hours before transfection the culture medium was removed and replaced with 1.8 ml of fresh medium. The cells were put back in the incubator until the moment of transfection. DNA-$Ca_3(PO4)_2$ precipitates were prepared one hour before transfection : For each transfection (1 well): 4 ug of DNA (=3-4 ul) was

combined with 76 ul of TE (Tris HCl-EDTA pH 8) 0.1M to a final volume of 80 ul. To th se DNA's diluted in TE, 20 ul of $CaCl_2$ Hepes solution was added to a final volume of 100 ul of DNA/$CaCl_2$ mixture. The 100 ul of DNA/$CaCl_2$ mixture was added very slowly, drop-by-drop to 100ul of 2x BS/Hepes while shaking, to a final volume of 200 ul. The resulting 200 ul DNA/Calcium Phosphate mixture was added to the cells and the mixture incubated for 8 hrs at 37 C in a CO_2 incubator. At the beginning of the ninth hour from the start of transfection, the supernatans with the DNA/Calcium phosphate mixture was replaced with 3 ml of complete culture medium. 72hrs post transfection, cells from each well were harvested, split1:24 in complete growth medium supplemented with 1mg/ml of Geneticin (G418, GIBCO-BRL) and plated out in 24 well plates. 15 days from the start of selection, single clones where picked and allowed to grow without selection. Three clones MCF7-pTB72-clone9, MCF7-pTB72-14 and MCF7-pTB72-15 were retained all of which have a similar phenotype.

1) Phenotyping UNC-53 transfected MCF-7 breast carcinoma cells:

The general morphology and motile behaviour of the three transfected MCF-7 clones are different from non-transfected cells.

The assay consists of a tyramide amplification of a classical immunofluorescent reaction. The cells were grown in defined medium with 10% charcoal treated serum and supplemented by 10 µg/ml insulin (final concentration) and 5 ng/ml basic fibroblast growth factor (final concentration). The substrate consisted of 50 µg/ml poly-L-lysine in chamber slides; cultures were maintained in a humidified atmosphere of 95/5% air/CO_2.

Inductin of expression of vimentin and f increased levels of fosfotyrosine was found in the transfected subclones. Vimentin formed dense clusters around the cell nucleus with some filamentous structures in the pseudo-podes. Fosfotyrosine, on the other hand, was predominantly found at the border of the cell ruffles, at the same subcellular area where UNC53 expression was found. This provides evidence of a controlling molecule functioning in a signal transduction pathway and that vimentin is an indicator of metastasis in cancerous cell lines.

2) Functional assay to establish the signal transduction role of UNC-53.

Cells locomote in tissues and on substrates. The type and amount of cell locomotion depends on different factors: (1) the physiological conditions perceived through receptors, which can be - for example - stimulation with or deprivation of serum, growth factor(s), cytokine(s), chemokine(s) or (pro-) inflammatory mediators; (2) the type and functionality of cell adhesion molecules expressed by cells and extracellular matrix molecules present in tissue or in culture model, (3) the actin, tubulin and/or intermediate filament cytoskeleton and (4) proper functioning of integrator proteins such as UNC-53, homologues or other molecules that translate physiological stimuli (or lack of stimuli) into increased or decreased cell motility, directional or random motility or different types of motility. Cell locomotion can be measured in different types of assays, such as disperse cells or in monolayer cultures, as cellular outgrowth from tissues in culture or in organotype cultures. Motility of live cells can be quantified microscopically as in example 8 or by time-lapse video or cinematography or by

phagokinetic assays (Albrecht-Buehler, 1977, Cell, 11:395) amongst other methods.

Cell motility assays are interesting tools to study the functioning and pharmacology of UNC-53 and the unc-53 pathway.

All previous observations were performed on MCF-7 cells grown in defined medium supplemented by 10 µg/ml insulin (final concentration) and 5ng/ml basic fibroblast growth factor (final concentration). This approach offers the possibility of investigating the role of FGF in the UNC53 role of signal transmission. Indeed, by comparing wild-type versus UNC53 transfected cells cultured in medium with or without FGF/insulin and/or by microinjection of UNC53 protein, it can be investigated if UNC53 is responsible directly for regulating a signal transduction pathway linking extracellular growth factors to the assembly of, amongst others, focal adhesions.

Example 10: Enhanced phagokinesis in Ce-unc-53 transfected MCF-7 cells.

In this example evidence is presented that transfection of a plasmid containing the Ce-unc-53 sequence under a suitable promoter enhances cell motility in the phagokinesis assay.

When culture plastics are coated with colloidal gold particles, a variety of cells types were shown to migrate over the plate and displace or phagocytose the gold lawn on their way while locomoting. The track left bare is a qualitative and quantitative measure of cell motility and/or locomotion. The basic methods have been described in detail elsewhere (Albrecht-Buehler, 1977, Cell, 11:395; Zetter, 1980, Nature, 285:41; O'Keefe et al., 1983, J. Invest. Dermatol., 85:130).

Methods

12 well plat s were coated for 15 minutes with 5 μg/ml gelatin in water and gold coated as described by Albrecht-Bueller (1977). Ce-unc-53 transfected MCF-7 cells and the parent MCF-7 were cultured in parallel, trypsinised dispersed in culture medium and seeded in 12-well plates at a density of 2550 cells per well. The cells were allowed to adhere to the plate and to locomote for 16 hours. After incubation the cells were chemically fixed to the plate using paraformaldehyde, washed with distilled water and finally air-dried.

Subsequently, images of the gold lawns were captured using automated videomicroscopy, composite images of the wells were generated and single-cell phagokinetic tracks were measured using a home-made routine in SCIL™ software.

Results

The parent MCF-7 line displayed two cell populations with different motile behaviour in phagokinesis assays. In table 3 the fraction of parent and Ce-unc-53 transfected MCF-7 cells that produced linear tracks in the phagokinesis assay are shown. In the parent MCF-7 cells, 88% of the cells produce a round track (long and short axis less than 2-fold different) and 12% cells produce 'linear' tracks (long and short axis more than 2-fold different). Ce-unc-53 transfection of MCF-7 cells produced an increase of the fraction of cells displaying 'linear' tracks to 28% at the cost of the cells producing round tracks.

These observation suggest that Ce-unc-53 transfection into MCF-7 is capable of increasing *in situ* locomotion of MCF-7 e.g. by increased spreading, ruffling or other forms of non-directional motility in

the 'round' population as well as by driving a fraction of transfect d MCF-7 cells from non-directional motility (round tracks) into directional migration (linear tracks).

In tissue culture, cells are provided with non-directional signals. It is likely that providing directionality to these signals will enhance observed effects. Significant enhancement was observed for the fraction of linear tracks.

In addition, a significant increase of 35% in the area of tracks was observed in the Ce-unc-53 transfected MCF-7 cells versus the parent MCF-7 cells (Table 3). This increase occurred in the round track population; the area of linear tracks was found not to be changed by transfection.

These obsevations in phagokinesis suggest that Ce-unc-53 transfection into MCF-7 cells is capable of increasing insitu locomotion in Ce-unc-53 MCF-7, e.g. by increasing spreading, ruffling, or other forms of non-directional motility in the "round" population. In addition the Ce-unc-53 transgene in MCF-7 cells drives a fraction of the MCF-7 cells from non-directional motility (round tracks) into directional migration (linear tracks).

Table 3. Analysis of phagokinesis assays with parent and *Ce-unc-53* transfected MCF-7 cells.

	parent MCF-7		*Ce-unc-53 MCF-7*		*increase*
Fraction linear tracks (*)	*% +- SD(n)* 12+-3 (8)		*%+-SD(n)* 28+-6 (8)		2.33
Track area (**)	*pixels+-SD(n)*		*picels+-SD (n)*		
all tracks	1261+-128(8)		1698+-179(8)		1.35
round tracks	1229+-162(8)		1464+-204(8)		1.19
linear tracks	2367+-424(8)		2300+-319(8)		0.97

(*) the fraction of linear tracks in 8 wells was pooled.

MCF-7 cells expressing low levels of UNC-53 exhibit increased motility.

Individual transfected cells are much more flattened in appearance than wild type and have a broad lamellipodium extending from the edge of the cell. Ruffling edges are more frequent than in wild type. Transfected cells in clusters have a broad lamellipodium edge around the cluster while cluster of the non-transfected. Within the cluster the nuclei are more widely spaced from one-another than in wild type cells (also due to a lamellipodium edge).

Example 11

Method for Protein micro-sequencing of co-affinity purifying proteins

UNC-53 protein was immuno-affinity purified from extracts of cells expressing C. elegans UNC-53 using monoclonal antibody 16-48-2. One to five mg of Mab 16-48-2 was prepared, purified on protein-G sepharose and subsequently covalently linked to sepharose beads. A column of such beads was loaded with both crude cytosolic and Triton-X100 extracts (containing solubilised RTKs) and eluted with 4M $MgCl_2$ or other chaotropic agents. A co-immuno-purifying band was identified on SDS-denaturing PAGE gels, eluted from these gels and micro-sequenced. This protein sequence or mass information of peptides generated by proteolysis was used to identify the co-immunoprecipitation directly from the sequence databases.

Alternatively the sequence was reverse translated

and oligonucleotides based on the sequence prepared. This is used to clone the corresponding gene as well as other techniques well known in the art.

Example 12 C. elegans as a model assay system.

We have constructed transgenic strains which overexpress UNC-53 in body muscle. This results in increased extension of muscle cells and embryonic lethality at low frequency. These strains were used to screen for drugs which interfere with UNC-53 activity and thereby suppress the background lethality.

Another related assay was used to screen specifically to identify inhibitors of downstream components in the signal transduction pathway. This assay utilised constitutively active mutant cDNA (or corresponding nucleic acid sequence). Such a mutant may be formed by mutating the nucleotide binding domain such that GTP or ATP is always bound or by covalently attaching SEM-5. In this strategy, transgenics/mutants (nematodes or tissue cultured cell lines) were generated which maintain the pathway in a permanently switched on state. Over-extension and subsequent lethality results in a greater frequency than that observed in the unc-54 - unc-53 wild-type lines. By screening for survivors after drug treatment, this assay specifically identifies inhibitors of downstream components in the signal transduction pathway.

A range of other embodiments of the assay are obvious to a person skilled in the art of C. elegans genetics, including the use of alternative selectable markers, genetic backgrounds, histochemical detection and visual detection systems to identify phenotypic

changes following contacting a single worm or a population of worms with a compound.

Another assay previously described herein utilizes the unc-53 promoter. The unc-53 promoter is fused to a nucleic acid sequence encoding a reporter molecule. By screening for cells which do not express the wild type pattern, molecules which increase or reduce transcription of unc-53 may be identified.

Example 13 - Heterologous expression of *C. elegans* UNC-53 in insect cells.

C. elegans UNC53 cDNAs have been expressed in a Baculovirus system to obtain sufficient amounts of protein for biochemical and structural studies.

Two UNC53 cDNA clones (UNC53(7A) and UNC53(8A) have been documented differing in the number of adenosine (A) residues (7 or 8) in a polyA stretch of the of the 3′ coding region; the two clones therefore have different reading frames in the carboxyterminal coding region.

The 5′ (N-terminal) part of the UNC53 coding region was excised from pTB564 with *SacII* after linearizing the plasmid with *NdeI* . The *Ndei* site was blunted with Klenow. The remaining C-terminal part of the coding region was excised from pTB68(7A) and pTB50(8A) with *SacII* plus *KpnI*. The *NdeI/SacII* fragment from pTB64 and the *SacII/KpnI* fragment from either pTB68 or pTB50 were ligated simultaneously into pBacPAK9 (Clontech) which had been linearized with *Ecl136II* (blunt end) and *KpnI*. In this way, a minimum amount of 5′ untranslated region is left in the final construct.

The desired recombinant viruses were obtained by

co-transfection of *Sf*21 cells (*Spodoptera frugiperda*) with one of the aforementioned pBacPAK9 constructs and BacPAK6 *Bsu*361-digested DNA (Clontech). Several candidate recombinant viruses plaques were picked and screened by PCR for the presence of the target gene and the absence of wild-type virus.

*Sf*9 cells were infected at a high multiplicity with UNC53(7A) or UNC53(8A) recombinant Baculoviruses for protein expression. Proteins from whole cell lysates were separated by denaturing (SDS) polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. The expression of UNC53 in those cell lysates was confirmed by immunoreaction with a monoclonal antibody (16-49-2) to UNC53 and subsequent chemiluminescent detection (ECL™ Amersham). A Coomassie-stained band of the expected size was observed in lysates of *Sf*9 cells infected with UNC-53(7A) or UNC53(8A) recombinant baculoviruses, but not with control constructs. Within the accuracy of the methods, this Coomassie-stained band coincided with the largest immunoreactive band. Their estimated mass was approximately 180 kDa, which is compatible with the theoretically calculated mass (167 kDa). We therefore conclude that this band most likely corresponds to intact UNC53.

For both UNC53(7A) and UNC53(8A) baculoviral expression constructs, mostly intact recombinant UNC53-protein was detected by immunoblotting in lysates from infected cells harvested 24 hours post infection. Larger amounts of recombinant protein could be detected in lysates from cells prepared during later stages of infection (48 and 72 hours post infection) but in those preparations a considerable amount of smaller fragments (presumptive degradation products) is observed.

Example 14

The UNC-53 protein expressed in Sf9 cells using a Baculovirus expression system is a valid tool to study its biochemical functions and a valid tool to identify interacting proteins.

3x10+6 SF9 cells infected with recombinant virus UNC53 7A(L2.3)/pBacPAK9 were resuspended in 100 microliter Phosphate Buffered Saline supplemented with 0.14 micromolar of pepstatin, 10 mM of benzamidine and 0.015 micromolar aprotinin. The cells were briefly sonicated and the obtained material was centrifuged at 30,000 g for 30 minutes at 4 degrees centrigade. The clear supernatant (soluble fraction) was frozen in 50% glycerol. An aliquot of this fraction was incubated in the cold room for 48 hrs. The protein samples were analyzed by SDS-PAGE, blotted to nitrocellulose and probed with mab 16-48-2. This showed that UNC-53 protein made in SF9 cells is soluble and stable under the conditions tested.

20 microlitres of the UNC-53 SF9 lysate were incubated with 5 microlitre GST-Sepharose beads loaded with equal amouts (approx. 10 microgram) of GST-GRB-2 or GST alone. The beads were rinsed 3 times in 500 microlitres of solution PBS-0.2% Tween 20 and eluted with 50 microliter SDS sample buffer. The eluted material was analyzed by SDS-PAGE and Western blot analysis with mab 16-48-2. UNC-53 was retained on the GST-GRB2 column and not on the GST demonstrating that UNC-53 interacts *in vitro* with GRB-2.

Example 15

Identification of proteins interacting with UNC-53 :

Vectors pCB50 and pCB51 were constructed as bait vectors for the yeast two hybrid system expressing resp. the full length and the carboxyterminal part of UNC-53.

pCB50 was constructed by cloning the full length UNC-53 cDNA (7A variant; *NdeI-NcoI* fragment from pTB74) into pAS1-CYH2 vector from Clontech. (Figure 30).

pCB51 (Figure 32) was constructed by cloning the 1880 bp *NdeI-NcoI* fragment from pTB74 into vector pAS1-CYH2 from Clontech. This protein encodes among others, the GTP/ATP binding domains, a leucine zipper domain, and an additional coiled-coil domain.

pCB50 and pCB51 were transformed in yeast strain Hf7C (YRG2). Expression was confirmed by western blotting using antibodies to the GAL4 protein fused to UNC-53 in these constructs. Bands of expected size (190 kd for pCB50 and 90 kd for pcB51) were observed both in yeast strains with pCB50 and pCB51 indicating that both fusion proteins are expressed in the yeast. The expression of the pCB50 and pCB51 fusion proteins in yeast strain Hf7C does not lead to expression of the LacZ or HIS reporter genes. These experiments demonstrate that the constructed fusions are useful baits in yeast two hybrid screens.

Vector pCB55 was made by cloning the 984 bp *BamHI-BglII* of pTB74 construct into the yeast two

hybrid activation vector (pGAD-424 vector from Clontech) (Figure 34). In order to check the possible interactions of UNC-53 either with itself (homodimerization) or other proteins.

This vector expresses a Gal-4 activation domain fused to amongst others the predicted coiled coil or leucine zipper domain of UNC-53.

The following combinations of plasmids were co-transformed in yeast strain HF7C : (1) pCB51 and pCB55 (2) pCB55 with control plasmid- pTD1 and (3) positive control plasmids pTD1 and PVA3 (two proteins known to interact (Bartel,P.L et al., Biotechniques Vol. 14 nr.6 (1993)). Yeast cotransformed with combination (1) and (3) grew well on -LEU;-TRYP plates and -LEU;-TRYP;-HIS plates indicating that an interacting protein is present in both co-transformations. Only yeast co-transformed with (3) was positive in a lacZ assay indicating that the observed interaction in (1) (between pCB50 and pCB 55) is weak.For co-transformation (2), colonies grew on -LEU;-TRYP plates and as expected not on -LEU;-TRYP;-HIS plates. The positive control were thus positive whereas the negative controls were negative. We conclude that there is a weak but significant interaction between pCB51 and pCB55, which is strong enough to activate the HIS but not the lacZ reporter gene in this Hf7c strain.

Example 16

Protocol to screen for components which inhibit or enhance UNC-53 using C. elegans cell line pTBIn76

Embryos from large liquid C. elegans cultures of line pTBIn76 (table 1) are collected by sucrose flotation of a bleached population (Goh and Bogaert (1991), Dev. Biol. 56, 110-156). Embryos are dispensed in 96 well microtiter plates with M9 medium and various concentrations of the compound to be tested. The embryos are allowed to hatch and are synchronised in the L1 stage by starvation. After a suitable exposure to the compound (by standard calibration) a standard quantity of E. coli (food) is dispersed in the 96 well plates, which starts C. elegans post-embryonic development. The microtiter plates are then placed in an incubator to induce heat shock and subsequently placed at 25°C to permit continued development. After 0 to 1 generations of C. elegans development wells are inspected to assess the degree of population growth inhibition. This inspection can consist of an optical density measurement to assess the amount of food consumed by the developing nematodes. Very little food is consumed when no test compound is present: most food is consumed if an UNC-53 inhibitor has blocked the lethal or subviable phenotype induced by the transgene. The inspection can also be a visual inspection of the number of healthy or subviable worms or a histochemical measurement of C. elegans viability or of the remainder of E. coli (food).

Example 17 - Protocol to screen for compounds which inhibit or enhance cell regulation or motility.

Transfected cells used in this example were the same as those obtained from example 8. Compounds to be tested were added to each of the cells and their effects on the cells monitored. Functional assays to determine neurite extension were also the same as used

in example 8 as described by Geests *et al*. One compound (of the Formula I below) was used for further testing.

Example 18 - Compounds targetted at the unc-53 pathway.

Snythesis of (1-(1H-pyrrol-2-ylmethyl)-2-piperidone.



Step 1

To a stirred solution of 150g of 1H-pyrrol-2-carboxaldehyde in 1500g parts of trichloromethane were added 690, of 5Å molecular Sieves. A kit solution of 264, of methyl 5-aminopentanoate hydrochloride in 1500g of tricholoromethane was added. After stirring for 5 minutes, 465g of thiethylamine were added over 10 minutes. Upon complete addition, the reaction mixture was stirred for 20 hours at ambient temperature. The mixture was filtered over diatomaceous earth and the filtrate was concentrated by evaporation of the solvent. The concentrate was triturated in 1,1'-oxybisethane. The precipitate was filtered off and the filtrate was concentrated, yielding 300g (91.1%) of 5-[[(1H-pyrrol-2-

Step 2

A mixture of 150g of 5-[[(1H-pyrrol-2-yl)methylen]amino]pentanoate hydrogenated at 3.10^5Pa and at ambient temperature with 3.3 parts of platinum oxide. After the calculated amount of hydrogen was consumed, the catalyst was filtered off and the filtrate was evaporated. The residue was dissolved in dichloromethane and the organic phase was washed three times with a sodium hydroxide 3 N solution. The product was distilled at 13.30 Pa (bp 100-130ºC). The residue was crystallized from cyclohexane and hexane. The product was filtered off and dried, yielding 193 parts (100%) of 1-(1H-pyrrol-2-ylmethyl)-2-piperidone. ; mp. 105.8ºC.

The compound (1-(1H-pyrrol-2-ylmethyl)-2-piperidinone) when applied for 24 hours to cultures of both wild-type and transfected N4 (mouse neuroblastoma) cells displays a differential behaviour. There is no effect (or at most a small stimulatory) effect on the wild-type N4 cells, up to concentrations of 1 μM, the compound clearly becomes toxic for both types of cells. The results indicate that this compound conteracts the effects of overexpression of UNC-53 and may have beneficial effects therefore in for example metastasis.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:
(A) NAME: BOGAERT; THIERRY
(B) STREET: Voorstraat 36 bus 11
(C) CITY: Kortrijk
(E) COUNTRY: Belgium
(F) POSTAL CODE (ZIP): B-8500

(A) NAME: STRINGHAM; EVE
(B) STREET: 9326-133 A Street
(C) CITY: Surrey
(D) STATE: British Columbia
(E) COUNTRY: Canada
(F) POSTAL CODE (ZIP): V3V 5R5

(A) NAME: VANDEKERCKHOVE; JOEL
(B) STREET: Rode Benkendreef 27
(C) CITY: Loppem
(D) STATE: -
(E) COUNTRY: Belgium
(F) POSTAL CODE (ZIP): none

(ii) TITLE OF INVENTION: Processes for the identification of compounds which control cell behaviour, the compounds identified and pharmaceutical compositions containing them and their use in the control of cell behaviour

(iii) NUMBER OF SEQUENCES: 48

(iv) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

(v) CURRENT APPLICATION DATA:
APPLICATION NUMBER: EP PCT/EP96/02311
(vi) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: GB 9510944.3
(B) FILING DATE: 31-MAY-1995

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5073 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Caenorhabditis elegans

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

GGTTTAATTA CCCAAGTTTG AGACATCAAT TCCATCGAAC GAAATGTTGG TGCTCCGAAT 60

AAAATGACGA CGTCAAATGT AGAATTGATA CCAATCTACA CGGATTGGGC CAATCGGCAC 120

CTTTCGAAGG GCAGCTTATC AAAGTCGATT AGGGATATTT CCAATGATTT TCGCGACTAT 180

CGACTGGTTT CTCAGCTTAT TAATGTGATC GTTCCGATCA ACGAATTCTC GCCTGCATTC 240

ACGAAACGTT TGGCAAAAAT CACATCGAAC CTGGATGGCC TCGAAACGTG TCTCGACTAC 300

CTGAAAAATC TGGGTCTCGA CTGCTCGAAA CTCACCAAAA CCGATATCGA CAGCGGAAAC 360

TTGGGTGCAG TTCTCCAGCT GCTCTTCCTG CTCTCCACCT ACAAGCAGAA GCTTCGGCAA 420

CTGAAAAAAG ATCAGAAGAA ATTGGAGCAA CTACCCACAT CCATTATGCC ACCCGCGGTT 480

TCTAAATTAC CCTCGCCACG TGTCGCCACG TCAGCAACCG CTTCAGCAAC TAACCCAAAT 540

TCCAACTTTC CACAAATGTC AACATCCAGG CTTCAGACTC CACAGTCAAG AATATCGAAA 600

ATTGATTCAT CAAAGATTGG TATCAAGCCA AAGACGTCTG GACTTAAACC ACCCTCATCA 660

TCAACCACTT CATCAAATAA TACAAATTCA TTCCGTCCGT CGAGCCGTTC GAGTGGCAAT 720

AATAATGTTG GCTCGACGAT ATCCACATCT GCGAAGAGCT TAGAATCATC ATCAACGTAC 780

AGCTCTATTT CGAATCTAAA CCGACCTACC TCCCAACTCC AAAAACCTTC TAGACCACAA 840

ACCCAGCTAG TTCGTGTTGC TACAACTACA AAAATCGGAA GCTCAAAGCT AGCCGCTCCG 900

AAAGCCGTGA GCACCCCAAA ACTTGCTTCT GTGAAGACTA TTGGAGCAAA ACAAGAGCCC 960

GATAACAGCG GTGGTGGTGG TGGTGGAATG CTGAAATTAA AGTTATTCAG TAGCAAAAAC 1020

CCATCTTCCT CATCGAATAG CCCACAACCT ACGAGAAAGG CGGCGGCGGT GCCTCAACAA 1080

CAAACTTTGT CGAAAATCGC TGCCCCAGTG AAAAGTGGCC TGAAGCCGCC GACCAGTAAG 1140

CTGGGAAGTG CCACGTCTAT GTCGAAGCTT TGTACGCCAA AAGTTTCCTA CCGTAAAACG 1200

GACGCCCCAA TCATATCTCA ACAAGACTCG AAACGATGCT CAAAGAGCAG TGAAGAAGAG 1260

TCCGGATACG CTGGATTCAA CAGCACGTCG CCAACGTCAT CATCGACGGA AGGTTCCCTA 1320

AGCATGCATT CCACATCTTC CAAGAGTTCA ACGTCAGACG AAAAGTCTCC GTCATCAGAC 1380

GATCTTACTC TTAACGCCTC CATCGTGACA GCTATCAGAC AGCCGATAGC CGCAACACCG 1440

GTTTCTCCAA ATATTATCAA CAAGCCTGTT GAGGAAAAAC CAACACTGGC AGTGAAAGGA 1500

GTGAAAAGCA CAGCGAAAAA AGATCCACCT CCAGCTGTTC CGCCACGTGA CACCCAGCCA 1560

ACAATCGGAG TTGTTAGTCC AATTATGGCA CATAAGAAGT TGACAAATGA CCCCGTGATA 1620

TCTGAAAAAC CAGAACCTGA AAAGCTCCAA TCAATGAGCA TCGACACGAC GGACGTTCCA 1680

CCGCTTCCAC CTCTAAAATC AGTTGTTCCA CTTAAAATGA CTTCAATCCG ACAACCACCA 1740

ACGTACGATG TTCTTCTAAA ACAAGGAAAA ATCACATCGC CTGTCAAGTC GTTTGGATAT 1800

GAGCAGTCGT CCGCGTCTGA AGACTCCATT GTGGCTCATG CGTCGGCTCA GGTGACTCCG 1860

CCGACAAAAA CTTCTGGTAA TCATTCGCTG GAGAGAAGGA TGGGAAAGAA TAAGACATCA 1920

GAATCCAGCG GCTACACCTC TGACGCCGGT GTTGCGATGT GCGCCAAAAT GAGGGAGAAG 1980

CTGAAAGAAT ACGATGACAT GACTCGTCGA GCACAGAACG GCTATCCTGA CAACTTCGAA 2040

GACAGTTCCT CCTTGTCGTC TGGAATATCC GATAACAACG AGCTCGACGA CATATCCACG 2100

GACGATTTGT CCGGAGTAGA CATGGCAACA GTCGCCTCCA AACATAGCGA CTATTCCCAC 2160

TTTGTTCGCC ATCCCACGTC TTCTTCCTCA AAGCCCCGAG TCCCCAGTCG GTCCTCCACA 2220

TCAGTCGATT CTCGATCTCG AGCAGAACAG GAGAATGTGT ACAAACTTCT GTCCCAGTGC 2280

CGAACGAGCC AACGTGGCGC CGCTGCCACC TCAACCTTCG GACAACATTC GCTAAGATCC 2340

CCGGGATACT CATCCTATTC TCCACACTTA TCAGTGTCAG CTGATAAGGA CACAATGTCT 2400

ATGCACTCAC AGACTAGTCG ACGACCTTCT TCACAAAAAC CAAGCTATTC AGGCCAATTT 2460

CATTCACTTG ATCGTAAATG CCACCTTCAA GAGTTCACAT CCACCGAGCA CAGAATGGCG 2520

GCTCTCTTGA GCCCGAGACG GGTGCCGAAC TCGATGTCGA AATATGATTC TTCAGGATCC 2580

TACTCGGCGC GTTCCCGAGG TGGAAGCTCT ACTGGTATCT ATGGAGAGAC GTTCCAACTG 2640

CACAGACTAT CCGATGAAAA ATCCCCCGCA CATTCTGCCA AAAGTGAGAT GGGATCCCAA 2700

CTATCACTGG CTAGCACGAC AGCATATGGA TCTCTCAATG AGAAGTACGA ACATGCTATT 2760

CGGGACATGG CACGTGACTT GGAGTGTTAC AAGAACACTG TCGACTCACT AACCAAGAAA 2820

CAGGAGAACT ATGGAGCATT GTTTGATCTT TTTGAGCAAA AGCTTAGAAA ACTCACTCAA 2880

CACATTGATC GATCCAACTT GAAGCCTGAA GAGGCAATAC GATTCAGGCA GGACATTGCT 2940

CATTTGAGGG ATATTAGCAA TCATCTTGCA TCCAACTCAG CTCATGCTAA CGAAGGCGCT 3000

GGTGAGCTTC TTCGTCAACC ATCTCTGGAA TCAGTTGCAT CCCATCGATC ATCGATGTCA 3060

TCGTCGTCGA AAAGCAGCAA GCAGGAGAAG ATCAGCTTGA GCTCGTTTGG CAAGAACAAG 3120

AAGAGCTGGA TCCGCTCCTC ACTCTCCAAG TTCACCAAGA AGAAGAACAA GAACTACGAC 3180

GAAGCACATA TGCCATCAAT TTCCGGATCT CAAGGAACTC TTGACAACAT TGATGTGATT 3240

GAGTTGAAGC AAGAGCTCAA AGAACGCGAT AGTGCACTTT ACGAAGTCCG CCTTGACAAT 3300

CTGGATCGTG CCCGCGAAGT TGATGTTCTG AGGGAGACAG TGAACAAGTT GAAAACCGAG 3360

AACAAGCAAT TAAAGAAAGA AGTGGACAAA CTCACCAACG GTCCAGCCAC TCGTGCTTCT 3420

TCCCGCGCCT CAATTCCAGT TATCTACGAC GATGAGCATG TCTATGATGC AGCGTGTAGC 3480

AGTACATCAG CTAGTCAATC TTCGAAACGA TCCTCTGGCT GCAACTCAAT CAAGGTTACT 3540

GTAAACGTGG ACATCGCTGG AGAAATCAGT TCGATCGTTA ACCCGGACAA AGAGATAATC 3600

GTAGGATATC TTGCCATGTC AACCAGTCAG TCATGCTGGA AAGACATTGA TGTTTCTATT 3660

CTAGGACTAT TTGAAGTCTA CCTATCCAGA ATTGATGTGG AGCATCAACT TGGAATCGAT 3720

GCTCGTGATT CTATCCTTGG CTATCAAATT GGTGAACTTC GACGCGTCAT TGGAGACTCC 3780

ACAACCATGA TAACCAGCCA TCCAACTGAC ATTCTTACTT CCTCAACTAC AATCCGAATG 3840

TTCATGCACG GTGCCGCACA GAGTCGCGTA GACAGTCTGG TCCTTGATAT GCTTCTTCCA 3900

AAGCAAATGA TTCTCCAACT CGTCAAGTCA ATTTTGACAG AGAGACGTCT GGTGTTAGCT 3960

GGAGCAACTG GAATTGGAAA GAGCAAACTG GCGAAGACCC TGGCTGCTTA TGTATCTATT 4020

CGAACAAATC AATCCGAAGA TAGTATTGTT AATATCAGCA TTCCTGAAAA CAATAAAGAA 4080

GAATTGCTTC AAGTGGAACG ACGCCTGGAA AAGATCTTGA GAAGCAAAGA ATCATGCATC 4140

GTAATTCTAG ATAATATCCC AAAGAATCGA ATTGCATTTG TTGTATCCGT TTTTGCAAAT 4200

GTCCCACTTC AAAACAACGA AGGTCCATTT GTAGTATGCA CAGTCAACCG ATATCAAATC 4260

CCTGAGCTTC AAATTCACCA CAATTTCAAA ATGTCAGTAA TGTCGAATCG TCTCGAAGGA 4320

TTCATCCTAC GTTACCTCCG ACGACGGGCG GTAGAGGATG AGTATCGTCT AACTGTACAG 4380

ATGCCATCAG AGCTCTTCAA AATCATTGAC TTCTTCCCAA TAGCTCTTCA GGCCGTCAAT 4440

AATTTTATTG AGAAAACGAA TTCTGTTGAT GTGACAGTTG GTCCAAGAGC ATGCTTGAAC 4500

TGTCCTCTAA CTGTCGATGG ATCCCGTGAA TGGTTCATTC GATTGTGGAA TGAGAACTTC 4560

ATTCCATATT TGGAACGTGT TGCTAGAGAT GGCAAAAAAA ACCTTCGGTC GCTGCACTTC 4620

CTTCGAGGAT CCCACCGACA TCGTCTCTAA AAAATGGCCG TGGTTCGATG GTGAAAACCC 4680

GGAGAATGTG CTCAAACGTC TTCAACTCCA AGACCTCGTC CCGTCACCTG CCAACTCATC 4740

CCGACAACAC TTCAATCCCC TCGAGTCGTT GATCCAATTG CATGCTACCA AGCATCAGAC 4800

CATCGACAAC ATTTGAACAG AAGACTCTAA TCTTCTCTCG CCTCTCCCCC GCTTTCCTTA 4860

TCTTCGTACC GGTACCTGAT GATTCCCCAT TTTCCCCCTT TTCCCCCCAA TTTCCCAGAA 4920

CCTCCTGTTC CCTTTGTTCC TAGTCCTCCC GGGTGCCGAC GCCGAAGCGA TTTAAAAACC 4980

TTTTTCTTTC CGAAACATTT CCCATTGCTC ATTAATAGTC AAATTGAATA AACAGTGTAT 5040

GTACTTAAAA AAAAAAAAAA AAAAAAAAAA AAA 5073

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5072 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

GGTTTAATTA CCCAAGTTTG AGACATCAAT TCCATCGAAC GAAATGTTGG TGCTCCGAAT 60

AAAATGACGA CGTCAAATGT AGAATTGATA CCAATCTACA CGGATTGGGC CAATCGGCAC 120

CTTTCGAAGG GCAGCTTATC AAAGTCGATT AGGGATATTT CCAATGATTT TCGCGACTAT 180

CGACTGGTTT CTCAGCTTAT TAATGTGATC GTTCCGATCA ACGAATTCTC GCCTGCATTC 240

ACGAAACGTT TGGCAAAAAT CACATCGAAC CTGGATGGCC TCGAAACGTG TCTCGACTAC 300

CTGAAAAATC TGGGTCTCGA CTGCTCGAAA CTCACCAAAA CCGATATCGA CAGCGGAAAC 360

TTGGGTGCAG TTCTCCAGCT GCTCTTCCTG CTCTCCACCT ACAAGCAGAA GCTTCGGCAA 420

CTGAAAAAAG ATCAGAAGAA ATTGGAGCAA CTACCCACAT CCATTATGCC ACCCGCGGTT 480

TCTAAATTAC CCTCGCCACG TGTCGCCACG TCAGCAACCG CTTCAGCAAC TAACCCAAAT 540

TCCAACTTTC CACAAATGTC AACATCCAGG CTTCAGACTC CACAGTCAAG AATATCGAAA 600

ATTGATTCAT CAAAGATTGG TATCAAGCCA AAGACGTCTG GACTTAAACC ACCCTCATCA 660

TCAACCACTT CATCAAATAA TACAAATTCA TTCCGTCCGT CGAGCCGTTC GAGTGGCAAT 720

AATAATGTTG GCTCGACGAT ATCCACATCT GCGAAGAGCT TAGAATCATC ATCAACGTAC 780

AGCTCTATTT CGAATCTAAA CCGACCTACC TCCCAACTCC AAAAACCTTC TAGACCACAA 840

ACCCAGCTAG TTCGTGTTGC TACAACTACA AAAATCGGAA GCTCAAAGCT AGCCGCTCCG 900

AAAGCCGTGA GCACCCCAAA ACTTGCTTCT GTGAAGACTA TTGGAGCAAA ACAAGAGCCC 960

GATAACAGCG GTGGTGGTGG TGGTGGAATG CTGAAATTAA AGTTATTCAG TAGCAAAAAC 1020

CCATCTTCCT CATCGAATAG CCCACAACCT ACGAGAAAGG CGGCGGCGGT GCCTCAACAA 1080

CAAACTTTGT CGAAAATCGC TGCCCCAGTG AAAAGTGGCC TGAAGCCGCC GACCAGTAAG 1140

CTGGGAAGTG CCACGTCTAT GTCGAAGCTT TGTACGCCAA AAGTTTCCTA CCGTAAAACG 1200

GACGCCCCAA TCATATCTCA ACAAGACTCG AAACGATGCT CAAAGAGCAG TGAAGAAGAG 1260

TCCGGATACG CTGGATTCAA CAGCACGTCG CCAACGTCAT CATCGACGGA AGGTTCCCTA 1320

AGCATGCATT CCACATCTTC CAAGAGTTCA ACGTCAGACG AAAAGTCTCC GTCATCAGAC 1380

GATCTTACTC TTAACGCCTC CATCGTGACA GCTATCAGAC AGCCGATAGC CGCAACACCG 1440

GTTTCTCCAA ATATTATCAA CAAGCCTGTT GAGGAAAAAC CAACACTGGC AGTGAAAGGA 1500

GTGAAAAGCA CAGCGAAAAA AGATCCACCT CCAGCTGTTC CGCCACGTGA CACCCAGCCA 1560

ACAATCGGAG TTGTTAGTCC AATTATGGCA CATAAGAAGT TGACAAATGA CCCCGTGATA 1620

TCTGAAAAAC CAGAACCTGA AAAGCTCCAA TCAATGAGCA TCGACACGAC GGACGTTCCA 1680

CCGCTTCCAC CTCTAAAATC AGTTGTTCCA CTTAAAATGA CTTCAATCCG ACAACCACCA 1740

ACGTACGATG TTCTTCTAAA ACAAGGAAAA ATCACATCGC CTGTCAAGTC GTTTGGATAT 1800

GAGCAGTCGT CCGCGTCTGA AGACTCCATT GTGGCTCATG CGTCGGCTCA GGTGACTCCG 1860

CCGACAAAAA CTTCTGGTAA TCATTCGCTG GAGAGAAGGA TGGGAAAGAA TAAGACATCA 1920

GAATCCAGCG GCTACACCTC TGACGCCGGT GTTGCGATGT GCGCCAAAAT GAGGGAGAAG 1980

CTGAAAGAAT ACGATGACAT GACTCGTCGA GCACAGAACG GCTATCCTGA CAACTTCGAA 2040

GACAGTTCCT CCTTGTCGTC TGGAATATCC GATAACAACG AGCTCGACGA CATATCCACG 2100

GACGATTTGT CCGGAGTAGA CATGGCAACA GTCGCCTCCA AACATAGCGA CTATTCCCAC 2160

TTTGTTCGCC ATCCCACGTC TTCTTCCTCA AAGCCCCGAG TCCCCAGTCG GTCCTCCACA 2220

TCAGTCGATT CTCGATCTCG AGCAGAACAG GAGAATGTGT ACAAACTTCT GTCCCAGTGC 2280

CGAACGAGCC AACGTGGCGC CGCTGCCACC TCAACCTTCG GACAACATTC GCTAAGATCC 2340

CCGGGATACT CATCCTATTC TCCACACTTA TCAGTGTCAG CTGATAAGGA CACAATGTCT 2400

ATGCACTCAC AGACTAGTCG ACGACCTTCT TCACAAAAAC CAAGCTATTC AGGCCAATTT 2460

CATTCACTTG ATCGTAAATG CCACCTTCAA GAGTTCACAT CCACCGAGCA CAGAATGGCG 2520

GCTCTCTTGA GCCCGAGACG GGTGCCGAAC TCGATGTCGA AATATGATTC TTCAGGATCC 2580

TACTCGGCGC GTTCCCGAGG TGGAAGCTCT ACTGGTATCT ATGGAGAGAC GTTCCAACTG 2640

CACAGACTAT CCGATGAAAA ATCCCCCGCA CATTCTGCCA AAAGTGAGAT GGGATCCCAA 2700

CTATCACTGG CTAGCACGAC AGCATATGGA TCTCTCAATG AGAAGTACGA ACATGCTATT 2760

CGGGACATGG CACGTGACTT GGAGTGTTAC AAGAACACTG TCGACTCACT AACCAAGAAA 2820

CAGGAGAACT ATGGAGCATT GTTTGATCTT TTTGAGCAAA AGCTTAGAAA ACTCACTCAA 2880

CACATTGATC GATCCAACTT GAAGCCTGAA GAGGCAATAC GATTCAGGCA GGACATTGCT 2940

CATTTGAGGG ATATTAGCAA TCATCTTGCA TCCAACTCAG CTCATGCTAA CGAAGGCGCT 3000

GGTGAGCTTC TTCGTCAACC ATCTCTGGAA TCAGTTGCAT CCCATCGATC ATCGATGTCA 3060

TCGTCGTCGA AAAGCAGCAA GCAGGAGAAG ATCAGCTTGA GCTCGTTTGG CAAGAACAAG 3120

AAGAGCTGGA TCCGCTCCTC ACTCTCCAAG TTCACCAAGA AGAAGAACAA GAACTACGAC 3180

GAAGCACATA TGCCATCAAT TTCCGGATCT CAAGGAACTC TTGACAACAT TGATGTGATT 3240

GAGTTGAAGC AAGAGCTCAA AGAACGCGAT AGTGCACTTT ACGAAGTCCG CCTTGACAAT 3300

CTGGATCGTG CCCGCGAAGT TGATGTTCTG AGGGAGACAG TGAACAAGTT GAAAACCGAG 3360

AACAAGCAAT TAAAGAAAGA AGTGGACAAA CTCACCAACG GTCCAGCCAC TCGTGCTTCT 3420

TCCCGCGCCT CAATTCCAGT TATCTACGAC GATGAGCATG TCTATGATGC AGCGTGTAGC 3480

AGTACATCAG CTAGTCAATC TTCGAAACGA TCCTCTGGCT GCAACTCAAT CAAGGTTACT 3540

GTAAACGTGG ACATCGCTGG AGAAATCAGT TCGATCGTTA ACCCGGACAA AGAGATAATC 3600

GTAGGATATC TTGCCATGTC AACCAGTCAG TCATGCTGGA AAGACATTGA TGTTTCTATT 3660

CTAGGACTAT TTGAAGTCTA CCTATCCAGA ATTGATGTGG AGCATCAACT TGGAATCGAT 3720

GCTCGTGATT CTATCCTTGG CTATCAAATT GGTGAACTTC GACGCGTCAT TGGAGACTCC 3780

ACAACCATGA TAACCAGCCA TCCAACTGAC ATTCTTACTT CCTCAACTAC AATCCGAATG 3840

TTCATGCACG GTGCCGCACA GAGTCGCGTA GACAGTCTGG TCCTTGATAT GCTTCTTCCA 3900

AAGCAAATGA TTCTCCAACT CGTCAAGTCA ATTTTGACAG AGAGACGTCT GGTGTTAGCT 3960

GGAGCAACTG GAATTGGAAA GAGCAAACTG GCGAAGACCC TGGCTGCTTA TGTATCTATT 4020

CGAACAAATC AATCCGAAGA TAGTATTGTT AATATCAGCA TTCCTGAAAA CAATAAAGAA 4080

GAATTGCTTC AAGTGGAACG ACGCCTGGAA AAGATCTTGA GAAGCAAAGA ATCATGCATC 4140

GTAATTCTAG ATAATATCCC AAAGAATCGA ATTGCATTTG TTGTATCCGT TTTTGCAAAT 4200

GTCCCACTTC AAAACAACGA AGGTCCATTT GTAGTATGCA CAGTCAACCG ATATCAAATC 4260

CCTGAGCTTC AAATTCACCA CAATTTCAAA ATGTCAGTAA TGTCGAATCG TCTCGAAGGA 4320

TTCATCCTAC GTTACCTCCG ACGACGGGCG GTAGAGGATG AGTATCGTCT AACTGTACAG 4380

ATGCCATCAG AGCTCTTCAA AATCATTGAC TTCTTCCCAA TAGCTCTTCA GGCCGTCAAT 4440

AATTTTATTG AGAAAACGAA TTCTGTTGAT GTGACAGTTG GTCCAAGAGC ATGCTTGAAC 4500

TGTCCTCTAA CTGTCGATGG ATCCCGTGAA TGGTTCATTC GATTGTGGAA TGAGAACTTC 4560

ATTCCATATT TGGAACGTGT TGCTAGAGAT GGCAAAAAAA CCTTCGGTCG CTGCACTTCC 4620

TTCGAGGATC CCACCGACAT CGTCTCTAAA AAATGGCCGT GGTTCGATGG TGAAAACCCG 4680

GAGAATGTGC TCAAACGTCT TCAACTCCAA GACCTCGTCC CGTCACCTGC CAACTCATCC 4740

CGACAACACT TCAATCCCCT CGAGTCGTTG ATCCAATTGC ATGCTACCAA GCATCAGACC 4800

ATCGACAACA TTTGAACAGA AGACTCTAAT CTTCTCTCGC CTCTCCCCCG CTTTCCTTAT 4860

CTTCGTACCG GTACCTGATG ATTCCCCATT TTCCCCCTTT TCCCCCCAAT TTCCCAGAAC 4920

CTCCTGTTCC CTTTGTTCCT AGTCCTCCCG GGTGCCGACG CCGAAGCGAT TTAAAAACCT 4980

TTTTCTTTCC GAAACATTTC CCATTGCTCA TTAATAGTCA AATTGAATAA ACAGTGTATG 5040

TACTTAAAAA AAAAAAAAAA AAAAAAAAAA AA 5072

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1528 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

Met Thr Thr Ser Asn Val Glu Leu Ile Pro Ile Tyr Thr Asp Trp Ala
1 5 10 15

Asn Arg His Leu Ser Lys Gly Ser Leu Ser Lys Ser Ile Arg Asp Ile
20 25 30

Ser Asn Asp Phe Arg Asp Tyr Arg Leu Val Ser Gln Leu Ile Asn Val
35 40 45

Ile Val Pro Ile Asn Glu Phe Ser Pro Ala Phe Thr Lys Arg Leu Ala
50 55 60

```
Lys Ile Thr Ser Asn Leu Asp Gly Leu Glu Thr Cys Leu Asp Tyr Leu
65                  70                  75                  80

Lys Asn Leu Gly Leu Asp Cys Ser Lys Leu Thr Lys Thr Asp Ile Asp
                85                  90                  95

Ser Gly Asn Leu Gly Ala Val Leu Gln Leu Leu Phe Leu Leu Ser Thr
            100                 105                 110

Tyr Lys Gln Lys Leu Arg Gln Leu Lys Lys Asp Gln Lys Lys Leu Glu
        115                 120                 125

Gln Leu Pro Thr Ser Ile Met Pro Pro Ala Val Ser Lys Leu Pro Ser
    130                 135                 140

Pro Arg Val Ala Thr Ser Ala Thr Ala Ser Ala Thr Asn Pro Asn Ser
145                 150                 155                 160

Asn Phe Pro Gln Met Ser Thr Ser Arg Leu Gln Thr Pro Gln Ser Arg
                165                 170                 175

Ile Ser Lys Ile Asp Ser Ser Lys Ile Gly Ile Lys Pro Lys Thr Ser
            180                 185                 190

Gly Leu Lys Pro Pro Ser Ser Ser Thr Thr Ser Ser Asn Asn Thr Asn
        195                 200                 205

Ser Phe Arg Pro Ser Ser Arg Ser Ser Gly Asn Asn Asn Val Gly Ser
    210                 215                 220

Thr Ile Ser Thr Ser Ala Lys Ser Leu Glu Ser Ser Ser Thr Tyr Ser
225                 230                 235                 240

Ser Ile Ser Asn Leu Asn Arg Pro Thr Ser Gln Leu Gln Lys Pro Ser
                245                 250                 255

Arg Pro Gln Thr Gln Leu Val Arg Val Ala Thr Thr Thr Lys Ile Gly
            260                 265                 270

Ser Ser Lys Leu Ala Ala Pro Lys Ala Val Ser Thr Pro Lys Leu Ala
        275                 280                 285

Ser Val Lys Thr Ile Gly Ala Lys Gln Glu Pro Asp Asn Ser Gly Gly
    290                 295                 300

Gly Gly Gly Gly Met Leu Lys Leu Lys Leu Phe Ser Ser Lys Asn Pro
305                 310                 315                 320

Ser Ser Ser Ser Asn Ser Pro Gln Pro Thr Arg Lys Ala Ala Ala Val
                325                 330                 335

Pro Gln Gln Gln Thr Leu Ser Lys Ile Ala Ala Pro Val Lys Ser Gly
            340                 345                 350

Leu Lys Pro Pro Thr Ser Lys Leu Gly Ser Ala Thr Ser Met Ser Lys
        355                 360                 365

Leu Cys Thr Pro Lys Val Ser Tyr Arg Lys Thr Asp Ala Pro Ile Ile
    370                 375                 380

Ser Gln Gln Asp Ser Lys Arg Cys Ser Lys Ser Ser Glu Glu Glu Ser
385                 390                 395                 400
```

```
Gly Tyr Ala Gly Phe Asn Ser Thr Ser Pro Thr Ser Ser Ser Thr Glu
                405                 410                 415

Gly Ser Leu Ser Met His Ser Thr Ser Ser Lys Ser Ser Thr Ser Asp
            420                 425                 430

Glu Lys Ser Pro Ser Ser Asp Asp Leu Thr Leu Asn Ala Ser Ile Val
        435                 440                 445

Thr Ala Ile Arg Gln Pro Ile Ala Ala Thr Pro Val Ser Pro Asn Ile
    450                 455                 460

Ile Asn Lys Pro Val Glu Glu Lys Pro Thr Leu Ala Val Lys Gly Val
465                 470                 475                 480

Lys Ser Thr Ala Lys Lys Asp Pro Pro Pro Ala Val Pro Pro Arg Asp
                485                 490                 495

Thr Gln Pro Thr Ile Gly Val Val Ser Pro Ile Met Ala His Lys Lys
            500                 505                 510

Leu Thr Asn Asp Pro Val Ile Ser Glu Lys Pro Glu Pro Glu Lys Leu
        515                 520                 525

Gln Ser Met Ser Ile Asp Thr Thr Asp Val Pro Pro Leu Pro Pro Leu
    530                 535                 540

Lys Ser Val Val Pro Leu Lys Met Thr Ser Ile Arg Gln Pro Pro Thr
545                 550                 555                 560

Tyr Asp Val Leu Leu Lys Gln Gly Lys Ile Thr Ser Pro Val Lys Ser
                565                 570                 575

Phe Gly Tyr Glu Gln Ser Ser Ala Ser Glu Asp Ser Ile Val Ala His
            580                 585                 590

Ala Ser Ala Gln Val Thr Pro Pro Thr Lys Thr Ser Gly Asn His Ser
        595                 600                 605

Leu Glu Arg Arg Met Gly Lys Asn Lys Thr Ser Glu Ser Ser Gly Tyr
    610                 615                 620

Thr Ser Asp Ala Gly Val Ala Met Cys Ala Lys Met Arg Glu Lys Leu
625                 630                 635                 640

Lys Glu Tyr Asp Asp Met Thr Arg Arg Ala Gln Asn Gly Tyr Pro Asp
                645                 650                 655

Asn Phe Glu Asp Ser Ser Ser Leu Ser Ser Gly Ile Ser Asp Asn Asn
            660                 665                 670

Glu Leu Asp Asp Ile Ser Thr Asp Asp Leu Ser Gly Val Asp Met Ala
        675                 680                 685

Thr Val Ala Ser Lys His Ser Asp Tyr Ser His Phe Val Arg His Pro
    690                 695                 700

Thr Ser Ser Ser Ser Lys Pro Arg Val Pro Ser Arg Ser Ser Thr Ser
705                 710                 715                 720

Val Asp Ser Arg Ser Arg Ala Glu Gln Glu Asn Val Tyr Lys Leu Leu
                725                 730                 735
```

```
Ser Gln Cys Arg Thr Ser Gln Arg Gly Ala Ala Ala Thr Ser Thr Phe
            740                 745                 750

Gly Gln His Ser Leu Arg Ser Pro Gly Tyr Ser Ser Tyr Ser Pro His
        755                 760                 765

Leu Ser Val Ser Ala Asp Lys Asp Thr Met Ser Met His Ser Gln Thr
    770                 775                 780

Ser Arg Arg Pro Ser Ser Gln Lys Pro Ser Tyr Ser Gly Gln Phe His
785                 790                 795                 800

Ser Leu Asp Arg Lys Cys His Leu Gln Glu Phe Thr Ser Thr Glu His
                805                 810                 815

Arg Met Ala Ala Leu Leu Ser Pro Arg Arg Val Pro Asn Ser Met Ser
            820                 825                 830

Lys Tyr Asp Ser Ser Gly Ser Tyr Ser Ala Arg Ser Arg Gly Gly Ser
        835                 840                 845

Ser Thr Gly Ile Tyr Gly Glu Thr Phe Gln Leu His Arg Leu Ser Asp
    850                 855                 860

Glu Lys Ser Pro Ala His Ser Ala Lys Ser Glu Met Gly Ser Gln Leu
865                 870                 875                 880

Ser Leu Ala Ser Thr Thr Ala Tyr Gly Ser Leu Asn Glu Lys Tyr Glu
                885                 890                 895

His Ala Ile Arg Asp Met Ala Arg Asp Leu Glu Cys Tyr Lys Asn Thr
            900                 905                 910

Val Asp Ser Leu Thr Lys Lys Gln Glu Asn Tyr Gly Ala Leu Phe Asp
        915                 920                 925

Leu Phe Glu Gln Lys Leu Arg Lys Leu Thr Gln His Ile Asp Arg Ser
    930                 935                 940

Asn Leu Lys Pro Glu Glu Ala Ile Arg Phe Arg Gln Asp Ile Ala His
945                 950                 955                 960

Leu Arg Asp Ile Ser Asn His Leu Ala Ser Asn Ser Ala His Ala Asn
                965                 970                 975

Glu Gly Ala Gly Glu Leu Leu Arg Gln Pro Ser Leu Glu Ser Val Ala
            980                 985                 990

Ser His Arg Ser Ser Met Ser Ser Ser Ser Lys Ser Ser Lys Gln Glu
        995                 1000                1005

Lys Ile Ser Leu Ser Ser Phe Gly Lys Asn Lys Lys Ser Trp Ile Arg
    1010                1015                1020

Ser Ser Leu Ser Lys Phe Thr Lys Lys Lys Asn Lys Asn Tyr Asp Glu
1025                1030                1035                1040

Ala His Met Pro Ser Ile Ser Gly Ser Gln Gly Thr Leu Asp Asn Ile
                1045                1050                1055

Asp Val Ile Glu Leu Lys Gln Glu Leu Lys Glu Arg Asp Ser Ala Leu
            1060                1065                1070
```

Tyr Glu Val Arg Leu Asp Asn Leu Asp Arg Ala Arg Glu Val Asp Val
1075 1080 1085

Leu Arg Glu Thr Val Asn Lys Leu Lys Thr Glu Asn Lys Gln Leu Lys
1090 1095 1100

Lys Glu Val Asp Lys Leu Thr Asn Gly Pro Ala Thr Arg Ala Ser Ser
1105 1110 1115 1120

Arg Ala Ser Ile Pro Val Ile Tyr Asp Asp Glu His Val Tyr Asp Ala
1125 1130 1135

Ala Cys Ser Ser Thr Ser Ala Ser Gln Ser Ser Lys Arg Ser Ser Gly
1140 1145 1150

Cys Asn Ser Ile Lys Val Thr Val Asn Val Asp Ile Ala Gly Glu Ile
1155 1160 1165

Ser Ser Ile Val Asn Pro Asp Lys Glu Ile Ile Val Gly Tyr Leu Ala
1170 1175 1180

Met Ser Thr Ser Gln Ser Cys Trp Lys Asp Ile Asp Val Ser Ile Leu
1185 1190 1195 1200

Gly Leu Phe Glu Val Tyr Leu Ser Arg Ile Asp Val Glu His Gln Leu
1205 1210 1215

Gly Ile Asp Ala Arg Asp Ser Ile Leu Gly Tyr Gln Ile Gly Glu Leu
1220 1225 1230

Arg Arg Val Ile Gly Asp Ser Thr Thr Met Ile Thr Ser His Pro Thr
1235 1240 1245

Asp Ile Leu Thr Ser Ser Thr Thr Ile Arg Met Phe Met His Gly Ala
1250 1255 1260

Ala Gln Ser Arg Val Asp Ser Leu Val Leu Asp Met Leu Leu Pro Lys
1265 1270 1275 1280

Gln Met Ile Leu Gln Leu Val Lys Ser Ile Leu Thr Glu Arg Arg Leu
1285 1290 1295

Val Leu Ala Gly Ala Thr Gly Ile Gly Lys Ser Lys Leu Ala Lys Thr
1300 1305 1310

Leu Ala Ala Tyr Val Ser Ile Arg Thr Asn Gln Ser Glu Asp Ser Ile
1315 1320 1325

Val Asn Ile Ser Ile Pro Glu Asn Asn Lys Glu Glu Leu Leu Gln Val
1330 1335 1340

Glu Arg Arg Leu Glu Lys Ile Leu Arg Ser Lys Glu Ser Cys Ile Val
1345 1350 1355 1360

Ile Leu Asp Asn Ile Pro Lys Asn Arg Ile Ala Phe Val Val Ser Val
1365 1370 1375

Phe Ala Asn Val Pro Leu Gln Asn Asn Glu Gly Pro Phe Val Val Cys
1380 1385 1390

Thr Val Asn Arg Tyr Gln Ile Pro Glu Leu Gln Ile His His Asn Phe
1395 1400 1405

```
Lys Met Ser Val Met Ser Asn Arg Leu Glu Gly Phe Ile Leu Arg Tyr
    1410                1415                1420

Leu Arg Arg Arg Ala Val Glu Asp Glu Tyr Arg Leu Thr Val Gln Met
1425                1430                1435                1440

Pro Ser Glu Leu Phe Lys Ile Ile Asp Phe Phe Pro Ile Ala Leu Gln
                1445                1450                1455

Ala Val Asn Asn Phe Ile Glu Lys Thr Asn Ser Val Asp Val Thr Val
            1460                1465                1470

Gly Pro Arg Ala Cys Leu Asn Cys Pro Leu Thr Val Asp Gly Ser Arg
        1475                1480                1485

Glu Trp Phe Ile Arg Leu Trp Asn Glu Asn Phe Ile Pro Tyr Leu Glu
    1490                1495                1500

Arg Val Ala Arg Asp Gly Lys Lys Asn Leu Arg Ser Leu His Phe Leu
1505                1510                1515                1520

Arg Gly Ser His Arg His Arg Leu
                1525
```

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1583 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

```
Met Thr Thr Ser Asn Val Glu Leu Ile Pro Ile Tyr Thr Asp Trp Ala
1               5                   10                  15

Asn Arg His Leu Ser Lys Gly Ser Leu Ser Lys Ser Ile Arg Asp Ile
            20                  25                  30

Ser Asn Asp Phe Arg Asp Tyr Arg Leu Val Ser Gln Leu Ile Asn Val
        35                  40                  45

Ile Val Pro Ile Asn Glu Phe Ser Pro Ala Phe Thr Lys Arg Leu Ala
    50                  55                  60

Lys Ile Thr Ser Asn Leu Asp Gly Leu Glu Thr Cys Leu Asp Tyr Leu
65                  70                  75                  80

Lys Asn Leu Gly Leu Asp Cys Ser Lys Leu Thr Lys Thr Asp Ile Asp
                85                  90                  95

Ser Gly Asn Leu Gly Ala Val Leu Gln Leu Leu Phe Leu Leu Ser Thr
            100                 105                 110

Tyr Lys Gln Lys Leu Arg Gln Leu Lys Lys Asp Gln Lys Lys Leu Glu
        115                 120                 125
```

```
Gln Leu Pro Thr Ser Ile Met Pro Pro Ala Val Ser Lys Leu Pro Ser
    130                 135                 140

Pro Arg Val Ala Thr Ser Ala Thr Ala Ser Ala Thr Asn Pro Asn Ser
145                 150                 155                 160

Asn Phe Pro Gln Met Ser Thr Ser Arg Leu Gln Thr Pro Gln Ser Arg
                165                 170                 175

Ile Ser Lys Ile Asp Ser Ser Lys Ile Gly Ile Lys Pro Lys Thr Ser
            180                 185                 190

Gly Leu Lys Pro Pro Ser Ser Ser Thr Thr Ser Ser Asn Asn Thr Asn
        195                 200                 205

Ser Phe Arg Pro Ser Ser Arg Ser Ser Gly Asn Asn Asn Val Gly Ser
    210                 215                 220

Thr Ile Ser Thr Ser Ala Lys Ser Leu Glu Ser Ser Ser Thr Tyr Ser
225                 230                 235                 240

Ser Ile Ser Asn Leu Asn Arg Pro Thr Ser Gln Leu Gln Lys Pro Ser
                245                 250                 255

Arg Pro Gln Thr Gln Leu Val Arg Val Ala Thr Thr Thr Lys Ile Gly
            260                 265                 270

Ser Ser Lys Leu Ala Ala Pro Lys Ala Val Ser Thr Pro Lys Leu Ala
        275                 280                 285

Ser Val Lys Thr Ile Gly Ala Lys Gln Glu Pro Asp Asn Ser Gly Gly
    290                 295                 300

Gly Gly Gly Gly Met Leu Lys Leu Lys Leu Phe Ser Ser Lys Asn Pro
305                 310                 315                 320

Ser Ser Ser Ser Asn Ser Pro Gln Pro Thr Arg Lys Ala Ala Ala Val
                325                 330                 335

Pro Gln Gln Gln Thr Leu Ser Lys Ile Ala Ala Pro Val Lys Ser Gly
            340                 345                 350

Leu Lys Pro Pro Thr Ser Lys Leu Gly Ser Ala Thr Ser Met Ser Lys
        355                 360                 365

Leu Cys Thr Pro Lys Val Ser Tyr Arg Lys Thr Asp Ala Pro Ile Ile
    370                 375                 380

Ser Gln Gln Asp Ser Lys Arg Cys Ser Lys Ser Ser Glu Glu Glu Ser
385                 390                 395                 400

Gly Tyr Ala Gly Phe Asn Ser Thr Ser Pro Thr Ser Ser Ser Thr Glu
                405                 410                 415

Gly Ser Leu Ser Met His Ser Thr Ser Ser Lys Ser Ser Thr Ser Asp
            420                 425                 430

Glu Lys Ser Pro Ser Ser Asp Asp Leu Thr Leu Asn Ala Ser Ile Val
        435                 440                 445

Thr Ala Ile Arg Gln Pro Ile Ala Ala Thr Pro Val Ser Pro Asn Ile
    450                 455                 460
```

```
Ile Asn Lys Pro Val Glu Glu Lys Pro Thr Leu Ala Val Lys Gly Val
465                 470                 475                 480

Lys Ser Thr Ala Lys Lys Asp Pro Pro Pro Ala Val Pro Pro Arg Asp
                485                 490                 495

Thr Gln Pro Thr Ile Gly Val Val Ser Pro Ile Met Ala His Lys Lys
            500                 505                 510

Leu Thr Asn Asp Pro Val Ile Ser Glu Lys Pro Glu Pro Glu Lys Leu
        515                 520                 525

Gln Ser Met Ser Ile Asp Thr Thr Asp Val Pro Pro Leu Pro Pro Leu
    530                 535                 540

Lys Ser Val Val Pro Leu Lys Met Thr Ser Ile Arg Gln Pro Pro Thr
545                 550                 555                 560

Tyr Asp Val Leu Leu Lys Gln Gly Lys Ile Thr Ser Pro Val Lys Ser
                565                 570                 575

Phe Gly Tyr Glu Gln Ser Ser Ala Ser Glu Asp Ser Ile Val Ala His
            580                 585                 590

Ala Ser Ala Gln Val Thr Pro Pro Thr Lys Thr Ser Gly Asn His Ser
        595                 600                 605

Leu Glu Arg Arg Met Gly Lys Asn Lys Thr Ser Glu Ser Ser Gly Tyr
    610                 615                 620

Thr Ser Asp Ala Gly Val Ala Met Cys Ala Lys Met Arg Glu Lys Leu
625                 630                 635                 640

Lys Glu Tyr Asp Asp Met Thr Arg Arg Ala Gln Asn Gly Tyr Pro Asp
                645                 650                 655

Asn Phe Glu Asp Ser Ser Ser Leu Ser Ser Gly Ile Ser Asp Asn Asn
            660                 665                 670

Glu Leu Asp Asp Ile Ser Thr Asp Asp Leu Ser Gly Val Asp Met Ala
        675                 680                 685

Thr Val Ala Ser Lys His Ser Asp Tyr Ser His Phe Val Arg His Pro
    690                 695                 700

Thr Ser Ser Ser Ser Lys Pro Arg Val Pro Ser Arg Ser Ser Thr Ser
705                 710                 715                 720

Val Asp Ser Arg Ser Arg Ala Glu Gln Glu Asn Val Tyr Lys Leu Leu
                725                 730                 735

Ser Gln Cys Arg Thr Ser Gln Arg Gly Ala Ala Ala Thr Ser Thr Phe
            740                 745                 750

Gly Gln His Ser Leu Arg Ser Pro Gly Tyr Ser Ser Tyr Ser Pro His
        755                 760                 765

Leu Ser Val Ser Ala Asp Lys Asp Thr Met Ser Met His Ser Gln Thr
    770                 775                 780

Ser Arg Arg Pro Ser Ser Gln Lys Pro Ser Tyr Ser Gly Gln Phe His
785                 790                 795                 800
```

Ser Leu Asp Arg Lys Cys His Leu Gln Glu Phe Thr Ser Thr Glu His
805 810 815

Arg Met Ala Ala Leu Leu Ser Pro Arg Arg Val Pro Asn Ser Met Ser
820 825 830

Lys Tyr Asp Ser Ser Gly Ser Tyr Ser Ala Arg Ser Arg Gly Gly Ser
835 840 845

Ser Thr Gly Ile Tyr Gly Glu Thr Phe Gln Leu His Arg Leu Ser Asp
850 855 860

Glu Lys Ser Pro Ala His Ser Ala Lys Ser Glu Met Gly Ser Gln Leu
865 870 875 880

Ser Leu Ala Ser Thr Thr Ala Tyr Gly Ser Leu Asn Glu Lys Tyr Glu
885 890 895

His Ala Ile Arg Asp Met Ala Arg Asp Leu Glu Cys Tyr Lys Asn Thr
900 905 910

Val Asp Ser Leu Thr Lys Lys Gln Glu Asn Tyr Gly Ala Leu Phe Asp
915 920 925

Leu Phe Glu Gln Lys Leu Arg Lys Leu Thr Gln His Ile Asp Arg Ser
930 935 940

Asn Leu Lys Pro Glu Glu Ala Ile Arg Phe Arg Gln Asp Ile Ala His
945 950 955 960

Leu Arg Asp Ile Ser Asn His Leu Ala Ser Asn Ser Ala His Ala Asn
965 970 975

Glu Gly Ala Gly Glu Leu Leu Arg Gln Pro Ser Leu Glu Ser Val Ala
980 985 990

Ser His Arg Ser Ser Met Ser Ser Ser Ser Lys Ser Ser Lys Gln Glu
995 1000 1005

Lys Ile Ser Leu Ser Ser Phe Gly Lys Asn Lys Lys Ser Trp Ile Arg
1010 1015 1020

Ser Ser Leu Ser Lys Phe Thr Lys Lys Lys Asn Lys Asn Tyr Asp Glu
1025 1030 1035 1040

Ala His Met Pro Ser Ile Ser Gly Ser Gln Gly Thr Leu Asp Asn Ile
1045 1050 1055

Asp Val Ile Glu Leu Lys Gln Glu Leu Lys Glu Arg Asp Ser Ala Leu
1060 1065 1070

Tyr Glu Val Arg Leu Asp Asn Leu Asp Arg Ala Arg Glu Val Asp Val
1075 1080 1085

Leu Arg Glu Thr Val Asn Lys Leu Lys Thr Glu Asn Lys Gln Leu Lys
1090 1095 1100

Lys Glu Val Asp Lys Leu Thr Asn Gly Pro Ala Thr Arg Ala Ser Ser
1105 1110 1115 1120

Arg Ala Ser Ile Pro Val Ile Tyr Asp Asp Glu His Val Tyr Asp Ala
1125 1130 1135

```
Ala Cys Ser Ser Thr Ser Ala Ser Gln Ser Ser Lys Arg Ser Ser Gly
            1140                1145                1150

Cys Asn Ser Ile Lys Val Thr Val Asn Val Asp Ile Ala Gly Glu Ile
        1155                1160                1165

Ser Ser Ile Val Asn Pro Asp Lys Glu Ile Ile Val Gly Tyr Leu Ala
    1170                1175                1180

Met Ser Thr Ser Gln Ser Cys Trp Lys Asp Ile Asp Val Ser Ile Leu
1185                1190                1195                1200

Gly Leu Phe Glu Val Tyr Leu Ser Arg Ile Asp Val Glu His Gln Leu
                1205                1210                1215

Gly Ile Asp Ala Arg Asp Ser Ile Leu Gly Tyr Gln Ile Gly Glu Leu
            1220                1225                1230

Arg Arg Val Ile Gly Asp Ser Thr Thr Met Ile Thr Ser His Pro Thr
        1235                1240                1245

Asp Ile Leu Thr Ser Ser Thr Thr Ile Arg Met Phe Met His Gly Ala
    1250                1255                1260

Ala Gln Ser Arg Val Asp Ser Leu Val Leu Asp Met Leu Leu Pro Lys
1265                1270                1275                1280

Gln Met Ile Leu Gln Leu Val Lys Ser Ile Leu Thr Glu Arg Arg Leu
                1285                1290                1295

Val Leu Ala Gly Ala Thr Gly Ile Gly Lys Ser Lys Leu Ala Lys Thr
            1300                1305                1310

Leu Ala Ala Tyr Val Ser Ile Arg Thr Asn Gln Ser Glu Asp Ser Ile
        1315                1320                1325

Val Asn Ile Ser Ile Pro Glu Asn Asn Lys Glu Glu Leu Leu Gln Val
    1330                1335                1340

Glu Arg Arg Leu Glu Lys Ile Leu Arg Ser Lys Glu Ser Cys Ile Val
1345                1350                1355                1360

Ile Leu Asp Asn Ile Pro Lys Asn Arg Ile Ala Phe Val Val Ser Val
                1365                1370                1375

Phe Ala Asn Val Pro Leu Gln Asn Asn Glu Gly Pro Phe Val Val Cys
            1380                1385                1390

Thr Val Asn Arg Tyr Gln Ile Pro Glu Leu Gln Ile His His Asn Phe
        1395                1400                1405

Lys Met Ser Val Met Ser Asn Arg Leu Glu Gly Phe Ile Leu Arg Tyr
    1410                1415                1420

Leu Arg Arg Arg Ala Val Glu Asp Glu Tyr Arg Leu Thr Val Gln Met
1425                1430                1435                1440

Pro Ser Glu Leu Phe Lys Ile Ile Asp Phe Phe Pro Ile Ala Leu Gln
                1445                1450                1455

Ala Val Asn Asn Phe Ile Glu Lys Thr Asn Ser Val Asp Val Thr Val
            1460                1465                1470
```

Gly Pro Arg Ala Cys Leu Asn Cys Pro Leu Thr Val Asp Gly Ser Arg
1475 1480 1485

Glu Trp Phe Ile Arg Leu Trp Asn Glu Asn Phe Ile Pro Tyr Leu Glu
1490 1495 1500

Arg Val Ala Arg Asp Gly Lys Lys Thr Phe Gly Arg Cys Thr Ser Phe
1505 1510 1515 1520

Glu Asp Pro Thr Asp Ile Val Ser Lys Lys Trp Pro Trp Phe Asp Gly
1525 1530 1535

Glu Asn Pro Glu Asn Val Leu Lys Arg Leu Gln Leu Gln Asp Leu Val
1540 1545 1550

Pro Ser Pro Ala Asn Ser Ser Arg Gln His Phe Asn Pro Leu Glu Ser
1555 1560 1565

Leu Ile Gln Leu His Ala Thr Lys His Gln Thr Ile Asp Asn Ile
1570 1575 1580

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 47 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

ATAAGAATGC GGCCGCCGCC ATGACGACGT CAAATGTAGA ATTGATA 47

(2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 41 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

GGAATTCCAA CCATATGACG ACGTCAAATG TAGAATTGAT A 41

(2) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 35 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

CGCGGATCCT CAAACCGCGG GTGGCATAAT GGATG 35

(2) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

Lys Lys Asp Pro Pro Pro Ala Val Pro Pro Arg Asp Thr
1 5 10

(2) INFORMATION FOR SEQ ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

Thr Thr Asp Val Pro Pro Leu Pro Pro Leu Lys Ser
1 5 10

(2) INFORMATION FOR SEQ ID NO: 10:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

Glu Val Pro Val Pro Pro Pro Val Pro Pro Arg Arg
1 5 10

(2) INFORMATION FOR SEQ ID NO: 11:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

His Leu Asp Ser Pro Pro Ala Ile Pro Pro Arg
1 5 10

(2) INFORMATION FOR SEQ ID NO: 12:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

His Ser Ile Ala Gly Pro Pro Val Pro Pro Arg
1 5 10

(2) INFORMATION FOR SEQ ID NO: 13:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

Tyr Arg Ala Val Pro Pro Pro Leu Pro Pro Arg Arg Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO: 14:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

Gly Glu Leu Ser Pro Pro Pro Ile Pro Pro Arg Leu Asn
1 5 10

(2) INFORMATION FOR SEQ ID NO: 15:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

Ala Pro Ala Val Pro Pro Ala Arg Pro Gly Ser
1 5 10

(2) INFORMATION FOR SEQ ID NO: 16:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

Pro Ala Val Pro Pro Ala Arg Pro
1 5

(2) INFORMATION FOR SEQ ID NO: 17:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

Pro Pro Arg Pro Leu Pro Val Ala Pro Gly Ser
1 5 10

(2) INFORMATION FOR SEQ ID NO: 18:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:

Pro Ala Pro Ala Pro Pro Lys Pro Pro Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO: 19:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

Pro Pro Asp Asn Gly Pro Pro Pro Leu Pro Thr Ser Ser
1 5 10

(2) INFORMATION FOR SEQ ID NO: 20:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:

Pro Pro Gln Met Pro Leu Pro Glu Ile Pro Gln Gln Trp
1 5 10

(2) INFORMATION FOR SEQ ID NO: 21:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

Ala Pro Thr Met Pro Pro Pro Leu Pro Pro Val Pro Pro
1 5 10

(2) INFORMATION FOR SEQ ID NO: 22:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:

Phe Pro Ala Tyr Pro Pro Pro Pro Val Pro Val Pro
1 5 10

(2) INFORMATION FOR SEQ ID NO: 23:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:

Leu Leu Phe Leu Leu Ser Thr Tyr Lys Gln Lys Leu Arg Gln Leu Lys
1 5 10 15

Lys Asp Gln Lys Lys Leu Glu Gln Leu Pro Thr Ser
20 25

(2) INFORMATION FOR SEQ ID NO: 24:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:

Glu Thr Val Asn Val Asn Lys Leu Lys Thr Glu Asn Lys Gln Leu Lys
1 5 10 15

Lys Glu Val Asp Lys Leu Thr Asn Gly Pro Ala Thr
20 25

(2) INFORMATION FOR SEQ ID NO: 25:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10443 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "plasmid"

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:

GGCCGCCGCC ATGACGACGT CAAATGTAGA ATTGATACCA ATCTACACGG ATTGGGCCAA 60

TCGGCACCTT TCGAAGGGCA GCTTATCAAA GTCGATTAGG GATATTTCCA ATGATTTTCG 120

CGACTATCGA CTGGTTTCTC AGCTTATTAA TGTGATCGTT CCGATCAACG AATTCTCGCC 180

TGCATTCACG AAACGTTTGG CAAAAATCAC ATCGAACCTG GATGGCCTCG AAACGTGTCT 240

CGACTACCTG AAAAATCTGG GTCTCGACTG CTCGAAACTC ACCAAAACCG ATATCGACAG 300

CGGAAACTTG GGTGCAGTTC TCCAGCTGCT CTTCCTGCTC TCCACCTACA AGCAGAAGCT 360

TCGGCAACTG AAAAAAGATC AGAAGAAATT GGAGCAACTA CCCACATCCA TTATGCCACC 420

CGCGGTTTCT AAATTACCCT CGCCACGTGT CGCCACGTCA GCAACCGCTT CAGCAACTAA 480

CCCAAATTCC AACTTTCCAC AAATGTCAAC ATCCAGGCTT CAGACTCCAC AGTCAAGAAT 540

ATCGAAAATT GATTCATCAA AGATTGGTAT CAAGCCAAAG ACGTCTGGAC TTAAACCACC 600

CTCATCATCA ACCACTTCAT CAAATAATAC AAATTCATTC CGTCCGTCGA GCCGTTCGAG 660

TGGCAATAAT AATGTTGGCT CGACGATATC CACATCTGCG AAGAGCTTAG AATCATCATC 720

AACGTACAGC TCTATTTCGA ATCTAAACCG ACCTACCTCC CAACTCCAAA AACCTTCTAG 780

ACCACAAACC CAGCTAGTTC GTGTTGCTAC AACTACAAAA ATCGGAAGCT CAAAGCTAGC 840

CGCTCCGAAA GCCGTGAGCA CCCCAAAACT TGCTTCTGTG AAGACTATTG GAGCAAAACA 900

AGAGCCCGAT AACAGCGGTG GTGGTGGTGG TGGAATGCTG AAATTAAAGT TATTCAGTAG 960

CAAAAACCCA TCTTCCTCAT CGAATAGCCC ACAACCTACG AGAAAGGCGG CGGCGGTGCC 1020

TCAACAACAA ACTTTGTCGA AAATCGCTGC CCCAGTGAAA AGTGGCCTGA AGCCGCCGAC 1080

CAGTAAGCTG GGAAGTGCCA CGTCTATGTC GAAGCTTTGT ACGCCAAAAG TTTCCTACCG 1140

TAAAACGGAC GCCCCAATCA TATCTCAACA AGACTCGAAA CGATGCTCAA AGAGCAGTGA 1200

AGAAGAGTCC GGATACGCTG GATTCAACAG CACGTCGCCA ACGTCATCAT CGACGGAAGG 1260

TTCCCTAAGC ATGCATTCCA CATCTTCCAA GAGTTCAACG TCAGACGAAA AGTCTCCGTC 1320

ATCAGACGAT CTTACTCTTA ACGCCTCCAT CGTGACAGCT ATCAGACAGC CGATAGCCGC 1380

AACACCGGTT TCTCCAAATA TTATCAACAA GCCTGTTGAG GAAAAACCAA CACTGGCAGT 1440

GAAAGGAGTG AAAAGCACAG CGAAAAAAGA TCCACCTCCA GCTGTTCCGC CACGTGACAC 1500

CCAGCCAACA ATCGGAGTTG TTAGTCCAAT TATGGCACAT AAGAAGTTGA CAAATGACCC 1560

CGTGATATCT GAAAAACCAG AACCTGAAAA GCTCCAATCA ATGAGCATCG ACACGACGGA 1620

CGTTCCACCG CTTCCACCTC TAAAATCAGT TGTTCCACTT AAAATGACTT CAATCCGACA 1680

ACCACCAACG TACGATGTTC TTCTAAAACA AGGAAAAATC ACATCGCCTG TCAAGTCGTT 1740

TGGATATGAG CAGTCGTCCG CGTCTGAAGA CTCCATTGTG GCTCATGCGT CGGCTCAGGT 1800

GACTCCGCCG ACAAAAACTT CTGGTAATCA TTCGCTGGAG AGAAGGATGG GAAAGAATAA 1860

GACATCAGAA TCCAGCGGCT ACACCTCTGA CGCCGGTGTT GCGATGTGCG CCAAAATGAG 1920

GGAGAAGCTG AAAGAATACG ATGACATGAC TCGTCGAGCA CAGAACGGCT ATCCTGACAA 1980

CTTCGAAGAC AGTTCCTCCT TGTCGTCTGG AATATCCGAT AACAACGAGC TCGACGACAT 2040

ATCCACGGAC GATTTGTCCG GAGTAGACAT GGCAACAGTC GCCTCCAAAC ATAGCGACTA 2100

TTCCCACTTT GTTCGCCATC CCACGTCTTC TTCCTCAAAG CCCCGAGTCC CCAGTCGGTC 2160

CTCCACATCA GTCGATTCTC GATCTCGAGC AGAACAGGAG AATGTGTACA AACTTCTGTC 2220

CCAGTGCCGA ACGAGCCAAC GTGGCGCCGC TGCCACCTCA ACCTTCGGAC AACATTCGCT 2280

AAGATCCCCG GGATACTCAT CCTATTCTCC ACACTTATCA GTGTCAGCTG ATAAGGACAC 2340

AATGTCTATG CACTCACAGA CTAGTCGACG ACCTTCTTCA CAAAAACCAA GCTATTCAGG 2400

CCAATTTCAT TCACTTGATC GTAAATGCCA CCTTCAAGAG TTCACATCCA CCGAGCACAG 2460

AATGGCGGCT CTCTTGAGCC CGAGACGGGT GCCGAACTCG ATGTCGAAAT ATGATTCTTC 2520

AGGATCCTAC TCGGCGCGTT CCCGAGGTGG AAGCTCTACT GGTATCTATG GAGAGACGTT 2580

CCAACTGCAC AGACTATCCG ATGAAAAATC CCCCGCACAT TCTGCCAAAA GTGAGATGGG 2640

ATCCCAACTA TCACTGGCTA GCACGACAGC ATATGGATCT CTCAATGAGA AGTACGAACA 2700

TGCTATTCGG GACATGGCAC GTGACTTGGA GTGTTACAAG AACACTGTCG ACTCACTAAC 2760

CAAGAAACAG GAGAACTATG GAGCATTGTT TGATCTTTTT GAGCAAAAGC TTAGAAAACT 2820

CACTCAACAC ATTGATCGAT CCAACTTGAA GCCTGAAGAG GCAATACGAT TCAGGCAGGA 2880

CATTGCTCAT TTGAGGGATA TTAGCAATCA TCTTGCATCC AACTCAGCTC ATGCTAACGA 2940

AGGCGCTGGT GAGCTTCTTC GTCAACCATC TCTGGAATCA GTTGCATCCC ATCGATCATC 3000

GATGTCATCG TCGTCGAAAA GCAGCAAGCA GGAGAAGATC AGCTTGAGCT CGTTTGGCAA 3060

GAACAAGAAG AGCTGGATCC GCTCCTCACT CTCCAAGTTC ACCAAGAAGA AGAACAAGAA 3120

CTACGACGAA GCACATATGC CATCAATTTC CGGATCTCAA GGAACTCTTG ACAACATTGA 3180

TGTGATTGAG TTGAAGCAAG AGCTCAAAGA ACGCGATAGT GCACTTTACG AAGTCCGCCT 3240

TGACAATCTG GATCGTGCCC GCGAAGTTGA TGTTCTGAGG GAGACAGTGA ACAAGTTGAA 3300

AACCGAGAAC AAGCAATTAA AGAAAGAAGT GGACAAACTC ACCAACGGTC CAGCCACTCG 3360

TGCTTCTTCC CGCGCCTCAA TTCCAGTTAT CTACGACGAT GAGCATGTCT ATGATGCAGC 3420

GTGTAGCAGT ACATCAGCTA GTCAATCTTC GAAACGATCC TCTGGCTGCA ACTCAATCAA 3480

GGTTACTGTA AACGTGGACA TCGCTGGAGA AATCAGTTCG ATCGTTAACC CGGACAAAGA 3540

GATAATCGTA GGATATCTTG CCATGTCAAC CAGTCAGTCA TGCTGGAAAG ACATTGATGT 3600

TTCTATTCTA GGACTATTTG AAGTCTACCT ATCCAGAATT GATGTGGAGC ATCAACTTGG 3660

AATCGATGCT CGTGATTCTA TCCTTGGCTA TCAAATTGGT GAACTTCGAC GCGTCATTGG 3720

AGACTCCACA ACCATGATAA CCAGCCATCC AACTGACATT CTTACTTCCT CAACTACAAT 3780

CCGAATGTTC ATGCACGGTG CCGCACAGAG TCGCGTAGAC AGTCTGGTCC TTGATATGCT 3840

TCTTCCAAAG CAAATGATTC TCCAACTCGT CAAGTCAATT TTGACAGAGA GACGTCTGGT 3900

GTTAGCTGGA GCAACTGGAA TTGGAAAGAG CAAACTGGCG AAGACCCTGG CTGCTTATGT 3960

ATCTATTCGA ACAAATCAAT CCGAAGATAG TATTGTTAAT ATCAGCATTC CTGAAAACAA 4020

TAAAGAAGAA TTGCTTCAAG TGGAACGACG CCTGGAAAAG ATCTTGAGAA GCAAAGAATC 4080

ATGCATCGTA ATTCTAGATA ATATCCCAAA GAATCGAATT GCATTTGTTG TATCCGTTTT 4140

TGCAAATGTC CCACTTCAAA ACAACGAAGG TCCATTTGTA GTATGCACAG TCAACCGATA 4200

TCAAATCCCT GAGCTTCAAA TTCACCACAA TTTCAAAATG TCAGTAATGT CGAATCGTCT 4260

CGAAGGATTC ATCCTACGTT ACCTCCGACG ACGGGCGGTA GAGGATGAGT ATCGTCTAAC 4320

TGTACAGATG CCATCAGAGC TCTTCAAAAT CATTGACTTC TTCCCAATAG CTCTTCAGGC 4380

CGTCAATAAT TTTATTGAGA AAACGAATTC TGTTGATGTG ACAGTTGGTC CAAGAGCATG 4440

CTTGAACTGT CCTCTAACTG TCGATGGATC CCGTGAATGG TTCATTCGAT TGTGGAATGA 4500

GAACTTCATT CCATATTTGG AACGTGTTGC TAGAGATGGC AAAAAAACCT TCGGTCGCTG 4560

CACTTCCTTC GAGGATCCCA CCGACATCGT CTCTAAAAAA TGGCCGTGGT TCGATGGTGA 4620

AAACCCGGAG AATGTGCTCA AACGTCTTCA ACTCCAAGAC CTCGTCCCGT CACCTGCCAA 4680

CTCATCCCGA CAACACTTCA ATCCCCTCGA GTCGTTGATC CAATTGCATG CTACCAAGCA 4740

TCAGACCATC GACAACATTT GAACAGAAGA CTCTAATCTT CTCTCGCCTC TCCCCCGCTT 4800

TCCTTATCTT CGTACCGGTA CCTGATGATT CCCCATTTTC CCCCTTTTCC CCCCAATTTC 4860

CCAGAACCTC CTGTTCCCTT TGTTCCTAGT CCTCCCGGGT GCCGACGCCG AAGCGATTTA 4920

AAAACCTTTT TCTTTCCGAA ACATTTCCCA TTGCTCATTA ATAGTCAAAT TGAATAAACA 4980

GTGTATGTAC TTAAAAAAAA AAAAAAAAAA ACTCGAGGGG GGGCCCTATT CTATAGTGTC 5040

ACCTAAATGC TAGAGCTCGC TGATCAGCCT CGACTGTGCC TTCTAGTTGC CAGCCATCTG 5100

TTGTTTGCCC CTCCCCCGTG CCTTCCTTGA CCCTGGAAGG TGCCACTCCC ACTGTCCTTT 5160

CCTAATAAAA TGAGGAAATT GCATCGCATT GTCTGAGTAG GTGTCATTCT ATTCTGGGGG 5220

GTGGGGTGGG GCAGGACAGC AAGGGGGAGG ATTGGGAAGA CAATAGCAGG CATGCTGGGG 5280

ATGCGGTGGG CTCTATGGCT TCTGAGGCGG AAAGAACCAG CTGGGGCTCT AGGGGGTATC 5340

CCCACGCGCC CTGTAGCGGC GCATTAAGCG CGGCGGGTGT GGTGGTTACG CGCAGCGTGA 5400

CCGCTACACT TGCCAGCGCC CTAGCGCCCG CTCCTTTCGC TTTCTTCCCT TCCTTTCTCG 5460

CCACGTTCGC CGGCTTTCCC CGTCAAGCTC TAAATCGGGG CATCCCTTTA GGGTTCCGAT 5520

TTAGTGCTTT ACGGCACCTC GACCCCAAAA AACTTGATTA GGGTGATGGT TCACGTAGTG 5580

GGCCATCGCC CTGATAGACG GTTTTTCGCC CTTTGACGTT GGAGTCCACG TTCTTTAATA 5640

GTGGACTCTT GTTCCAAACT GGAACAACAC TCAACCCTAT CTCGGTCTAT TCTTTTGATT 5700

TATAAGGGAT TTTGGGGATT TCGGCCTATT GGTTAAAAAA TGAGCTGATT TAACAAAAAT 5760

TTAACGCGAA TTAATTCTGT GGAATGTGTG TCAGTTAGGG TGTGGAAAGT CCCCAGGCTC 5820

CCCAGGCAGG CAGAAGTATG CAAAGCATGC ATCTCAATTA GTCAGCAACC AGGTGTGGAA 5880

AGTCCCCAGG CTCCCCAGCA GGCAGAAGTA TGCAAAGCAT GCATCTCAAT TAGTCAGCAA 5940

CCATAGTCCC GCCCCTAACT CCGCCCATCC CGCCCCTAAC TCCGCCCAGT TCCGCCCATT 6000

CTCCGCCCCA TGGCTGACTA ATTTTTTTTA TTTATGCAGA GGCCGAGGCC GCCTCTGCCT 6060

CTGAGCTATT CCAGAAGTAG TGAGGAGGCT TTTTTGGAGG CCTAGGCTTT TGCAAAAAGC 6120

TCCCGGGAGC TTGTATATCC ATTTTCGGAT CTGATCAAGA GACAGGATGA GGATCGTTTC 6180

GCATGATTGA ACAAGATGGA TTGCACGCAG GTTCTCCGGC CGCTTGGGTG GAGAGGCTAT 6240

TCGGCTATGA CTGGGCACAA CAGACAATCG GCTGCTCTGA TGCCGCCGTG TTCCGGCTGT 6300

CAGCGCAGGG GCGCCCGGTT CTTTTTGTCA AGACCGACCT GTCCGGTGCC CTGAATGAAC 6360

TGCAGGACGA GGCAGCGCGG CTATCGTGGC TGGCCACGAC GGGCGTTCCT TGCGCAGCTG 6420

TGCTCGACGT TGTCACTGAA GCGGGAAGGG ACTGGCTGCT ATTGGGCGAA GTGCCGGGGC 6480

AGGATCTCCT GTCATCTCAC CTTGCTCCTG CCGAGAAAGT ATCCATCATG GCTGATGCAA 6540

TGCGGCGGCT GCATACGCTT GATCCGGCTA CCTGCCCATT CGACCACCAA GCGAAACATC 6600

GCATCGAGCG AGCACGTACT CGGATGGAAG CCGGTCTTGT CGATCAGGAT GATCTGGACG 6660

AAGAGCATCA GGGGCTCGCG CCAGCCGAAC TGTTCGCCAG GCTCAAGGCG CGCATGCCCG 6720

ACGGCGAGGA TCTCGTCGTG ACCCATGGCG ATGCCTGCTT GCCGAATATC ATGGTGGAAA 6780

ATGGCCGCTT TTCTGGATTC ATCGACTGTG GCCGGCTGGG TGTGGCGGAC CGCTATCAGG 6840

ACATAGCGTT GGCTACCCGT GATATTGCTG AAGAGCTTGG CGGCGAATGG GCTGACCGCT 6900

TCCTCGTGCT TTACGGTATC GCCGCTCCCG ATTCGCAGCG CATCGCCTTC TATCGCCTTC 6960

TTGACGAGTT CTTCTGAGCG GGACTCTGGG GTTCGAAATG ACCGACCAAG CGACGCCCAA 7020

CCTGCCATCA CGAGATTTCG ATTCCACCGC CGCCTTCTAT GAAAGGTTGG GCTTCGGAAT 7080

CGTTTTCCGG GACGCCGGCT GGATGATCCT CCAGCGCGGG GATCTCATGC TGGAGTTCTT 7140

CGCCCACCCC AACTTGTTTA TTGCAGCTTA TAATGGTTAC AAATAAAGCA ATAGCATCAC 7200

AAATTTCACA AATAAAGCAT TTTTTTCACT GCATTCTAGT TGTGGTTTGT CCAAACTCAT 7260

CAATGTATCT TATCATGTCT GTATACCGTC GACCTCTAGC TAGAGCTTGG CGTAATCATG 7320

GTCATAGCTG TTTCCTGTGT GAAATTGTTA TCCGCTCACA ATTCCACACA ACATACGAGC 7380

CGGAAGCATA AAGTGTAAAG CCTGGGGTGC CTAATGAGTG AGCTAACTCA CATTAATTGC 7440

GTTGCGCTCA CTGCCCGCTT TCCAGTCGGG AAACCTGTCG TGCCAGCTGC ATTAATGAAT 7500

CGGCCAACGC GCGGGGAGAG GCGGTTTGCG TATTGGGCGC TCTTCCGCTT CCTCGCTCAC 7560

TGACTCGCTG CGCTCGGTCG TTCGGCTGCG GCGAGCGGTA TCAGCTCACT CAAAGGCGGT 7620

AATACGGTTA TCCACAGAAT CAGGGGATAA CGCAGGAAAG AACATGTGAG CAAAAGGCCA 7680

GCAAAAGGCC AGGAACCGTA AAAAGGCCGC GTTGCTGGCG TTTTTCCATA GGCTCCGCCC 7740

CCCTGACGAG CATCACAAAA ATCGACGCTC AAGTCAGAGG TGGCGAAACC CGACAGGACT 7800

ATAAAGATAC CAGGCGTTTC CCCCTGGAAG CTCCCTCGTG CGCTCTCCTG TTCCGACCCT 7860

GCCGCTTACC GGATACCTGT CCGCCTTTCT CCCTTCGGGA AGCGTGGCGC TTTCTCAATG 7920

CTCACGCTGT AGGTATCTCA GTTCGGTGTA GGTCGTTCGC TCCAAGCTGG GCTGTGTGCA 7980

CGAACCCCCC GTTCAGCCCG ACCGCTGCGC CTTATCCGGT AACTATCGTC TTGAGTCCAA 8040

CCCGGTAAGA CACGACTTAT CGCCACTGGC AGCAGCCACT GGTAACAGGA TTAGCAGAGC 8100

GAGGTATGTA GGCGGTGCTA CAGAGTTCTT GAAGTGGTGG CCTAACTACG GCTACACTAG 8160

AAGGACAGTA TTTGGTATCT GCGCTCTGCT GAAGCCAGTT ACCTTCGGAA AAAGAGTTGG 8220

TAGCTCTTGA TCCGGCAAAC AAACCACCGC TGGTAGCGGT GGTTTTTTTG TTTGCAAGCA 8280

GCAGATTACG CGCAGAAAAA AAGGATCTCA AGAAGATCCT TTGATCTTTT CTACGGGGTC 8340

TGACGCTCAG TGGAACGAAA ACTCACGTTA AGGGATTTTG GTCATGAGAT TATCAAAAAG 8400

GATCTTCACC TAGATCCTTT TAAATTAAAA ATGAAGTTTT AAATCAATCT AAAGTATATA 8460

TGAGTAAACT TGGTCTGACA GTTACCAATG CTTAATCAGT GAGGCACCTA TCTCAGCGAT 8520

CTGTCTATTT CGTTCATCCA TAGTTGCCTG ACTCCCCGTC GTGTAGATAA CTACGATACG 8580

GGAGGGCTTA CCATCTGGCC CCAGTGCTGC AATGATACCG CGAGACCCAC GCTCACCGGC 8640

TCCAGATTTA TCAGCAATAA ACCAGCCAGC CGGAAGGGCC GAGCGCAGAA GTGGTCCTGC 8700

AACTTTATCC GCCTCCATCC AGTCTATTAA TTGTTGCCGG GAAGCTAGAG TAAGTAGTTC 8760

GCCAGTTAAT AGTTTGCGCA ACGTTGTTGC CATTGCTACA GGCATCGTGG TGTCACGCTC 8820

GTCGTTTGGT ATGGCTTCAT TCAGCTCCGG TTCCCAACGA TCAAGGCGAG TTACATGATC 8880

CCCCATGTTG TGCAAAAAAG CGGTTAGCTC CTTCGGTCCT CCGATCGTTG TCAGAAGTAA 8940

GTTGGCCGCA GTGTTATCAC TCATGGTTAT GGCAGCACTG CATAATTCTC TTACTGTCAT 9000

GCCATCCGTA AGATGCTTTT CTGTGACTGG TGAGTACTCA ACCAAGTCAT TCTGAGAATA 9060

GTGTATGCGG CGACCGAGTT GCTCTTGCCC GGCGTCAATA CGGGATAATA CCGCGCCACA 9120

TAGCAGAACT TTAAAAGTGC TCATCATTGG AAAACGTTCT TCGGGGCGAA AACTCTCAAG 9180

GATCTTACCG CTGTTGAGAT CCAGTTCGAT GTAACCCACT CGTGCACCCA ACTGATCTTC 9240

AGCATCTTTT ACTTTCACCA GCGTTTCTGG GTGAGCAAAA ACAGGAAGGC AAAATGCCGC 9300

AAAAAAGGGA ATAAGGGCGA CACGGAAATG TTGAATACTC ATACTCTTCC TTTTTCAATA 9360

TTATTGAAGC ATTTATCAGG GTTATTGTCT CATGAGCGGA TACATATTTG AATGTATTTA 9420

GAAAAATAAA CAAATAGGGG TTCCGCGCAC ATTTCCCCGA AAAGTGCCAC CTGACGTCGA 9480

CGGATCGGGA GATCTCCCGA TCCCCTATGG TCGACTCTCA GTACAATCTG CTCTGATGCC 9540

GCATAGTTAA GCCAGTATCT GCTCCCTGCT TGTGTGTTGG AGGTCGCTGA GTAGTGCGCG 9600

AGCAAAATTT AAGCTACAAC AAGGCAAGGC TTGACCGACA ATTGCATGAA GAATCTGCTT 9660

AGGGTTAGGC GTTTTGCGCT GCTTCGCGAT GTACGGGCCA GATATACGCG TTGACATTGA 9720

TTATTGACTA GTTATTAATA GTAATCAATT ACGGGGTCAT TAGTTCATAG CCCATATATG 9780

GAGTTCCGCG TTACATAACT TACGGTAAAT GGCCCGCCTG GCTGACCGCC CAACGACCCC 9840

CGCCCATTGA CGTCAATAAT GACGTATGTT CCCATAGTAA CGCCAATAGG GACTTTCCAT 9900

TGACGTCAAT GGGTGGACTA TTTACGGTAA ACTGCCCACT TGGCAGTACA TCAAGTGTAT 9960

CATATGCCAA GTACGCCCCC TATTGACGTC AATGACGGTA AATGGCCCGC CTGGCATTAT 10020

GCCCAGTACA TGACCTTATG GGACTTTCCT ACTTGGCAGT ACATCTACGT ATTAGTCATC 10080

GCTATTACCA TGGTGATGCG GTTTTGGCAG TACATCAATG GGCGTGGATA GCGGTTTGAC 10140

TCACGGGGAT TTCCAAGTCT CCACCCCATT GACGTCAATG GGAGTTTGTT TTGGCACCAA 10200

AATCAACGGG ACTTTCCAAA ATGTCGTAAC AACTCCGCCC CATTGACGCA AATGGGCGGT 10260

AGGCGTGTAC GGTGGGAGGT CTATATAAGC AGAGCTCTCT GGCTAACTAG AGAACCCACT 10320

GCTTACTGGC TTATCGAAAT TAATACGACT CACTATAGGG AGACCCAAGC TTGGTACCGA 10380

GCTCGGATCC ACTAGTAACG GCCGCCAGTG TGCTGGAATT CTGCAGATAT CCATCACACT 10440

GGC 10443

(2) INFORMATION FOR SEQ ID NO: 26:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7474 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "plasmid"

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:

CTAAATTGTA AGCGTTAATA TTTTGTTAAA ATTCGCGTTA AATTTTTGTT AAATCAGCTC 60

ATTTTTTAAC CAATAGGCCG AAATCGGCAA AATCCCTTAT AAATCAAAAG AATAGACCGA 120

GATAGGGTTG AGTGTTGTTC CAGTTTGGAA CAAGAGTCCA CTATTAAAGA ACGTGGACTC 180

CAACGTCAAA GGGCGAAAAA CCGTCTATCA GGGCGATGGC CCACTACGTG AACCATCACC 240

CTAATCAAGT TTTTTGGGGT CGAGGTGCCG TAAAGCACTA AATCGGAACC CTAAAGGGAG 300

CCCCCGATTT AGAGCTTGAC GGGGAAAGCC GGCGAACGTG GCGAGAAAGG AAGGGAAGAA 360

AGCGAAAGGA GCGGGCGCTA GGGCGCTGGC AAGTGTAGCG GTCACGCTGC GCGTAACCAC 420

CACACCCGCC GCGCTTAATG CGCCGCTACA GGGCGCGTCC CATTCGCCAT TCAGGCTGCG 480

CAACTGTTGG GAAGGGCGAT CGGTGCGGGC CTCTTCGCTA TTACGCCAGC TGGCGAAAGG 540

GGGATGTGCT GCAAGGCGAT TAAGTTGGGT AACGCCAGGG TTTTCCCAGT CACGACGTTG 600

TAAAACGACG GCCAGTGAGC GCGCGTAATA CGACTCACTA TAGGGCGAAT TGGAGCTCCA 660

CCGCGGTTTC TAAATTACCC TCGCCACGTG TCGCCACGTC AGCAACCGCT TCAGCAACTA 720

ACCCAAATTC CAACTTTCCA CAAATGTCAA CATCCAGGCT TCAGACTCCA CAGTCAAGAA 780

TATCGAAAAT TGATTCATCA AAGATTGGTA TCAAGCCAAA GACGTCTGGA CTTAAACCAC 840

CCTCATCATC AACCACTTCA TCAAATAATA CAAATTCATT CCGTCCGTCG AGCCGTTCGA 900

GTGGCAATAA TAATGTTGGC TCGACGATAT CCACATCTGC GAAGAGCTTA GAATCATCAT 960

CAACGTACAG CTCTATTTCG AATCTAAACC GACCTACCTC CCAACTCCAA AAACCTTCTA 1020

GACCACAAAC CCAGCTAGTT CGTGTTGCTA CAACTACAAA AATCGGAAGC TCAAAGCTAG 1080

CCGCTCCGAA AGCCGTGAGC ACCCCAAAAC TTGCTTCTGT GAAGACTATT GGAGCAAAAC 1140

AAGAGCCCGA TAACAGCGGT GGTGGTGGTG GTGGAATGCT GAAATTAAAG TTATTCAGTA 1200

GCAAAAACCC ATCTTCCTCA TCGAATAGCC CACAACCTAC GAGAAAGGCG GCGGCGGTGC 1260

CTCAACAACA AACTTTGTCG AAAATCGCTG CCCCAGTGAA AAGTGGCCTG AAGCCGCCGA 1320

CCAGTAAGCT GGGAAGTGCC ACGTCTATGT CGAAGCTTTG TACGCCAAAA GTTTCCTACC 1380

GTAAAACGGA CGCCCCAATC ATATCTCAAC AAGACTCGAA ACGATGCTCA AAGAGCAGTG 1440

AAGAAGAGTC CGGATACGCT GGATTCAACA GCACGTCGCC AACGTCATCA TCGACGGAAG 1500

GTTCCCTAAG CATGCATTCC ACATCTTCCA AGAGTTCAAC GTCAGACGAA AAGTCTCCGT 1560

CATCAGACGA TCTTACTCTT AACGCCTCCA TCGTGACAGC TATCAGACAG CCGATAGCCG 1620

CAACACCGGT TTCTCCAAAT ATTATCAACA AGCCTGTTGA GGAAAAACCA ACACTGGCAG 1680

TGAAAGGAGT GAAAAGCACA GCGAAAAAAG ATCCACCTCC AGCTGTTCCG CCACGTGACA 1740

CCCAGCCAAC AATCGGAGTT GTTAGTCCAA TTATGGCACA TAAGAAGTTG ACAAATGACC 1800

CCGTGATATC TGAAAAACCA GAACCTGAAA AGCTCCAATC AATGAGCATC GACACGACGG 1860

ACGTTCCACC GCTTCCACCT CTAAAATCAG TTGTTCCACT TAAAATGACT TCAATCCGAC 1920

AACCACCAAC GTACGATGTT CTTCTAAAAC AAGGAAAAAT CACATCGCCT GTCAAGTCGT 1980

TTGGATATGA GCAGTCGTCC GCGTCTGAAG ACTCCATTGT GGCTCATGCG TCGGCTCAGG 2040

TGACTCCGCC GACAAAAACT TCTGGTAATC ATTCGCTGGA GAGAAGGATG GGAAAGAATA 2100

AGACATCAGA ATCCAGCGGC TACACCTCTG ACGCCGGTGT TGCGATGTGC GCCAAAATGA 2160

GGGAGAAGCT GAAAGAATAC GATGACATGA CTCGTCGAGC ACAGAACGGC TATCCTGACA 2220

ACTTCGAAGA CAGTTCCTCC TTGTCGTCTG GAATATCCGA TAACAACGAG CTCGACGACA 2280

TATCCACGGA CGATTTGTCC GGAGTAGACA TGGCAACAGT CGCCTCCAAA CATAGCGACT 2340

ATTCCCACTT TGTTCGCCAT CCCACGTCTT CTTCCTCAAA GCCCCGAGTC CCCAGTCGGT 2400

CCTCCACATC AGTCGATTCT CGATCTCGAG CAGAACAGGA GAATGTGTAC AAACTTCTGT 2460

CCCAGTGCCG AACGAGCCAA CGTGGCGCCG CTGCCACCTC AACCTTCGGA CAACATTCGC 2520

TAAGATCCCC GGGATACTCA TCCTATTCTC CACACTTATC AGTGTCAGCT GATAAGGACA 2580

CAATGTCTAT GCACTCACAG ACTAGTCGAC GACCTTCTTC ACAAAAACCA AGCTATTCAG 2640

GCCAATTTCA TTCACTTGAT CGTAAATGCC ACCTTCAAGA GTTCACATCC ACCGAGCACA 2700

GAATGGCGGC TCTCTTGAGC CCGAGACGGG TGCCGAACTC GATGTCGAAA TATGATTCTT 2760

CAGGATCCTA CTCGGCGCGT TCCCGAGGTG GAAGCTCTAC TGGTATCTAT GGAGAGACGT 2820

TCCAACTGCA CAGACTATCC GATGAAAAAT CCCCCGCACA TTCTGCCAAA AGTGAGATGG 2880

GATCCCAACT ATCACTGGCT AGCACGACAG CATATGGATC TCTCAATGAG AAGTACGAAC 2940

ATGCTATTCG GGACATGGCA CGTGACTTGG AGTGTTACAA GAACACTGTC GACTCACTAA 3000

CCAAGAAACA GGAGAACTAT GGAGCATTGT TTGATCTTTT TGAGCAAAAG CTTAGAAAAC 3060

TCACTCAACA CATTGATCGA TCCAACTTGA AGCCTGAAGA GGCAATACGA TTCAGGCAGG 3120

ACATTGCTCA TTTGAGGGAT ATTAGCAATC ATCTTGCATC CAACTCAGCT CATGCTAACG 3180

AAGGCGCTGG TGAGCTTCTT CGTCAACCAT CTCTGGAATC AGTTGCATCC CATCGATCAT 3240

CGATGTCATC GTCGTCGAAA AGCAGCAAGC AGGAGAAGAT CAGCTTGAGC TCGTTTGGCA 3300

AGAACAAGAA GAGCTGGATC CGCTCCTCAC TCTCCAAGTT CACCAAGAAG AAGAACAAGA 3360

ACTACGACGA AGCACATATG CCATCAATTT CCGGATCTCA AGGAACTCTT GACAACATTG 3420

ATGTGATTGA GTTGAAGCAA GAGCTCAAAG AACGCGATAG TGCACTTTAC GAAGTCCGCC 3480

TTGACAATCT GGATCGTGCC CGCGAAGTTG ATGTTCTGAG GGAGACAGTG AACAAGTTGA 3540

AAACCGAGAA CAAGCAATTA AAGAAAGAAG TGGACAAACT CACCAACGGT CCAGCCACTC 3600

GTGCTTCTTC CCGCGCCTCA ATTCCAGTTA TCTACGACGA TGAGCATGTC TATGATGCAG 3660

CGTGTAGCAG TACATCAGCT AGTCAATCTT CGAAACGATC CTCTGGCTGC AACTCAATCA 3720

AGGTTACTGT AAACGTGGAC ATCGCTGGAG AAATCAGTTC GATCGTTAAC CCGGACAAAG 3780

AGATAATCGT AGGATATCTT GCCATGTCAA CCAGTCAGTC ATGCTGGAAA GACATTGATG 3840

TTTCTATTCT AGGACTATTT GAAGTCTACC TATCCAGAAT TGATGTGGAG CATCAACTTG 3900

GAATCGATGC TCGTGATTCT ATCCTTGGCT ATCAAATTGG TGAACTTCGA CGCGTCATTG 3960

GAGACTCCAC AACCATGATA ACCAGCCATC CAACTGACAT TCTTACTTCC TCAACTACAA 4020

TCCGAATGTT CATGCACGGT GCCGCACAGA GTCGCGTAGA CAGTCTGGTC CTTGATATGC 4080

TTCTTCCAAA GCAAATGATT CTCCAACTCG TCAAGTCAAT TTTGACAGAG AGACGTCTGG 4140

TGTTAGCTGG AGCAACTGGA ATTGGAAAGA GCAAACTGGC GAAGACCCTG GCTGCTTATG 4200

TATCTATTCG AACAAATCAA TCCGAAGATA GTATTGTTAA TATCAGCATT CCTGAAAACA 4260

ATAAAGAAGA ATTGCTTCAA GTGGAACGAC GCCTGGAAAA GATCTTGAGA AGCAAAGAAT 4320

CATGCATCGT AATTCTAGAT AATATCCCAA AGAATCGAAT TGCATTTGTT GTATCCGTTT 4380

TTGCAAATGT CCCACTTCAA AACAACGAAG GTCCATTTGT AGTATGCACA GTCAACCGAT 4440

ATCAAATCCC TGAGCTTCAA ATTCACCACA ATTTCAAAAT GTCAGTAATG TCGAATCGTC 4500

TCGAAGGATT CATCCTACGT TACCTCCGAC GACGGGCGGT AGAGGATGAG TATCGTCTAA 4560

CTGTACAGAT GCCATCAGAG CTCTTCAAAA TCATTGACTT CTTCCCAATA GCTCTTCAGG 4620

CCGTCAATAA TTTTATTGAG AAAACGAATT CTGTTGATGT GACAGTTGGT CCAAGAGCAT 4680

GCTTGAACTG TCCTCTAACT GTCGATGGAT CCCGTGAATG GTTCATTCGA TTGTGGAATG 4740

AGAACTTCAT TCCATATTTG GAACGTGTTG CTAGAGATGG CAAAAAAACC TTCGGTCGCT 4800

GCACTTCCTT CGAGGATCCC ACCGACATCG TCTCTAAAAA ATGGCCGTGG TTCGATGGTG 4860

AAAACCCGGA GAATGTGCTC AAACGTCTTC AACTCCAAGA CCTCGTCCCG TCACCTGCCA 4920

ACTCATCCCG ACAACACTTC AATCCCCTCG AGTCGTTGAT CCAATTGCAT GCTACCAAGC 4980

ATCAGACCAT CGACAACATT TGAACAGAAG ACTCTAATCT TCTCTCGCCT CTCCCCCGCT 5040

TTCCTTATCT TCGTACCGGT ACCTGATGAT TCCCCATTTT CCCCCTTTTC CCCCCAATTT 5100

CCCAGAACCT CCTGTTCCCT TTGTTCCTAG TCCTCCCGGG TGCCGACGCC GAAGCGATTT 5160

AAAAACCTTT TTCTTTCCGA AACATTTCCC ATTGCTCATT AATAGTCAAA TTGAATAAAC 5220

AGTGTATGTA CTTAAAAAAA AAAAAAAAAA AACTCGAGGG GGGGCCCGGT ACCCAGCTTT 5280

TGTTCCCTTT AGTGAGGGTT AATTGCGCGC TTGGCGTAAT CATGGTCATA GCTGTTTCCT 5340

GTGTGAAATT GTTATCCGCT CACAATTCCA CACAACATAC GAGCCGGAAG CATAAAGTGT 5400

AAAGCCTGGG GTGCCTAATG AGTGAGCTAA CTCACATTAA TTGCGTTGCG CTCACTGCCC 5460

GCTTTCCAGT CGGGAAACCT GTCGTGCCAG CTGCATTAAT GAATCGGCCA ACGCGCGGGG 5520

AGAGGCGGTT TGCGTATTGG GCGCTCTTCC GCTTCCTCGC TCACTGACTC GCTGCGCTCG 5580

GTCGTTCGGC TGCGGCGAGC GGTATCAGCT CACTCAAAGG CGGTAATACG GTTATCCACA 5640

GAATCAGGGG ATAACGCAGG AAAGAACATG TGAGCAAAAG GCCAGCAAAA GGCCAGGAAC 5700

CGTAAAAAGG CCGCGTTGCT GGCGTTTTTC CATAGGCTCC GCCCCCCTGA CGAGCATCAC 5760

AAAAATCGAC GCTCAAGTCA GAGGTGGCGA AACCCGACAG GACTATAAAG ATACCAGGCG 5820

TTTCCCCCTG GAAGCTCCCT CGTGCGCTCT CCTGTTCCGA CCCTGCCGCT TACCGGATAC 5880

CTGTCCGCCT TTCTCCCTTC GGGAAGCGTG GCGCTTTCTC ATAGCTCACG CTGTAGGTAT 5940

CTCAGTTCGG TGTAGGTCGT TCGCTCCAAG CTGGGCTGTG TGCACGAACC CCCCGTTCAG 6000

CCCGACCGCT GCGCCTTATC CGGTAACTAT CGTCTTGAGT CCAACCCGGT AAGACACGAC 6060

TTATCGCCAC TGGCAGCAGC CACTGGTAAC AGGATTAGCA GAGCGAGGTA TGTAGGCGGT 6120

GCTACAGAGT TCTTGAAGTG GTGGCCTAAC TACGGCTACA CTAGAAGGAC AGTATTTGGT 6180

ATCTGCGCTC TGCTGAAGCC AGTTACCTTC GGAAAAAGAG TTGGTAGCTC TTGATCCGGC 6240

AAACAAACCA CCGCTGGTAG CGGTGGTTTT TTTGTTTGCA AGCAGCAGAT TACGCGCAGA 6300

AAAAAAGGAT CTCAAGAAGA TCCTTTGATC TTTTCTACGG GGTCTGACGC TCAGTGGAAC 6360

GAAAACTCAC GTTAAGGGAT TTTGGTCATG AGATTATCAA AAAGGATCTT CACCTAGATC 6420

CTTTTAAATT AAAAATGAAG TTTTAAATCA ATCTAAAGTA TATATGAGTA AACTTGGTCT 6480

GACAGTTACC AATGCTTAAT CAGTGAGGCA CCTATCTCAG CGATCTGTCT ATTTCGTTCA 6540

TCCATAGTTG CCTGACTCCC CGTCGTGTAG ATAACTACGA TACGGGAGGG CTTACCATCT 6600

GGCCCCAGTG CTGCAATGAT ACCGCGAGAC CCACGCTCAC CGGCTCCAGA TTTATCAGCA 6660

ATAAACCAGC CAGCCGGAAG GGCCGAGCGC AGAAGTGGTC CTGCAACTTT ATCCGCCTCC 6720

ATCCAGTCTA TTAATTGTTG CCGGGAAGCT AGAGTAAGTA GTTCGCCAGT TAATAGTTTG 6780

CGCAACGTTG TTGCCATTGC TACAGGCATC GTGGTGTCAC GCTCGTCGTT TGGTATGGCT 6840

TCATTCAGCT CCGGTTCCCA ACGATCAAGG CGAGTTACAT GATCCCCCAT GTTGTGCAAA 6900

AAAGCGGTTA GCTCCTTCGG TCCTCCGATC GTTGTCAGAA GTAAGTTGGC CGCAGTGTTA 6960

TCACTCATGG TTATGGCAGC ACTGCATAAT TCTCTTACTG TCATGCCATC CGTAAGATGC 7020

TTTTCTGTGA CTGGTGAGTA CTCAACCAAG TCATTCTGAG AATAGTGTAT GCGGCGACCG 7080

AGTTGCTCTT GCCCGGCGTC AATACGGGAT AATACCGCGC CACATAGCAG AACTTTAAAA 7140

GTGCTCATCA TTGGAAAACG TTCTTCGGGG CGAAAACTCT CAAGGATCTT ACCGCTGTTG 7200

AGATCCAGTT CGATGTAACC CACTCGTGCA CCCAACTGAT CTTCAGCATC TTTTACTTTC 7260

ACCAGCGTTT CTGGGTGAGC AAAAACAGGA AGGCAAAATG CCGCAAAAAA GGGAATAAGG 7320

GCGACACGGA AATGTTGAAT ACTCATACTC TTCCTTTTTC AATATTATTG AAGCATTTAT 7380

CAGGGTTATT GTCTCATGAG CGGATACATA TTTGAATGTA TTTAGAAAAA TAAACAAATA 7440

GGGGTTCCGC GCACATTTCC CCGAAAAGTG CCAC 7474

(2) INFORMATION FOR SEQ ID NO: 27:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13414 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "plasmid"

(iii) HYPOTHETICAL: NO

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION:11582
(D) OTHER INFORMATION:/note= "N is A,G,C or T"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:

TATGACGACG TCAAATGTAG AATTGATACC ATTCTACACG GATTGGGCCA ATCGGCACCT 60

TTCGAAGGGC AGCTTATCAA AGTCGATTAG GGATATTTCC AATGATTTTC GCGACTATCG 120

ACTGGTTTCT CAGCTTATTA ATGTGATCGT TCCGATCAAC GAATTCTCGC CTGCATTCAC 180

GAAACGTTTG GCAAAAATCA CATCGAACCT GGATGGCCTC GAAACGTGTC TCGACTACCT 240

GAAAAATCTG GGTCTCGACT GCTCGAAACT CACCAAAACC GATATCGACA GCGGAAACTT 300

GGGTGCAGTT CTCCAGCTGC TCTTCCTGCT CTCCACCTAC AAGCAGAAGC TTCGGCAACT 360

GAAAAAAGAT CAGAAGAAAT TGGAGCAACT ACCCACATCC ATTATGCCAC CCGCGGTTTC 420

TAAATTACCC TCGCCACGTG TCGCCACGTC AGCAACCGCT TCAGCAACTA ACCCAAATTC 480

CAACTTTCCA CAAATGTCAA CATCCAGGCT TCAGACTCCA CAGTCAAGAA TATCGAAAAT 540

TGATTCATCA AAGATTGGTA TCAAGCCAAA GACGTCTGGA CTTAAACCAC CCTCATCATC 600

AACCACTTCA TCAAATAATA CAAATTCATT CCGTCCGTCG AGCCGTTCGA GTGGCAATAA 660

TAATGTTGGC TCGACGATAT CCACATCTGC GAAGAGCTTA GAATCATCAT CAACGTACAG 720

CTCTATTTCG AATCTAAACC GACCTACCTC CCAACTCCAA AAACCTTCTA GACCACAAAC 780

CCAGCTAGTT CGTGTTGCTA CAACTACAAA AATCGGAAGC TCAAAGCTAG CCGCTCCGAA 840

AGCCGTGAGC ACCCCAAAAC TTGCTTCTGT GAAGACTATT GGAGCAAAAC AAGAGCCCGA 900

TAACAGCGGT GGTGGTGGTG GTGGAATGCT GAAATTAAAG TTATTCAGTA GCAAAAACCC 960

ATCTTCCTCA TCGAATAGCC CACAACCTAC GAGAAAGGCG GCGGCGGTGC CTCAACAACA 1020

AACTTTGTCG AAAATCGCTG CCCCAGTGAA AAGTGGCCTG AAGCCGCCGA CCAGTAAGCT 1080

GGGAAGTGCC ACGTCTATGT CGAAGCTTTG TACGCCAAAA GTTTCCTACC GTAAAACGGA 1140

CGCCCCAATC ATATCTCAAC AAGACTCGAA ACGATGCTCA AAGAGCAGTG AAGAAGAGTC 1200

CGGATACGCT GGATTCAACA GCACGTCGCC AACGTCATCA TCGACGGAAG GTTCCCTAAG 1260

CATGCATTCC ACATCTTCCA AGAGTTCAAC GTCAGACGAA AAGTCTCCGT CATCAGACGA 1320

TCTTACTCTT AACGCCTCCA TCGTGACAGC TATCAGACAG CCGATAGCCG CAACACCGGT 1380

TTCTCCAAAT ATTATCAACA AGCCTGTTGA GGAAAAACCA ACACTGGCAG TGAAAGGAGT 1440

GAAAAGCACA GCGAAAAAAG ATCCACCTCC AGCTGTTCCG CCACGTGACA CCCAGCCAAC 1500

AATCGGAGTT GTTAGTCCAA TTATGGCACA TAAGAAGTTG ACAAATGACC CCGTGATATC 1560

TGAAAAACCA GAACCTGAAA AGCTCCAATC AATGAGCATC GACACGACGG ACGTTCCACC 1620

GCTTCCACCT CTAAAATCAG TTGTTCCACT TAAAATGACT TCAATCCGAC AACCACCAAC 1680

GTACGATGTT CTTCTAAAAC AAGGAAAAAT CACATCGCCT GTCAAGTCGT TTGGATATGA 1740

GCAGTCGTCC GCGTCTGAAG ACTCCATTGT GGCTCATGCG TCGGCTCAGG TGACTCCGCC 1800

GACAAAAACT TCTGGTAATC ATTCGCTGGA GAGAAGGATG GGAAAGAATA AGACATCAGA 1860

ATCCAGCGGC TACACCTCTG ACGCCGGTGT TGCGATGTGC GCCAAAATGA GGGAGAAGCT 1920

GAAAGAATAC GATGACATGA CTCGTCGAGC ACAGAACGGC TATCCTGACA ACTTCGAAGA 1980

CAGTTCCTCC TTGTCGTCTG GAATATCCGA TAACAACGAG CTCGACGACA TATCCACGGA 2040

CGATTTGTCC GGAGTAGACA TGGCAACAGT CGCCTCCAAA CATAGCGACT ATTCCCACTT 2100

TGTTCGCCAT CCCACGTCTT CTTCCTCAAA GCCCCGAGTC CCCAGTCGGT CCTCCACATC 2160

AGTCGATTCT CGATCTCGAG CAGAACAGGA GAATGTGTAC AAACTTCTGT CCCAGTGCCG 2220

AACGAGCCAA CGTGGCGCCG CTGCCACCTC AACCTTCGGA CAACATTCGC TAAGATCCCC 2280

GGGATACTCA TCCTATTCTC CACACTTATC AGTGTCAGCT GATAAGGACA CAATGTCTAT 2340

GCACTCACAG ACTAGTCGAC GACCTTCTTC ACAAAAACCA AGCTATTCAG GCCAATTTCA 2400

TTCACTTGAT CGTAAATGCC ACCTTCAAGA GTTCACATCC ACCGAGCACA GAATGGCGGC 2460

TCTCTTGAGC CCGAGACGGG TGCCGAACTC GATGTCGAAA TATGATTCTT CAGGATCCTA 2520

CTCGGCGCGT TCCCGAGGTG GAAGCTCTAC TGGTATCTAT GGAGAGACGT TCCAACTGCA 2580

CAGACTATCC GATGAAAAAT CCCCCGCACA TTCTGCCAAA AGTGAGATGG GATCCCAACT 2640

ATCACTGGCT AGCACGACAG CATATGGATC TCTCAATGAG AAGTACGAAC ATGCTATTCG 2700

GGACATGGCA CGTGACTTGG AGTGTTACAA GAACACTGTC GACTCACTAA CCAAGAAACA 2760

GGAGAACTAT GGAGCATTGT TTGATCTTTT TGAGCAAAAG CTTAGAAAAC TCACTCAACA 2820

CATTGATCGA TCCAACTTGA AGCCTGAAGA GGCAATACGA TTCAGGCAGG ACATTGCTCA 2880

TTTGAGGGAT ATTAGCAATC ATCTTGCATC CAACTCAGCT CATGCTAACG AAGGCGCTGG 2940

TGAGCTTCTT CGTCAACCAT CTCTGGAATC AGTTGCATCC CATCGATCAT CGATGTCATC 3000

GTCGTCGAAA AGCAGCAAGC AGGAGAAGAT CAGCTTGAGC TCGTTTGGCA AGAACAAGAA 3060

GAGCTGGATC CGCTCCTCAC TCTCCAAGTT CACCAAGAAG AAGAACAAGA ACTACGACGA 3120

AGCACATATG CCATCAATTT CCGGATCTCA AGGAACTCTT GACAACATTG ATGTGATTGA 3180

GTTGAAGCAA GAGCTCAAAG AACGCGATAG TGCACTTTAC GAAGTCCGCC TTGACAATCT 3240

GGATCGTGCC CGCGAAGTTG ATGTTCTGAG GGAGACAGTG AACAAGTTGA AAACCGAGAA 3300

CAAGCAATTA AAGAAAGAAG TGGACAAACT CACCAACGGT CCAGCCACTC GTGCTTCTTC 3360

CCGCGCCTCA ATTCCAGTTA TCTACGACGA TGAGCATGTC TATGATGCAG CGTGTAGCAG 3420

TACATCAGCT AGTCAATCTT CGAAACGATC CTCTGGCTGC AACTCAATCA AGGTTACTGT 3480

AAACGTGGAC ATCGCTGGAG AAATCAGTTC GATCGTTAAC CCGGACAAAG AGATAATCGT 3540

AGGATATCTT GCCATGTCAA CCAGTCAGTC ATGCTGGAAA GACATTGATG TTTCTATTCT 3600

AGGACTATTT GAAGTCTACC TATCCAGAAT TGATGTGGAG CATCAACTTG GAATCGATGC 3660

TCGTGATTCT ATCCTTGGCT ATCAAATTGG TGAACTTCGA CGCGTCATTG GAGACTCCAC 3720

AACCATGATA ACCAGCCATC CAACTGACAT TCTTACTTCC TCAACTACAA TCCGAATGTT 3780

CATGCACGGT GCCGCACAGA GTCGCGTAGA CAGTCTGGTC CTTGATATGC TTCTTCCAAA 3840

GCAAATGATT CTCCAACTCG TCAAGTCAAT TTTGACAGAG AGACGTCTGG TGTTAGCTGG 3900

AGCAACTGGA ATTGGAAAGA GCAAACTGGC GAAGACCCTG GCTGCTTATG TATCTATTCG 3960

AACAAATCAA TCCGAAGATA GTATTGTTAA TATCAGCATT CCTGAAAACA ATAAAGAAGA 4020

ATTGCTTCAA GTGGAACGAC GCCTGGAAAA GATCTTGAGA AGCAAAGAAT CATGCATCGT 4080

AATTCTAGAT AATATCCCAA AGAATCGAAT TGCATTTGTT GTATCCGTTT TTGCAAATGT 4140

CCCACTTCAA AACAACGAAG GTCCATTTGT AGTATGCACA GTCAACCGAT ATCAAATCCC 4200

TGAGCTTCAA ATTCACCACA ATTTCAAAAT GTCAGTAATG TCGAATCGTC TCGAAGGATT 4260

CATCCTACGT TACCTCCGAC GACGGGCGGT AGAGGATGAG TATCGTCTAA CTGTACAGAT 4320

GCCATCAGAG CTCTTCAAAA TCATTGACTT CTTCCCAATA GCTCTTCAGG CCGTCAATAA 4380

TTTTATTGAG AAAACGAATT CTGTTGATGT GACAGTTGGT CCAAGAGCAT GCTTGAACTG 4440

TCCTCTAACT GTCGATGGAT CCCGTGAATG GTTCATTCGA TTGTGGAATG AGAACTTCAT 4500

TCCATATTTG GAACGTGTTG CTAGAGATGG CAAAAAAACC TTCGGTCGCT GCACTTCCTT 4560

CGAGGATCCC ACCGACATCG TCTCTAAAAA ATGGCCGTGG TTCGATGGTG AAAACCCGGA 4620

GAATGTGCTC AAACGTCTTC AACTCCAAGA CCTCGTCCCG TCACCTGCCA ACTCATCCCG 4680

ACAACACTTC AATCCCCTCG AGTCGTTGAT CCAATTGCAT GCTACCAAGC ATCAGACCAT 4740

CGACAACATT TGAACAGAAG ACTCTAATCT TCTCTCGCCT CTCCCCCGCT TTCCTTATCT 4800

TCGTACCGGT ACCTGATGAT TCCCCATTTT CCCCCTTTTC CCCCCAATTT CCCAGAACCT 4860

CCTGTTCCCT TTGTTCCTAG TCCTCCCGGG TGCCGACGCC GAAGCGATTT AAAAACCTTT 4920

TTCTTTCCGA AACATTTCCC ATTGCTCATT AATAGTCAAA TTGAATAAAC AGTGTATGTA 4980

CTTAAAAAAA AAAAAAAAAA AAAAAAAAAA GGCCTATGCG GCCGGGCCAT GGAGGCCGAA 5040

TTCCCGGGGA TCCGTCGACC TGCAGCCAAG CTAATTCCGG GCGAATTTCT TATGATTTAT 5100

GATTTTTATT ATTAAATAAG TTATAAAAAA AATAAGTGTA TACAAATTTT AAAGTGACTC 5160

TTAGGTTTTA AAACGAAAAT TCTTGTTCTT GAGTAACTCT TTCCTGTAGG TCAGGTTGCT 5220

TTCTCAGGTA TAGCATGAGG TCGCTCTTAT TGACCACACC TCTACCGGCA TGCAAGCTTG 5280

GCGTAATCAT GGTCATAGCT GTTTCCTGTG TGAAATTGTT ATCCGCTCAC AATTCCACAC 5340

AACATACGAG CCGGAAGCAT AAAGTGTAAA GCCTGGGGTG CCTAATGAGT GAGGTAACTC 5400

ACATTAATTG CGTTGCGCTC ACTGCCCGCT TTCCAGTCGG GAAACCTGTC GTGCCAGCTG 5460

GATTAATGAA TCGGCCAACG CGCGGGGAGA GGCGGTTTGC GTATTGGGCG CTCTTCCGCT 5520

TCCTCGCTCA CTGACTCGCT GCGCTCGGTC GTTCGGCTGC GGCGAGCGGT ATCAGCTCAC 5580

TCAAAGGCGG TAATACGGTT ATCCACAGAA TCAGGGGATA ACGCAGGAAA GAACATGTGA 5640

GCAAAAGGCC AGCAAAAGGC CAGGAACCGT AAAAAGGCCG CGTTGCTGGC GTTTTTCCAT 5700

AGGCTCCGCC CCCCTGACGA GCATCACAAA AATCGACGCT CAAGTCAGAG GTGGCGAAAC 5760

CCGACAGGAC TATAAAGATA CCAGGCGTTT CCCCCTGGAA GCTCCCTCGT GCGCTCTCCT 5820

GTTCCGACCC TGCCGCTTAC CGGATACCTG TCCGCCTTTC TCCCTTCGGG AAGCGTGGCG 5880

CTTTCTCATA GCTCACGCTG TAGGTATCTC AGTTCGGTGT AGGTCGTTCG CTCCAAGCTG 5940

GGCTGTGTGC ACGAACCCCC CGTTCAGCCC GACCGCTGCG CCTTATCCGG TAACTATCGT 6000

CTTGAGTCCA ACCCGGTAAG ACACGACTTA TCGCCACTGG CAGCAGCCAC TGGTAACAGG 6060

ATTAGCAGAG CGAGGTATGT AGGCGGTGCT ACAGAGTTCT TGAAGTGGTG GCCTAACTAC 6120

GGCTACACTA GAAGGACAGT ATTTGGTATC TGCGCTCTGC TGAAGCCAGT TACCTTCGGA 6180

AAAAGAGTTG GTAGCTCTTG ATCCGGCAAA CAAACCACCG CTGGTAGCGG TGGTTTTTTT 6240

GTTTGCAAGC AGCAGATTAC GCGCAGAAAA AAAGGATCTC AAGAAGATCC TTTGATCTTT 6300

TCTACGGGGT CTGACGCTCA GTGGAACGAA AACTCACGTT AAGGGATTTT GGTCATGAGA 6360

TTATCAAAAA GGATCTTCAC CTAGATCCTT TTAAATTAAA AATGAAGTTT TAAATCAATC 6420

TAAAGTATAT ATGAGTAAAC TTGGTCTGAC AGTTACCAAT GCTTAATCAG TGAGGCACCT 6480

ATCTCAGCGA TCTGTCTATT TCGTTCATCC ATAGTTGCCT GACTCCCCGT CGTGTAGATA 6540

ACTACGATAC GGGAGGGCTT ACCATCTGGC CCCAGTGCTG CAATGATACC GCGAGACCCA 6600

CGCTCACCGG CTCCAGATTT ATCAGCAATA AACCAGCCAG CCGGAAGGGC CGAGCGCAGA 6660

AGTGGTCCTG CAACTTTATC CGCCTCCATC CAGTCTATTA ATTGTTGCCG GGAAGCTAGA 6720

GTAAGTAGTT CGCCAGTTAA TAGTTTGCGC AACGTTGTTG CCATTGCTAC AGGCATCGTG 6780

GTGTCACGCT CGTCGTTTGG TATGGCTTCA TTCAGCTCCG GTTCCCAACG ATCAAGGCGA 6840

GTTACATGAT CCCCCATGTT GTGCAAAAAA GCGGTTAGCT CCTTCGGTCC TCCGATCGTT 6900

GTCAGAAGTA AGTTGGCCGC AGTGTTATCA CTCATGGTTA TGGCAGCACT GCATAATTCT 6960

CTTACTGTCA TGCCATCCGT AAGATGCTTT TCTGTGACTG GTGAGTACTC AACCAAGTCA 7020

TTCTGAGAAT AGTGTATGCG GCGACCGAGT TGCTCTTGCC CGGCGTCAAT ACGGGATAAT 7080

ACCGCGCCAC ATAGCAGAAC TTTAAAAGTG CTCATCATTG GAAAACGTTC TTCGGGGCGA 7140

AAACTCTCAA GGATCTTACC GCTGTTGAGA TCCAGTTCGA TGTAACCCAC TCGTGCACCC 7200

AACTGATCTT CAGCATCTTT TACTTTCACC AGCGTTTCTG GGTGAGCAAA AACAGGAAGG 7260

CAAAATGCCG CAAAAAAGGG AATAAGGGCG ACACGGAAAT GTTGAATACT CATACTCTTC 7320

CTTTTTCAAT ATTATTGAAG CATTTATCAG GGTTATTGTC TCATGAGCGG ATACATATTT 7380

GAATGTATTT AGAAAAATAA ACAAATAGGG GTTCCGCGCA CATTTCCCCG AAAAGTGCCA 7440

CCTGAACGAA GCATCTGTGC TTCATTTTGT AGAACAAAAA TGCAACGCGA GAGCGCTAAT 7500

TTTTCAAACA AAGAATCTGA GCTGCATTTT TACAGAACAG AAATGCAACG CGAAAGCGCT 7560

ATTTTACCAA CGAAGAATCT GTGCTTCATT TTTGTAAAAC AAAAATGCAA CGCGAGAGCG 7620

CTAATTTTTC AAACAAAGAA TCTGAGCTGC ATTTTTACAG AACAGAAATG CAACGCGAGA 7680

GCGCTATTTT ACCAACAAAG AATCTATACT TCTTTTTTGT TCTACAAAAA TGCATCCCGA 7740

GAGCGCTATT TTTCTAACAA AGCATCTTAG ATTACTTTTT TTCTCCTTTG TGCGCTCTAT 7800

AATGCAGTCT CTTGATAACT TTTTGCACTG TAGGTCCGTT AAGGTTAGAA GAAGGCTACT 7860

TTGGTGTCTA TTTTCTCTTC CATAAAAAAA GCCTGACTCC ACTTCCCGCG TTTACTGATT 7920

ACTAGCGAAG CTGCGGGTGC ATTTTTTCAA GATAAAGGCA TCCCCGATTA TATTCTATAC 7980

CGATGTGGAT TGCGCATACT TTGTGAACAG AAAGTGATAG CGTTGATGAT TCTTCATTGG 8040

TCAGAAAATT ATGAACGGTT TCTTCTATTT TGTCTCTATA TACTACGTAT AGGAAATGTT 8100

TACATTTTCG TATTGTTTTC GATTCACTCT ATGAATAGTT CTTACTACAA TTTTTTTGTC 8160

TAAAGAGTAA TACTAGAGAT AAACATAAAA AATGTAGAGG TCGAGTTTAG ATGCAAGTTC 8220

AAGGAGCGAA AGGTGGATGG GTAGGTTATA TAGGGATATA GCACAGAGAT ATATAGCAAA 8280

GAGATACTTT TGAGCAATGT TTGTGGAAGC GGTATTCGCA ATATTTTAGT AGCTCGTTAC 8340

AGTCCGGTGC GTTTTTGGTT TTTTGAAAGT GCGTCTTCAG AGCGCTTTTG GTTTTCAAAA 8400

GCGCTCTGAA GTTCCTATAC TTTCTAGAGA ATAGGAACTT CGGAATAGGA ACTTCAAAGC 8460

GTTTCCGAAA ACGAGCGCTT CCGAAAATGC AACGCGAGCT GCGCACATAC AGCTCACTGT 8520

TCACGTCGCA CCTATATCTG CGTGTTGCCT GTATATATAT ATACATGAGA AGAACGGCAT 8580

AGTGCGTGTT TATGCTTAAA TGCGTACTTA TATGCGTCTA TTTATGTAGG ATGAAAGGTA 8640

GTCTAGTACC TCCTGTGATA TTATCCCATT CCATGCGGGG TATCGTATGC TTCCTTCAGC 8700

ACTACCCTTT AGCTGTTCTA TATGCTGCCA CTCCTCAATT GGATTAGTCT CATCCTTCAA 8760

TGCTATCATT TCCTTTGATA TTGGATCATA TTAAGAAACC ATTATTATCA TGACATTAAC 8820

CTATAAAAAT AGGCGTATCA CGAGGCCCTT TCGTCTCGCG CGTTTCGGTG ATGACGGTGA 8880

AAACCTCTGA CACATGCAGC TCCCGGAGAC GGTCACAGCT TGTCTGTAAG CGGATGCCGG 8940

GAGCAGACAA GCCCGTCAGG GCGCGTCAGC GGGTGTTGGC GGGTGTCGGG GCTGGCTTAA 9000

CTATGCGGCA TCAGAGCAGA TTGTACTGAG AGTGCACCAT AGATCAACGA CATTACTATA 9060

TATATAATAT AGGAAGCATT TAATAGACAG CATCGTAATA TATGTGTACT TTGCAGTTAT 9120

GACGCCAGAT GGCAGTAGTG GAAGATATTC TTTATTGAAA AATAGCTTGT CACCTTACGT 9180

ACAATCTTGA TCCGGAGCTT TTCTTTTTTT GCCGATTAAG AATTAATTCG GTCGAAAAAA 9240

GAAAAGGAGA GGGCCAAGAG GGAGGGCATT GGTGACTATT GAGCACGTGA GTATACGTGA 9300

TTAAGCACAC AAAGGCAGCT TGGAGTATGT CTGTTATTAA TTTCACAGGT AGTTCTGGTC 9360

CATTGGTGAA AGTTTGCGGC TTGCAGAGCA CAGAGGCCGC AGAATGTGCT CTAGATTCCG 9420

ATGCTGACTT GCTGGGTATT ATATGTGTGC CCAATAGAAA GAGAACAATT GACCCGGTTA 9480

TTGCAAGGAA AATTTCAAGT CTTGTAAAAG CATATAAAAA TAGTTCAGGC ACTCCGAAAT 9540

ACTTGGTTGG CGTGTTTCGT AATCAACCTA AGGAGGATGT TTTGGCTCTG GTCAATGATT 9600

ACGGCATTGA TATCGTCCAA CTGCATGGAG ATGAGTCGTG GCAAGAATAC CAAGAGTTCC 9660

TCGGTTTGCC AGTTATTAAA AGACTCGTAT TTCCAAAAGA CTGCAACATA CTACTCAGTG 9720

CAGCTTCACA GAAACCTCAT TCGTTTATTC CCTTGTTTGA TTCAGAAGCA GGTGGGACAG 9780

GTGAACTTTT GGATTGGAAC TCGATTTCTG ACTGGGTTGG AAGGCAAGAG AGCCCCGAAA 9840

GCTTACATTT TATGTTAGCT GGTGGACTGA CGCCAGAAAA TGTTGGTGAT GCGCTTAGAT 9900

TAAATGGCGT TATTGGTGTT GATGTAAGCG GAGGTGTGGA GACAAATGGT GTAAAAGACT 9960

CTAACAAAAT AGCAAATTTC GTCAAAAATG CTAAGAAATA GGTTATTACT GAGTAGTATT 10020

TATTTAAGTA TTGTTTGTGC ACTTGCCGAT CTATGCGGTG TGAAATACCG CACAGATGCG 10080

TAAGGAGAAA ATACCGCATC AGGAAATTGT AAACGTTAAT ATTTTGTTAA AATTCGCGTT 10140

AAATTTTTGT TAAATCAGCT CATTTTTTAA CCAATAGGCC GAAATCGGCA AAATCCCTTA 10200

TAAATCAAAA GAATAGACCG AGATAGGGTT GAGTGTTGTT CCAGTTTGGA ACAAGAGTCC 10260

ACTATTAAAG AACGTGGACT CCAACGTCAA AGGGCGAAAA ACCGTCTATC AGGGCGATGG 10320

CCCACTACGT GAACCATCAC CCTAATCAAG TTTTTTGGGG TCGAGGTGCC GTAAAGCACT 10380

AAATCGGAAC CCTAAAGGGA GCCCCCGATT TAGAGCTTGA CGGGGAAAGC CGGCGAACGT 10440

GGCGAGAAAG GAAGGGAAGA AAGCGAAAGG AGCGGGCGCT AGGGCGCTGG CAAGTGTAGC 10500

GGTCACGCTG CGCGTAACCA CCACACCCGC CGCGCTTAAT GCGCCGCTAC AGGGCGCGTC 10560

GCGCCATTCG CCATTCAGGC TGCGCAACTG TTGGGAAGGG CGATCGGTGC GGGCCTCTTC 10620

GCTATTACGC CAGCTGGCGA AAGGGGGATG TGCTGCAAGG CGATTAAGTT GGGTAACGCC 10680

AGGGTTTTCC CAGTCACGAC GTTGTAAAAC GACGGCCAGT CGTCCAAGCT TTCGCGAGCT 10740

CGAGATCCCG AGCTTTGCAA ATTAAAGCCT TCGAGCGTCC CAAAACCTTC TCAAGCAAGG 10800

TTTTCAGTAT AATGTTACAT GCGTACACGC GTCTGTACAG AAAAAAAAGA AAAATTTGAA 10860

ATATAAATAA CGTTCTTAAT ACTAACATAA CTATAAAAAA ATAAATAGGG ACCTAGACTT 10920

CAGGTTGTCT AACTCCTTCC TTTTCGGTTA GAGCGGATGT GGGGGGAGGG CGTGAATGTA 10980

AGCGTGACAT AACTAATTAC ATGATATCGA CAAAGGAAAA GGGGCCTGTT TACTCACAGG 11040

CTTTTTTCAA GTAGGTAATT AAGTCGTTTC TGTCTTTTTC CTTCTTCAAC CCACCAAAGG 11100

CCATCTTGGT ACTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT 11160

TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTCATA GAAATAATAC 11220

AGAAGTAGAT GTTGAATTAG ATTAAACTGA AGATATATAA TTTATTGGAA AATACATAGA 11280

GCTTTTTGTT GATGCGCTTA AGCGATCAAT TCAACAACAC CACCAGCAGC TCTGATTTTT 11340

TCTTCAGCCA ACTTGGAGAC GAATCTAGCT TTGACGATAA CTGGAACATT TGGGATTCTA 11400

CCCTTACCCA AGATCTTACC GTAACCGGCT GCCAAAGTGT CAATAACTGG AGCAGTTTCC 11460

TTAGAAGCAG ATTTCAAGTA TTGGTCTCTC TTGTCTTCTG GGATCAATGT CCACAATTTG 11520

TCCAAGTTCA AGACTGGCTT CCAGAAATGA GCTTGTTGCT TGTGGAAGTA TCTCATACCA 11580

ANCCTTACCG AAATAACCTG GATGGTATTT ATCCATGTTA ATTCTGTGGT GATGTTGACC 11640

ACCGGCCATA CCTCTACCAC CGGGGTGCTT TCTGTGCTTA CCGATACGAC CTTTACCGGC 11700

TGAGACGTGA CCTCTGTGCT TTCTAGTCTT AGTGAATCTG GAAGGCATTC TTGATTAGTT 11760

GGATGATTGT TCTGGGATTT AATGCAAAAA AATCACTAAG AAGGAAAAAA ATCAACGGAG 11820

AAAGCAAACG CCATCTTAAA TATACGGGAT ACAGATGAAA GGTTTGAACC TATCTGGGAA 11880

AATACGCATT AAACAAGCGA AAAACTGCGA GGAAAATTGT TTGCGTCTCT GCGGGCTATT 11940

CACGCGCCAG AGGAAAATAG GAAAAATAAC AGGGCATTAG AAAAATAATT TTGATTTTGG 12000

TAATGTGTGG GTCCCTGGTG TACAGATGTT ACATTGGTTA CAGTACTCTT GTTTTTGCTG 12060

TGTTTTTCGA TGAATCTCCA AAATGGTTGT TAGCACATGG AAGAGTCACC GATGCTAAGT 12120

TATCTCTATG TAAGCTACGT GGCGTGACTT TTGATGAAGC CGCACAAGAG ATACAGGATT 12180

GGCAACTGCA AATAGAATCT GGGGATCTAG ATATCCTTTT GTTGTTTCCG GGTGTACAAT 12240

ATGGACTTCC TCTTTTCTGG CAACCAAACC CATACATCGG GATTCCTATA ATACCTTCGT 12300

TGGTCTCCCT AACATGTAGG TGGCGGAGGG GAGATATACA ATAGAACAGA TACCAGACAA 12360

GACATAATGG GCTAAACAAG ACTACACCAA TTACACTGCC TCATTGATGG TGGTACATAA 12420

CGAACTAATA CTGTAGCCCT AGACTTGATA GCCATCATCA TATCGAAGTT TCACTACCCT 12480

TTTTCCATTT GCCATCTATT GAAGTAATAA TAGGCGCATG CAACTTCTTT TCTTTTTTTT 12540

TCTTTTCTCT CTCCCCCGTT GTTGTCTCAC CATATCCGCA ATGACAAAAA AAATGATGGA 12600

AGACACTAAA GGAAAAAATT AACGACAAAG ACAGCACCAA CAGATGTCGT TGTTCCAGAG 12660

CTGATGAGGG GTATCTTCGA ACACACGAAA CTTTTTCCTT CCTTCATTCA CGCACACTAC 12720

TCTCTAATGA GCAACGGTAT ACGGCCTTCC TTCCAGTTAC TTGAATTTGA AATAAAAAAA 12780

GTTTGCCGCT TTGCTATCAA GTATAAATAG ACCTGCAATT ATTAATCTTT TGTTTCCTCG 12840

TCATTGTTCT CGTTCCCTTT CTTCCTTGTT TCTTTTTCTG CACAATATTT CAAGCTATAC 12900

CAAGCATACA ATCAACTCCA AGCTTGAAGC AAGCCTCCTG AAAGATGAAG CTACTGTCTT 12960

CTATCGAACA AGCATGCGAT ATTTGCCGAC TTAAAAAGCT CAAGTGCTCC AAAGAAAAAC 13020

CGAAGTGCGC CAAGTGTCTG AAGAACAACT GGGAGTGTCG CTACTCTCCC AAAACCAAAA 13080

GGTCTCCGCT GACTAGGGCA CATCTGACAG AAGTGGAATC AAGGCTAGAA AGACTGGAAC 13140

AGCTATTTCT ACTGATTTTT CCTCGAGAAG ACCTTGACAT GATTTTGAAA ATGGATTCTT 13200

TACAGGATAT AAAAGCATTG TTAACAGGAT TATTTGTACA AGATAATGTG AATAAAGATG 13260

CCGTCACAGA TAGATTGGCT TCAGTGGAGA CTGATATGCC TCTAACATTG AGACAGCATA 13320

GAATAAGTGC GACATCATCA TCGGAAGAGA GTAGTAACAA AGGTCAAAGA CAGTTGACTG 13380

TATCGCCGGA ATTGCAATAC CCAGCTTTGA CTCA 13414

(2) INFORMATION FOR SEQ ID NO: 28:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10288 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "plasmid"

(iii) HYPOTHETICAL: NO

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION:8456
(D) OTHER INFORMATION:/note= "N is A,C,G, or T"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28:

TATGCCATCA ATTTCCGGAT CTCAAGGAAC TCTTGACAAC ATTGATGTGA TTGAGTTGAA 60

GCAAGAGCTC AAAGAACGCG ATAGTGCACT TTACGAAGTC CGCCTTGACA ATCTGGATCG 120

TGCCCGCGAA GTTGATGTTC TGAGGGAGAC AGTGAACAAG TTGAAAACCG AGAACAAGCA 180

ATTAAAGAAA GAAGTGGACA AACTCACCAA CGGTCCAGCC ACTCGTGCTT CTTCCCGCGC 240

CTCAATTCCA GTTATCTACG ACGATGAGCA TGTCTATGAT GCAGCGTGTA GCAGTACATC 300

AGCTAGTCAA TCTTCGAAAC GATCCTCTGG CTGCAACTCA ATCAAGGTTA CTGTAAACGT 360

GGACATCGCT GGAGAAATCA GTTCGATCGT TAACCCGGAC AAAGAGATAA TCGTAGGATA 420

TCTTGCCATG TCAACCAGTC AGTCATGCTG GAAAGACATT GATGTTTCTA TTCTAGGACT 480

ATTTGAAGTC TACCTATCCA GAATTGATGT GGAGCATCAA CTTGGAATCG ATGCTCGTGA 540

TTCTATCCTT GGCTATCAAA TTGGTGAACT TCGACGCGTC ATTGGAGACT CCACAACCAT 600

GATAACCAGC CATCCAACTG ACATTCTTAC TTCCTCAACT ACAATCCGAA TGTTCATGCA 660

CGGTGCCGCA CAGAGTCGCG TAGACAGTCT GGTCCTTGAT ATGCTTCTTC CAAAGCAAAT 720

GATTCTCCAA CTCGTCAAGT CAATTTTGAC AGAGAGACGT CTGGTGTTAG CTGGAGCAAC 780

TGGAATTGGA AAGAGCAAAC TGGCGAAGAC CCTGGCTGCT TATGTATCTA TTCGAACAAA 840

TCAATCCGAA GATAGTATTG TTAATATCAG CATTCCTGAA AACAATAAAG AAGAATTGCT 900

TCAAGTGGAA CGACGCCTGG AAAAGATCTT GAGAAGCAAA GAATCATGCA TCGTAATTCT 960

AGATAATATC CCAAAGAATC GAATTGCATT TGTTGTATCC GTTTTTGCAA ATGTCCCACT 1020

TCAAAACAAC GAAGGTCCAT TTGTAGTATG CACAGTCAAC CGATATCAAA TCCCTGAGCT 1080

TCAAATTCAC CACAATTTCA AAATGTCAGT AATGTCGAAT CGTCTCGAAG GATTCATCCT 1140

ACGTTACCTC CGACGACGGG CGGTAGAGGA TGAGTATCGT CTAACTGTAC AGATGCCATC 1200

AGAGCTCTTC AAAATCATTG ACTTCTTCCC AATAGCTCTT CAGGCCGTCA ATAATTTTAT 1260

TGAGAAAACG AATTCTGTTG ATGTGACAGT TGGTCCAAGA GCATGCTTGA ACTGTCCTCT 1320

AACTGTCGAT GGATCCCGTG AATGGTTCAT TCGATTGTGG AATGAGAACT TCATTCCATA 1380

TTTGGAACGT GTTGCTAGAG ATGGCAAAAA AACCTTCGGT CGCTGCACTT CCTTCGAGGA 1440

TCCCACCGAC ATCGTCTCTA AAAAATGGCC GTGGTTCGAT GGTGAAAACC CGGAGAATGT 1500

GCTCAAACGT CTTCAACTCC AAGACCTCGT CCCGTCACCT GCCAACTCAT CCCGACAACA 1560

CTTCAATCCC CTCGAGTCGT TGATCCAATT GCATGCTACC AAGCATCAGA CCATCGACAA 1620

CATTTGAACA GAAGACTCTA ATCTTCTCTC GCCTCTCCCC CGCTTTCCTT ATCTTCGTAC 1680

CGGTACCTGA TGATTCCCCA TTTTCCCCCT TTTCCCCCCA ATTTCCCAGA ACCTCCTGTT 1740

CCCTTTGTTC CTAGTCCTCC CGGGTGCCGA CGCCGAAGCG ATTTAAAAAC CTTTTTCTTT 1800

CCGAAACATT TCCCATTGCT CATTAATAGT CAAATTGAAT AAACAGTGTA TGTACTTAAA 1860

AAAAAAAAAA AAAAAAAAAA AAAAGGCCTA TGCGGCCGGG CCATGGAGGC CGAATTCCCG 1920

GGGATCCGTC GACCTGCAGC CAAGCTAATT CCGGGCGAAT TTCTTATGAT TTATGATTTT 1980

TATTATTAAA TAAGTTATAA AAAAAATAAG TGTATACAAA TTTTAAAGTG ACTCTTAGGT 2040

TTTAAAACGA AAATTCTTGT TCTTGAGTAA CTCTTTCCTG TAGGTCAGGT TGCTTTCTCA 2100

GGTATAGCAT GAGGTCGCTC TTATTGACCA CACCTCTACC GGCATGCAAG CTTGGCGTAA 2160

TCATGGTCAT AGCTGTTTCC TGTGTGAAAT TGTTATCCGC TCACAATTCC ACACAACATA 2220

CGAGCCGGAA GCATAAAGTG TAAAGCCTGG GGTGCCTAAT GAGTGAGGTA ACTCACATTA 2280

ATTGCGTTGC GCTCACTGCC CGCTTTCCAG TCGGGAAACC TGTCGTGCCA GCTGGATTAA 2340

TGAATCGGCC AACGCGCGGG GAGAGGCGGT TTGCGTATTG GGCGCTCTTC CGCTTCCTCG 2400

CTCACTGACT CGCTGCGCTC GGTCGTTCGG CTGCGGCGAG CGGTATCAGC TCACTCAAAG 2460

GCGGTAATAC GGTTATCCAC AGAATCAGGG GATAACGCAG GAAAGAACAT GTGAGCAAAA 2520

GGCCAGCAAA AGGCCAGGAA CCGTAAAAAG GCCGCGTTGC TGGCGTTTTT CCATAGGCTC 2580

CGCCCCCCTG ACGAGCATCA CAAAAATCGA CGCTCAAGTC AGAGGTGGCG AAACCCGACA 2640

GGACTATAAA GATACCAGGC GTTTCCCCCT GGAAGCTCCC TCGTGCGCTC TCCTGTTCCG 2700

ACCCTGCCGC TTACCGGATA CCTGTCCGCC TTTCTCCCTT CGGGAAGCGT GGCGCTTTCT 2760

CATAGCTCAC GCTGTAGGTA TCTCAGTTCG GTGTAGGTCG TTCGCTCCAA GCTGGGCTGT 2820

GTGCACGAAC CCCCCGTTCA GCCCGACCGC TGCGCCTTAT CCGGTAACTA TCGTCTTGAG 2880

TCCAACCCGG TAAGACACGA CTTATCGCCA CTGGCAGCAG CCACTGGTAA CAGGATTAGC 2940

AGAGCGAGGT ATGTAGGCGG TGCTACAGAG TTCTTGAAGT GGTGGCCTAA CTACGGCTAC 3000

ACTAGAAGGA CAGTATTTGG TATCTGCGCT CTGCTGAAGC CAGTTACCTT CGGAAAAAGA 3060

GTTGGTAGCT CTTGATCCGG CAAACAAACC ACCGCTGGTA GCGGTGGTTT TTTTGTTTGC 3120

AAGCAGCAGA TTACGCGCAG AAAAAAAGGA TCTCAAGAAG ATCCTTTGAT CTTTTCTACG 3180

GGGTCTGACG CTCAGTGGAA CGAAAACTCA CGTTAAGGGA TTTTGGTCAT GAGATTATCA 3240

AAAAGGATCT TCACCTAGAT CCTTTTAAAT TAAAAATGAA GTTTTAAATC AATCTAAAGT 3300

ATATATGAGT AAACTTGGTC TGACAGTTAC CAATGCTTAA TCAGTGAGGC ACCTATCTCA 3360

GCGATCTGTC TATTTCGTTC ATCCATAGTT GCCTGACTCC CCGTCGTGTA GATAACTACG 3420

ATACGGGAGG GCTTACCATC TGGCCCCAGT GCTGCAATGA TACCGCGAGA CCCACGCTCA 3480

CCGGCTCCAG ATTTATCAGC AATAAACCAG CCAGCCGGAA GGGCCGAGCG CAGAAGTGGT 3540

CCTGCAACTT TATCCGCCTC CATCCAGTCT ATTAATTGTT GCCGGGAAGC TAGAGTAAGT 3600

AGTTCGCCAG TTAATAGTTT GCGCAACGTT GTTGCCATTG CTACAGGCAT CGTGGTGTCA 3660

CGCTCGTCGT TTGGTATGGC TTCATTCAGC TCCGGTTCCC AACGATCAAG GCGAGTTACA 3720

TGATCCCCCA TGTTGTGCAA AAAAGCGGTT AGCTCCTTCG GTCCTCCGAT CGTTGTCAGA 3780

AGTAAGTTGG CCGCAGTGTT ATCACTCATG GTTATGGCAG CACTGCATAA TTCTCTTACT 3840

GTCATGCCAT CCGTAAGATG CTTTTCTGTG ACTGGTGAGT ACTCAACCAA GTCATTCTGA 3900

GAATAGTGTA TGCGGCGACC GAGTTGCTCT TGCCCGGCGT CAATACGGGA TAATACCGCG 3960

CCACATAGCA GAACTTTAAA AGTGCTCATC ATTGGAAAAC GTTCTTCGGG GCGAAAACTC 4020

TCAAGGATCT TACCGCTGTT GAGATCCAGT TCGATGTAAC CCACTCGTGC ACCCAACTGA 4080

TCTTCAGCAT CTTTTACTTT CACCAGCGTT TCTGGGTGAG CAAAAACAGG AAGGCAAAAT 4140

GCCGCAAAAA AGGGAATAAG GGCGACACGG AAATGTTGAA TACTCATACT CTTCCTTTTT 4200

CAATATTATT GAAGCATTTA TCAGGGTTAT TGTCTCATGA GCGGATACAT ATTTGAATGT 4260

ATTTAGAAAA ATAAACAAAT AGGGGTTCCG CGCACATTTC CCCGAAAAGT GCCACCTGAA 4320

CGAAGCATCT GTGCTTCATT TTGTAGAACA AAAATGCAAC GCGAGAGCGC TAATTTTTCA 4380

AACAAAGAAT CTGAGCTGCA TTTTTACAGA ACAGAAATGC AACGCGAAAG CGCTATTTTA 4440

CCAACGAAGA ATCTGTGCTT CATTTTTGTA AAACAAAAAT GCAACGCGAG AGCGCTAATT 4500

TTTCAAACAA AGAATCTGAG CTGCATTTTT ACAGAACAGA AATGCAACGC GAGAGCGCTA 4560

TTTTACCAAC AAAGAATCTA TACTTCTTTT TTGTTCTACA AAAATGCATC CCGAGAGCGC 4620

TATTTTTCTA ACAAAGCATC TTAGATTACT TTTTTTCTCC TTTGTGCGCT CTATAATGCA 4680

GTCTCTTGAT AACTTTTTGC ACTGTAGGTC CGTTAAGGTT AGAAGAAGGC TACTTTGGTG 4740

TCTATTTTCT CTTCCATAAA AAAAGCCTGA CTCCACTTCC CGCGTTTACT GATTACTAGC 4800

GAAGCTGCGG GTGCATTTTT TCAAGATAAA GGCATCCCCG ATTATATTCT ATACCGATGT 4860

GGATTGCGCA TACTTTGTGA ACAGAAAGTG ATAGCGTTGA TGATTCTTCA TTGGTCAGAA 4920

AATTATGAAC GGTTTCTTCT ATTTTGTCTC TATATACTAC GTATAGGAAA TGTTTACATT 4980

TTCGTATTGT TTTCGATTCA CTCTATGAAT AGTTCTTACT ACAATTTTTT TGTCTAAAGA 5040

GTAATACTAG AGATAAACAT AAAAAATGTA GAGGTCGAGT TTAGATGCAA GTTCAAGGAG 5100

CGAAAGGTGG ATGGGTAGGT TATATAGGGA TATAGCACAG AGATATATAG CAAAGAGATA 5160

CTTTTGAGCA ATGTTTGTGG AAGCGGTATT CGCAATATTT TAGTAGCTCG TTACAGTCCG 5220

GTGCGTTTTT GGTTTTTTGA AAGTGCGTCT TCAGAGCGCT TTTGGTTTTC AAAAGCGCTC 5280

TGAAGTTCCT ATACTTTCTA GAGAATAGGA ACTTCGGAAT AGGAACTTCA AAGCGTTTCC 5340

GAAAACGAGC GCTTCCGAAA ATGCAACGCG AGCTGCGCAC ATACAGCTCA CTGTTCACGT 5400

CGCACCTATA TCTGCGTGTT GCCTGTATAT ATATATACAT GAGAAGAACG GCATAGTGCG 5460

TGTTTATGCT TAAATGCGTA CTTATATGCG TCTATTTATG TAGGATGAAA GGTAGTCTAG 5520

TACCTCCTGT GATATTATCC CATTCCATGC GGGGTATCGT ATGCTTCCTT CAGCACTACC 5580

CTTTAGCTGT TCTATATGCT GCCACTCCTC AATTGGATTA GTCTCATCCT TCAATGCTAT 5640

CATTTCCTTT GATATTGGAT CATATTAAGA AACCATTATT ATCATGACAT TAACCTATAA 5700

AAATAGGCGT ATCACGAGGC CCTTTCGTCT CGCGCGTTTC GGTGATGACG GTGAAAACCT 5760

CTGACACATG CAGCTCCCGG AGACGGTCAC AGCTTGTCTG TAAGCGGATG CCGGGAGCAG 5820

ACAAGCCCGT CAGGGCGCGT CAGCGGGTGT TGGCGGGTGT CGGGGCTGGC TTAACTATGC 5880

GGCATCAGAG CAGATTGTAC TGAGAGTGCA CCATAGATCA ACGACATTAC TATATATATA 5940

ATATAGGAAG CATTTAATAG ACAGCATCGT AATATATGTG TACTTTGCAG TTATGACGCC 6000

AGATGGCAGT AGTGGAAGAT ATTCTTTATT GAAAAATAGC TTGTCACCTT ACGTACAATC 6060

TTGATCCGGA GCTTTTCTTT TTTTGCCGAT TAAGAATTAA TTCGGTCGAA AAAAGAAAAG 6120

GAGAGGGCCA AGAGGGAGGG CATTGGTGAC TATTGAGCAC GTGAGTATAC GTGATTAAGC 6180

ACACAAAGGC AGCTTGGAGT ATGTCTGTTA TTAATTTCAC AGGTAGTTCT GGTCCATTGG 6240

TGAAAGTTTG CGGCTTGCAG AGCACAGAGG CCGCAGAATG TGCTCTAGAT TCCGATGCTG 6300

ACTTGCTGGG TATTATATGT GTGCCCAATA GAAAGAGAAC AATTGACCCG GTTATTGCAA 6360

GGAAAATTTC AAGTCTTGTA AAAGCATATA AAAATAGTTC AGGCACTCCG AAATACTTGG 6420

TTGGCGTGTT TCGTAATCAA CCTAAGGAGG ATGTTTTGGC TCTGGTCAAT GATTACGGCA 6480

TTGATATCGT CCAACTGCAT GGAGATGAGT CGTGGCAAGA ATACCAAGAG TTCCTCGGTT 6540

TGCCAGTTAT TAAAAGACTC GTATTTCCAA AAGACTGCAA CATACTACTC AGTGCAGCTT 6600

CACAGAAACC TCATTCGTTT ATTCCCTTGT TTGATTCAGA AGCAGGTGGG ACAGGTGAAC 6660

TTTTGGATTG GAACTCGATT TCTGACTGGG TTGGAAGGCA AGAGAGCCCC GAAAGCTTAC 6720

ATTTTATGTT AGCTGGTGGA CTGACGCCAG AAAATGTTGG TGATGCGCTT AGATTAAATG 6780

GCGTTATTGG TGTTGATGTA AGCGGAGGTG TGGAGACAAA TGGTGTAAAA GACTCTAACA 6840

AAATAGCAAA TTTCGTCAAA AATGCTAAGA AATAGGTTAT TACTGAGTAG TATTTATTTA 6900

AGTATTGTTT GTGCACTTGC CGATCTATGC GGTGTGAAAT ACCGCACAGA TGCGTAAGGA 6960

GAAAATACCG CATCAGGAAA TTGTAAACGT TAATATTTTG TTAAAATTCG CGTTAAATTT 7020

TTGTTAAATC AGCTCATTTT TTAACCAATA GGCCGAAATC GGCAAAATCC CTTATAAATC 7080

AAAAGAATAG ACCGAGATAG GGTTGAGTGT TGTTCCAGTT TGGAACAAGA GTCCACTATT 7140

AAAGAACGTG GACTCCAACG TCAAAGGGCG AAAAACCGTC TATCAGGGCG ATGGCCCACT 7200

ACGTGAACCA TCACCCTAAT CAAGTTTTTT GGGGTCGAGG TGCCGTAAAG CACTAAATCG 7260

GAACCCTAAA GGGAGCCCCC GATTTAGAGC TTGACGGGGA AAGCCGGCGA ACGTGGCGAG 7320

AAAGGAAGGG AAGAAAGCGA AAGGAGCGGG CGCTAGGGCG CTGGCAAGTG TAGCGGTCAC 7380

GCTGCGCGTA ACCACCACAC CCGCCGCGCT TAATGCGCCG CTACAGGGCG CGTCGCGCCA 7440

TTCGCCATTC AGGCTGCGCA ACTGTTGGGA AGGGCGATCG GTGCGGGCCT CTTCGCTATT 7500

ACGCCAGCTG GCGAAAGGGG GATGTGCTGC AAGGCGATTA AGTTGGGTAA CGCCAGGGTT 7560

TTCCCAGTCA CGACGTTGTA AAACGACGGC CAGTCGTCCA AGCTTTCGCG AGCTCGAGAT 7620

CCCGAGCTTT GCAAATTAAA GCCTTCGAGC GTCCCAAAAC CTTCTCAAGC AAGGTTTTCA 7680

GTATAATGTT ACATGCGTAC ACGCGTCTGT ACAGAAAAAA AAGAAAAATT TGAAATATAA 7740

ATAACGTTCT TAATACTAAC ATAACTATAA AAAAATAAAT AGGGACCTAG ACTTCAGGTT 7800

GTCTAACTCC TTCCTTTTCG GTTAGAGCGG ATGTGGGGGG AGGGCGTGAA TGTAAGCGTG 7860

ACATAACTAA TTACATGATA TCGACAAAGG AAAAGGGGCC TGTTTACTCA CAGGCTTTTT 7920

TCAAGTAGGT AATTAAGTCG TTTCTGTCTT TTTCCTTCTT CAACCCACCA AAGGCCATCT 7980

TGGTACTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT 8040

TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT CATAGAAATA ATACAGAAGT 8100

AGATGTTGAA TTAGATTAAA CTGAAGATAT ATAATTTATT GGAAAATACA TAGAGCTTTT 8160

TGTTGATGCG CTTAAGCGAT CAATTCAACA ACACCACCAG CAGCTCTGAT TTTTTCTTCA 8220

GCCAACTTGG AGACGAATCT AGCTTTGACG ATAACTGGAA CATTTGGGAT TCTACCCTTA 8280

CCCAAGATCT TACCGTAACC GGCTGCCAAA GTGTCAATAA CTGGAGCAGT TTCCTTAGAA 8340

GCAGATTTCA AGTATTGGTC TCTCTTGTCT TCTGGGATCA ATGTCCACAA TTTGTCCAAG 8400

TTCAAGACTG GCTTCCAGAA ATGAGCTTGT TGCTTGTGGA AGTATCTCAT ACCAANCCTT 8460

ACCGAAATAA CCTGGATGGT ATTTATCCAT GTTAATTCTG TGGTGATGTT GACCACCGGC 8520

CATACCTCTA CCACCGGGGT GCTTTCTGTG CTTACCGATA CGACCTTTAC CGGCTGAGAC 8580

GTGACCTCTG TGCTTTCTAG TCTTAGTGAA TCTGGAAGGC ATTCTTGATT AGTTGGATGA 8640

TTGTTCTGGG ATTTAATGCA AAAAAATCAC TAAGAAGGAA AAAAATCAAC GGAGAAAGCA 8700

AACGCCATCT TAAATATACG GGATACAGAT GAAAGGTTTG AACCTATCTG GGAAAATACG 8760

CATTAAACAA GCGAAAAACT GCGAGGAAAA TTGTTTGCGT CTCTGCGGGC TATTCACGCG 8820

CCAGAGGAAA ATAGGAAAAA TAACAGGGCA TTAGAAAAAT AATTTTGATT TTGGTAATGT 8880

GTGGGTCCCT GGTGTACAGA TGTTACATTG GTTACAGTAC TCTTGTTTTT GCTGTGTTTT 8940

TCGATGAATC TCCAAAATGG TTGTTAGCAC ATGGAAGAGT CACCGATGCT AAGTTATCTC 9000

TATGTAAGCT ACGTGGCGTG ACTTTTGATG AAGCCGCACA AGAGATACAG GATTGGCAAC 9060

TGCAAATAGA ATCTGGGGAT CTAGATATCC TTTTGTTGTT TCCGGGTGTA CAATATGGAC 9120

TTCCTCTTTT CTGGCAACCA AACCCATACA TCGGGATTCC TATAATACCT TCGTTGGTCT 9180

CCCTAACATG TAGGTGGCGG AGGGGAGATA TACAATAGAA CAGATACCAG ACAAGACATA 9240

ATGGGCTAAA CAAGACTACA CCAATTACAC TGCCTCATTG ATGGTGGTAC ATAACGAACT 9300

AATACTGTAG CCCTAGACTT GATAGCCATC ATCATATCGA AGTTTCACTA CCCTTTTTCC 9360

ATTTGCCATC TATTGAAGTA ATAATAGGCG CATGCAACTT CTTTTCTTTT TTTTTCTTTT 9420

CTCTCTCCCC CGTTGTTGTC TCACCATATC CGCAATGACA AAAAAAATGA TGGAAGACAC 9480

TAAAGGAAAA AATTAACGAC AAAGACAGCA CCAACAGATG TCGTTGTTCC AGAGCTGATG 9540

AGGGGTATCT TCGAACACAC GAAACTTTTT CCTTCCTTCA TTCACGCACA CTACTCTCTA 9600

ATGAGCAACG GTATACGGCC TTCCTTCCAG TTACTTGAAT TTGAAATAAA AAAAGTTTGC 9660

CGCTTTGCTA TCAAGTATAA ATAGACCTGC AATTATTAAT CTTTTGTTTC CTCGTCATTG 9720

TTCTCGTTCC CTTTCTTCCT TGTTTCTTTT TCTGCACAAT ATTTCAAGCT ATACCAAGCA 9780

TACAATCAAC TCCAAGCTTG AAGCAAGCCT CCTGAAAGAT GAAGCTACTG TCTTCTATCG 9840

AACAAGCATG CGATATTTGC CGACTTAAAA AGCTCAAGTG CTCCAAAGAA AAACCGAAGT 9900

GCGCCAAGTG TCTGAAGAAC AACTGGGAGT GTCGCTACTC TCCCAAAACC AAAAGGTCTC 9960

CGCTGACTAG GGCACATCTG ACAGAAGTGG AATCAAGGCT AGAAAGACTG GAACAGCTAT 10020

TTCTACTGAT TTTTCCTCGA GAAGACCTTG ACATGATTTT GAAAATGGAT TCTTTACAGG 10080

ATATAAAAGC ATTGTTAACA GGATTATTTG TACAAGATAA TGTGAATAAA GATGCCGTCA 10140

CAGATAGATT GGCTTCAGTG GAGACTGATA TGCCTCTAAC ATTGAGACAG CATAGAATAA 10200

GTGCGACATC ATCATCGGAA GAGAGTAGTA ACAAAGGTCA AAGACAGTTG ACTGTATCGC 10260

CGGAATTGCA ATACCCAGCT TTGACTCA 10288

(2) INFORMATION FOR SEQ ID NO: 29:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7625 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "plasmid"

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29:

GCTTGCATGC AACTTCTTTT CTTTTTTTTT CTTTTCTCTC TCCCCCGTTG TTGTCTCACC 60

ATATCCGCAA TGACAAAAAA AATGATGGAA GACACTAAAG GAAAAAATTA ACGACAAAGA 120

CAGCACCAAC AGATGTCGTT GTTCCAGAGC TGATGAGGGG TATCTTCGAA CACACGAAAC 180

TTTTTCCTTC CTTCATTCAC GCACACTACT CTCTAATGAG CAACGGTATA CGGCCTTCCT 240

TCCAGTTACT TGAATTTGAA ATAAAAAAAG TTTGCCGCTT TGCTATCAAG TATAAATAGA 300

CCTGCAATTA TTAATCTTTT GTTTCCTCGT CATTGTTCTC GTTCCCTTTC TTCCTTGTTT 360

CTTTTTCTGC ACAATATTTC AAGCTATACC AAGCATACAA TCAACTCCAA GCTTTGCAAA 420

GATGGATAAA GCGGAATTAA TTCCCGAGCC TCCAAAAAAG AAGAGAAAGG TCGAATTGGG 480

TACCGCCGCC AATTTTAATC AAAGTGGGAA TATTGCTGAT AGCTCATTGT CCTTCACTTT 540

CACTAACAGT AGCAACGGTC CGAACCTCAT AACAACTCAA ACAAATTCTC AAGCGCTTTC 600

ACAACCAATT GCCTCCTCTA ACGTTCATGA TAACTTCATG AATAATGAAA TCACGGCTAG 660

TAAAATTGAT GATGGTAATA ATTCAAAACC ACTGTCACCT GGTTGGACGG ACCAAACTGC 720

GTATAACGCG TTTGGAATCA CTACAGGGAT GTTTAATACC ACTACAATGG ATGATGTATA 780

TAACTATCTA TTCGATGATG AAGATACCCC ACCAAACCCA AAAAAAGAGA TCGAATTCCC 840

GGGGATCCGC TCCTCACTCT CCAAGTTCAC CAAGAAGAAG AACAAGAACT ACGACGAAGC 900

ACATATGCCA TCAATTTCCG GATCTCAAGG AACTCTTGAC AACATTGATG TGATTGAGTT 960

GAAGCAAGAG CTCAAAGAAC GCGATAGTGC ACTTTACGAA GTCCGCCTTG ACAATCTGGA 1020

TCGTGCCCGC GAAGTTGATG TTCTGAGGGA GACAGTGAAC AAGTTGAAAA CCGAGAACAA 1080

GCAATTAAAG AAAGAAGTGG ACAAACTCAC CAACGGTCCA GCCACTCGTG CTTCTTCCCG 1140

CGCCTCAATT CCAGTTATCT ACGACGATGA GCATGTCTAT GATGCAGCGT GTAGCAGTAC 1200

ATCAGCTAGT CAATCTTCGA AACGATCCTC TGGCTGCAAC TCAATCAAGG TTACTGTAAA 1260

CGTGGACATC GCTGGAGAAA TCAGTTCGAT CGTTAACCCG GACAAAGAGA TAATCGTAGG 1320

ATATCTTGCC ATGTCAACCA GTCAGTCATG CTGGAAAGAC ATTGATGTTT CTATTCTAGG 1380

ACTATTTGAA GTCTACCTAT CCAGAATTGA TGTGGAGCAT CAACTTGGAA TCGATGCTCG 1440

TGATTCTATC CTTGGCTATC AAATTGGTGA ACTTCGACGC GTCATTGGAG ACTCCACAAC 1500

CATGATAACC AGCCATCCAA CTGACATTCT TACTTCCTCA ACTACAATCC GAATGTTCAT 1560

GCACGGTGCC GCACAGAGTC GCGTAGACAG TCTGGTCCTT GATATGCTTC TTCCAAAGCA 1620

AATGATTCTC CAACTCGTCA AGTCAATTTT GACAGAGAGA CGTCTGGTGT TAGCTGGAGC 1680

AACTGGAATT GGAAAGAGCA AACTGGCGAA GACCCTGGCT GCTTATGTAT CTATTCGAAC 1740

AAATCAATCC GAAGATAGTA TTGTTAATAT CAGCATTCCT GAAAACAATA AAGAAGAATT 1800

GCTTCAAGTG GAACGACGCC TGGAAAAGAT CTATGAATCG TAGATACTGA AAAACCCCGC 1860

AAGTTCACTT CAACTGTGCA TCGTGCACCA TCTCAATTTC TTTCATTTAT ACATCGTTTT 1920

GCCTTCTTTT ATGTAACTAT ACTCCTCTAA GTTTCAATCT TGGCCATGTA ACCTCTGATC 1980

TATAGAATTT TTTAAATGAC TAGAATTAAT GCCCATCTTT TTTTTGGACC TAAATTCTTC 2040

ATGAAAATAT ATTACGAGGG CTTATTCAGA AGCTTTGGAC TTCTTCGCCA GAGGTTTGGT 2100

CAAGTCTCCA ATCAAGGTTG TCGGCTTGTC TACCTTGCCA GAAATTTACG AAAAGATGGA 2160

AAAGGGTCAA ATCGTTGGTA GATACGTTGT TGACACTTCT AAATAAGCGA ATTTCTTATG 2220

ATTTATGATT TTTATTATTA AATAAGTTAT AAAAAAAATA AGTGTATACA AATTTTAAAG 2280

TGACTCTTAG GTTTTAAAAC GAAAATTCTT GTTCTTGAGT AACTCTTTCC TGTAGGTCAG 2340

GTTGCTTTCT CAGGTATAGC ATGAGGTCGC TCTTATTGAC CACACCTCTA CCGGCATGCC 2400

CGAAATTCCC CTACCCTATG AACATATTCC ATTTTGTAAT TTCGTGTCGT TTCTATTATG 2460

AATTTCATTT ATAAAGTTTA TGTACAAATA TCATAAAAAA AGAGAATCTT TTTAAGCAAG 2520

GATTTTCTTA ACTTCTTCGG CGACAGCATC ACCGACTTCG GTGGTACTGT TGGAACCACC 2580

TAAATCACCA GTTCTGATAC CTGCATCCAA AACCTTTTTA ACTGCATCTT CAATGGCCTT 2640

ACCTTCTTCA GGCAAGTTCA ATGACAATTT CAACATCATT GCAGCAGACA AGATAGTGGC 2700

GATAGGGTCA ACCTTATTCT TTGGCAAATC TGGAGCAGAA CCGTGGCATG GTTCGTACAA 2760

ACCAAATGCG GTGTTCTTGT CTGGCAAAGA GGCCAAGGAC GCAGATGGCA ACAAACCCAA 2820

GGAACCTGGG ATAACGGAGG CTTCATCGGA GATGATATCA CCAAACATGT TGCTGGTGAT 2880

TATAATACCA TTTAGGTGGG TTGGGTTCTT AACTAGGATC ATGGCGGCAG AATCAATCAA 2940

TTGATGTTGA ACCTTCAATG TAGGAAATTC GTTCTTGATG GTTTCCTCCA CAGTTTTTCT 3000

CCATAATCTT GAAGAGGCCA AAACATTAGC TTTATCCAAG GACCAAATAG GCAATGGTGG 3060

CTCATGTTGT AGGGCCATGA AAGCGGCCAT TCTTGTGATT CTTTGCACTT CTGGAACGGT 3120

GTATTGTTCA CTATCCCAAG CGACACCATC ACCATCGTCT TCCTTTCTCT TACCAAAGTA 3180

AATACCTCCC ACTAATTCTC TGACAACAAC GAAGTCAGTA CCTTTAGCAA ATTGTGGCTT 3240

GATTGGAGAT AAGTCTAAAA GAGAGTCGGA TGCAAAGTTA CATGGTCTTA AGTTGGCGTA 3300

CAATTGAAGT TCTTTACGGA TTTTTAGTAA ACCTTGTTCA GGTCTAACAC TACCTGTACC 3360

CCATTTAGGA CCACCCACAG CACCTAACAA AACGGCATCA ACCTTCTTGG AGGCTTCCAG 3420

CGCCTCATCT GGAAGTGGGA CACCTGTAGC ATCGATAGCA GCACCACCAA TTAAATGATT 3480

TTCGAAATCG AACTTGACAT TGGAACGAAC ATCAGAAATA GCTTTAAGAA CCTTAATGGC 3540

TTCGGCTGTG ATTTCTTGAC CAACGTGGTC ACCTGGCAAA ACGACGATCT TCTTAGGGGC 3600

AGACATTAGA ATGGTATATC CTTGAAATAT ATATATATAT TGCTGAAATG TAAAAGGTAA 3660

GAAAAGTTAG AAAGTAAGAC GATTGCTAAC CACCTATTGG AAAAAACAAT AGGTCCTTAA 3720

ATAATATTGT CAACTTCAAG TATTGTGATG CAAGCATTTA GTCATGAACG CTTCTCTATT 3780

CTATATGAAA AGCCGGTTCC GGCCTCTCAC CTTTCCTTTT TCTCCCAATT TTTCAGTTGA 3840

AAAAGGTATA TGCGTCAGGC GACCTCTGAA ATTAACAAAA AATTTCCAGT CATCGAATTT 3900

GATTCTGTGC GATAGCGCCC CTGTGTGTTC TCGTTATGTT GAGGAAAAAA ATAATGGTTG 3960

CTAAGAGATT CGAACTCTTG CATCTTACGA TACCTGAGTA TTCCCACAGT TGGGGATCTC 4020

GACTCTAGCT AGAGGATCAA TTCGTAATCA TGGTCATAGC TGTTTCCTGT GTGAAATTGT 4080

TATCCGCTCA CAATTCCACA CAACATACGA GCCGGAAGCA TAAAGTGTAA AGCCTGGGGT 4140

GCCTAATGAG TGAGGTAACT CACATTAATT GCGTTGCGCT CACTGCCCGC TTTCCAGTCG 4200

GGAAACCTGT CGTGCCAGCT GGATTAATGA ATCGGCCAAC GCGCGGGGAG AGGCGGTTTG 4260

CGTATTGGGC GCTCTTCCGC TTCCTCGCTC ACTGACTCGC TGCGCTCGGT CGTTCGGCTG 4320

CGGCGAGCGG TATCAGCTCA CTCAAAGGCG GTAATACGGT TATCCACAGA ATCAGGGGAT 4380

AACGCAGGAA AGAACATGTG AGCAAAAGGC CAGCAAAAGG CCAGGAACCG TAAAAAGGCC 4440

GCGTTGCTGG CGTTTTTCCA TAGGCTCCGC CCCCCTGACG AGCATCACAA AAATCGACGC 4500

TCAAGTCAGA GGTGGCGAAA CCCGACAGGA CTATAAAGAT ACCAGGCGTT TCCCCCTGGA 4560

AGCTCCCTCG TGCGCTCTCC TGTTCCGACC CTGCCGCTTA CCGGATACCT GTCCGCCTTT 4620

CTCCCTTCGG GAAGCGTGGC GCTTTCTCAT AGCTCACGCT GTAGGTATCT CAGTTCGGTG 4680

TAGGTCGTTC GCTCCAAGCT GGGCTGTGTG CACGAACCCC CCGTTCAGCC CGACCGCTGC 4740

GCCTTATCCG GTAACTATCG TCTTGAGTCC AACCCGGTAA GACACGACTT ATCGCCACTG 4800

GCAGCAGCCA CTGGTAACAG GATTAGCAGA GCGAGGTATG TAGGCGGTGC TACAGAGTTC 4860

TTGAAGTGGT GGCCTAACTA CGGCTACACT AGAAGGACAG TATTTGGTAT CTGCGCTCTG 4920

CTGAAGCCAG TTACCTTCGG AAAAAGAGTT GGTAGCTCTT GATCCGGCAA ACAAACCACC 4980

GCTGGTAGCG GTGGTTTTTT TGTTTGCAAG CAGCAGATTA CGCGCAGAAA AAAAGGATCT 5040

CAAGAAGATC CTTTGATCTT TTCTACGGGG TCTGACGCTC AGTGGAACGA AAACTCACGT 5100

TAAGGGATTT TGGTCATGAG ATTATCAAAA AGGATCTTCA CCTAGATCCT TTTAAATTAA 5160

AAATGAAGTT TTAAATCAAT CTAAAGTATA TATGAGTAAA CTTGGTCTGA CAGTTACCAA 5220

TGCTTAATCA GTGAGGCACC TATCTCAGCG ATCTGTCTAT TTCGTTCATC CATAGTTGCC 5280

TGACTCCCCG TCGTGTAGAT AACTACGATA CGGGAGGGCT TACCATCTGG CCCCAGTGCT 5340

GCAATGATAC CGCGAGACCC ACGCTCACCG GCTCCAGATT TATCAGCAAT AAACCAGCCA 5400

GCCGGAAGGG CCGAGCGCAG AAGTGGTCCT GCAACTTTAT CCGCCTCCAT CCAGTCTATT 5460

AATTGTTGCC GGGAAGCTAG AGTAAGTAGT TCGCCAGTTA ATAGTTTGCG CAACGTTGTT 5520

GCCATTGCTA CAGGCATCGT GGTGTCACGC TCGTCGTTTG GTATGGCTTC ATTCAGCTCC 5580

GGTTCCCAAC GATCAAGGCG AGTTACATGA TCCCCCATGT TGTGCAAAAA AGCGGTTAGC 5640

TCCTTCGGTC CTCCGATCGT TGTCAGAAGT AAGTTGGCCG CAGTGTTATC ACTCATGGTT 5700

ATGGCAGCAC TGCATAATTC TCTTACTGTC ATGCCATCCG TAAGATGCTT TTCTGTGACT 5760

GGTGAGTACT CAACCAAGTC ATTCTGAGAA TAGTGTATGC GGCGACCGAG TTGCTCTTGC 5820

CCGGCGTCAA TACGGGATAA TACCGCGCCA CATAGCAGAA CTTTAAAAGT GCTCATCATT 5880

GGAAAACGTT CTTCGGGGCG AAAACTCTCA AGGATCTTAC CGCTGTTGAG ATCCAGTTCG 5940

ATGTAACCCA CTCGTGCACC CAACTGATCT TCAGCATCTT TTACTTTCAC CAGCGTTTCT 6000

GGGTGAGCAA AAACAGGAAG GCAAAATGCC GCAAAAAAGG GAATAAGGGC GACACGGAAA 6060

TGTTGAATAC TCATACTCTT CCTTTTTCAA TATTATTGAA GCATTTATCA GGGTTATTGT 6120

CTCATGAGCG GATACATATT TGAATGTATT TAGAAAAATA AACAAATAGG GGTTCCGCGC 6180

ACATTTCCCC GAAAAGTGCC ACCTGACGTC TAAGAAACCA TTATTATCAT GACATTAACC 6240

TATAAAAATA GGCGTATCAC GAGGCCCTTT CGTCTCGCGC GTTTCGGTGA TGACGGTGAA 6300

AACCTCTGAC ACATGCAGCT CCCGGAGACG GTCACAGCTT GTCTGTAAGC GGATGCCGGG 6360

AGCAGACAAG CCCGTCAGGG CGCGTCAGCG GGTGTTGGCG GGTGTCGGGG CTGGCTTAAC 6420

TATGCGGCAT CAGAGCAGAT TGTACTGAGA GTGCACCATA ACGCATTTAA GCATAAACAC 6480

GCACTATGCC GTTCTTCTCA TGTATATATA TATACAGGCA ACACGCAGAT ATAGGTGCGA 6540

CGTGAACAGT GAGCTGTATG TGCGCAGCTC GCGTTGCATT TTCGGAAGCG CTCGTTTTCG 6600

GAAACGCTTT GAAGTTCCTA TTCCGAAGTT CCTATTCTCT AGCTAGAAAG TATAGGAACT 6660

TCAGAGCGCT TTTGAAAACC AAAAGCGCTC TGAAGACGCA CTTTCAAAAA ACCAAAAACG 6720

CACCGGACTG TAACGAGCTA CTAAAATATT GCGAATACCG CTTCCACAAA CATTGCTCAA 6780

AAGTATCTCT TTGCTATATA TCTCTGTGCT ATATCCCTAT ATAACCTACC CATCCACCTT 6840

TCGCTCCTTG AACTTGCATC TAAACTCGAC CTCTACATTT TTTATGTTTA TCTCTAGTAT 6900

TACTCTTTAG ACAAAAAAAT TGTAGTAAGA ACTATTCATA GAGTGAATCG AAAACAATAC 6960

GAAAATGTAA ACATTTCCTA TACGTAGTAT ATAGAGACAA AATAGAAGAA ACCGTTCATA 7020

ATTTTCTGAC CAATGAAGAA TCATCAACGC TATCACTTTC TGTTCACAAA GTATGCGCAA 7080

TCCACATCGG TATAGAATAT AATCGGGGAT GCCTTTATCT TGAAAAAATG CACCCGCAGC 7140

TTCGCTAGTA ATCAGTAAAC GCGGGAAGTG GAGTCAGGCT TTTTTTATGG AAGAGAAAAT 7200

AGACACCAAA GTAGCCTTCT TCTAACCTTA ACGGACCTAC AGTGCAAAAA GTTATCAAGA 7260

GACTGCATTA TAGAGCGCAC AAAGGAGAAA AAAAGTAATC TAAGATGCTT TGTTAGAAAA 7320

ATAGCGCTCT CGGGATGCAT TTTTGTAGAA CAAAAAAGAA GTATAGATTC TTTGTTGGTA 7380

AAATAGCGCT CTCGCGTTGC ATTTCTGTTC TGTAAAAATG CAGCTCAGAT TCTTTGTTTG 7440

AAAAATTAGC GCTCTCGCGT TGCATTTTTG TTTTACAAAA ATGAAGCACA GATTCTTCGT 7500

TGGTAAAATA GCGCTTTCGC GTTGCATTTC TGTTCTGTAA AAATGCAGCT CAGATTCTTT 7560

GTTTGAAAAA TTAGCGCTCT CGCGTTGCAT TTTTGTTCTA CAAAATGAAG CACAGATGCT 7620

TCGTT 7625

(2) INFORMATION FOR SEQ ID NO: 30:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9642 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "plasmid"

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30:

ATGACCATGA TTACGCCAAG CTTGTCTTCT TCTAAATTCC CATAAAATCC CGAAACTCCT 60

TCCCTCTATC TTCTTTTTCT TCTCGTTTTC AAATGTTTCT CTCTATCCCA TTCTCTCATC 120

AATTGAGTGG GATGAGGCTA TCTCTGCCTC TCTTCTGAAT CTCTGAACCA TCTTACATTA 180

CACTGTGGAT GACGAGCCCC ACAGGCTCCC TTGCATCAGA TACTGCCATT GGGGATGGCA 240

AAGAAGAGAG AAGGTATTGT GAGGATATAT TTTTCTAAGA AAAAACGTTT GAAGAAAAGA 300

AGATGAAGAA GATCTGCTTG ATTCATTGCA CAAGTTAGAA GTAACAGGGG TCTATATTTC 360

GAAGAACTTA AAGGGAATGC AACTGAACAT AAAATTAAAC AAAGGGATTG AATCCTGCAG 420

TGAGTATTTT CGGTTTTTCA CTGGTTCTCT GTAAAAAGAG TAATGCAAAG GGCAAGTTAA 480

CTTAGGTCGT AAATGTATTG AATTTGCTTA AAATCTGAAG ATCTAGTGGT GAACCGTGGA 540

AGATTATCAA GAGGAGGCTG AAGATCTGTT TAAGAACCAT TAATCAAACT GGTATTCTAT 600

TTTCACTGGT TGTATGTAAA CATTCTATCT TATTCCTTTT ATCACTGTTC TGCACTTTCC 660

TATAAAAAAA GTTGACCGAC CGTACTCTCT GAATTCATTT TTCCCGATCT TACCAACTCC 720

CGATCTATCT CTATCCCTGG TTTTTTCTTC GTGCTCCAAT GGAATTCTTG AGACTTCCAC 780

TATCTTCTCT GGCACCCTCC ACTACGCGTA GGCGTCTCTC GCTTCGTGTA TTCCCGGGAA 840

GCCGGTTCCC GTCTCTCCCG CCGCTGCCGC TGCCGCACAC AGCTTTACAC CTCGTAGAAT 900

CCCCAAAGAG GGGCGTGGCT TGCGGGTGCC AACATCCTCC TGCCGAGGAA GAAGCAGGCA 960

CTCATCACTC GCATCATCAA CCTCGGGATT GGCCAAAGGA CCCAAAGGTA TGTTTCGAAT 1020

GATACTAACA TAACATAGAA CATTTTCAGG AGGACCCTTG GCTAGAACTA GTGGATCCGA 1080

GCTCTCCCAT ATGACGACGT CAAATGTAGA ATTGATACCA ATCTACACGG ATTGGGCCAA 1140

TCGGCACCTT TCGAAGGGCA GCTTATCAAA GTCGATTAGG GATATTTCCA ATGATTTTCG 1200

CGACTATCGA CTGGTTTCTC AGCTTATTAA TGTGATCGTT CCGATCAACG AATTCTCGCC 1260

TGCATTCACG AAACGTTTGG CAAAAATCAC ATCGAACCTG GATGGCCTCG AAACGTGTCT 1320

CGACTACCTG AAAAATCTGG GTCTCGACTG CTCGAAACTC ACCAAAACCG ATATCGACAG 1380

CGGAAACTTG GGTGCAGTTC TCCAGCTGCT CTTCCTGCTC TCCACCTACA AGCAGAAGCT 1440

TCGGCAACTG AAAAAAGATC AGAAGAAATT GGAGCAACTA CCCACATCCA TTATGCCACC 1500

CGCGGTTTCT AAATTACCCT CGCCACGTGT CGCCACGTCA GCAACCGCTT CAGCAACTAA 1560

CCCAAATTCC AACTTTCCAC AAATGTCAAC ATCCAGGCTT CAGACTCCAC AGTCAAGAAT 1620

ATCGAAAATT GATTCATCAA AGATTGGTAT CAAGCCAAAG ACGTCTGGAC TTAAACCACC 1680

CTCATCATCA ACCACTTCAT CAAATAATAC AAATTCATTC CGTCCGTCGA GCCGTTCGAG 1740

TGGCAATAAT AATGTTGGCT CGACGATATC CACATCTGCG AAGAGCTTAG AATCATCATC 1800

AACGTACAGC TCTATTTCGA ATCTAAACCG ACCTACCTCC CAACTCCAAA AACCTTCTAG 1860

ACCACAAACC CAGCTAGTTC GTGTTGCTAC AACTACAAAA ATCGGAAGCT CAAAGCTAGC 1920

CGCTCCGAAA GCCGTGAGCA CCCCAAAACT TGCTTCTGTG AAGACTATTG GAGCAAAACA 1980

AGAGCCCGAT AACAGCGGTG GTGGTGGTGG TGGAATGCTG AAATTAAAGT TATTCAGTAG 2040

CAAAAACCCA TCTTCCTCAT CGAATAGCCC ACAACCTACG AGAAAGGCGG CGGCGGTGCC 2100

TCAACAACAA ACTTTGTCGA AAATCGCTGC CCCAGTGAAA AGTGGCCTGA AGCCGCCGAC 2160

CAGTAAGCTG GGAAGTGCCA CGTCTATGTC GAAGCTTTGT ACGCCAAAAG TTTCCTACCG 2220

TAAAACGGAC GCCCCAATCA TATCTCAACA AGACTCGAAA CGATGCTCAA AGAGCAGTGA 2280

AGAAGAGTCC GGATACGCTG GATTCAACAG CACGTCGCCA ACGTCATCAT CGACGGAAGG 2340

TTCCCTAAGC ATGCATTCCA CATCTTCCAA GAGTTCAACG TCAGACGAAA AGTCTCCGTC 2400

ATCAGACGAT CTTACTCTTA ACGCCTCCAT CGTGACAGCT ATCAGACAGC CGATAGCCGC 2460

AACACCGGTT TCTCCAAATA TTATCAACAA GCCTGTTGAG GAAAAACCAA CACTGGCAGT 2520

GAAAGGAGTG AAAAGCACAG CGAAAAAAGA TCCACCTCCA GCTGTTCCGC CACGTGACAC 2580

CCAGCCAACA ATCGGAGTTG TTAGTCCAAT TATGGCACAT AAGAAGTTGA CAAATGACCC 2640

CGTGATATCT GAAAAACCAG AACCTGAAAA GCTCCAATCA ATGAGCATCG ACACGACGGA 2700

CGTTCCACCG CTTCCACCTC TAAAATCAGT TGTTCCACTT AAAATGACTT CAATCCGACA 2760

ACCACCAACG TACGATGTTC TTCTAAAACA AGGAAAAATC ACATCGCCTG TCAAGTCGTT 2820

TGGATATGAG CAGTCGTCCG CGTCTGAAGA CTCCATTGTG GCTCATGCGT CGGCTCAGGT 2880

GACTCCGCCG ACAAAAACTT CTGGTAATCA TTCGCTGGAG AGAAGGATGG GAAAGAATAA 2940

GACATCAGAA TCCAGCGGCT ACACCTCTGA CGCCGGTGTT GCGATGTGCG CCAAAATGAG 3000

GGAGAAGCTG AAAGAATACG ATGACATGAC TCGTCGAGCA CAGAACGGCT ATCCTGACAA 3060

CTTCGAAGAC AGTTCCTCCT TGTCGTCTGG AATATCCGAT AACAACGAGC TCGACGACAT 3120

ATCCACGGAC GATTTGTCCG GAGTAGACAT GGCAACAGTC GCCTCCAAAC ATAGCGACTA 3180

TTCCCACTTT GTTCGCCATC CCACGTCTTC TTCCTCAAAG CCCCGAGTCC CCAGTCGGTC 3240

CTCCACATCA GTCGATTCTC GATCTCGAGC AGAACAGGAG AATGTGTACA AACTTCTGTC 3300

CCAGTGCCGA ACGAGCCAAC GTGGCGCCGC TGCCACCTCA ACCTTCGGAC AACATTCGCT 3360

AAGATCCCCG GGATACTCAT CCTATTCTCC ACACTTATCA GTGTCAGCTG ATAAGGACAC 3420

AATGTCTATG CACTCACAGA CTAGTCGACG ACCTTCTTCA CAAAAACCAA GCTATTCAGG 3480

CCAATTTCAT TCACTTGATC GTAAATGCCA CCTTCAAGAG TTCACATCCA CCGAGCACAG 3540

AATGGCGGCT CTCTTGAGCC CGAGACGGGT GCCGAACTCG ATGTCGAAAT ATGATTCTTC 3600

AGGATCCTAC TCGGCGCGTT CCCGAGGTGG AAGCTCTACT GGTATCTATG GAGAGACGTT 3660

CCAACTGCAC AGACTATCCG ATGAAAAATC CCCCGCACAT TCTGCCAAAA GTGAGATGGG 3720

ATCCCAACTA TCACTGGCTA GCACGACAGC ATATGGATCT CTCAATGAGA AGTACGAACA 3780

TGCTATTCGG GACATGGCAC GTGACTTGGA GTGTTACAAG AACACTGTCG ACTCACTAAC 3840

CAAGAAACAG GAGAACTATG GAGCATTGTT TGATCTTTTT GAGCAAAAGC TTAGAAAACT 3900

CACTCAACAC ATTGATCGAT CCAACTTGAA GCCTGAAGAG GCAATACGAT TCAGGCAGGA 3960

CATTGCTCAT TTGAGGGATA TTAGCAATCA TCTTGCATCC AACTCAGCTC ATGCTAACGA 4020

AGGCGCTGGT GAGCTTCTTC GTCAACCATC TCTGGAATCA GTTGCATCCC ATCGATCATC 4080

GATGTCATCG TCGTCGAAAA GCAGCAAGCA GGAGAAGATC AGCTTGAGCT CGTTTGGCAA 4140

GAACAAGAAG AGCTGGATCC GCTCCTCACT CTCCAAGTTC ACCAAGAAGA AGAACAAGAA 4200

CTACGACGAA GCACATATGC CATCAATTTC CGGATCTCAA GGAACTCTTG ACAACATTGA 4260

TGTGATTGAG TTGAAGCAAG AGCTCAAAGA ACGCGATAGT GCACTTTACG AAGTCCGCCT 4320

TGACAATCTG GATCGTGCCC GCGAAGTTGA TGTTCTGAGG GAGACAGTGA ACAAGTTGAA 4380

AACCGAGAAC AAGCAATTAA AGAAAGAAGT GGACAAACTC ACCAACGGTC CAGCCACTCG 4440

TGCTTCTTCC CGCGCCTCAA TTCCAGTTAT CTACGACGAT GAGCATGTCT ATGATGCAGC 4500

GTGTAGCAGT ACATCAGCTA GTCAATCTTC GAAACGATCC TCTGGCTGCA ACTCAATCAA 4560

GGTTACTGTA AACGTGGACA TCGCTGGAGA AATCAGTTCG ATCGTTAACC CGGACAAAGA 4620

GATAATCGTA GGATATCTTG CCATGTCAAC CAGTCAGTCA TGCTGGAAAG ACATTGATGT 4680

TTCTATTCTA GGACTATTTG AAGTCTACCT ATCCAGAATT GATGTGGAGC ATCAACTTGG 4740

AATCGATGCT CGTGATTCTA TCCTTGGCTA TCAAATTGGT GAACTTCGAC GCGTCATTGG 4800

AGACTCCACA ACCATGATAA CCAGCCATCC AACTGACATT CTTACTTCCT CAACTACAAT 4860

CCGAATGTTC ATGCACGGTG CCGCACAGAG TCGCGTAGAC AGTCTGGTCC TTGATATGCT 4920

TCTTCCAAAG CAAATGATTC TCCAACTCGT CAAGTCAATT TTGACAGAGA GACGTCTGGT 4980

GTTAGCTGGA GCAACTGGAA TTGGAAAGAG CAAACTGGCG AAGACCCTGG CTGCTTATGT 5040

ATCTATTCGA ACAAATCAAT CCGAAGATAG TATTGTTAAT ATCAGCATTC CTGAAAACAA 5100

TAAAGAAGAA TTGCTTCAAG TGGAACGACG CCTGGAAAAG ATCTTGAGAA GCAAAGAATC 5160

ATGCATCGTA ATTCTAGATA ATATCCCAAA GAATCGAATT GCATTTGTTG TATCCGTTTT 5220

TGCAAATGTC CCACTTCAAA ACAACGAAGG TCCATTTGTA GTATGCACAG TCAACCGATA 5280

TCAAATCCCT GAGCTTCAAA TTCACCACAA TTTCAAAATG TCAGTAATGT CGAATCGTCT 5340

CGAAGGATTC ATCCTACGTT ACCTCCGACG ACGGGCGGTA GAGGATGAGT ATCGTCTAAC 5400

TGTACAGATG CCATCAGAGC TCTTCAAAAT CATTGACTTC TTCCCAATAG CTCTTCAGGC 5460

CGTCAATAAT TTTATTGAGA AAACGAATTC TGTTGATGTG ACAGTTGGTC CAAGAGCATG 5520

CTTGAACTGT CCTCTAACTG TCGATGGATC CCGTGAATGG TTCATTCGAT TGTGGAATGA 5580

GAACTTCATT CCATATTTGG AACGTGTTGC TAGAGATGGC AAAAAAACCT TCGGTCGCTG 5640

CACTTCCTTC GAGGATCCCA CCGACATCGT CTCTAAAAAA TGGCCGTGGT TCGATGGTGA 5700

AAACCCGGAG AATGTGCTCA AACGTCTTCA ACTCCAAGAC CTCGTCCCGT CACCTGCCAA 5760

CTCATCCCGA CAACACTTCA ATCCCCTCGA GTCGTTGATC CAATTGCATG CTACCAAGCA 5820

TCAGACCATC GACAACATTT GAACAGAAGA CTCTAATCTT CTCTCGCCTC TCCCCCGCTT 5880

TCCTTATCTT CGTACCGGTA CCATGGTATT GATATCTGAG CTCCGCATCG GCCGCTGTCA 5940

TCAGATCGCC ATCTCGCGCC CGTGCCTCTG ACTTCTAAGT CCAATTACTC TTCAACATCC 6000

CTACATGCTC TTTCTCCCTG TGCTCCCACC CCCTATTTTT GTTATTATCA AAAAAACTTC 6060

TTCTTAATTT CTTTGTTTTT TAGCTTCTTT TAAGTCACCT CTAACAATGA AATTGTGTAG 6120

ATTCAAAAAT AGAATTAATT CGTAATAAAA AGTCGAAAAA AATTGTGCTC CCTCCCCCCA 6180

TTAATAATAA TTCTATCCCA AAATCTACAC AATGTTCTGT GTACACTTCT TATGTTTTTT 6240

TTACTTCTGA TAAATTTTTT TTGAAACATC ATAGAAAAAA CCGCACACAA AATACCTTAT 6300

CATATGTTAC GTTTCAGTTT ATGACCGCAA TTTTTATTTC TTCGCACGTC TGGGCCTCTC 6360

ATGACGTCAA ATCATGCTCA TCGTGAAAAA GTTTTGGAGT ATTTTTGGAA TTTTTCAATC 6420

AAGTGAAAGT TTATGAAATT AATTTTCCTG CTTTTGCTTT TTGGGGGTTT CCCCTATTGT 6480

TTGTCAAGAG TTTCGAGGAC GGCGTTTTTC TTGCTAAAAT CACAAGTATT GATGAGCACG 6540

ATGCAAGAAA GATCGGAAGA AGGTTTGGGT TTGAGGCTCA GTGGAAGGTG AGTAGAAGTT 6600

GATAATTTGA AAGTGGAGTA GTGTCTATGG GGTTTTTGCC TTAAATGACA GAATACATTC 6660

CCAATATACC AAACATAACT GTTTAAAATT AAACATTTTT CTAAATTTTA TATGATTTCT 6720

TTTAAATTTG CAAAAATTAC TTAAATTTGA ATTCCCGCGC AAATGAGTGA CTTCATTTTC 6780

TGCATTATTG TGTTTTCCGG CTATATTAAT AGGTATTTGT TTGTGTTTTT CTTTATTTTA 6840

TGATTCGAAC TCCAATTTGT AAATTTTCGA ACATATTTCC CTAAAGAAAA AATATGATTA 6900

ATCTGGAAAA ATTGGAAAAT TATTTTTCAA ATAAAAAACA AAGAAAAAAA TGAAGAAAAA 6960

CCTATTAGTT TGGCCATAAA ACGCAAAAAT GTCGAAAATG ACGTCACTCA TCTGCGCGGG 7020

AAATCAAGAA TAATTCGGCC TTTTTTATTT TTTTGGAAAA TCGTAAAACA TTTAGAAAAA 7080

TTTTTTAATA GTTATAGTGG GACTGTATTC TGTCATTTAG GGCAAAAGCC AGAGACGCTA 7140

CTCCACCGTT GGGGGATCCA CTAGTCGGCC GTACGGGCCC TTTCGTCTCG CGCGTTTCGG 7200

TGATGACGGT GAAAACCTCT GACACATGCA GCTCCCGGAG ACGGTCACAG CTTGTCTGTA 7260

AGCGGATGCC GGGAGCAGAC AAGCCCGTCA GGGCGCGTCA GCGGGTGTTG GCGGGTGTCG 7320

GGGCTGGCTT AACTATGCGG CATCAGAGCA GATTGTACTG AGAGTGCACC ATATGCGGTG 7380

TGAAATACCG CACAGATGCG TAAGGAGAAA ATACCGCATC AGGCGGCCTT AAGGGCCTCG 7440

TGATACGCCT ATTTTTATAG GTTAATGTCA TGATAATAAT GGTTTCTTAG ACGTCAGGTG 7500

GCACTTTTCG GGGAAATGTG CGCGGAACCC CTATTTGTTT ATTTTTCTAA ATACATTCAA 7560

ATATGTATCC GCTCATGAGA CAATAACCCT GATAAATGCT TCAATAATAT TGAAAAAGGA 7620

AGAGTATGAG TATTCAACAT TTCCGTGTCG CCCTTATTCC CTTTTTTGCG GCATTTTGCC 7680

TTCCTGTTTT TGCTCACCCA GAAACGCTGG TGAAAGTAAA AGATGCTGAA GATCAGTTGG 7740

GTGCACGAGT GGGTTACATC GAACTGGATC TCAACAGCGG TAAGATCCTT GAGAGTTTTC 7800

GCCCCGAAGA ACGTTTTCCA ATGATGAGCA CTTTTAAAGT TCTGCTATGT GGCGCGGTAT 7860

TATCCCGTAT TGACGCCGGG CAAGAGCAAC TCGGTCGCCG CATACACTAT TCTCAGAATG 7920

ACTTGGTTGA GTACTCACCA GTCACAGAAA AGCATCTTAC GGATGGCATG ACAGTAAGAG 7980

AATTATGCAG TGCTGCCATA ACCATGAGTG ATAACACTGC GGCCAACTTA CTTCTGACAA 8040

CGATCGGAGG ACCGAAGGAG CTAACCGCTT TTTTGCACAA CATGGGGGAT CATGTAACTC 8100

GCCTTGATCG TTGGGAACCG GAGCTGAATG AAGCCATACC AAACGACGAG CGTGACACCA 8160

CGATGCCTGT AGCAATGGCA ACAACGTTGC GCAAACTATT AACTGGCGAA CTACTTACTC 8220

TAGCTTCCCG GCAACAATTA ATAGACTGGA TGGAGGCGGA TAAAGTTGCA GGACCACTTC 8280

TGCGCTCGGC CCTTCCGGCT GGCTGGTTTA TTGCTGATAA ATCTGGAGCC GGTGAGCGTG 8340

GGTCTCGCGG TATCATTGCA GCACTGGGGC CAGATGGTAA GCCCTCCCGT ATCGTAGTTA 8400

TCTACACGAC GGGGAGTCAG GCAACTATGG ATGAACGAAA TAGACAGATC GCTGAGATAG 8460

GTGCCTCACT GATTAAGCAT TGGTAACTGT CAGACCAAGT TTACTCATAT ATACTTTAGA 8520

TTGATTTAAA ACTTCATTTT TAATTTAAAA GGATCTAGGT GAAGATCCTT TTTGATAATC 8580

TCATGACCAA AATCCCTTAA CGTGAGTTTT CGTTCCACTG AGCGTCAGAC CCCGTAGAAA 8640

AGATCAAAGG ATCTTCTTGA GATCCTTTTT TTCTGCGCGT AATCTGCTGC TTGCAAACAA 8700

AAAAACCACC GCTACCAGCG GTGGTTTGTT TGCCGGATCA AGAGCTACCA ACTCTTTTTC 8760

CGAAGGTAAC TGGCTTCAGC AGAGCGCAGA TACCAAATAC TGTCCTTCTA GTGTAGCCGT 8820

AGTTAGGCCA CCACTTCAAG AACTCTGTAG CACCGCCTAC ATACCTCGCT CTGCTAATCC 8880

TGTTACCAGT GGCTGCTGCC AGTGGCGATA AGTCGTGTCT TACCGGGTTG GACTCAAGAC 8940

GATAGTTACC GGATAAGGCG CAGCGGTCGG GCTGAACGGG GGGTTCGTGC ACACAGCCCA 9000

GCTTGGAGCG AACGACCTAC ACCGAACTGA GATACCTACA GCGTGAGCAT TGAGAAAGCG 9060

CCACGCTTCC CGAAGGGAGA AAGGCGGACA GGTATCCGGT AAGCGGCAGG GTCGGAACAG 9120

GAGAGCGCAC GAGGGAGCTT CCAGGGGGAA ACGCCTGGTA TCTTTATAGT CCTGTCGGGT 9180

TTCGCCACCT CTGACTTGAG CGTCGATTTT TGTGATGCTC GTCAGGGGGG CGGAGCCTAT 9240

GGAAAAACGC CAGCAACGCG GCCTTTTTAC GGTTCCTGGC CTTTTGCTGG CCTTTTGCTC 9300

ACATGTTCTT TCCTGCGTTA TCCCCTGATT CTGTGGATAA CCGTATTACC GCCTTTGAGT 9360

GAGCTGATAC CGCTCGCCGC AGCCGAACGA CCGAGCGCAG CGAGTCAGTG AGCGAGGAAG 9420

CGGAAGAGCG CCCAATACGC AAACCGCCTC TCCCCGCGCG TTGGCCGATT CATTAATGCA 9480

GCTGGCACGA CAGGTTTCCC GACTGGAAAG CGGGCAGTGA GCGCAACGCA ATTAATGTGA 9540

GTTAGCTCAC TCATTAGGCA CCCCAGGCTT TACACTTTAT GCTTCCGGCT CGTATGTTGT 9600

GTGGAATTGT GAGCGGATAA CAATTTCACA CAGGAAACAG CT 9642

(2) INFORMATION FOR SEQ ID NO: 31:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 110 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31:

Met Thr Thr Ser Asn Val Glu Leu Ile Pro Ile Tyr Thr Asp Trp Ala
1 5 10 15

Asn Arg His Leu Ser Lys Gly Ser Leu Ser Lys Ser Ile Arg Asp Ile
20 25 30

Ser Asn Asp Phe Arg Asp Tyr Arg Leu Val Ser Gln Leu Ile Asn Val
35 40 45

Ile Val Pro Ile Asn Glu Phe Ser Pro Ala Phe Thr Lys Arg Leu Ala
50 55 60

Lys Ile Thr Ser Asn Leu Asp Gly Leu Glu Thr Cys Leu Asp Tyr Leu
65 70 75 80

Lys Asn Leu Gly Leu Asp Cys Ser Lys Leu Thr Lys Thr Asp Ile Asp
85 90 95

Ser Gly Asn Leu Gly Ala Val Leu Gln Leu Leu Phe Leu Leu
100 105 110

(2) INFORMATION FOR SEQ ID NO: 32:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32:

Lys Gln Lys Leu Arg Gln Leu Lys Lys Asp Gln Lys Lys Leu Glu Gln
1 5 10 15

Leu Pro Thr Ser
20

(2) INFORMATION FOR SEQ ID NO: 33:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33:

Asp Pro Pro Pro Ala Val Pro Pro Arg
1 5

(2) INFORMATION FOR SEQ ID NO: 34:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34:

Asp Val Pro Pro Leu Pro Pro Leu Lys
1 5

(2) INFORMATION FOR SEQ ID NO: 35:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35:

Lys Lys Lys Asn Lys
1 5

(2) INFORMATION FOR SEQ ID NO: 36:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36:

Lys Thr Glu Asn Lys Gln Leu Lys Lys Glu Val Asp Lys Leu Thr Asn
1 5 10 15

Gly Pro Ala Thr
20

(2) INFORMATION FOR SEQ ID NO: 37:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 37:

Gly Ala Thr Gly Ile Gly Lys Ser
1 5

(2) INFORMATION FOR SEQ ID NO: 38:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 58 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 38:

Met Ser Glu Glu Pro Thr Pro Val Ser Gly Asn Asp Lys Gln Leu Leu
1 5 10 15

Asn Lys Ala Trp Glu Ile Thr Gln Lys Lys Thr Phe Thr Ala Trp Cys
20 25 30

Asn Ser His Leu Arg Lys Leu Gly Ser Ser Ile Glu Gln Ile Asp Thr
35 40 45

Asp Phe Thr Asp Gly Ile Lys Leu Ala Gln
50 55

(2) INFORMATION FOR SEQ ID NO: 39:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 44 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 39:

Met Thr Thr Ser Asn Val Glu Leu Ile Pro Ile Tyr Thr Asp Trp Ala
1 5 10 15

Asn Arg His Leu Ser Lys Gly Ser Leu Ser Lys Ser Ile Arg Asp Ile
20 25 30

Ser Asn Asp Phe Arg Asp Tyr Arg Leu Val Ser Gln
35 40

(2) INFORMATION FOR SEQ ID NO: 40:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 51 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 40:

```
Phe Glu Arg Ser Arg Ile Lys Ala Leu Ala Asp Glu Arg Glu Val Val
1               5                  10                  15

Gln Lys Lys Thr Phe Thr Lys Trp Val Asn Ser His Leu Ala Arg Val
            20                  25                  30

Ser Cys Arg Ile Thr Asp Leu Tyr Lys Asp Leu Arg Asp Gly Arg Met
        35                  40                  45

Leu Ile Lys
    50
```

(2) INFORMATION FOR SEQ ID NO: 41:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 59 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 41:

```
Leu Leu Glu Val Ile Ser Asn Asp Pro Val Phe Lys Val Asn Lys Thr
1               5                  10                  15

Pro Lys Leu Arg Arg Ile His Asn Ile Gln Asn Val Gly Leu Cys Leu
            20                  25                  30

Lys His Ile Glu Ser His Gly Val Lys Leu Val Gly Ile Gly Ala Glu
        35                  40                  45

Glu Leu Val Asp Lys Asn Leu Lys Met Thr Leu
    50                  55
```

(2) INFORMATION FOR SEQ ID NO: 42:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 60 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 42:

```
Leu Ile Asn Val Ile Val Pro Ile Asn Glu Phe Ser Pro Ala Phe Thr
1               5                  10                  15

Lys Arg Leu Ala Lys Ile Thr Ser Asn Leu Asp Gly Leu Glu Thr Cys
            20                  25                  30

Leu Asp Tyr Leu Lys Asn Leu Gly Leu Asp Cys Ser Lys Leu Thr Lys
        35                  40                  45

Thr Asp Ile Asp Ser Gly Asn Leu Gly Ala Val Leu
    50                  55                  60
```

(2) INFORMATION FOR SEQ ID NO: 43:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 57 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 43:

Leu Leu Glu Val Leu Ser Gly Glu Met Leu Pro Lys Pro Thr Lys Gly
1 5 10 15

Lys Met Arg Ile His Cys Leu Glu Asn Val Asp Lys Ala Leu Gln Phe
20 25 30

Leu Lys Glu Gln Arg Val His Leu Glu Asn Met Gly Ser His Asp Ile
35 40 45

Val Asp Gly Asn His Arg Leu Val Leu
50 55

(2) INFORMATION FOR SEQ ID NO: 44:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 42 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 44:

Gly Met Ile Trp Thr Ile Ile Leu Arg Phe Ala Ile Gln Asp Ile Ser
1 5 10 15

Ile Glu Glu Leu Ser Ala Lys Glu Ala Leu Leu Leu Trp Cys Gln Arg
20 25 30

Lys Thr Glu Gly Tyr Asp Arg Val Lys Val
35 40

(2) INFORMATION FOR SEQ ID NO: 45:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 46 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 45:

Gln Leu Leu Phe Leu Leu Ser Thr Tyr Lys Gln Lys Leu Arg Gln Leu
1 5 10 15

Lys Lys Asp Gln Lys Lys Leu Glu Gln Leu Pro Thr Ser Ile Met Pro
20 25 30

Pro Ala Val Ser Lys Leu Pro Ser Pro Arg Val Ala Thr Ser
35 40 45

(2) INFORMATION FOR SEQ ID NO: 46:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 48 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 46:

Gly Leu Ile Trp Thr Ile Ile Leu Arg Phe Gln Ile Gln Asp Ile Val
1 5 10 15

Val Gln Thr Gln Glu Gly Arg Glu Thr Arg Ser Ala Lys Asp Ala Leu
20 25 30

Leu Gln Phe Leu Lys Glu Gln Arg Val His Leu Glu Asn Met Gly Ser
35 40 45

(2) INFORMATION FOR SEQ ID NO: 47:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 100 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cosmid DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 47:

GATCAGAAGA AATTGGAGCA ACTACCCACA TCCATTATGC CACCCGCGGT TTCTAAGTGA 60

GTTTAATTTT GAGTTTACGA CTACAAAAAT GTGTTCTTTA 100

(2) INFORMATION FOR SEQ ID NO: 48:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 91 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cosmid DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 48:

CCGCCTTCTG ACTTCGTGAC GACAGTCTCG ACACGTGGGG TTGCAGGTAG GAGTGGATGA 60

GTCGAAACTG ATAAGATAGT CATTTGAGAT C 91

CLAIMS:

1. A cDNA encoding an UNC-53 protein of C. elegans or a functional equivalent derivative fragment or bioprecursor of said protein, which cDNA comprises at least from nucleotide position 431 to nucleotide position 4647 of the sequence shown in Figure 1.

2. A cDNA as claimed in claim 1 comprising at least from nucleotide position 431 to the 3′ end of the sequence shown in Figure 1.

3. A cDNA as claimed in Claim 1 comprising at least from nucleotide position 64 to nucleotide position 4647 of the sequence as shown in Figure 1.

4. A cDNA as claimed in claim 3 comprising at least from nucleotide position 64 to the 3′ end of the sequence shown in Figure 1.

5. A cDNA as claimed in Claims 1 to 4 comprising the nucleotide sequence shown in Figure 1.

6. A cDNA encoding an UNC-53 protein of C. elegans or a functional equivalent, derivative, fragment or bioprecursor of said protein, which cDNA comprises at least from nucleotide position 431 to nucleotide position 4812 of the 7A variant of the sequence shown in Figure 2.

7. A cDNA as claimed in claim 6 comprising at least

from nucleotide position 431 to the 3′ end of the 7A variant of the sequences shown in figure 2.

8. A cDNA as claimed in Claim 6 comprising at least from nucleotide position 64 to nucleotide position 4812 of the sequence shown in Figure 2.

9. A cDNA as claimed in claim 8 comprising at least from nucleotide position 64 to the 3′ end of the 7A variant of the sequence shown in figure 2.

10. A cDNA as claimed in any of claims 6 to 9 comprising the nucleotide sequence of the 7A variant of the sequence shown in Figure 2.

11. A DNA expression vector which comprises a cDNA as claimed in any one of Claims 1 to 10.

12. A host cell transformed or transfected with the vector of Claim 11.

13. A host cell as claimed in Claim 12 which is a bacterial, an animal, a plant or an insect cell.

14. A transgenic cell comprising a transgene capable of expressing UNC-53 protein of C. elegans or a functional equivalent, derivative, fragment or bioprecursor of said protein.

15. A transgenic cell as claimed in Claim 14 which

cell is a C. elegans cell, an N4 neuroblastoma cell or an MCF-7 breast carcinoma cell.

16. A transgenic organism comprising a transgene capable of expressing UNC-53 protein of C. elegans or a functional equivalent, derivative, fragment or bioprecursor of said protein.

17. A transgenic organism as claimed in Claim 16 wherein said organism is C. elegans.

18. A transgenic organism as claimed in Claim 16 wherein said organism is an insect, a non-human mammal or a plant.

19. A mutant of C. elegans which comprises an induced mutation in the wild-type unc-53 gene, which mutation affects the regulation of cell motility or the shape or direction of cell migration.

20. An UNC-53 protein encoded by the cDNA of Claim 1 and which protein has the amino acid sequence shown in Figure 4 from amino acid position 135 to amino acid position 1528.

21. An UNC-53 protein encoded by the cDNA sequence of any of Claims 2 to 5 and which protein has the amino acid sequence shown in Figure 4.

22. An UNC-53 protein encoded by the cDNA sequence of Claim 6 and which protein has the amino acid

sequence shown in Figure 6 from amino acid position 135 to amino acid position 1583.

23. An UNC-53 protein encoded by the cDNA sequence according to any of Claims 7 to 10 and which protein has the amino acid sequence shown in Figure 6.

24. An UNC-53 protein of C. elegans, or a functional equivalent, derivative, fragment or bioprecursor of said protein, for use as a medicament to promote neuronal regeneration, revascularisation or wound healing, or for treatment of chronic neuro-degenerative diseases or acute traumatic injuries.

25. An UNC-53 protein as claimed in any one of Claims 20 to 23 for use as a medicament to promote neuronal regeneration, revascularisation or wound healing, or for treatment of chronic neuro-degenerative diseases or acute traumatic injuries.

26. Use of an UNC-53 protein of C. elegans, or a functional equivalent, derivative, fragment or bioprecursor of said protein in the manufacture of a medicament for promoting neuronal regeneration, revascularisation or wound healing, or for treatment of chronic neuro-degenerative diseases or acute traumatic injuries.

27. Use of an UNC-53 protein as claimed in any one of Claims 20 to 23 in the manufacture of a medicament for promoting neuronal regeneration, revascularisation or wound healing, or for treatment of chronic neuro-degenerative or acute traumatic injuries.

28. A pharmaceutical composition comprising an UNC-53 protein of C. elegans, a functional equivalent, derivative, bioprecursor or fragment of said protein and an acceptable carrier, diluent or excipient therefor.

29. A pharmaceutical composition as claimed in Claim 28 which comprises an UNC-53 protein as claimed in any one of Claims 20 to 23.

30. A nucleic acid sequence encoding an UNC-53 protein of C. elegans or a functional fragment, equivalent, derivative or bioprecursor of said protein, for use as a medicament to promote neuronal regeneration, vascularisation or wound healing, or for treatment of chronic neuro-degenerative diseases or acute traumatic injuries.

31. A nucleic acid sequence for use as claimed in Claim 27 wherein said sequence is a cDNA sequence as claimed in any one of Claims 1 to 10 or a functional fragment of said nucleic acid sequence.

32. Use of a nucleic acid sequence encoding and UNC-53 protein of C. elegans or a functional equivalent fragment, derivative or bioprecursor of said protein, in the manufacture of a medicament to promote neuronal regeneration, vascularization or wound healing, or for treatment of chronic neuro-degenerative diseases or acute traumatic injuries.

33. Use of a nucleic acid sequence as claimed in Claim 32 wherein said sequence is a cDNA sequence as

claimed in any one of Claims 1 to 10 or a functional fragment of said nucleic acid sequence.

34. A pharmaceutical composition comprising a nucleic sequence acid encoding an UNC-53 protein of C. elegans or a functional equivalent, derivative fragment or bioprecursor of said protein and an acceptable carrier, diluent, or excipient therefor.

35. A pharmaceutical composition as claimed in Claim 34 wherein said nucleic acid sequence is a cDNA sequence as claimed in any one of Claims 1 to 10.

36. A method of determining whether a compound is an inhibitor or an enhancer of the regulation of cell shape or motility or the direction of cell migration, which method comprises contacting said compound with a transgenic cell as claimed in Claims 14 or 15 and screening for a phenotypic change in said cell.

37. A method as claimed in Claim 36 wherein said compound is an inhibitor or an enhancer of a protein of the signal transduction pathway of said transgenic cell of which pathway UNC-53 protein or a functional equivalent, fragment or bioprecursor thereof is a component or said compound is an inhibitor or an enhancer of a parallel or redundant signal transduction pathway in said cell.

38. A method as claimed in Claim 36 or 37 wherein said protein is UNC-53 protein or a functional equivalent, fragment, derivative or bioprecursor thereof.

39. A method as claimed in any of Claims 36 to 38 wherein said phenotypic change to be screened is a change in cell shape or a change in cell motility.

40. A method as claimed in any of claims 36 to 38 wherein said phenotypic change to be screened is a change in filipodia outgrowth, ruffling behaviour, cell adhesion or the length of neurite growth.

41. A method as claimed in any of Claims 36 to 40 wherein said transgenic cell is an N4 neuroblastoma cell and the phenotypic change to be screened is the length of neurite growth.

42. A method as claimed in any of Claims 36 to 40 wherein said transgenic cell is an MCF-7 breast carcinoma cell and the phenotypic change to be screened is the extent of phagokinesis.

43. A method of determining whether a compound is an inhibitor or an enhancer of the regulation of cell shape or motility or of the direction of cell migration which method comprises administering said compound to a transgenic organism as claimed in any one of Claims 16 to 20, or a mutant organism as claimed in Claim 19, and screening for a phenotypic change in said organism.

44. A method as claimed in Claim 43 wherein said compound is an inhibitor or enhancer of a protein of the signal transduction pathway of said transgenic or mutant organisms, of which pathway UNC-53 protein or a functional equivalent, derivative or bioprecursor

thereof is a component or said compound is an inhibitor or an enhancer of a parallel or redundant signal transduction pathway in said cell.

45. A method as claimed in Claim 44 wherein said protein of the signal transduction pathway is UNC-53 protein itself or a functional equivalent, fragment, derivative or bioprecursor of said protein.

46. A compound which is identifiable by the method according to any one of Claims 36 to 45 as an enhancer of the regulation of cell shape or motility or the direction of cell migration for use as a medicament for promoting neuronal regeneration, revascularisation or wound healing, or for treatment of chronic neuro-degenerative diseases or acute traumatic injuries.

47. Use of a compound identifiable by the method of any one of Claims 36 to 45 as an enhancer of the regulation of cell shape or motility or the direction of cell migration in C. elegans in the manufacture of a medicament for promoting neuronal regeneration, revascularisation or wound healing, or for treatment of chronic neuro-degenerative diseases or acute traumatic injuries.

48. A pharmaceutical composition comprising the compound as claimed in Claim 46 and an acceptable carrier, diluent or excipient therefor.

49. A compound which is identifiable by the method according to any one of Claims 36 to 45 as an inhibitor of the regulation of cell motility or shape

or the direction of cell migration of C. elegans for use as a medicament for alleviating the spread of disease inducing cells or metastasis.

50. Use of a compound identifiable by the method according to any one of Claims 36 to 45 in the manufacture of a medicament for alleviating the spread of disease inducing cells or metastasis.

51. A pharmaceutical composition comprising the compound as claimed in Claim 49 and an acceptable carrier diluent or excipient therefor.

52. A transgenic cell which has been constructed to comprise a promoter sequence of an unc-53 gene of C. elegans fused to a nucleic acid sequence encoding a reporter molecule.

53. A transgenic cell as claimed in Claim 52 wherein said reporter molecule is green fluorescent protein (GFP).

54. A method of determining whether a compound is an inhibitor or an enhancer of transcription of an unc-53 gene in C. elegans or a functional fragment of said gene, which method comprises the steps of (a) contacting said compound with a transgenic cell according to Claim 52 and (b) monitoring of said reporter molecule and comparing the results obtained from said monitoring step with a control comprising a transgenic cell as claimed in Claim 48, which cell has not been contacted with said compound.

55. A method as claimed in Claim 54 wherein said reporter molecule detected is mRNA.

56. A method as claimed in Claim 54 wherein said reporter molecule detected is green fluorescent protein (GFP).

57. A compound which is identifiable by the method according to any one of Claims 54 to 56, as an enhancer of transcription of an unc-53 gene of C. elegans or a functional fragment of said gene for use in promoting neuronal regeneration, revascularisation or wound healing, or for treatment of chronic neuro-degenerative diseases or acute traumatic injuries.

58. Use of a compound which is identifiable by the method of any one of Claims 54 to 56 as an enhancer of transcription of an unc-53 gene of C. elegans or a functional fragment of said gene in the manufacture of a medicament for promoting neuronal regeneration, revascularisation or wound healing, or for treatment of chronic neuro-degenerative diseases or acute traumatic injuries.

59. A pharmaceutical composition which comprises the compound of Claim 57 and an acceptable carrier, diluent or excipient therefor.

60. A compound which is identifiable by the method of any one of Claims 54 to 56 as an inhibitor of transcription of an unc-53 gene of C. elegans or a functional fragment of said gene for use in

alleviating the spread of disease inducing cells or metastasis.

61. Use of a compound which is identifiable by the method of any one of Claims 54 to 56 as an inhibitor of transcription of an unc-53 gene of C. elegans or a functional fragment of said gene in the manufacture of a medicament for alleviating spread of disease inducing cells or metastasis.

62. A pharmaceutical composition which comprises the compound of Claim 60 and an acceptable carrier, diluent or excipient therefor.

63. A kit for determining whether a compound is an enhancer or an inhibitor of the regulation of cell motility or shape or the direction of cell migration which kit comprises at least a plurality of transgenic cells as claimed in any one of Claims 14 or 15 and a plurality of wild-type cells of the same cell or cell-line.

64. A kit for determining whether a compound is an inhibitor or an enhancer of transcription of an unc-53 gene of C. elegans or a functional fragment of said gene which kit comprises at least a plurality of transgenic cells as claimed in Claims 52 or 53 and means for monitoring the reporter molecule.

65. A kit for determining whether a compound is an enhancer or an inhibitor of the activity of UNC-53 protein or a functional equivalent, derivative, fragment or bioprecusor of said protein, which kit

comprises at least, one mutant organism of C. elegans as claimed in claim 10 or a transgenic organism as claimed in any of claims 16 to 18 and a wild type organism of C. elegans.

66. An oligonucleotide probe which comprises the carboxy-terminal 1.5 kb of the coding nucleic acid sequence shown in Figure 1 or a fragment thereof comprising between 18 and 24 base pairs.

67. An oligonucleotide probe comprising a nucleic acid sequence encoding the amino acid sequence as numbered 1 to 110, 114 to 133, 487 to 495, 537 to 545, 1032 to 1037, 1097 to 1116 or 1300 to 1307 shown in Figure 3 or a fragment thereof.

68. A probe as claimed in Claim 66 or 67 which is labelled for detection.

69. A method of identifying homologues of a C. elegans unc-53 gene or a functional fragment thereof which method comprises hybridizing to a C. elegans DNA library an oligonucleotide probe as claimed in any one of Claims 66 to 68 under appropriate conditions of stringency to identify genes having statistically significant homology with the cDNA of any one of Claims 1 to 10.

70. A method of identifying a protein which is active in the signal transduction pathway of a cell of which an UNC-53 protein or a functional equivalent, fragment or bioprecursor of said UNC-53 protein is a component, which method comprises:

component, which method comprises:

(a) contacting an extract of said c ll with an antibody to the UNC-53 protein of C.elegans or a functional equivalent, fragment, derivative or bioprecursor of said protein,

(b) identifying the antibody/UNC-53 complex, and

(c) analysing the complex to identify any protein bound to the UNC-53 protein other than the antibody.

71. A method of identifying a further protein which is active in the signal transduction pathway of a cell of which an UNC-53 protein or a functional equivalent, fragment or bioprecursor of said UNC-53 protein is a component which method comprises:

(a) forming an antibody to the identified protein bound to the UNC-53 protein in Claim 65,

(b) contacting a cell extract with said antibody and identifying the antibody/protein complex,

(c) analysing the complex to identify any further protein bound to the first protein other than the antibody, and

(d) optionally repeating steps (a) to (c) to identify further proteins in said pathway.

72. A method of identifying a protein which is active in the signal transduction pathway of a cell of which an UNC-53 protein or a functional equivalent, fragment or bioprecursor of said UNC-53 protein is a component, which method comprises

(a) contacting an extract of said cell with UNC-53 protein of C. elegans or a functional equivalent, derivative or bioprecursor of said UNC-53 protein

(b) identifying UNC-53 protein/protein complex formed and

(c) analysing the complex to identify any protein bound to the UNC-53 protein other than another UNC-53 protein.

73. A method according to claim 72 which further comprises contacting a cell extract with any protein identified from step (c) not being UNC-53 protein and repeating steps (b) and (c) so as to identify any further protein involved in the signal transduction pathway of said cell.

74. A method of identifying a protein involved in the signal transduction pathway of C. elegans which method comprises:

(a) constructing at least two nucleotide vectors, the first of which comprises a nucleotide segment encoding for a DNA binding domain of GAL4 protein fused to a sequence encoding UNC-53 protein of C. elegans or a functional equivalent, derivative, fragment or bioprecursor thereof, the second vector comprising a nucleotide sequence encoding a protein binding domain of GAL4 protein fused to a nucleotide sequence encoding a protein to be tested,

(b) co-transforming each of said vectors into a yeast cell being deficient for transcription of genes encoding galactose metabolites, wherein

interaction between said test protein and said UNC-53 protein leads to transcription of said galactose metabolite genes.

75. A protein identified by the method, of any one of claims 70 to 74 for use as a medicament to promote neuronal regeneration, revascularisation or wound healing, or for treatment of chronic neuro-degeroactive diseases or acute traumatic injuries.

76. Use of a protein identified by the methods of any one of claims 70 to 74 in the manufacture of a medicament for promoting neuronal regeneration, revasculerisation or wound healing, or for treatment of chronic neurodegenerative diseases or acute traumatic injuries.

77. A pharmaceutical composition comprising a protein identified by the methods of any one of Claims 70 to 74 and an acceptable carrier diluent, or excipient therefor.

78. A process for producing an UNC-53 protein of C. elegans or a functional equivalent fragment, derivative or bioprecursor of said UNC-53 protein which process comprises culturing the transfected or transformed cells of Claim 12 or Claim 13 and recovering the expressed UNC-53 protein.

79. A process for producing an UNC-53 protein of C. elegans or a functional equivalent fragment, derivative or bioprecursor of said protein which process comprises culturing an insect cell transfected

with a recombinant Baculovirus vector, said vector comprising a DNA insert encoding said UNC-53 protein or a functional equivalent, fragment or bioprecursor thereof, downstream of the Baculovirus polyhedrin promoter, and recovering the expressed UNC-53 protein.

80. A hybridoma cell line deposited under the LMBP Accession No. 1383CB.

81. Monoclonal antibody 16-48-2 obtainable from the hybridoma deposited under the LMBP Accession No. 1383CB.

82. Plasmid pTB54 deposited under the LMBP Accession No. 3296.

83. Plasmid pBT112 deposited under the Accession No. 3295.

84. Plasmid pTB72 deposited under the LMBP Accession No. 3486.

85. Transgenic cell-line of C.elegans designated TB4EX25 and deposited under the LMBP Accession No. 1384CB.

86. Transgenic cell-line of C. elegans designated TBAIn76 and deposited under the Accession No. 1385CB.

87. A transgenic cell-line of MCF-7 breast carcinoma

cells deposited under the LMBP Accession No. 1550CB.

88. A transgenic cell-line of N4 neuroblastoma cells deposited under LMBP Accession No. 1549CB.

1/99

FIG. 1.


TB6 & TB3
BSP1286
HGIAI
GGTTTAATTACCCAAGTTTGAGACATCAATTCCATCGAACGAAATGTTGGTGCTCCGA AT
10 20 30 40 50 60
OUT OF FRAME ATG
TTHIIII
.AHAII
.. AATII
BANI
AAAATGACGACGTCAAATGTAGAATTGATACCAATCTACACGGATTGGGCCAATCGGC AC
70 80 90 100 110 120
M T T S N V E L I P I Y T D W A N R H
ATG1
ASUII
BBVI
NRUI
CTTTCGAAGGGCAGCTTATCAAAGTCGATTAGGGATATTTCCAATGATTTTCGCGACT AT
130 140 150 160 170 180
L S K G S L S K S I R D I S N D F R D Y
TB1B
ECORI
BSMI
CGACTGGTTTCTCAGCTTATTAATGTGATCGTTCCGATCAACGAATTCTCGCCTGCAT TC
190 200 210 220 230 240
R L V S Q L I N V I V P I N E F S P A F
TB16
BSTNI
AFLIII
FOKI
ACGAAACGTTTGGCAAAAATCACATCGAACCTGGATGGCCTCGAAACGTGTCTCGACT AC
250 260 270 280 290 300
T K R L A K I T S N L D G L E T C L D Y
TB1
HPHI
ECORV
NSPBII
CTGAAAAATCTGGGTCTCGACTGCTCGAAACTCACCAAAACCGATATCGACAGCGGAA AC
310 320 330 340 350 360
L K N L G L D C S K L T K T D I D S G N
BBVI
MBOII
NSPBII
PVUII
HINDIII
TTGGGTGCAGTTCTCCAGCTGCTCTTCCTGCTCTCCACCTACAAGCAGAAGCTTCGGC AA
370 380 390 400 410 420
L G A V L Q L L F L L S T Y K Q K L R Q
FOKI
MBOII
NSPBII
.SACII
CTGAAAAAAGATCAGAAGAAATTGGAGCAACTACCCACATCCATTATGCCACCCGCGG TT
430 440 450 460 470 480
L K K D Q K K L E Q L P T S I M P P A V
ATG 2
AFLIII
TCTAAATTACCCTCGCCACGTGTCGCCACGTCAGCAACCGCTTCAGCAACTAACCCAA AT
490 500 510 520 530 540
S K L P S P R V A T S A T A S A T N P N
FOKI
HINCII
BSTNI
TCCAACTTTCCACAAATGTCAACATCCAGGCTTCAGACTCCACAGTCAAGAATATCGA AA
550 560 570 580 590 600
S N F P Q M S T S R L Q T P Q S R I S K
ATG3

FIG. 1 CONTINUED. 2/99



FIG. 1 CONTINUED. 3/99

```
     MBOII
     .BSPMII
     .. MBOII
TCCGGATACGCTGGATTCAACAGCACGTCGCCAACGTCATCATCGACGGAAGGTTCCC TA
      1270       1280       1290       1300       1310       1320
 S  G  Y  A  G  F  N  S  T  S  P  T  S  S  S  T  E  G  S  L

       BSMI
       SPHI
       . MBOII
       . NSII
AGCATGCATTCCACATCTTCCAAGAGTTCAACGTCAGACGAAAAGTCTCCGTCATCAG AC
      1330       1340       1350       1360       1370       1380
 S  M  H  S  T  S  S  K  S  S  T  S  D  E  K  S  P  S  S  D
   ATG5

GATCTTACTCTTAACGCCTCCATCGTGACAGCTATCAGACAGCCGATAGCCGCAACAC CG
      1390       1400       1410       1420       1430       1440
 D  L  T  L  N  A  S  I  V  T  A  I  R  Q  P  I  A  A  T  P

            SSPI
GTTTCTCCAAATATTATCAACAAGCCTGTTGAGGAAAAACCAACACTGGCAGTGAAAG GA
      1450       1460       1470       1480       1490       1500
 V  S  P  N  I  I  N  K  P  V  E  E  K  P  T  L  A  V  K  G

                BINI XHOII         NSPBII
                .    .             PVUII
GTGAAAAGCACAGCGAAAAAAGATCCACCTCCAGCTGTTCCGCCACGTGACACCCAGC CA
      1510       1520       1530       1540       1550       1560
 V  K  S  T  A  K  K  D  P  P  P  A  V  P  P  R  D  T  Q  P

                                                 HINCII             ECORV
ACAATCGGAGTTGTTAGTCCAATTATGGCACATAAGAAGTTGACAAATGACCCCGTGA TA
      1570       1580       1590       1600       1610       1620
 T  I  G  V  V  S  P  I  M  A  H  K  K  L  T  N  D  P  V  I

                              SFANI
TCTGAAAAACCAGAACCTGAAAAGCTCCAATCAATGAGCATCGACACGACGGACGTTC  CA
      1630       1640       1650       1660       1670       1680
 S  E  K  P  E  P  E  K  L  Q  S  M  S  I  D  T  T  D  V  P


CCGCTTCCACCTCTAAAATCAGTTGTTCCACTTAAAATGACTTCAATCCGACAACCAC CA
      1690       1700       1710       1720       1730       1740
 P  L  P  P  L  K  S  V  V  P  L  K  M  T  S  I  R  Q  P  P

    MBOII
ACGTACGATGTTCTTCTAAAACAAGGAAAAATCACATCGCCTGTCAAGTCGTTTGGAT AT
      1750       1760       1770       1780       1790       1800
 T  Y  D  V  L  L  K  Q  G  K  I  T  S  P  V  K  S  F  G  Y

  HGAI                        HGAI
  .                           . MBOII
GAGCAGTCGTCCGCGTCTGAAGACTCCATTGTGGCTCATGCGTCGGCTCAGGTGACTC CG
      1810       1820       1830       1840       1850       1860
 E  Q  S  S  A  S  E  D  S  I  V  A  H  A  S  A  Q  V  T  P

   HPHI                                                  FOKI
CCGACAAAAACTTCTGGTAATCATTCGCTGGAGAGAAGGATGGGAAAGAATAAGACAT CA
      1870       1880       1890       1900       1910       1920
 P  T  K  T  S  G  N  H  S  L  E  R  R  M  G  K  N  K  T  S

        NSPBII          AHAII   HGAI
GAATCCAGCGGCTACACCTCTGACGCCGGTGTTGCGATGTGCGCCAAAATGAGGGAGA AG
```

FIG. 1 CONTINUED. 4/99



FIG. 1 CONTINUED.

```
                SPEI
                .   SALI
                .   .ACCI
                .   ..HINCII
                .   ...MBOII
ATGCACTCACAGACTAGTCGACGACCTTCTTCACAAAAACCAAGCTATTCAGGCCAAT TT
     2410      2420      2430      2440      2450      2460
 M  H  S  Q  T  S  R  R  P  S  S  Q  K  P  S  Y  S  G  Q  F

                          FOKI                        BSP1286
                          .                           HGIAI
CATTCACTTGATCGTAAATGCCACCTTCAAGAGTTCACATCCACCGAGCACAGAATGG CG
     2470      2480      2490      2500      2510      2520
 H  S  L  D  R  K  C  H  L  Q  E  F  T  S  T  E  H  R  M  A

            AVAI
            .BANII
            .BSP1286 BANI                MBOII     BINI BAMHI
            ..       .                   .         .    XHOII
GCTCTCTTGAGCCCGAGACGGGTGCCGAACTCGATGTCGAAATATGATTCTTCAGGAT CC
     2530      2540      2550      2560      2570      2580
 A  L  L  S  P  R  R  V  P  N  S  M  S  K  Y  D  S  S  G  S

   BINI       AVAI
TACTCGGCGCGTTCCCGAGGTGGAAGCTCTACTGGTATCTATGGAGAGACGTTCCAAC TG
     2590      2600      2610      2620      2630      2640
 Y  S  A  R  S  R  G  G  S  S  T  G  I  Y  G  E  T  F  Q  L

                                                  BINI BAMHI
                                                  .    XHOII
CACAGACTATCCGATGAAAAATCCCCCGCACATTCTGCCAAAAGTGAGATGGGATCCC AA
     2650      2660      2670      2680      2690      2700
 H  R  L  S  D  E  K  S  P  A  H  S  A  K  S  E  M  G  S  Q

BINI       NHEI           NDEI
.          .              .   XHOII    BINI
CTATCACTGGCTAGCACGACAGCATATGGATCTCTCAATGAGAAGTACGAACATGCTA TT
     2710      2720      2730      2740      2750      2760
   L  S  L  A  S  T  T  A  Y  G  S  L  N  E  K  Y  E  H  A  I

                                          SALI
                                          .ACCI
                                          ..HINCII
CGGGACATGGCACGTGACTTGGAGTGTTACAAGAACACTGTCGACTCACTAACCAAGA AA
     2770      2780      2790      2800      2810      2820
 R  D  M  A  R  D  L  E  C  Y  K  N  T  V  D  S  L  T  K  K

                                             HINDIII
CAGGAGAACTATGGAGCATTGTTTGATCTTTTTGAGCAAAAGCTTAGAAAACTCACTC AA
     2830      2840      2850      2860      2870      2880
 Q  E  N  Y  G  A  L  F  D  L  F  E  Q  K  L  R  K  L  T  Q

     BINI
     .   CLAI                             MBOII
CACATTGATCGATCCAACTTGAAGCCTGAAGAGGCAATACGATTCAGGCAGGACATTG CT
     2890      2900      2910      2920      2930      2940
 H  I  D  R  S  N  L  K  P  E  E  A  I  R  F  R  Q  D  I  A
```

FIG. 1 CONTINUED.



7/99

FIG. 1 CONTINUED.

```
                                                                  SFANI
TCCCGCGCCTCAATTCCAGTTATCTACGACGATGAGCATGTCTATGATGCAGCGTGTA GC
      3430       3440       3450       3460       3470       3480
 S  R  A  S  I  P  V  I  Y  D  D  E  H  V  Y  D  A  A  C  S

 BBVI       MBOII       ASUII
 .          .           .BINI
 .          .           .. BBVI
AGTACATCAGCTAGTCAATCTTCGAAACGATCCTCTGGCTGCAACTCAATCAAGGTTA CT
      3490       3500       3510       3520       3530       3540
 S  T  S  A  S  Q  S  S  K  R  S  S  G  C  N  S  I  K  V  T

                                     PVUI
                                     .   HINCII
                                     .   HPAI
                                     .   .   NCII
GTAAACGTGGACATCGCTGGAGAAATCAGTTCGATCGTTAACCCGGACAAAGAGATAA TC
      3550       3560       3570       3580       3590       3600
 V  N  V  D  I  A  G  E  I  S  S  I  V  N  P  D  K  E  I  I

       ECORV        HINCII
GTAGGATATCTTGCCATGTCAACCAGTCAGTCATGCTGGAAAGACATTGATGTTTCTA TT
      3610       3620       3630       3640       3650       3660
 V  G  Y  L  A  M  S  T  S  Q  S  C  W  K  D  I  D  V  S  I

                  ACCI            SFANI                        CLAI
CTAGGACTATTTGAAGTCTACCTATCCAGAATTGATGTGGAGCATCAACTTGGAATCG AT
      3670       3680       3690       3700       3710       3720
 L  G  L  F  E  V  Y  L  S  R  I  D  V  E  H  Q  L  G  I  D

       SFANI   STYI               HGAI      AFLIII
       .       .                  .         MLUI
       .       .                  .         .HPHI    HGAI
GCTCGTGATTCTATCCTTGGCTATCAAATTGGTGAACTTCGACGCGTCATTGGAGACT CC
      3730       3740       3750       3760       3770       3780
 A  R  D  S  I  L  G  Y  Q  I  G  E  L  R  R  V  I  G  D  S

      FOKI
ACAACCATGATAACCAGCCATCCAACTGACATTCTTACTTCCTCAACTACAATCCGAA TG
      3790       3800       3810       3820       3830       3840
 T  T  M  I  T  S  H  P  T  D  I  L  T  S  S  T  T  I  R  M

          BANI                ACCI       AVAII  MBOII
TTCATGCACGGTGCCGCACAGAGTCGCGTAGACAGTCTGGTCCTTGATATGCTTCTTC CA
      3850       3860       3870       3880       3890       3900
 F  M  H  G  A  A  Q  S  R  V  D  S  L  V  L  D  M  L  L  P

                                                 AHAII
                                                 .  AATII
AAGCAAATGATTCTCCAACTCGTCAAGTCAATTTTGACAGAGAGACGTCTGGTGTTAG CT
      3910       3920       3930       3940       3950       3960
 K  Q  M  I  L  Q  L  V  K  S  I  L  T  E  R  R  L  V  L  A

                                  BBVI       BSTNI
                                  .          .    MBOII
GGAGCAACTGGAATTGGAAAGAGCAAACTGGCGAAGACCCTGGCTGCTTATGTATCTA TT
      3970       3980       3990       4000       4010       4020
 G  A  T  G  I  G  K  S  K  L  A  K  T  L  A  A  Y  V  S  I
```

FIG. 1 CONTINUED. 8/99



FIG. 1 CONTINUED. 9/99

```
  BINI BAMHI
   .    XHOII    BINI TTHIIII        EAEI                      NCII
CTTCGAGGATCCCACCGACATCGTCTCTAAAAAATGGCCGTGGTTCGATGGTGAAAAC CC
      4630       4640       4650       4660       4670       4680
 L  R  G  S  H  R  H  R  L

  HPHI      MBOII
   .        .BSP1286
   .        .HGIAI                   TTHIIII
   .        ..                       .HPHI    FOKI         BSPMI
GGAGAATGTGCTCAAACGTCTTCAACTCCAAGACCTCGTCCCGTCACCTGCCAACTCA TC
      4690       4700       4710       4720       4730       4740

                    AVAI
                    XHOI BINI              SFANI
                    .    .                 . SPHI
CCGACAACACTTCAATCCCCTCGAGTCGTTGATCCAATTGCATGCTACCAAGCATCAG AC
      4750       4760       4770       4780       4790       4800

                          MBOII     MBOII                 MBOII
CATCGACAACATTTGAACAGAAGACTCTAATCTTCTCTCGCCTCTCCCCCGCTTTCCT TA
      4810       4820       4830       4840       4850       4860

            BANI
            .   KPNI
TCTTCGTACCGGTACCTGATGATTCCCCATTTTCCCCCTTTTCCCCCCAATTTCCCAG AA
      4870       4880       4890       4900       4910       4920

                              AVAI
                              .NCII
                              ..NCII
                              ..SMAI
                              ... BANI   AHAII   HGAI  DRAI
CCTCCTGTTCCCTTTGTTCCTAGTCCTCCCGGGTGCCGACGCCGAAGCGATTTAAAAA CC
      4930       4940       4950       4960       4970       4980

                  XMNI
TTTTTCTTTCCGAAACATTTCCCATTGCTCATTAATAGTCAAATTGAATAAACAGTGT AT
      4990       5000       5010       5020       5030       5040


GTACTTAAAAAAAAAAAAAAAAAAAAAAAAAAA
      5050       5060       5070
```

COMPARISON OF 7A VS 8A CLONE 10/99 FIG. 2.



FIG. 2 CONTINUED. 11/99



FIG. 2 CONTINUED. 12/99

```
   MBOII
   .BSPMII
   .. MBOII
TCCGGATACGCTGGATTCAACAGCACGTCGCCAACGTCATCATCGACGGAAGGTTCCCTA
     1270      1280      1290      1300      1310      1320
 S G Y A G F N S T S P T S S S T E G S L

     BSMI
     SPHI
     . MBOII
     . NSII                                          |START CE7
AGCATGCATTCCACATCTTCCAAGAGTTCAACGTCAGACGAAAAGTCTCCGTCATCAGAC
     1330      1340      1350      1360      1370      1380
 S M H S T S S K S S T S D E K S P S S D

GATCTTACTCTTAACGCCTCCATCGTGACAGCTATCAGACAGCCGATAGCCGCAACACCG
     1390      1400      1410      1420      1430      1440
 D L T L N A S I V T A I R Q P I A A T P

           SSPI
GTTTCTCCAAATATTATCAACAAGCCTGTTGAGGAAAAACCAACACTGGCAGTGAAAGGA
     1450      1460      1470      1480      1490      1500
 V S P N I I N K P V E E K P T L A V K G

               BINI XHOII        NSPBII
                .   .            PVUII
GTGAAAAGCACAGCGAAAAAAGATCCACCTCCAGCTGTTCCGCCACGTGACACCCAGCCA
     1510      1520      1530      1540      1550      1560
 V K S T A K K D P P P A V P P R D T Q P

                                          HINCII          ECORV
ACAATCGGAGTTGTTAGTCCAATTATGGCACATAAGAAGTTGACAAATGACCCCGTGATA
     1570      1580      1590      1600      1610      1620
 T I G V V S P I M A H K K L T N D P V I

                          SFANI
TCTGAAAAACCAGAACCTGAAAAGCTCCAATCAATGAGCATCGACACGACGGACGTTCCA
     1630      1640      1650      1660      1670      1680
 S E K P E P E K L Q S M S I D T T D V P

CCGCTTCCACCTCTAAAATCAGTTGTTCCACTTAAAATGACTTCAATCCGACAACCACCA
     1690      1700      1710      1720      1730      1740
 P L P P L K S V V P L K M T S I R Q P P

   MBOII
ACGTACGATGTTCTTCTAAAACAAGGAAAAATCACATCGCCTGTCAAGTCGTTTGGATAT
     1750      1760      1770      1780      1790      1800
 T Y D V L L K Q G K I T S P V K S F G Y

  BGAI                      HGAI
  .                         . MBOII
GAGCAGTCGTCCGCGTCTGAAGACTCCATTGTGGCTCATGCGTCGGCTCAGGTGACTCCG
     1810      1820      1830      1840      1850      1860
 E Q S S A S E D S I V A H A S A Q V T P

  HPHI                                                FOKI
CCGACAAAAACTTCTGGTAATCATTCGCTGGAGAGAAGGATGGGAAAGAATAAGACATCA
     1870      1880      1890      1900      1910      1920
 P T K T S G N H S L E R R M G K N K T S
```

FIG. 2 CONTINUED. 13/99

```
        NSPBII          AHAII   HGAI
GAATCCAGCGGCTACACCTCTGACGCCGGTGTTGCGATGTGCGCCAAAATGAGGGAGAAG
      1930      1940      1950      1960      1970      1980
 E  S  S  G  Y  T  S  D  A  G  V  A  M  C  A  K  M  R  E  K

                                  BSP1286
                                  HGIAI                   ASUII
CTGAAAGAATACGATGACATGACTCGTCGAGCACAGAACGGCTATCCTGACAACTTCGAA
      1990      2000      2010      2020      2030      2040
 L  K  E  Y  D  D  M  T  R  R  A  Q  N  G  Y  P  D  N  F  E

          MBOII                                  BANII
          .                                      BSP1286
          .                                      HGIAI
          .                                      SACI
GACAGTTCCTCCTTGTCGTCTGGAATATCCGATAACAACGAGCTCGACGACATATCCACG
      2050      2060      2070      2080      2090      2100
 D  S  S  S  L  S  S  G  I  S  D  N  N  E  L  D  D  I  S  T


              BSPMII
              .  ACCI                                    FOKI
GACGATTTGTCCGGAGTAGACATGGCAACAGTCGCCTCCAAACATAGCGACTATTCCCAC
      2110      2120      2130      2140      2150      2160
 D  D  L  S  G  V  D  M  A  T  V  A  S  K  H  S  D  Y  S  H

            MBOII
            .  MBOII                AVAI            AVAII
TTTGTTCGCCATCCCACGTCTTCTTCCTCAAAGCCCCGAGTCCCCAGTCGGTCCTCCACA
      2170      2180      2190      2200      2210      2220
 F  V  R  H  P  T  S  S  S  S  K  P  R  V  P  S  R  S  S  T

                AVAI
                XHOI
TCAGTCGATTCTCGATCTCGAGCAGAACAGGAGAATGTGTACAAACTTCTGTCCCAGTGC
      2230      2240      2250      2260      2270      2280
 S  V  D  S  R  S  R  A  E  Q  E  N  V  Y  K  L  L  S  Q  C

          BBVI BGLI
          .    . BANI
          .    . .AHAII
          .    . .NARI
          .    . ..  HAEII
          .    . ..  . NSPBII                        BINI XHOII
          .    . ..  . .                             .    . FOKI
CGAACGAGCCAACGTGGCGCCGCTGCCACCTCAACCTTCGGACAACATTCGCTAAGATCC
      2290      2300      2310      2320      2330      2340
 R  T  S  Q  R  G  A  A  A  T  S  T  F  G  Q  H  S  L  R  S


AVAI
.NCII
..NCII
..SMAI                                  NSPBII
...                                     PVUII
CCGGGATACTCATCCTATTCTCCACACTTATCAGTGTCAGCTGATAAGGACACAATGTCT
      2350      2360      2370      2380      2390      2400
 P  G  Y  S  S  Y  S  P  H  L  S  V  S  A  D  K  D  T  M  S
```

FIG. 2 CONTINUED. 14/99



FIG. 2 CONTINUED. 15/99



FIG. 2 CONTINUED. 16/99

```
                                                                  SFANI
TCCCGCGCCTCAATTCCAGTTATCTACGACGATGAGCATGTCTATGATGCAGCGTGTAGC
      3430       3440       3450       3460       3470       3480
 S  R  A  S  I  P  V  I  Y  D  D  E  H  V  Y  D  A  A  C  S

 BBVI       MBOII       ASUII
 .          .           .BINI
 .          .           .. BBVI
AGTACATCAGCTAGTCAATCTTCGAAACGATCCTCTGGCTGCAACTCAATCAAGGTTACT
      3490       3500       3510       3520       3530       3540
 S  T  S  A  S  Q  S  S  K  R  S  S  G  C  N  S  I  K  V  T

                                      PVUI
                                      .   HINCII
                                      .   HPAI
                                      .   .   NCII
GTAAACGTGGACATCGCTGGAGAAATCAGTTCGATCGTTAACCCGGACAAAGAGATAATC
      3550       3560       3570       3580       3590       3600
 V  N  V  D  I  A  G  E  I  S  S  I  V  N  P  D  K  E  I  I

       ECORV       HINCII
GTAGGATATCTTGCCATGTCAACCAGTCAGTCATGCTGGAAAGACATTGATGTTTCTATT
      3610       3620       3630       3640       3650       3660
 V  G  Y  L  A  M  S  T  S  Q  S  C  W  K  D  I  D  V  S  I

                 ACCI            SFANI                        CLAI
CTAGGACTATTTGAAGTCTACCTATCCAGAATTGATGTGGAGCATCAACTTGGAATCGAT
      3670       3680       3690       3700       3710       3720
 L  G  L  F  E  V  Y  L  S  R  I  D  V  E  H  Q  L  G  I  D

       SFANI   STYI              HGAI      AFLIII
       .       .                 .         MLUI
       .       .                 .         .HPHI   HGAI
GCTCGTGATTCTATCCTTGGCTATCAAATTGGTGAACTTCGACGCGTCATTGGAGACTCC
      3730       3740       3750       3760       3770       3780
 A  R  D  S  I  L  G  Y  Q  I  G  E  L  R  R  V  I  G  D  S

     FOKI
ACAACCATGATAACCAGCCATCCAACTGACATTCTTACTTCCTCAACTACAATCCGAATG
      3790       3800       3810       3820       3830       3840
 T  T  M  I  T  S  H  P  T  D  I  L  T  S  S  T  T  I  R  M

          BANI                ACCI       AVAII  MBOII
TTCATGCACGGTGCCGCACAGAGTCGCGTAGACAGTCTGGTCCTTGATATGCTTCTTCCA
      3850       3860       3870       3880       3890       3900
 F  M  H  G  A  A  Q  S  R  V  D  S  L  V  L  D  M  L  L  P

                                                 AHAII
                                                 .  AATII
AAGCAAATGATTCTCCAACTCGTCAAGTCAATTTTGACAGAGAGACGTCTGGTGTTAGCT
      3910       3920       3930       3940       3950       3960
 K  Q  M  I  L  Q  L  V  K  S  I  L  T  E  R  R  L  V  L  A

                                BBVI       BSTNI
                                .          .    MBOII
GGAGCAACTGGAATTGGAAAGAGCAAACTGGCGAAGACCCTGGCTGCTTATGTATCTATT
      3970       3980       3990       4000       4010       4020
 G  A  T  G  I  G  K  S  K  L  A  K  T  L  A  A  Y  V  S  I
```

FIG. 2 CONTINUED. 17/99



18/99

FIG. 2 CONTINUED.



FIG. 3 19/99

Sequences of low complexity in UNC-53 TB3-M5 identified with the FILTER and SEG algorithms of the BLAST sequence homology package.

MTTSNVELIPIYTDWANRHLSKGSLSKSIRDISNDFRDYRLVSQLINVIVPINEFSPAFT
KRLAKITSNLDGLETCLDYLKNLGLDCSKLTKTDIDSGNLGAVLQLLFLLSTYXXXXXXX
XXXXXXXXXXPTSIMPPAVSKLXXXXXXXXXXXXXXXXXXXXFPQMSTSRLQTPQXXXXXX
XXXXXXXXXXTSGLKPXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
XXXNLNRPTSQLQKPSRPQTQLVRVATTTKIGSSKLAAPKAVSTPKLASVKTIGAKQEPD
NSXXXXXXMXXXXXXXXXXXXXXXXXXQPTRKAAAVPQQQTLSKIAAPVKSGLKPPTSKL
GSATSMSKLCTPKVSYRKTDAPIISQQDSKRCSKXXXXXXGYAGFNXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXDDLTLNASIVTAIRQPIAATPVSPNIINKPVEEKPTLAVKGV
KSTAKKDPPPAVPPRDTQPTIGVVSPIMAHKKLTNDPVISEKPEPEKLQSMSIDTTDXXX
XXXXXXXXXXXMTSIRQPPTYDVLLKQGKITSPVKSFGYEQSSASEDSIVAHASAQVTPP
TKTSGNHSLERRMGKNKTSESSGYTSDAGVAMCAKMREKLKEYDDMTRRAQNGYPDNFED
XXXXXXXXXDNNELDDISTDDLSGVDMATVASKHSDYSHFVRHPXXXXXXXXXXXXXXXX
XXXXXXAEQENVYKLLSQCRTSQRGAAATSTFGQHSLRSPGYSSYSPHLSVSADKDTMSM
HSQTSRRPSSQKPSYSGQFHSLDRKCHLQEFTSTEHRMAALLSPRRVPNXXXXXXXXXXX
XXXXXXXXXXXIYGETFQLHRLSDEKSPAHSAKSEMGSQLSLASTTAYGSLNEKYEHAIR
DMARDLECYKNTVDSLTKKQENYGALFDLFEQKLRKLTQHIDRSNLKPEEAIRFRQDIAH
LRDISNHLASNSAHANEGAGELLRQPSLEXXXXXXXXXXXXXXXXXXXXXXXXXFGKNKK
SWIRSSLSKFTKKKNKNYDEAHMPSISGSQGTLDNIDVIELKQELKERDSALYEVRLDNL
DRAREVDVLRETVNKLKTENKQLKKEVDKLTNGPATRASSRASIPVIYDDEHVYDXXXXX
XXXXXXXXXXXGCNXXXXXXXXXXXXXXXXXXXXDKEIIVGYLAMSTSQSCWKDIDVSIL
GLFEVYLSRIDVEHQLGIDARDSILGYQIGELRRVIGDSTTMITSHPTDILTSSTTIRMF
MHGAAQSRVDSLVLDMLLPKQMILQLVKSILTERRLVLAGATGIGKSKLAKTLAAYVSIR
TNQSEDSIVNISIPENNKEELLQVERRLEKILRSKESCIVILDNIPKNRIAFVVSVFANV
PLQNNEGPFVVCTVNRYQIPELQIHHNFKMSVMSNRLEGFILRYLRRRAVEDEYRLTVQM
PSELFKIIDFFPIALQAVNNFIEKTNSVDVTVGPRACLNCPLTVDGSREWFIRLWNENFI
PYLERVARDGKKNLRSLHFLRGSHRHRL

MTTSNVELIPIYTDWANRHLSKGSLSKSIRDISNDFRDYRLVSQLINVIVPINEFSPAFT
KRLAKITSNLDGLETCLDYLKNLGLDCSKLTKTDIDSGNLGAVLQLLFLLSTYKQKLRQL
KKDQKKLEQLPTSIMPPAVSKLPSPRVATSATASATNPNSNFPQMSTSRLQTPQSRISKI
DSSKIGIKPKTSGLKPPSSSTTSSNNTNSFRPSSRSSGNNNVGSTISTSAKSLESSSTYS
SISNLNRPTSQLQKPSRPQTQLVRVATTTKIGSSKLAAPKAVSTPKLASVKTIGAKQEPD
NSGGGGGGMLKLKLFSSKNPSSSSNSPQPTRKAAAVPQQQTLSKIAAPVKSGLKPPTSKL
GSATSMSKLCTPKVSYRKTDAPIISQQDSKRCSKSSEEESGYAGFNSTSPTSSSTEGSLS
MHSTSSKSSTSDEKSPSSDDLTLNASIVTAIRQPIAATPVSPNIINKPVEEKPTLAVKGV
KSTAKKDPPPAVPPRDTQPTIGVVSPIMAHKKLTNDPVISEKPEPEKLQSMSIDTTDVPP
LPPLKSVVPLKMTSIRQPPTYDVLLKQGKITSPVKSFGYEQSSASEDSIVAHASAQVTPP
TKTSGNHSLERRMGKNKTSESSGYTSDAGVAMCAKMREKLKEYDDMTRRAQNGYPDNFED
SSSLSSGISDNNELDDISTDDLSGVDMATVASKHSDYSHFVRHPTSSSSKPRVPSRSSTS
VDSRSRAEQENVYKLLSQCRTSQRGAAATSTFGQHSLRSPGYSSYSPHLSVSADKDTMSM
HSQTSRRPSSQKPSYSGQFHSLDRKCHLQEFTSTEHRMAALLSPRRVPNSMSKYDSSGSY
SARSRGGSSTGIYGETFQLHRLSDEKSPAHSAKSEMGSQLSLASTTAYGSLNEKYEHAIR
DMARDLECYKNTVDSLTKKQENYGALFDLFEQKLRKLTQHIDRSNLKPEEAIRFRQDIAH
LRDISNHLASNSAHANEGAGELLRQPSLESVASHRSSMSSSSKSSKQEKISLSSFGKNKK
SWIRSSLSKFTKKKNKNYDEAHMPSISGSQGTLDNIDVIELKQELKERDSALYEVRLDNL
DRAREVDVLRETVNKLKTENKQLKKEVDKLTNGPATRASSRASIPVIYDDEHVYDAACSS

FIG. 3 CONTINUED.

TSASQSSKRSSGCNSIKVTVNVDIAGEISSIVNPDKEIIVGYLAMSTSQSCWKDIDVSIL
GLFEVYLSRIDVEHQLGIDARDSILGYQIGELRRVIGDSTTMITSHPTDILTSSTTIRMF
MHGAAQSRVDSLVLDMLLPKQMILQLVKSILTERRLVLAGATGIGKSKLAKTLAAYVSIR
TNQSEDSIVNISIPENNKEELLQVERRLEKILRSKESCIVILDNIPKNRIAFVVSVFANV
PLQNNEGPFVVCTVNRYQIPELQIHHNFKMSVMSNRLEGFILRYLRRRAVEDEYRLTVQM
PSELFKIIDFFPIALQAVNNFIEKTNSVDVTVGPRACLNCPLTVDGSREWFIRLWNENFI
PYLERVARDGKKNLRSLHFLRGSHRHRL

FIG. 4 21/99

Length of tb3-m5.pro from cDNA pTB54 : 1528 aa; +1 at: 1;
Listed (Ordinary) from: 1 to: 1528; din, 23 apr 1996 11:49

Met Thr Thr Ser Asn Val Glu Leu Ile Pro Ile Tyr Thr Asp Trp 15

Ala Asn Arg His Leu Ser Lys Gly Ser Leu Ser Lys Ser Ile Arg 30

Asp Ile Ser Asn Asp Phe Arg Asp Tyr Arg Leu Val Ser Gln Leu 45

Ile Asn Val Ile Val Pro Ile Asn Glu Phe Ser Pro Ala Phe Thr 60

Lys Arg Leu Ala Lys Ile Thr Ser Asn Leu Asp Gly Leu Glu Thr 75

Cys Leu Asp Tyr Leu Lys Asn Leu Gly Leu Asp Cys Ser Lys Leu 90

Thr Lys Thr Asp Ile Asp Ser Gly Asn Leu Gly Ala Val Leu Gln 105

Leu Leu Phe Leu Leu Ser Thr Tyr Lys Gln Lys Leu Arg Gln Leu 120

Lys Lys Asp Gln Lys Lys Leu Glu Gln Leu Pro Thr Ser Ile Met 135

Pro Pro Ala Val Ser Lys Leu Pro Ser Pro Arg Val Ala Thr Ser 150

Ala Thr Ala Ser Ala Thr Asn Pro Asn Ser Asn Phe Pro Gln Met 165

Ser Thr Ser Arg Leu Gln Thr Pro Gln Ser Arg Ile Ser Lys Ile 180

Asp Ser Ser Lys Ile Gly Ile Lys Pro Lys Thr Ser Gly Leu Lys 195

Pro Pro Ser Ser Ser Thr Thr Ser Ser Asn Asn Thr Asn Ser Phe 210

Arg Pro Ser Ser Arg Ser Ser Gly Asn Asn Asn Val Gly Ser Thr 225

Ile Ser Thr Ser Ala Lys Ser Leu Glu Ser Ser Ser Thr Tyr Ser 240

Ser Ile Ser Asn Leu Asn Arg Pro Thr Ser Gln Leu Gln Lys Pro 255

Ser Arg Pro Gln Thr Gln Leu Val Arg Val Ala Thr Thr Thr Lys 270

Ile Gly Ser Ser Lys Leu Ala Ala Pro Lys Ala Val Ser Thr Pro 285

Lys Leu Ala Ser Val Lys Thr Ile Gly Ala Lys Gln Glu Pro Asp 300

Asn Ser Gly Gly Gly Gly Gly Gly Met Leu Lys Leu Lys Leu Phe 315

Ser Ser Lys Asn Pro Ser Ser Ser Ser Asn Ser Pro Gln Pro Thr 330

Arg Lys Ala Ala Ala Val Pro Gln Gln Gln Thr Leu Ser Lys Ile 345

Ala Ala Pro Val Lys Ser Gly Leu Lys Pro Pro Thr Ser Lys Leu 360

Gly Ser Ala Thr Ser Met Ser Lys Leu Cys Thr Pro Lys Val Ser 375

Tyr Arg Lys Thr Asp Ala Pro Ile Ile Ser Gln Gln Asp Ser Lys 390

FIG. 4 CONTINUED. 22/99

Arg Cys Ser Lys Ser Ser Glu Glu Glu Ser Gly Tyr Ala Gly Phe 405

Asn Ser Thr Ser Pro Thr Ser Ser Ser Thr Glu Gly Ser Leu Ser 420

Met His Ser Thr Ser Ser Lys Ser Ser Thr Ser Asp Glu Lys Ser 435

Pro Ser Ser Asp Asp Leu Thr Leu Asn Ala Ser Ile Val Thr Ala 450

Ile Arg Gln Pro Ile Ala Ala Thr Pro Val Ser Pro Asn Ile Ile 465

Asn Lys Pro Val Glu Glu Lys Pro Thr Leu Ala Val Lys Gly Val 480

Lys Ser Thr Ala Lys Lys Asp Pro Pro Pro Ala Val Pro Pro Arg 495

Asp Thr Gln Pro Thr Ile Gly Val Val Ser Pro Ile Met Ala His 510

Lys Lys Leu Thr Asn Asp Pro Val Ile Ser Glu Lys Pro Glu Pro 525

Glu Lys Leu Gln Ser Met Ser Ile Asp Thr Thr Asp Val Pro Pro 540

Leu Pro Pro Leu Lys Ser Val Val Pro Leu Lys Met Thr Ser Ile 555

Arg Gln Pro Pro Thr Tyr Asp Val Leu Leu Lys Gln Gly Lys Ile 570

Thr Ser Pro Val Lys Ser Phe Gly Tyr Glu Gln Ser Ser Ala Ser 585

Glu Asp Ser Ile Val Ala His Ala Ser Ala Gln Val Thr Pro Pro 600

Thr Lys Thr Ser Gly Asn His Ser Leu Glu Arg Arg Met Gly Lys 615

Asn Lys Thr Ser Glu Ser Ser Gly Tyr Thr Ser Asp Ala Gly Val 630

Ala Met Cys Ala Lys Met Arg Glu Lys Leu Lys Glu Tyr Asp Asp 645

Met Thr Arg Arg Ala Gln Asn Gly Tyr Pro Asp Asn Phe Glu Asp 660

Ser Ser Ser Leu Ser Ser Gly Ile Ser Asp Asn Asn Glu Leu Asp 675

Asp Ile Ser Thr Asp Asp Leu Ser Gly Val Asp Met Ala Thr Val 690

Ala Ser Lys His Ser Asp Tyr Ser His Phe Val Arg His Pro Thr 705

Ser Ser Ser Ser Lys Pro Arg Val Pro Ser Arg Ser Ser Thr Ser 720

Val Asp Ser Arg Ser Arg Ala Glu Gln Glu Asn Val Tyr Lys Leu 735

Leu Ser Gln Cys Arg Thr Ser Gln Arg Gly Ala Ala Ala Thr Ser 750

Thr Phe Gly Gln His Ser Leu Arg Ser Pro Gly Tyr Ser Ser Tyr 765

FIG. 4 CONTINUED. 23/99

```
Ser Pro His Leu Ser Val Ser Ala Asp Lys Asp Thr Met Ser Met     780
His Ser Gln Thr Ser Arg Arg Pro Ser Ser Gln Lys Pro Ser Tyr     795
Ser Gly Gln Phe His Ser Leu Asp Arg Lys Cys His Leu Gln Glu     810
Phe Thr Ser Thr Glu His Arg Met Ala Ala Leu Leu Ser Pro Arg     825
Arg Val Pro Asn Ser Met Ser Lys Tyr Asp Ser Ser Gly Ser Tyr     840
Ser Ala Arg Ser Arg Gly Gly Ser Ser Thr Gly Ile Tyr Gly Glu     855
Thr Phe Gln Leu His Arg Leu Ser Asp Glu Lys Ser Pro Ala His     870
Ser Ala Lys Ser Glu Met Gly Ser Gln Leu Ser Leu Ala Ser Thr     885
Thr Ala Tyr Gly Ser Leu Asn Glu Lys Tyr Glu His Ala Ile Arg     900
Asp Met Ala Arg Asp Leu Glu Cys Tyr Lys Asn Thr Val Asp Ser     915
Leu Thr Lys Lys Gln Glu Asn Tyr Gly Ala Leu Phe Asp Leu Phe     930
Glu Gln Lys Leu Arg Lys Leu Thr Gln His Ile Asp Arg Ser Asn     945
Leu Lys Pro Glu Glu Ala Ile Arg Phe Arg Gln Asp Ile Ala His     960
Leu Arg Asp Ile Ser Asn His Leu Ala Ser Asn Ser Ala His Ala     975
Asn Glu Gly Ala Gly Glu Leu Leu Arg Gln Pro Ser Leu Glu Ser     990
Val Ala Ser His Arg Ser Ser Met Ser Ser Ser Ser Lys Ser Ser    1005
Lys Gln Glu Lys Ile Ser Leu Ser Ser Phe Gly Lys Asn Lys Lys    1020
Ser Trp Ile Arg Ser Ser Leu Ser Lys Phe Thr Lys Lys Lys Asn    1035
Lys Asn Tyr Asp Glu Ala His Met Pro Ser Ile Ser Gly Ser Gln    1050
Gly Thr Leu Asp Asn Ile Asp Val Ile Glu Leu Lys Gln Glu Leu    1065
Lys Glu Arg Asp Ser Ala Leu Tyr Glu Val Arg Leu Asp Asn Leu    1080
Asp Arg Ala Arg Glu Val Asp Val Leu Arg Glu Thr Val Asn Lys    1095
Leu Lys Thr Glu Asn Lys Gln Leu Lys Lys Glu Val Asp Lys Leu    1110
Thr Asn Gly Pro Ala Thr Arg Ala Ser Ser Arg Ala Ser Ile Pro    1125
Val Ile Tyr Asp Asp Glu His Val Tyr Asp Ala Ala Cys Ser Ser    1140
```

FIG. 4 CONTINUED. 24/99

Thr Ser Ala Ser Gln Ser Ser Lys Arg Ser Ser Gly Cys Asn Ser 1155
Ile Lys Val Thr Val Asn Val Asp Ile Ala Gly Glu Ile Ser Ser 1170
Ile Val Asn Pro Asp Lys Glu Ile Ile Val Gly Tyr Leu Ala Met 1185
Ser Thr Ser Gln Ser Cys Trp Lys Asp Ile Asp Val Ser Ile Leu 1200
Gly Leu Phe Glu Val Tyr Leu Ser Arg Ile Asp Val Glu His Gln 1215
Leu Gly Ile Asp Ala Arg Asp Ser Ile Leu Gly Tyr Gln Ile Gly 1230
Glu Leu Arg Arg Val Ile Gly Asp Ser Thr Thr Met Ile Thr Ser 1245
His Pro Thr Asp Ile Leu Thr Ser Ser Thr Thr Ile Arg Met Phe 1260
Met His Gly Ala Ala Gln Ser Arg Val Asp Ser Leu Val Leu Asp 1275
Met Leu Leu Pro Lys Gln Met Ile Leu Gln Leu Val Lys Ser Ile 1290
Leu Thr Glu Arg Arg Leu Val Leu Ala Gly Ala Thr Gly Ile Gly 1305
Lys Ser Lys Leu Ala Lys Thr Leu Ala Ala Tyr Val Ser Ile Arg 1320
Thr Asn Gln Ser Glu Asp Ser Ile Val Asn Ile Ser Ile Pro Glu 1335
Asn Asn Lys Glu Glu Leu Leu Gln Val Glu Arg Arg Leu Glu Lys 1350
Ile Leu Arg Ser Lys Glu Ser Cys Ile Val Ile Leu Asp Asn Ile 1365
Pro Lys Asn Arg Ile Ala Phe Val Val Ser Val Phe Ala Asn Val 1380
Pro Leu Gln Asn Asn Glu Gly Pro Phe Val Val Cys Thr Val Asn 1395
Arg Tyr Gln Ile Pro Glu Leu Gln Ile His His Asn Phe Lys Met 1410
Ser Val Met Ser Asn Arg Leu Glu Gly Phe Ile Leu Arg Tyr Leu 1425
Arg Arg Arg Ala Val Glu Asp Glu Tyr Arg Leu Thr Val Gln Met 1440
Pro Ser Glu Leu Phe Lys Ile Ile Asp Phe Phe Pro Ile Ala Leu 1455
Gln Ala Val Asn Asn Phe Ile Glu Lys Thr Asn Ser Val Asp Val 1470
Thr Val Gly Pro Arg Ala Cys Leu Asn Cys Pro Leu Thr Val Asp 1485
Gly Ser Arg Glu Trp Phe Ile Arg Leu Trp Asn Glu Asn Phe Ile 1500
Pro Tyr Leu Glu Arg Val Ala Arg Asp Gly Lys Lys Asn Leu Arg 1515
Ser Leu His Phe Leu Arg Gly Ser His Arg His Arg Leu

FIG. 5.

Annotated sequence of 7A variant of UNC-53

```
        10          20          30          40          50          60
MTTSNVELIP IYTDWANRHL SKGSLSKSIR DISNDFRDYR LVSQLINVIV PINEFSPAFT
start tb6 and tb3 similarity to amino-termini of alfa-actinin,

        70          80          90         100         110         120
KRLAKITSNL DGLETCLDYL KNLGLDCSKL TKTDIDSGNL GAVLQLLFLL STYKQKLRQL
beta-spectrin, dystrosphin, fimbrin, filamin actin-binding site 1
                                                          (114 - 133)

       130         140         150         160         170         180
KKDQKKLEQL PTSIMPPAVS KLPSPRVATS ATASATNPNS NFPQMSTSRL QTPQSRISKI
   Start S4     poss. start tb1b & tb6 & tb1 lamda clone

       190         200         210         220         230         240
DSSKIGIKPK TSGLKPPSSS TTSSNNTNSF RPSSRSSGNN NVGSTISTSA KSLESSSTYS

       250         260         270         280         290         300
SISNLNRPTS QLQKPSRPQT QLVRVATTTK IGSSKLAAPK AVSTPKLASV KTIGAKQEPD

       310         320         330         340         350         360
NSGGGGGGML KLKLFSSKNP SSSSNSPQPT RKAAAVPQQQ TLSKIAAPVK SGLKPPTSKL

       370         380         390         400         410         420
GSATSMSKLC TPKVSYRKTD APIISQQDSK RCSKSSEEES GYAGFNSTSP TSSSTEGSLS

       430         440         450         460         470         480
MHSTSSKSST SDEKSPSSDD LTLNASIVTA IRQPIAATPV SPNIINKPVE EKPTLAVKGV
poss. start tb22
       490         500         510         520         530         540
KSTAKKDPPP AVPPRDTQPT IGVVSPIMAH KKLTNDPVIS EKPEPEKLQS MSIDTTDVPP
     SH3-binding 1                                              SH3-

       550         560         570         580         590         600
LPPLKSVVPL KMTSIRQPPT YDVLLKQGKI TSPVKSFGYE QSSASEDSIV AHASAQVTPP
binding 2

       610         620         630         640         650         660
TKTSGNHSLE RRMGKNKTSE SSGYTSDAGV AMCAKMREKL KEYDDMTRRA QNGYPDNFED

       670         680         690         700         710         720
SSSLSSGISD NNELDDISTD DLSGVDMATV ASKHSDYSHF VRHPTSSSSK PRVPSRSSTS

       730         740         750         760         770         780
VDSRSRAEQE NVYKLLSQCR TSQRGAAATS TFGQHSLRSP GYSSYSPHLS VSADKDTMSM

       790         800         810         820         830         840
HSQTSRRPSS QKPSYSGQFH SLDRKCHLQE FTSTEHRMAA LLSPRRVPNS MSKYDSSGSY
                        Kohara Exon deleted in cDNA YK25D6
```

FIG. 5 CONTINUED.

```
          10        20        30        40        50        60        70
AALNASGMSR SMILLESLSP RPPRRHQSPA DSCIITASPS APRRSHSPRG PTARIPLSLA SSPVHVNNNW
predicted exon (alternative/additional to Kohara exon to be inserted after
aminoacid 838 )

       850       860       870       880       890       900
SARSRGGSST GIYGETFQLH RLSDEKSPAH SAKSEMGSQL SLASTTAYGS LNEKYEHAIR

       910       920       930       940       950       960
DMARDLECYK NTVDSLTKKQ ENYGALFDLF EQKLRKLTQH IDRSNLKPEE AIRFRQDIAH

       970       980       990      1000      1010      1020
LRDISNHLAS NSAHANEGAG ELLRQPSLES VASHRSSMSS SSKSSKQEKI SLSSFGKNKK

      1030      1040      1050      1060      1070      1080
SWIRSSLSKF TKKKNKNYDE AHMPSISGSQ GTLDNIDVIE LKQELKERDS ALYEVRLDNL
    candidate nuclear   Start GP45   localization signal

      1090      1100      1110      1120      1130      1140
DRAREVDVLR ETVNKLKTEN KQLKKEVDKL TNGPATRASS RASIPVIYDD EHVYDAACSS
                actin binding site 2
                (1097-1116)
          *       *       *       *
        canditate leucine zipper.pattern

      1150      1160      1170      1180      1190      1200
TSASQSSKRS SGCNSIKVTV NVDIAGEISS IVNPDKEIIV GYLAMSTSQS CWKDIDVSIL

      1210      1220      1230      1240      1250      1260
GLFEVYLSRI DVEHQLGIDA RDSILGYQIG ELRRVIGDST TMITSHPTDI LTSSTTIRMF

      1270      1280      1290      1300      1310      1320
MHGAAQSRVD SLVLDMLLPK QMILQLVKSI LTERRLVLAG ATGIGKSKLA KTLAAYVSIR
                *       *       *       * nucleotide binding pocket
                  canditate leucine zipper.pattern
      1330      1340      1350      1360      1370      1380
TNQSEDSIVN ISIPENNKEE LLQVERRLEK ILRSKESCIV ILDNIPKNRI AFVVSVFANV

      1390      1400      1410      1420      1430      1440
PLQNNEGPFV VCTVNRYQIP ELQIHHNFKM SVMSNRLEGF ILRYLRRRAV EDEYRLTVQM

      1450      1460      1470      1480      1490      1500
PSELFKIIDF FPIALQAVNN FIEKTNSVDV TVGPRACLNC PLTVDGSREW FIRLWNENFI
                          end GP45

      1510      1520      1530      1540      1550      1560
PYLERVARDG KKTFGRCTSF EDPTDIVSEK WPWFDGENPE NVLKRLQLQD LVPSPANSSR

      1570      1580
QHFNPLESLI  QLHATKHQTI DNI
```

FIG. 6. 27/99

Length of Untitled : 1583 aa from cDNA pTB72; +1 at: 1;
Listed (Ordinary) from: 1 to: 1583; din, 23 apr 1996 11:37

Met Thr Thr Ser Asn Val Glu Leu Ile Pro Ile Tyr Thr Asp Trp	15
Ala Asn Arg His Leu Ser Lys Gly Ser Leu Ser Lys Ser Ile Arg	30
Asp Ile Ser Asn Asp Phe Arg Asp Tyr Arg Leu Val Ser Gln Leu	45
Ile Asn Val Ile Val Pro Ile Asn Glu Phe Ser Pro Ala Phe Thr	60
Lys Arg Leu Ala Lys Ile Thr Ser Asn Leu Asp Gly Leu Glu Thr	75
Cys Leu Asp Tyr Leu Lys Asn Leu Gly Leu Asp Cys Ser Lys Leu	90
Thr Lys Thr Asp Ile Asp Ser Gly Asn Leu Gly Ala Val Leu Gln	105
Leu Leu Phe Leu Leu Ser Thr Tyr Lys Gln Lys Leu Arg Gln Leu	120
Lys Lys Asp Gln Lys Lys Leu Glu Gln Leu Pro Thr Ser Ile Met	135
Pro Pro Ala Val Ser Lys Leu Pro Ser Pro Arg Val Ala Thr Ser	150
Ala Thr Ala Ser Ala Thr Asn Pro Asn Ser Asn Phe Pro Gln Met	165
Ser Thr Ser Arg Leu Gln Thr Pro Gln Ser Arg Ile Ser Lys Ile	180
Asp Ser Ser Lys Ile Gly Ile Lys Pro Lys Thr Ser Gly Leu Lys	195
Pro Pro Ser Ser Ser Thr Thr Ser Ser Asn Asn Thr Asn Ser Phe	210
Arg Pro Ser Ser Arg Ser Ser Gly Asn Asn Asn Val Gly Ser Thr	225
Ile Ser Thr Ser Ala Lys Ser Leu Glu Ser Ser Ser Thr Tyr Ser	240
Ser Ile Ser Asn Leu Asn Arg Pro Thr Ser Gln Leu Gln Lys Pro	255
Ser Arg Pro Gln Thr Gln Leu Val Arg Val Ala Thr Thr Thr Lys	270
Ile Gly Ser Ser Lys Leu Ala Ala Pro Lys Ala Val Ser Thr Pro	285
Lys Leu Ala Ser Val Lys Thr Ile Gly Ala Lys Gln Glu Pro Asp	300
Asn Ser Gly Gly Gly Gly Gly Gly Met Leu Lys Leu Lys Leu Phe	315
Ser Ser Lys Asn Pro Ser Ser Ser Ser Asn Ser Pro Gln Pro Thr	330
Arg Lys Ala Ala Ala Val Pro Gln Gln Gln Thr Leu Ser Lys Ile	345
Ala Ala Pro Val Lys Ser Gly Leu Lys Pro Pro Thr Ser Lys Leu	360
Gly Ser Ala Thr Ser Met Ser Lys Leu Cys Thr Pro Lys Val Ser	375

FIG. 6 CONTINUED. 28/99

Tyr Arg Lys Thr Asp Ala Pro Ile Ile Ser Gln Gln Asp Ser Lys 390

Arg Cys Ser Lys Ser Ser Glu Glu Glu Ser Gly Tyr Ala Gly Phe 405

Asn Ser Thr Ser Pro Thr Ser Ser Ser Thr Glu Gly Ser Leu Ser 420

Met His Ser Thr Ser Ser Lys Ser Ser Thr Ser Asp Glu Lys Ser 435

Pro Ser Ser Asp Asp Leu Thr Leu Asn Ala Ser Ile Val Thr Ala 450

Ile Arg Gln Pro Ile Ala Ala Thr Pro Val Ser Pro Asn Ile Ile 465

Asn Lys Pro Val Glu Glu Lys Pro Thr Leu Ala Val Lys Gly Val 480

Lys Ser Thr Ala Lys Lys Asp Pro Pro Pro Ala Val Pro Pro Arg 495

Asp Thr Gln Pro Thr Ile Gly Val Val Ser Pro Ile Met Ala His 510

Lys Lys Leu Thr Asn Asp Pro Val Ile Ser Glu Lys Pro Glu Pro 525

Glu Lys Leu Gln Ser Met Ser Ile Asp Thr Thr Asp Val Pro Pro 540

Leu Pro Pro Leu Lys Ser Val Val Pro Leu Lys Met Thr Ser Ile 555

Arg Gln Pro Pro Thr Tyr Asp Val Leu Leu Lys Gln Gly Lys Ile 570

Thr Ser Pro Val Lys Ser Phe Gly Tyr Glu Gln Ser Ser Ala Ser 585

Glu Asp Ser Ile Val Ala His Ala Ser Ala Gln Val Thr Pro Pro 600

Thr Lys Thr Ser Gly Asn His Ser Leu Glu Arg Arg Met Gly Lys 615

Asn Lys Thr Ser Glu Ser Ser Gly Tyr Thr Ser Asp Ala Gly Val 630

Ala Met Cys Ala Lys Met Arg Glu Lys Leu Lys Glu Tyr Asp Asp 645

Met Thr Arg Arg Ala Gln Asn Gly Tyr Pro Asp Asn Phe Glu Asp 660

Ser Ser Ser Leu Ser Ser Gly Ile Ser Asp Asn Asn Glu Leu Asp 675

Asp Ile Ser Thr Asp Asp Leu Ser Gly Val Asp Met Ala Thr Val 690

Ala Ser Lys His Ser Asp Tyr Ser His Phe Val Arg His Pro Thr 705

Ser Ser Ser Ser Lys Pro Arg Val Pro Ser Arg Ser Ser Thr Ser 720

Val Asp Ser Arg Ser Arg Ala Glu Gln Glu Asn Val Tyr Lys Leu 735

Leu Ser Gln Cys Arg Thr Ser Gln Arg Gly Ala Ala Ala Thr Ser 750

Thr Phe Gly Gln His Ser Leu Arg Ser Pro Gly Tyr Ser Ser Tyr 765

Ser Pro His Leu Ser Val Ser Ala Asp Lys Asp Thr Met Ser Met 780

FIG. 6 CONTINUED. 29/99

```
His Ser Gln Thr Ser Arg Arg Pro Ser Ser Gln Lys Pro Ser Tyr      795
Ser Gly Gln Phe His Ser Leu Asp Arg Lys Cys His Leu Gln Glu      810
Phe Thr Ser Thr Glu His Arg Met Ala Ala Leu Leu Ser Pro Arg      825
Arg Val Pro Asn Ser Met Ser Lys Tyr Asp Ser Ser Gly Ser Tyr      840
Ser Ala Arg Ser Arg Gly Gly Ser Ser Thr Gly Ile Tyr Gly Glu      855
Thr Phe Gln Leu His Arg Leu Ser Asp Glu Lys Ser Pro Ala His      870
Ser Ala Lys Ser Glu Met Gly Ser Gln Leu Ser Leu Ala Ser Thr      885
Thr Ala Tyr Gly Ser Leu Asn Glu Lys Tyr Glu His Ala Ile Arg      900
Asp Met Ala Arg Asp Leu Glu Cys Tyr Lys Asn Thr Val Asp Ser      915
Leu Thr Lys Lys Gln Glu Asn Tyr Gly Ala Leu Phe Asp Leu Phe      930
Glu Gln Lys Leu Arg Lys Leu Thr Gln His Ile Asp Arg Ser Asn      945
Leu Lys Pro Glu Glu Ala Ile Arg Phe Arg Gln Asp Ile Ala His      960
Leu Arg Asp Ile Ser Asn His Leu Ala Ser Asn Ser Ala His Ala      975
Asn Glu Gly Ala Gly Glu Leu Leu Arg Gln Pro Ser Leu Glu Ser      990
Val Ala Ser His Arg Ser Ser Met Ser Ser Ser Ser Lys Ser Ser     1005
Lys Gln Glu Lys Ile Ser Leu Ser Ser Phe Gly Lys Asn Lys Lys     1020
Ser Trp Ile Arg Ser Ser Leu Ser Lys Phe Thr Lys Lys Lys Asn     1035
Lys Asn Tyr Asp Glu Ala His Met Pro Ser Ile Ser Gly Ser Gln     1050
Gly Thr Leu Asp Asn Ile Asp Val Ile Glu Leu Lys Gln Glu Leu     1065
Lys Glu Arg Asp Ser Ala Leu Tyr Glu Val Arg Leu Asp Asn Leu     1080
Asp Arg Ala Arg Glu Val Asp Val Leu Arg Glu Thr Val Asn Lys     1095
Leu Lys Thr Glu Asn Lys Gln Leu Lys Lys Glu Val Asp Lys Leu     1110
Thr Asn Gly Pro Ala Thr Arg Ala Ser Ser Arg Ala Ser Ile Pro     1125
Val Ile Tyr Asp Asp Glu His Val Tyr Asp Ala Ala Cys Ser Ser     1140
Thr Ser Ala Ser Gln Ser Ser Lys Arg Ser Ser Gly Cys Asn Ser     1155
Ile Lys Val Thr Val Asn Val Asp Ile Ala Gly Glu Ile Ser Ser     1170
Ile Val Asn Pro Asp Lys Glu Ile Ile Val Gly Tyr Leu Ala Met     1185
```

FIG. 6 CONTINUED. 30/99

Ser Thr Ser Gln Ser Cys Trp Lys Asp Ile Asp Val Ser Ile Leu 1200

Gly Leu Phe Glu Val Tyr Leu Ser Arg Ile Asp Val Glu His Gln 1215

Leu Gly Ile Asp Ala Arg Asp Ser Ile Leu Gly Tyr Gln Ile Gly 1230

Glu Leu Arg Arg Val Ile Gly Asp Ser Thr Thr Met Ile Thr Ser 1245

His Pro Thr Asp Ile Leu Thr Ser Ser Thr Thr Ile Arg Met Phe 1260

Met His Gly Ala Ala Gln Ser Arg Val Asp Ser Leu Val Leu Asp 1275

Met Leu Leu Pro Lys Gln Met Ile Leu Gln Leu Val Lys Ser Ile 1290

Leu Thr Glu Arg Arg Leu Val Leu Ala Gly Ala Thr Gly Ile Gly 1305

Lys Ser Lys Leu Ala Lys Thr Leu Ala Ala Tyr Val Ser Ile Arg 1320

Thr Asn Gln Ser Glu Asp Ser Ile Val Asn Ile Ser Ile Pro Glu 1335

Asn Asn Lys Glu Glu Leu Leu Gln Val Glu Arg Arg Leu Glu Lys 1350

Ile Leu Arg Ser Lys Glu Ser Cys Ile Val Ile Leu Asp Asn Ile 1365

Pro Lys Asn Arg Ile Ala Phe Val Val Ser Val Phe Ala Asn Val 1380

Pro Leu Gln Asn Asn Glu Gly Pro Phe Val Val Cys Thr Val Asn 1395

Arg Tyr Gln Ile Pro Glu Leu Gln Ile His His Asn Phe Lys Met 1410

Ser Val Met Ser Asn Arg Leu Glu Gly Phe Ile Leu Arg Tyr Leu 1425

Arg Arg Arg Ala Val Glu Asp Glu Tyr Arg Leu Thr Val Gln Met 1440

Pro Ser Glu Leu Phe Lys Ile Ile Asp Phe Phe Pro Ile Ala Leu 1455

Gln Ala Val Asn Asn Phe Ile Glu Lys Thr Asn Ser Val Asp Val 1470

Thr Val Gly Pro Arg Ala Cys Leu Asn Cys Pro Leu Thr Val Asp 1485

Gly Ser Arg Glu Trp Phe Ile Arg Leu Trp Asn Glu Asn Phe Ile 1500

Pro Tyr Leu Glu Arg Val Ala Arg Asp Gly Lys Lys Thr Phe Gly 1515

Arg Cys Thr Ser Phe Glu Asp Pro Thr Asp Ile Val Ser Lys Lys 1530

Trp Pro Trp Phe Asp Gly Glu Asn Pro Glu Asn Val Leu Lys Arg 1545

Leu Gln Leu Gln Asp Leu Val Pro Ser Pro Ala Asn Ser Ser Arg 1560

Gln His Phe Asn Pro Leu Glu Ser Leu Ile Gln Leu His Ala Thr 1575

Lys His Gln Thr Ile Asp Asn Ile .

FIG. 7. 31/99

MTTSNVELIPIYTDWANRHLSKGSLSKSIRDISNDFRDYRLVSQLINVIVPINEFSPAFT
KRLAKITSNLDGLETCLDYLKNLGLDCSKLTKTDIDSGNLGAVLQLLFLLSTYXXXXXXX
XXXXXXXXXXPTSIMPPAVSKLXXXXXXXXXXXXXXXXXXXXFPQMSTSRLQTPQXXXXXX
XXXXXXXXXXTSGLKPXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
XXXNLNRPTSQLQKPSRPQTQLVRVATTTKIGSSKLAAPKAVSTPKLASVKTIGAKQEPD
NSXXXXXXMXXXXXXXXXXXXXXXXXXQPTRKAAAVPQQQTLSKIAAPVKSGLKPPTSKL
GSATSMSKLCTPKVSYRKTDAPIISQQDSKRCSKXXXXXXGYAGFNXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXDDLTLNASIVTAIRQPIAATPVSPNIINKPVEEKPTLAVKGV
KSTAKKDPPPAVPPRDTQPTIGVVSPIMAHKKLTNDPVISEKPEPEKLQSMSIDTTDXXX
XXXXXXXXXXXMTSIRQPPTYDVLLKQGKITSPVKSFGYEQSSASEDSIVAHASAQVTPP
TKTSGNHSLERRMGKNKTSESSGYTSDAGVAMCAKMREKLKEYDDMTRRAQNGYPDNFED
XXXXXXXXXDNNELDDISTDDLSGVDMATVASKHSDYSHFVRHPXXXXXXXXXXXXXXXX
XXXXXXAEQENVYKLLSQCRTSQRGAAATSTFGQHSLRSPGYSSYSPHLSVSADKDTMSM
HSQTSRRPSSQKPSYSGQFHSLDRKCHLQEFTSTEHRMAALLSPRRVPNXXXXXXXXXXX
XXXXXXXXXXXIYGETFQLHRLSDEKSPAHSAKSEMGSQLSLASTTAYGSLNEKYEHAIR
DMARDLECYKNTVDSLTKKQENYGALFDLFEQKLRKLTQHIDRSNLKPEEAIRFRQDIAH
LRDISNHLASNSAHANEGAGELLRQPSLEXXXXXXXXXXXXXXXXXXXXXXXXXFGKNKK
SWIRSSLSKFTKKKNKNYDEAHMPSISGSQGTLDNIDVIELKQELKERDSALYEVRLDNL
DRAREVDVLRETVNKLKTENKQLKKEVDKLTNGPATRASSRASIPVIYDDEHVYDXXXXX
XXXXXXXXXXXGCNXXXXXXXXXXXXXXXXXXXXDKEIIVGYLAMSTSQSCWKDIDVSIL
GLFEVYLSRIDVEHQLGIDARDSILGYQIGELRRVIGDSTTMITSHPTDILTSSTTIRMF
MHGAAQSRVDSLVLDMLLPKQMILQLVKSILTERRLVLAGATGIGKSKLAKTLAAYVSIR
TNQSEDSIVNISIPENNKEELLQVERRLEKILRSKESCIVILDNIPKNRIAFVVSVFANV
PLQNNEGPFVVCTVNRYQIPELQIHHNFKMSVMSNRLEGFILRYLRRRAVEDEYRLTVQM
PSELFKIIDFFPIALQAVNNFIEKTNSVDVTVGPRACLNCPLTVDGSREWFIRLWNENFI
PYLERVARDGKKNLRSLHFLRGSHRHRL

MTTSNVELIPIYTDWANRHLSKGSLSKSIRDISNDFRDYRLVSQLINVIVPINEFSPAFT
KRLAKITSNLDGLETCLDYLKNLGLDCSKLTKTDIDSGNLGAVLQLLFLLSTYKQKLRQL
KKDQKKLEQLPTSIMPPAVSKLPSPRVATSATASATNPNSNFPQMSTSRLQTPQSRISKI
DSSKIGIKPKTSGLKPPSSSTTSSNNTNSFRPSSRSSGNNNVGSTISTSAKSLESSSTYS
SISNLNRPTSQLQKPSRPQTQLVRVATTTKIGSSKLAAPKAVSTPKLASVKTIGAKQEPD
NSGGGGGGMLKLKLKLFSSKNPSSSSNSPQPTRKAAAVPQQQTLSKIAAPVKSGLKPPTSKL
GSATSMSKLCTPKVSYRKTDAPIISQQDSKRCSKSSEEESGYAGFNSTSPTSSSTEGSLS
MHSTSSKSSTSDEKSPSSDDLTLNASIVTAIRQPIAATPVSPNIINKPVEEKPTLAVKGV
KSTAKKDPPPAVPPRDTQPTIGVVSPIMAHKKLTNDPVISEKPEPEKLQSMSIDTTDVPP
LPPLKSVVPLKMTSIRQPPTYDVLLKQGKITSPVKSFGYEQSSASEDSIVAHASAQVTPP
TKTSGNHSLERRMGKNKTSESSGYTSDAGVAMCAKMREKLKEYDDMTRRAQNGYPDNFED
SSSLSSGISDNNELDDISTDDLSGVDMATVASKHSDYSHFVRHPTSSSSKPRVPSRSSTS
VDSRSRAEQENVYKLLSQCRTSQRGAAATSTFGQHSLRSPGYSSYSPHLSVSADKDTMSM
HSQTSRRPSSQKPSYSGQFHSLDRKCHLQEFTSTEHRMAALLSPRRVPNSMSKYDSSGSY
SARSRGGSSTGIYGETFQLHRLSDEKSPAHSAKSEMGSQLSLASTTAYGSLNEKYEHAIR
DMARDLECYKNTVDSLTKKQENYGALFDLFEQKLRKLTQHIDRSNLKPEEAIRFRQDIAH
LRDISNHLASNSAHANEGAGELLRQPSLESVASHRSSMSSSSKSSKQEKISLSSFGKNKK
SWIRSSLSKFTKKKNKNYDEAHMPSISGSQGTLDNIDVIELKQELKERDSALYEVRLDNL
DRAREVDVLRETVNKLKTENKQLKKEVDKLTNGPATRASSRASIPVIYDDEHVYDAACSS

32/99

FIG. 7 CONTINUED.

TSASQSSKRSSGCNSIKVTVNVDIAGEISSIVNPDKEIIVGYLAMSTSQSCWKDIDVSIL
GLFEVYLSRIDVEHQLGIDARDSILGYQIGELRRVIGDSTTMITSHPTDILTSSTTIRMF
MHGAAQSRVDSLVLDMLLPKQMILQLVKSILTERRLVLAGATGIGKSKLAKTLAAYVSIR
TNQSEDSIVNISIPENNKEELLQVERRLEKILRSKESCIVILDNIPKNRIAFVVSVFANV
PLQNNEGPFVVCTVNRYQIPELQIHHNFKMSVMSNRLEGFILRYLRRRAVEDEYRLTVQM
PSELFKIIDFFPIALQAVNNFIEKTNSVDVTVGPRACLNCPLTVDGSREWFIRLWNENFI
PYLERVARDGKKNLRSLHFLRGSHRHRL


Genistein
AG 1296, AG 1478, AG 879
PTK
RTPh
Grb2
Grbstatins
SOS
SOSstatins
(in yeast)
PLC-gamma
Ins(1,3) + Acyl2 Gro
P13-kinase
Inositol lipid
second
messengers
CAL
1651582
Ca++
PKC
bryostatin
sphingosine
CGP41251
Ras
?
Raf1
MAPKK
MAPK
dynamin
UNC-53
L731, L734
BZA-1
RAC/RHO
ENDPOINTS:
A: MITOGENESIS - APOPTOSIS
B: CEL MOTILITY
C: DEVELOPMENT - DIFFERENTIATION
D: ENDOCYTOSIS - VESICLE TRANSPORT ?

FIG. 8.

FIG. 9.


REDUCED ACTIVITY
WILD TYPE ACTIVITY
INCREASED ACTIVITY

FIG. 10.


UNC-53 activity
increased
wild type
reduced
Growth cone extension rate
Anterio-posterior signal strength - (sem-5/egl-15)

FIG. 11.


pTB50.pTB51.pTB54.pTB55.pTB56.pTB61.pTB109.pTB110.pTB111.pTB112.
ABPH ABS1 SH3BS ABS2 nucleotide binding domain
pTB52.53
pTB57.pTB58.pTB59.pTB60.pTB63.pTB64.
pTB62
pTB65
pTB66
LEGEND
ABPH actin binding protein homology
ABS actin binding site
SH3BS SH3 binding site
NBD nucleotide binding domain

FIG. 12.

5'ataagaatgcggccgccgccATGACGTCAAATGTAGAATTGATA (oligo BG03)

5'ggaattccaaccatATGACGACGTCAAATGTAGAATTGATA (oligo BG01)

ATGACGACGTCAAATGTAGAATTGATACCAATCTACACGGATTGGGCCAATCGGCACCTTTCG

AAGGGCAGCTTATCAAAGTCGATTAGGGATATTTCCAATGATTTTCGCGACTATCGACTGGTT

TCTCAGCTTATTAATGTGATCGTTCCGATCAACGAATTCTCGCCTGCATTCACGAAACGTTTG

GCAAAAATCACATCGAACCTGGATGGCCTCGAAACGTGTCTCGACTACCTGAAAAATCTGGGT

CTCGACTGCTCGAAACTCACCAAAACCGATATCGACAGCGGAAACTTGGGTGCAGTTCTCCAG

CTGCTCTTCCTGCTCTCCACCTACAAGCAGAAGCTTCGGCAACTGAAAAAAGATCAGAAGAA

TTGGAGCAACTACCCACATCCATTATGCCACCCGCGGTTTCTAAATTACCCTCGCCACGTGTC

(oligo BG02)GTAGGTAATACGGTGGGCGCCAAActcctagcgc-5'

FIG. 15.


pTB109
BamHI/AflIII
SmaI
NotI
6H
ATG
unc-53 RBS
SacII
Promoter
hsp-16.41
5'-UTR
from
unc-53
unc-53 ORF TB3-M5
(4584 bp)
TGA
KpnI
3'-UTR from
unc-53 cDNA M5
(incl. poly-A)
ApaI
poly-A
tail
poly-A
signal
= poly-linker or plasmid backbone
pTB110, pTBHH, pTB112
NheI/XbaI
AfeI
SacII
SV40
intron
ATG
(NdeI)
unc-53 ORF TB3-M5
(4584 bp)
TGA
KpnI
3'-UTR
from
unc-53
3'-UTR
+
poly A
signal from
unc-54
Promoter
-hsp-16.41 in pTB110
-mec-7 in pTB111
-unc-54+enhancer
in pTB112
5'-UTR
from expression
vector
= poly-linker or plasmid backbone


poly-A
5073 bp
ATG
1324
tab2
1338
start
cDNA M5
1281
TB22
1177
ATG
988
TB6B
604
ATG
556
ATG
466
430
first exon
rescuing on
lamda S4
TB1
345
TB16
271
TB1b
210
ATG
63
TB3
23

FIG. 14a.

FIG. 14b. 39/99


MOLECULAR DATA ON UNC-53
TZ8D2 rescue
I 1kb
S4 rescue
Altern. Splice
Genomic : 30kb
RNA : major one 5kb
23 exons
alternative splicing
no significant homology
SL1 (TB6) ATG
SL1 (TB1B)
SL1 (TB16)
SL1 (TB1) ATG ATG
SL1 (TB6B) ATG
SL1 (TB22) ATG
Actin Binding domain
SH3 domain
SH3 domain
Coiled coil domain
Actin Binding domain
ATP/GTP Binding domain

FIG. 14c.

S4

5′
gatcagaagaaattggagcaactacccacatccattatgccacccgcggtttctaagtgagt
ttaattttgagtttacgactacaaaaatgtgttcttta

.....

ccgccttctgacttcgtgacgacagtctcgacacgtggggttgcaggtaggagtggatgagt
cgaaactgataagatagtcatttgagatc 3′

Co-ordinates in ACEDB.
5′ begins at position 2260 in C09HIO.
3′ finishes at 3287 in F45 E10.

Total 16818 bp.

41/99

FIG. 15.


(a) aact 1 MSEEPTPVSGNDKQLLNKAWEITQKKTFTAWCNSHLRK--LGSSIEQIDTDFTDGIKLAQ
(b) unc-53 1 MTTSNVELIPIYTDWANRHLSKGSLSKSIRDISNDFRDYRLVSQ
(c) spectrin 40 FERSRIKALADEREVVQKKTFTKWVNSHLAR--VSCRITDLYKDLRDGRMLIK
(d) aact LLEVISNDPVFKVNKTPKLRRIH-NIQNVGLCLKHIESHGVKLVGIGAEELVDKNLKMTL
(e) unc-53 LINVIVPINEFSPAFTKRLAKITSNLDGLETCLDYLKNLGLDCSKLTKTDIDSGNLGAVL
(f) spectrin LLEVL-S-GEMLPKPTKGKMRIHC-LENVDKALQFLKEQRVHLENMGSHDIVDGNHRLVL
(g) aact GMIWTIILRFAIQDISIEEL------SAKEALLLWCQRKTEGYDRVKV
(h) unc-53 QLLF-LLSTYK-QKLRQLKKDQKKLEQLPTSIMPPAVSKLPSPRVATS
(i) spectrin GLIWTIILRFQIQDIVVQTQEGRETRSAKDALLQFLKEQRVHLENMGS
actin binding region in unc-53 ?

FIG. 16.

```
LLFLLSTYKQKLRQLKKDQKKLEQLPTS unc-53 106 to 133
    :   |   :||||:  ||   |::
ETVNVNKLKTENKQLKKEVDKLTNGPAT unc-53 1093 to 1120
```

FIG. 17.

		side on helix	1	4	7
			X	ph	PpxP
(a)	UNC-53		KKDPP	P	AVPPRDT
(b)	UNC-53		TTDVPP	L	PPLKS
(c)	mSOS		EVPVPP	P	VPPRR
(d)	mSOS		HLDSPP	A	IPPR
(e)	mSOS		HSIAGP	P	VPPR
(f)	SOS 1359		YRAVPP	P	LPPRRK
(g)	SOS 1377		GELSPP	P	IPPRLN
(h)	Dynamin		APAVPP	A	RPGS
(i)	dynamin		PAVPP	A	RP
(j)	PI3K p85		PPRPLP	V	APGS
(k)	PI3K p85		PAPALP	P	KPPK
(l)	AFAP-110		PPDNGPP	P	LPTSS
(m)	AFAP-110		PPQMPLP	E	IPQQW
(n)	3BP-1		APTMPPP	L	PVPP
(o)	3BP-2		FPAYPPP	P	VPVP

FIG. 18.


```
V     1          11         21         31         41         51
      MTTSNVELIP IYTDWANRHL SKGSLSKSIR DISNDFRDYR LVSQLINVIV PINEFSPAFT

      ---------- ---------- ---------- ---------- ---------- ----------
H     1          11         21         31         41         51
V    61          71         81         91        101        111
      KRLAKITSNL DGLETCLDYL KNLGLDCSKL TKTDIDSGNL GAVLQLLFLL STYKQKLRQL

      ---------- ---------- ---------- ---------- ---------- ----------
H    61          71         81         91        101        111
V   121         131        141        151        161        171
      KKDQKKLEQL PTSIMPPAVS KLPSPRVATS ATASATNPNS NFPQMSTSRL QTPQSRISKI

      ---------- ---------- ---------- ---------- ---------- ----------
H   121         131        141        151        161        171
V   181         191        201        211        221        231
      DSSKIGIKPK TSGLKPPSSS TTSSNNTNSF RPSSRSSGNN NVGSTISTSA KSLESSSTYS

      ---------- ---------- ---------- ---------- ---------- ----------
H   181         191        201        211        221        231
V   241         251        261        271        281        291
      SISNLNRPTS QLQKPSRPQT QLVRVATTTK IGSSKLAAPK AVSTPKLASV KTIGAKQEPD

      ---------- ---------- ---------- ---------- ---------- ----------
H   241         251        261        271        281        291
V   301         311        321        331        341        351
      NSGGGGGGML KLKLFSSKNP SSSSNSPQPT RKAAAVPQQQ TLSKIAAPVK SGLKPPTSKL
                ** ********** ********** ********** ********** **********

      --------ML KLKLFSSKNP SSSSNSPQPT RKAAAVPQQQ TLSKIAAPVK SGLKPPTSKL
H   301         311        321        331        341        351
V   361         371        381        391        401        411
      GSATSMSKLC TPKVSYRKTD APIISQQDSK RCSKSSEEES GYAGFNSTSP TSSSTEGSLS
      ********** ********** ********** ********** ********** **********

      GSATSMSKLC TPKVSYRKTD APIISQQDSK RCSKSSEEES GYAGFNSTSP TSSSTEGSLS
H   361         371        381        391        401        411
V   421         431        441        451        461        471
      MHSTSSKSST SDEKSPSSDD LTLNASIVTA IRQPIAATPV SPNIINKPVE  EKPTLAVKGV
      ********** ********** ********** ********** ********** **********

      MHSTSSKSST SDEKSPSSDD LTLNASIVTA IRQPIAATPV SPNIINKPVE EKPTLAVKGV
H   421         431        441        451        461        471
V   481         491        501        511        521        531
      KSTAKKDPPP AVPPRDTQPT IGVVSPIMAH KKLTNDPVIS EKPEPEKLQS MSIDTTDVPP
      ********** ********** ********** ********** ********** **********

      KSTAKKDPPP AVPPRDTQPT IGVVSPIMAH KKLTNDPVIS EKPEPEKLQS MSIDTTDVPP
H   481         491        501        511        521        531
V   541         551        561        571        581        591
      LPPLKSVVPL KMTSIRQPPT YDVLLKQGKI TSPVKSFGYE QSSASEDSIV AHASAQVTPP
      ********** ********** ********** ********** ********** **********

      LPPLKSVVPL KMTSIRQPPT YDVLLKQGKI TSPVKSFGYE QSSASEDSIV AHASAQVTPP
H   541         551        561        571        581        591
V   601         611        621        631        641        651
      TKTSGNHSLE RRMGKNKTSE SSGYTSDAGV AMCAKMREKL KEYDDMTRRA QNGYPDNFED
      ********** ********** ********** ********** ********** **********

      TKTSGNHSLE RRMGKNKTSE SSGYTSDAGV AMCAKMREKL KEYDDMTRRA QNGYPDNFED
H   601         611        621        631        641        651
V   661         671        681        691        701        711
      SSSLSSGISD NNELDDISTD DLSGVDMATV ASKHSDYSHF VRHPTSSSSK PRVPSRSSTS
      ********** ********** ********** ********** ********** **********

      SSSLSSGISD NNELDDISTD DLSGVDMATV ASKHSDYSHF VRHPTSSSSK PRVPSRSSTS
H   661         671        681        691        701        711
V   721         731        741        751        761        771
      VDSRSRAEQE NVYKLLSQCR TSQRGAAATS TFGQHSLRSP GYSSYSPHLS VSADKDTMSM
      ********** ********** ********** ********** ********** **********
```

FIG. 18 CONTINUED.

```
      VDSRSRAEQE NVYKLLSQCR TSQRGAAATS TFGQHSLRSP GYSSYSPHLS VSADKDTMSM
H   721        731        741        751        761        771
V   781        791        801        811        821        831
      HSQTSRRPSS QKPSYSGQFH SLDRKCHLQE FTSTEHRMAA LLSPRRVPNS MSKYDSSGSY
      ********** ********** ********** ********** ********** **********
      HSQTSRRPSS QKPSYSGQFH SLDRKCHLQE FTSTEHRMAA LLSPRRVPNS MSKYDSSGSY
H   781        791        801        811        821        831
V   841        851        861        871        881        891
      SARSRGGSST GIYGETFQLH RLSDEKSPAH SAKSEMGSQL SLASTTAYGS LNEKYEHAIR
      ********** ********** ********** ********** ********** **********
      SARSRGGSST GIYGETFQLH RLSDEKSPAH SAKSEMGSQL SLASTTAYGS LNEKYEHAIR
H   841        851        861        871        881        891
V   901        911        921        931        941        951
      DMARDLECYK NTVDSLTKKQ ENYGALFDLF EQKLRKLTQH IDRSNLKPEE AIRFRQDIAH
      ********** ********** ********** ********** ********** **********
      DMARDLECYK NTVDSLTKKQ ENYGALFDLF EQKLRKLTQH IDRSNLKPEE AIRFRQDIAH
H   901        911        921        931        941        951
V   961        971        981        991        1001       1011
      LRDISNHLAS NSAHANEGAG ELLRQPSLES VASHRSSMSS SSKSSKQEKI SLSSFGKNKK
      ********** ********** ********** ********** ********** **********
      LRDISNHLAS NSAHANEGAG ELLRQPSLES VASHRSSMSS SSKSSKQEKI SLSSFGKNKK
H   961        971        981        991        1001       1011
V   1021       1031       1041       1051       1061       1071
      SWIRSSLSKF TKKKNKNYDE AHMPSISGSQ GTLDNIDVIE LKQELKERDS ALYEVRLDNL
      ********** ********** ********** ********** ********** **********
      SWIRSSLSKF TKKKNKNYDE AHMPSISGSQ GTLDNIDVIE LKQELKERDS ALYEVRLDNL
H   1021       1031       1041       1051       1061       1071
V   1081       1091       1101       1111       1121       1131
      DRAREVDVLR ETVNKLKTEN KQLKKEVDKL TNGPATRASS RASIPVIYDD EHVYDAACSS
      ********** ********** ********** ********** ********** **********
      DRAREVDVLR ETVNKLKTEN KQLKKEVDKL TNGPATRASS RASIPVIYDD EHVYDAACSS
H   1081       1091       1101       1111       1121       1131
V   1141       1151       1161       1171       1181       1191
      TSASQSSKRS SGCNSIKVTV NVDIAGEISS IVNPDKEIIV GYLAMSTSQS CWKDIDVSIL
      ********** ********** ********** ********** *****?**** **********
      TSASQSSKRS SGCNSIKVTV NVDIAGEISS IVNPDKEIIV GYLAMPTSQS CWKDIDVSIL
H   1141       1151       1161       1171       1181       1191
V   1201       1211       1221       1231       1241       1251
      GLFEVYLSRI DVEHQLGIDA RDSILGYQIG ELRRVIGDST TMITSHPTDI LTSSTTIRMF
      ********** ********** ********** ********** ********** **********
      GLFEVYLSRI DVEHQLGIDA RDSILGYQIG ELRRVIGDST TMITSHPTDI LTSSTTIRMF
H   1201       1211       1221       1231       1241       1251
V   1261       1271       1281       1291       1301       1311
      MHGAAQSRVD SLVLDMLLPK QMILQLVKSI LTERRLVLAG ATGIGKSKLA KTLAAYVSIR
      ********** ********** ********** ********** ********** **********
      MHGAAQSRVD SLVLDMLLPK QMILQLVKSI LTERRLVLAG ATGIGKSKLA  KTLAAYVSIR
H   1261       1271       1281       1291       1301       1311
V   1321       1331       1341       1351       1361       1371
      TNQSEDSIVN ISIPENNKEE LLQVERRLEK ILRSKESCIV ILDNIPKNRI AFVVSVFANV
      ********** ********** ********** ********** ********** **********
      TNQSEDSIVN ISIPENNKEE LLQVERRLEK ILRSKESCIV ILDNIPKNRI AFVVSVFANV
H   1321       1331       1341       1351       1361       1371
V   1381       1391       1401       1411       1421       1431
      PLQNNEGPFV VCTVNRYQIP ELQIHHNFKM SVMSNRLEGF ILRYLRRRAV EDEYRLTVQM
      ********** ********** ********** ********** ********** **********
      PLQNNEGPFV VCTVNRYQIP ELQIHHNFKM SVMSNRLEGF ILRYLRRRAV EDEYRLTVQM
H   1381       1391       1401       1411       1421       1431
V   1441       1451       1461       1471       1481       1491
      PSELFKIIDF FPIALQAVNN FIEKTNSVDV TVGPRACLNC PLTVDGSREW FIRLWNENFI
      ********** ********** ********** ********** ********** **********
```

45/99

FIG. 18 CONTINUED

```
      PSELFKIIDF FPIALQAVNN FIEKTNSVDV TVGPRACLNC PLTVDGSREW FIRLWNENFI
H  1441       1451       1461       1471       1481       1491
V  1501       1511       1521       1531       1541       1551
      PYLERVARDG KKNLRSLHFL RGSHRHRL-- ---------- ---------- ----------
      ************
      PYLERVARDG KKTFGRCTSF EDPTDIVSEK WPWFDGENPE NVLKRLQLQD LVPSPANSSR
H  1501       1511       1521       1531       1541       1551
V     ---------- ---------- ---

      QHFNPLESLI QLHATKHQTI DNI
H  1561       1571       1581
```

FIG. 19.



FIG. 20.



FIG. 21.



FIG. 22.


470 Bal I
627 EcoN I
678 Nru I
980 Sac II
1640 BstX I
2803 Bbe I
2803 Nar I
4084 Hpa I
4269 Mlu I
Bgl II 4619
Asp718 5378
Kpn I 5378
Nco I 5382
Apa I 6184
Afl II 6437
Sca I 6939
Fsp I 7197
pTB110 (HS-tb3M5)
8651 base pairs
Unique Sites

FIG. 23.


415 Pst I
1147 EcoN I
1198 Nru I
1500 Sac II
2160 BstX I
3323 Bbe I
3323 Nar I
Nco I 5902
Kpn I 5898
Asp718 5898
BspM I 5753
Fsp I 8189
Sca I 7931
Afl II 7429
Apa I 7176
pTB112
9643 base pairs
Unique Sites

51/99

FIG. 24.


Sca I 10098
588 SnaB I
964 Not I
1118 EcoN I
Hca I 8346
pcDNA3 tb3M5 (pTB54)
10543 base pairs
Unique Sites
2740 Spl I
Asr II 7891
BssH II 7773
Bal I 7456
Avr II 7166
Stu I 7163
Dra III 6637
Apa I 6086
PpuM I 6072
4575 Hpa I

FIG. 25.


NotI
EcoNI
SnaBI
SacII
ScaI
pCMV
SpeI
SgrAI
AMP
10000
2000
unc53
0000
pTB72
10443 bps
XcoI
4000
6000
Neo
HpaI
RsrII
pSV40
BssHII
BoII
AurII
StuI
SexAI
DraIII
ApaI
Bsp120I

FIG. 26.

```
GGCCGCCGCC ATGACGACGT CAAATGTAGA ATTGATACCA ATCTACACGG ATTGGGCCAA      60
TCGGCACCTT TCGAAGGGCA GCTTATCAAA GTCGATTAGG GATATTTCCA ATGATTTTCG     120
CGACTATCGA CTGGTTTCTC AGCTTATTAA TGTGATCGTT CCGATCAACG AATTCTCGCC     180
TGCATTCACG AAACGTTTGG CAAAAATCAC ATCGAACCTG GATGGCCTCG AAACGTGTCT     240
CGACTACCTG AAAAATCTGG GTCTCGACTG CTCGAAACTC ACCAAAACCG ATATCGACAG     300
CGGAAACTTG GGTGCAGTTC TCCAGCTGCT CTTCCTGCTC TCCACCTACA AGCAGAAGCT     360
TCGGCAACTG AAAAAAGATC AGAAGAAATT GGAGCAACTA CCCACATCCA TTATGCCACC     420
CGCGGTTTCT AAATTACCCT CGCCACGTGT CGCCACGTCA GCAACCGCTT CAGCAACTAA     480
CCCAAATTCC AACTTTCCAC AAATGTCAAC ATCCAGGCTT CAGACTCCAC AGTCAAGAAT     540
ATCGAAAATT GATTCATCAA AGATTGGTAT CAAGCCAAAG ACGTCTGGAC TTAAACCACC     600
CTCATCATCA ACCACTTCAT CAAATAATAC AAATTCATTC CGTCCGTCGA GCCGTTCGAG     660
TGGCAATAAT AATGTTGGCT CGACGATATC CACATCTGCG AAGAGCTTAG AATCATCATC     720
AACGTACAGC TCTATTTCGA ATCTAAACCG ACCTACCTCC CAACTCCAAA AACCTTCTAG     780
ACCACAAACC CAGCTAGTTC GTGTTGCTAC AACTACAAAA ATCGGAAGCT CAAAGCTAGC     840
CGCTCCGAAA GCCGTGAGCA CCCCAAAACT TGCTTCTGTG AAGACTATTG GAGCAAAACA     900
AGAGCCCGAT AACAGCGGTG GTGGTGGTGG TGGAATGCTG AAATTAAAGT TATTCAGTAG     960
CAAAAACCCA TCTTCCTCAT CGAATAGCCC ACAACCTACG AGAAAGGCGG CGGCGGTGCC    1020
TCAACAACAA ACTTTGTCGA AAATCGCTGC CCCAGTGAAA AGTGGCCTGA AGCCGCCGAC    1080
CAGTAAGCTG GGAAGTGCCA CGTCTATGTC GAAGCTTTGT ACGCCAAAAG TTTCCTACCG    1140
TAAAACGGAC GCCCCAATCA TATCTCAACA AGACTCGAAA CGATGCTCAA AGAGCAGTGA    1200
AGAAGAGTCC GGATACGCTG GATTCAACAG CACGTCGCCA ACGTCATCAT CGACGGAAGG    1260
TTCCCTAAGC ATGCATTCCA CATCTTCCAA GAGTTCAACG TCAGACGAAA AGTCTCCGTC    1320
ATCAGACGAT CTTACTCTTA ACGCCTCCAT CGTGACAGCT ATCAGACAGC CGATAGCCGC    1380
AACACCGGTT TCTCCAAATA TTATCAACAA GCCTGTTGAG GAAAAACCAA CACTGGCAGT    1440
```

FIG. 26 CONTINUED.

```
GAAAGGAGTG AAAAGCACAG CGAAAAAAGA TCCACCTCCA GCTGTTCCGC CACGTGACAC    1500
CCAGCCAACA ATCGGAGTTG TTAGTCCAAT TATGGCACAT AAGAAGTTGA CAAATGACCC    1560
CGTGATATCT GAAAAACCAG AACCTGAAAA GCTCCAATCA ATGAGCATCG ACACGACGGA    1620
CGTTCCACCG CTTCCACCTC TAAAATCAGT TGTTCCACTT AAAATGACTT CAATCCGACA    1680
ACCACCAACG TACGATGTTC TTCTAAAACA AGGAAAAATC ACATCGCCTG TCAAGTCGTT    1740
TGGATATGAG CAGTCGTCCG CGTCTGAAGA CTCCATTGTG GCTCATGCGT CGGCTCAGGT    1800
GACTCCGCCG ACAAAAACTT CTGGTAATCA TTCGCTGGAG AGAAGGATGG GAAAGAATAA    1860
GACATCAGAA TCCAGCGGCT ACACCTCTGA CGCCGGTGTT GCGATGTGCG CCAAAATGAG    1920
GGAGAAGCTG AAAGAATACG ATGACATGAC TCGTCGAGCA CAGAACGGCT ATCCTGACAA    1980
CTTCGAAGAC AGTTCCTCCT TGTCGTCTGG AATATCCGAT AACAACGAGC TCGACGACAT    2040
ATCCACGGAC GATTTGTCCG GAGTAGACAT GGCAACAGTC GCCTCCAAAC ATAGCGACTA    2100
TTCCCACTTT GTTCGCCATC CCACGTCTTC TTCCTCAAAG CCCCGAGTCC CCAGTCGGTC    2160
CTCCACATCA GTCGATTCTC GATCTCGAGC AGAACAGGAG AATGTGTACA AACTTCTGTC    2220
CCAGTGCCGA ACGAGCCAAC GTGGCGCCGC TGCCACCTCA ACCTTCGGAC AACATTCGCT    2280
AAGATCCCCG GGATACTCAT CCTATTCTCC ACACTTATCA GTGTCAGCTG ATAAGGACAC    2340
AATGTCTATG CACTCACAGA CTAGTCGACG ACCTTCTTCA CAAAAACCAA GCTATTCAGG    2400
CCAATTTCAT TCACTTGATC GTAAATGCCA CCTTCAAGAG TTCACATCCA CCGAGCACAG    2460
AATGGCGGCT CTCTTGAGCC CGAGACGGGT GCCGAACTCG ATGTCGAAAT ATGATTCTTC    2520
AGGATCCTAC TCGGCGCGTT CCCGAGGTGG AAGCTCTACT GGTATCTATG GAGAGACGTT    2580
CCAACTGCAC AGACTATCCG ATGAAAAATC CCCCGCACAT TCTGCCAAAA GTGAGATGGG    2640
ATCCCAACTA TCACTGGCTA GCACGACAGC ATATGGATCT CTCAATGAGA AGTACGAACA    2700
TGCTATTCGG GACATGGCAC GTGACTTGGA GTGTTACAAG AACACTGTCG ACTCACTAAC    2760
CAAGAAACAG GAGAACTATG GAGCATTGTT TGATCTTTTT GAGCAAAAGC TTAGAAAACT    2820
CACTCAACAC ATTGATCGAT CCAACTTGAA GCCTGAAGAG GCAATACGAT TCAGGCAGGA    2880
CATTGCTCAT TTGAGGGATA TTAGCAATCA TCTTGCATCC AACTCAGCTC ATGCTAACGA    2940
AGGCGCTGGT GAGCTTCTTC GTCAACCATC TCTGGAATCA GTTGCATCCC ATCGATCATC    3000
GATGTCATCG TCGTCGAAAA GCAGCAAGCA GGAGAAGATC AGCTTGAGCT CGTTTGGCAA    3060
GAACAAGAAG AGCTGGATCC GCTCCTCACT CTCCAAGTTC ACCAAGAAGA AGAACAAGAA    3120
CTACGACGAA GCACATATGC CATCAATTTC CGGATCTCAA GGAACTCTTG ACAACATTGA    3180
TGTGATTGAG TTGAAGCAAG AGCTCAAAGA ACGCGATAGT GCACTTTACG AAGTCCGCCT    3240
TGACAATCTG GATCGTGCCC GCGAAGTTGA TGTTCTGAGG GAGACAGTGA ACAAGTTGAA    3300
AACCGAGAAC AAGCAATTAA AGAAAGAAGT GGACAAACTC ACCAACGGTC CAGCCACTCG    3360
```

FIG. 26 CONTINUED. 55/99

```
TGCTTCTTCC CGCGCCTCAA TTCCAGTTAT CTACGACGAT GAGCATGTCT ATGATGCAGC   3420
GTGTAGCAGT ACATCAGCTA GTCAATCTTC GAAACGATCC TCTGGCTGCA ACTCAATCAA   3480
GGTTACTGTA AACGTGGACA TCGCTGGAGA AATCAGTTCG ATCGTTAACC CGGACAAAGA   3540
GATAATCGTA GGATATCTTG CCATGTCAAC CAGTCAGTCA TGCTGGAAAG ACATTGATGT   3600
TTCTATTCTA GGACTATTTG AAGTCTACCT ATCCAGAATT GATGTGGAGC ATCAACTTGG   3660
AATCGATGCT CGTGATTCTA TCCTTGGCTA TCAAATTGGT GAACTTCGAC GCGTCATTGG   3720
AGACTCCACA ACCATGATAA CCAGCCATCC AACTGACATT CTTACTTCCT CAACTACAAT   3780
CCGAATGTTC ATGCACGGTG CCGCACAGAG TCGCGTAGAC AGTCTGGTCC TTGATATGCT   3840
TCTTCCAAAG CAAATGATTC TCCAACTCGT CAAGTCAATT TTGACAGAGA GACGTCTGGT   3900
GTTAGCTGGA GCAACTGGAA TTGGAAAGAG CAAACTGGCG AAGACCCTGG CTGCTTATGT   3960
ATCTATTCGA ACAAATCAAT CCGAAGATAG TATTGTTAAT ATCAGCATTC CTGAAAACAA   4020
TAAAGAAGAA TTGCTTCAAG TGGAACGACG CCTGGAAAAG ATCTTGAGAA GCAAAGAATC   4080
ATGCATCGTA ATTCTAGATA ATATCCCAAA GAATCGAATT GCATTTGTTG TATCCGTTTT   4140
TGCAAATGTC CCACTTCAAA ACAACGAAGG TCCATTTGTA GTATGCACAG TCAACCGATA   4200
TCAAATCCCT GAGCTTCAAA TTCACCACAA TTTCAAAATG TCAGTAATGT CGAATCGTCT   4260
CGAAGGATTC ATCCTACGTT ACCTCCGACG ACGGGCGGTA GAGGATGAGT ATCGTCTAAC   4320
TGTACAGATG CCATCAGAGC TCTTCAAAAT CATTGACTTC TTCCCAATAG CTCTTCAGGC   4380
CGTCAATAAT TTTATTGAGA AAACGAATTC TGTTGATGTG ACAGTTGGTC CAAGAGCATG   4440
CTTGAACTGT CCTCTAACTG TCGATGGATC CCGTGAATGG TTCATTCGAT TGTGGAATGA   4500
GAACTTCATT CCATATTTGG AACGTGTTGC TAGAGATGGC AAAAAAACCT TCGGTCGCTG   4560
CACTTCCTTC GAGGATCCCA CCGACATCGT CTCTAAAAAA TGGCCGTGGT TCGATGGTGA   4620
AAACCCGGAG AATGTGCTCA AACGTCTTCA ACTCCAAGAC CTCGTCCCGT CACCTGCCAA   4680
CTCATCCCGA CAACACTTCA ATCCCCTCGA GTCGTTGATC CAATTGCATG CTACCAAGCA   4740
TCAGACCATC GACAACATTT GAACAGAAGA CTCTAATCTT CTCTCGCCTC TCCCCCGCTT   4800
TCCTTATCTT CGTACCGGTA CCTGATGATT CCCCATTTTC CCCCTTTTCC CCCCAATTTC   4860
CCAGAACCTC CTGTTCCCTT TGTTCCTAGT CCTCCCGGGT GCCGACGCCG AAGCGATTTA   4920
AAAACCTTTT TCTTTCCGAA ACATTTCCCA TTGCTCATTA ATAGTCAAAT TGAATAAACA   4980
GTGTATGTAC TTAAAAAAAA AAAAAAAAAA ACTCGAGGGG GGGCCCTATT CTATAGTGTC   5040
ACCTAAATGC TAGAGCTCGC TGATCAGCCT CGACTGTGCC TTCTAGTTGC CAGCCATCTG   5100
TTGTTTGCCC CTCCCCCGTG CCTTCCTTGA CCCTGGAAGG TGCCACTCCC ACTGTCCTTT   5160
CCTAATAAAA TGAGGAAATT GCATCGCATT GTCTGAGTAG GTGTCATTCT ATTCTGGGGG   5220
GTGGGGTGGG GCAGGACAGC AAGGGGGAGG ATTGGGAAGA CAATAGCAGG CATGCTGGGG   5280
```

FIG. 26 CONTINUED.

```
ATGCGGTGGG CTCTATGGCT TCTGAGGCGG AAAGAACCAG CTGGGGCTCT AGGGGGTATC   5340
CCCACGCGCC CTGTAGCGGC GCATTAAGCG CGGCGGGTGT GGTGGTTACG CGCAGCGTGA   5400
CCGCTACACT TGCCAGCGCC CTAGCGCCCG CTCCTTTCGC TTTCTTCCCT TCCTTTCTCG   5460
CCACGTTCGC CGGCTTTCCC CGTCAAGCTC TAAATCGGGG CATCCCTTTA GGGTTCCGAT   5520
TTAGTGCTTT ACGGCACCTC GACCCCAAAA AACTTGATTA GGGTGATGGT TCACGTAGTG   5580
GGCCATCGCC CTGATAGACG GTTTTTCGCC CTTTGACGTT GGAGTCCACG TTCTTTAATA   5640
GTGGACTCTT GTTCCAAACT GGAACAACAC TCAACCCTAT CTCGGTCTAT TCTTTTGATT   5700
TATAAGGGAT TTTGGGGATT TCGGCCTATT GGTTAAAAAA TGAGCTGATT TAACAAAAAT   5760
TTAACGCGAA TTAATTCTGT GGAATGTGTG TCAGTTAGGG TGTGGAAAGT CCCCAGGCTC   5820
CCCAGGCAGG CAGAAGTATG CAAAGCATGC ATCTCAATTA GTCAGCAACC AGGTGTGGAA   5880
AGTCCCCAGG CTCCCCAGCA GGCAGAAGTA TGCAAAGCAT GCATCTCAAT TAGTCAGCAA   5940
CCATAGTCCC GCCCCTAACT CCGCCCATCC CGCCCCTAAC TCCGCCCAGT TCCGCCCATT   6000
CTCCGCCCCA TGGCTGACTA ATTTTTTTTA TTTATGCAGA GGCCGAGGCC GCCTCTGCCT   6060
CTGAGCTATT CCAGAAGTAG TGAGGAGGCT TTTTTGGAGG CCTAGGCTTT TGCAAAAAGC   6120
TCCCGGGAGC TTGTATATCC ATTTTCGGAT CTGATCAAGA GACAGGATGA GGATCGTTTC   6180
GCATGATTGA ACAAGATGGA TTGCACGCAG GTTCTCCGGC CGCTTGGGTG GAGAGGCTAT   6240
TCGGCTATGA CTGGGCACAA CAGACAATCG GCTGCTCTGA TGCCGCCGTG TTCCGGCTGT   6300
CAGCGCAGGG GCGCCCGGTT CTTTTTGTCA AGACCGACCT GTCCGGTGCC CTGAATGAAC   6360
TGCAGGACGA GGCAGCGCGG CTATCGTGGC TGGCCACGAC GGGCGTTCCT TGCGCAGCTG   6420
TGCTCGACGT TGTCACTGAA GCGGGAAGGG ACTGGCTGCT ATTGGGCGAA GTGCCGGGGC   6480
AGGATCTCCT GTCATCTCAC CTTGCTCCTG CCGAGAAAGT ATCCATCATG GCTGATGCAA   6540
TGCGGCGGCT GCATACGCTT GATCCGGCTA CCTGCCCATT CGACCACCAA GCGAAACATC   6600
GCATCGAGCG AGCACGTACT CGGATGGAAG CCGGTCTTGT CGATCAGGAT GATCTGGACG   6660
AAGAGCATCA GGGGCTCGCG CCAGCCGAAC TGTTCGCCAG GCTCAAGGCG CGCATGCCCG   6720
ACGGCGAGGA TCTCGTCGTG ACCCATGGCG ATGCCTGCTT GCCGAATATC ATGGTGGAAA   6780
ATGGCCGCTT TTCTGGATTC ATCGACTGTG GCCGGCTGGG TGTGGCGGAC CGCTATCAGG   6840
ACATAGCGTT GGCTACCCGT GATATTGCTG AAGAGCTTGG CGGCGAATGG GCTGACCGCT   6900
TCCTCGTGCT TTACGGTATC GCCGCTCCCG ATTCGCAGCG CATCGCCTTC TATCGCCTTC   6960
TTGACGAGTT CTTCTGAGCG GGACTCTGGG GTTCGAAATG ACCGACCAAG CGACGCCCAA   7020
CCTGCCATCA CGAGATTTCG ATTCCACCGC CGCCTTCTAT GAAAGGTTGG GCTTCGGAAT   7080
CGTTTTCCGG GACGCCGGCT GGATGATCCT CCAGCGCGGG GATCTCATGC TGGAGTTCTT   7140
CGCCCACCCC AACTTGTTTA TTGCAGCTTA TAATGGTTAC AAATAAAGCA ATAGCATCAC   7200
```

FIG. 26 CONTINUED.

```
AAATTTCACA AATAAAGCAT TTTTTTCACT GCATTCTAGT TGTGGTTTGT CCAAACTCAT   7260
CAATGTATCT TATCATGTCT GTATACCGTC GACCTCTAGC TAGAGCTTGG CGTAATCATG   7320
GTCATAGCTG TTTCCTGTGT GAAATTGTTA TCCGCTCACA ATTCCACACA ACATACGAGC   7380
CGGAAGCATA AAGTGTAAAG CCTGGGGTGC CTAATGAGTG AGCTAACTCA CATTAATTGC   7440
GTTGCGCTCA CTGCCCGCTT TCCAGTCGGG AAACCTGTCG TGCCAGCTGC ATTAATGAAT   7500
CGGCCAACGC GCGGGGAGAG GCGGTTTGCG TATTGGGCGC TCTTCCGCTT CCTCGCTCAC   7560
TGACTCGCTG CGCTCGGTCG TTCGGCTGCG GCGAGCGGTA TCAGCTCACT CAAAGGCGGT   7620
AATACGGTTA TCCACAGAAT CAGGGGATAA CGCAGGAAAG AACATGTGAG CAAAAGGCCA   7680
GCAAAAGGCC AGGAACCGTA AAAAGGCCGC GTTGCTGGCG TTTTTCCATA GGCTCCGCCC   7740
CCCTGACGAG CATCACAAAA ATCGACGCTC AAGTCAGAGG TGGCGAAACC CGACAGGACT   7800
ATAAAGATAC CAGGCGTTTC CCCCTGGAAG CTCCCTCGTG CGCTCTCCTG TTCCGACCCT   7860
GCCGCTTACC GGATACCTGT CCGCCTTTCT CCCTTCGGGA AGCGTGGCGC TTTCTCAATG   7920
CTCACGCTGT AGGTATCTCA GTTCGGTGTA GGTCGTTCGC TCCAAGCTGG GCTGTGTGCA   7980
CGAACCCCCC GTTCAGCCCG ACCGCTGCGC CTTATCCGGT AACTATCGTC TTGAGTCCAA   8040
CCCGGTAAGA CACGACTTAT CGCCACTGGC AGCAGCCACT GGTAACAGGA TTAGCAGAGC   8100
GAGGTATGTA GGCGGTGCTA CAGAGTTCTT GAAGTGGTGG CCTAACTACG GCTACACTAG   8160
AAGGACAGTA TTTGGTATCT GCGCTCTGCT GAAGCCAGTT ACCTTCGGAA AAAGAGTTGG   8220
TAGCTCTTGA TCCGGCAAAC AAACCACCGC TGGTAGCGGT GGTTTTTTTG TTTGCAAGCA   8280
GCAGATTACG CGCAGAAAAA AAGGATCTCA AGAAGATCCT TTGATCTTTT CTACGGGGTC   8340
TGACGCTCAG TGGAACGAAA ACTCACGTTA AGGGATTTTG GTCATGAGAT TATCAAAAAG   8400
GATCTTCACC TAGATCCTTT TAAATTAAAA ATGAAGTTTT AAATCAATCT AAAGTATATA   8460
TGAGTAAACT TGGTCTGACA GTTACCAATG CTTAATCAGT GAGGCACCTA TCTCAGCGAT   8520
CTGTCTATTT CGTTCATCCA TAGTTGCCTG ACTCCCCGTC GTGTAGATAA CTACGATACG   8580
GGAGGGCTTA CCATCTGGCC CCAGTGCTGC AATGATACCG CGAGACCCAC GCTCACCGGC   8640
TCCAGATTTA TCAGCAATAA ACCAGCCAGC CGGAAGGGCC GAGCGCAGAA GTGGTCCTGC   8700
AACTTTATCC GCCTCCATCC AGTCTATTAA TTGTTGCCGG GAAGCTAGAG TAAGTAGTTC   8760
GCCAGTTAAT AGTTTGCGCA ACGTTGTTGC CATTGCTACA GGCATCGTGG TGTCACGCTC   8820
GTCGTTTGGT ATGGCTTCAT TCAGCTCCGG TTCCCAACGA TCAAGGCGAG TTACATGATC   8880
CCCCATGTTG TGCAAAAAAG CGGTTAGCTC CTTCGGTCCT CCGATCGTTG TCAGAAGTAA   8940
GTTGGCCGCA GTGTTATCAC TCATGGTTAT GGCAGCACTG CATAATTCTC TTACTGTCAT   9000
GCCATCCGTA AGATGCTTTT CTGTGACTGG TGAGTACTCA ACCAAGTCAT TCTGAGAATA   9060
GTGTATGCGG CGACCGAGTT GCTCTTGCCC GGCGTCAATA CGGGATAATA CCGCGCCACA   9120
```

FIG. 26 CONTINUED

```
TAGCAGAACT TTAAAAGTGC TCATCATTGG AAAACGTTCT TCGGGGCGAA AACTCTCAAG    9180
GATCTTACCG CTGTTGAGAT CCAGTTCGAT GTAACCCACT CGTGCACCCA ACTGATCTTC    9240
AGCATCTTTT ACTTTCACCA GCGTTTCTGG GTGAGCAAAA ACAGGAAGGC AAAATGCCGC    9300
AAAAAAGGGA ATAAGGGCGA CACGGAAATG TTGAATACTC ATACTCTTCC TTTTTCAATA    9360
TTATTGAAGC ATTTATCAGG GTTATTGTCT CATGAGCGGA TACATATTTG AATGTATTTA    9420
GAAAAATAAA CAAATAGGGG TTCCGCGCAC ATTTCCCCGA AAAGTGCCAC CTGACGTCGA    9480
CGGATCGGGA GATCTCCCGA TCCCCTATGG TCGACTCTCA GTACAATCTG CTCTGATGCC    9540
GCATAGTTAA GCCAGTATCT GCTCCCTGCT TGTGTGTTGG AGGTCGCTGA GTAGTGCGCG    9600
AGCAAAATTT AAGCTACAAC AAGGCAAGGC TTGACCGACA ATTGCATGAA GAATCTGCTT    9660
AGGGTTAGGC GTTTTGCGCT GCTTCGCGAT GTACGGGCCA GATATACGCG TTGACATTGA    9720
TTATTGACTA GTTATTAATA GTAATCAATT ACGGGGTCAT TAGTTCATAG CCCATATATG    9780
GAGTTCCGCG TTACATAACT TACGGTAAAT GGCCCGCCTG GCTGACCGCC CAACGACCCC    9840
CGCCCATTGA CGTCAATAAT GACGTATGTT CCCATAGTAA CGCCAATAGG GACTTTCCAT    9900
TGACGTCAAT GGGTGGACTA TTTACGGTAA ACTGCCCACT TGGCAGTACA TCAAGTGTAT    9960
CATATGCCAA GTACGCCCCC TATTGACGTC AATGACGGTA AATGGCCCGC CTGGCATTAT   10020
GCCCAGTACA TGACCTTATG GGACTTTCCT ACTTGGCAGT ACATCTACGT ATTAGTCATC   10080
GCTATTACCA TGGTGATGCG GTTTTGGCAG TACATCAATG GGCGTGGATA GCGGTTTGAC   10140
TCACGGGGAT TTCCAAGTCT CCACCCCATT GACGTCAATG GGAGTTTGTT TTGGCACCAA   10200
AATCAACGGG ACTTTCCAAA ATGTCGTAAC AACTCCGCCC CATTGACGCA AATGGGCGGT   10260
AGGCGTGTAC GGTGGGAGGT CTATATAAGC AGAGCTCTCT GGCTAACTAG AGAACCCACT   10320
GCTTACTGGC TTATCGAAAT TAATACGACT CACTATAGGG AGACCCAAGC TTGGTACCGA   10380
GCTCGGATCC ACTAGTAACG GCCGCCAGTG TGCTGGAATT CTGCAGATAT CCATCACACT   10440
GGC                                                                 10443
```

FIG. 27.


DraIII
NaeI
NgoMI
ScaI
SacII
Eco31
f1
amp
7000
1000
BstXI
6000
pTB 73
7474 bps
2000
SplI
SgrAI
5000
Bsp120I
ApaI
PssI
DraII
3000
4000
unc53
BheI
Eco78
KasI
NarI
MunI
BspMI
EcoRI
SpeI
BglII
MluI
StyI
HpaI

60/99

FIG. 28.

```
CTAAATTGTA AGCGTTAATA TTTTGTTAAA ATTCGCGTTA AATTTTTGTT AAATCAGCTC      60
ATTTTTTAAC CAATAGGCCG AAATCGGCAA AATCCCTTAT AAATCAAAAG AATAGACCGA     120
GATAGGGTTG AGTGTTGTTC CAGTTTGGAA CAAGAGTCCA CTATTAAAGA ACGTGGACTC     180
CAACGTCAAA GGGCGAAAAA CCGTCTATCA GGGCGATGGC CCACTACGTG AACCATCACC     240
CTAATCAAGT TTTTTGGGGT CGAGGTGCCG TAAAGCACTA AATCGGAACC CTAAAGGGAG     300
CCCCCGATTT AGAGCTTGAC GGGGAAAGCC GGCGAACGTG GCGAGAAAGG AAGGGAAGAA     360
AGCGAAAGGA GCGGGCGCTA GGGCGCTGGC AAGTGTAGCG GTCACGCTGC GCGTAACCAC     420
CACACCCGCC GCGCTTAATG CGCCGCTACA GGGCGCGTCC CATTCGCCAT TCAGGCTGCG     480
CAACTGTTGG GAAGGGCGAT CGGTGCGGGC CTCTTCGCTA TTACGCCAGC TGGCGAAAGG     540
GGGATGTGCT GCAAGGCGAT TAAGTTGGGT AACGCCAGGG TTTTCCCAGT CACGACGTTG     600
TAAAACGACG GCCAGTGAGC GCGCGTAATA CGACTCACTA TAGGGCGAAT TGGAGCTCCA     660
CCGCGGTTTC TAAATTACCC TCGCCACGTG TCGCCACGTC AGCAACCGCT TCAGCAACTA     720
ACCCAAATTC CAACTTTCCA CAAATGTCAA CATCCAGGCT TCAGACTCCA CAGTCAAGAA     780
TATCGAAAAT TGATTCATCA AAGATTGGTA TCAAGCCAAA GACGTCTGGA CTTAAACCAC     840
CCTCATCATC AACCACTTCA TCAAATAATA CAAATTCATT CCGTCCGTCG AGCCGTTCGA     900
GTGGCAATAA TAATGTTGGC TCGACGATAT CCACATCTGC GAAGAGCTTA GAATCATCAT     960
CAACGTACAG CTCTATTTCG AATCTAAACC GACCTACCTC CCAACTCCAA AAACCTTCTA    1020
GACCACAAAC CCAGCTAGTT CGTGTTGCTA CAACTACAAA AATCGGAAGC TCAAAGCTAG    1080
CCGCTCCGAA AGCCGTGAGC ACCCCAAAAC TTGCTTCTGT GAAGACTATT GGAGCAAAAC    1140
AAGAGCCCGA TAACAGCGGT GGTGGTGGTG GTGGAATGCT GAAATTAAAG TTATTCAGTA    1200
GCAAAAACCC ATCTTCCTCA TCGAATAGCC CACAACCTAC GAGAAAGGCG GCGGCGGTGC    1260
CTCAACAACA AACTTTGTCG AAAATCGCTG CCCCAGTGAA AAGTGGCCTG AAGCCGCCGA    1320
CCAGTAAGCT GGGAAGTGCC ACGTCTATGT CGAAGCTTTG TACGCCAAAA GTTTCCTACC    1380
GTAAAACGGA CGCCCCAATC ATATCTCAAC AAGACTCGAA ACGATGCTCA AAGAGCAGTG    1440
AAGAAGAGTC CGGATACGCT GGATTCAACA GCACGTCGCC AACGTCATCA TCGACGGAAG    1500
GTTCCCTAAG CATGCATTCC ACATCTTCCA AGAGTTCAAC GTCAGACGAA AAGTCTCCGT    1560
CATCAGACGA TCTTACTCTT AACGCCTCCA TCGTGACAGC TATCAGACAG CCGATAGCCG    1620
CAACACCGGT TTCTCCAAAT ATTATCAACA AGCCTGTTGA GGAAAAACCA ACACTGGCAG    1680
TGAAAGGAGT GAAAAGCACA GCGAAAAAAG ATCCACCTCC AGCTGTTCCG CCACGTGACA    1740
CCCAGCCAAC AATCGGAGTT GTTAGTCCAA TTATGGCACA TAAGAAGTTG ACAAATGACC    1800
CCGTGATATC TGAAAAACCA GAACCTGAAA AGCTCCAATC AATGAGCATC GACACGACGG    1860
```

FIG. 28 CONTINUED.

```
ACGTTCCACC GCTTCCACCT CTAAAATCAG TTGTTCCACT TAAAATGACT TCAATCCGAC  1920
AACCACCAAC GTACGATGTT CTTCTAAAAC AAGGAAAAAT CACATCGCCT GTCAAGTCGT  1980
TTGGATATGA GCAGTCGTCC GCGTCTGAAG ACTCCATTGT GGCTCATGCG TCGGCTCAGG  2040
TGACTCCGCC GACAAAAACT TCTGGTAATC ATTCGCTGGA GAGAAGGATG GGAAAGAATA  2100
AGACATCAGA ATCCAGCGGC TACACCTCTG ACGCCGGTGT TGCGATGTGC GCCAAAATGA  2160
GGGAGAAGCT GAAAGAATAC GATGACATGA CTCGTCGAGC ACAGAACGGC TATCCTGACA  2220
ACTTCGAAGA CAGTTCCTCC TTGTCGTCTG GAATATCCGA TAACAACGAG CTCGACGACA  2280
TATCCACGGA CGATTTGTCC GGAGTAGACA TGGCAACAGT CGCCTCCAAA CATAGCGACT  2340
ATTCCCACTT TGTTCGCCAT CCCACGTCTT CTTCCTCAAA GCCCCGAGTC CCCAGTCGGT  2400
CCTCCACATC AGTCGATTCT CGATCTCGAG CAGAACAGGA GAATGTGTAC AAACTTCTGT  2460
CCCAGTGCCG AACGAGCCAA CGTGGCGCCG CTGCCACCTC AACCTTCGGA CAACATTCGC  2520
TAAGATCCCC GGGATACTCA TCCTATTCTC CACACTTATC AGTGTCAGCT GATAAGGACA  2580
CAATGTCTAT GCACTCACAG ACTAGTCGAC GACCTTCTTC ACAAAAACCA AGCTATTCAG  2640
GCCAATTTCA TTCACTTGAT CGTAAATGCC ACCTTCAAGA GTTCACATCC ACCGAGCACA  2700
GAATGGCGGC TCTCTTGAGC CCGAGACGGG TGCCGAACTC GATGTCGAAA TATGATTCTT  2760
CAGGATCCTA CTCGGCGCGT TCCCGAGGTG GAAGCTCTAC TGGTATCTAT GGAGAGACGT  2820
TCCAACTGCA CAGACTATCC GATGAAAAAT CCCCCGCACA TTCTGCCAAA AGTGAGATGG  2880
GATCCCAACT ATCACTGGCT AGCACGACAG CATATGGATC TCTCAATGAG AAGTACGAAC  2940
ATGCTATTCG GGACATGGCA CGTGACTTGG AGTGTTACAA GAACACTGTC GACTCACTAA  3000
CCAAGAAACA GGAGAACTAT GGAGCATTGT TTGATCTTTT TGAGCAAAAG CTTAGAAAAC  3060
TCACTCAACA CATTGATCGA TCCAACTTGA AGCCTGAAGA GGCAATACGA TTCAGGCAGG  3120
ACATTGCTCA TTTGAGGGAT ATTAGCAATC ATCTTGCATC CAACTCAGCT CATGCTAACG  3180
AAGGCGCTGG TGAGCTTCTT CGTCAACCAT CTCTGGAATC AGTTGCATCC CATCGATCAT  3240
CGATGTCATC GTCGTCGAAA AGCAGCAAGC AGGAGAAGAT CAGCTTGAGC TCGTTTGGCA  3300
AGAACAAGAA GAGCTGGATC CGCTCCTCAC TCTCCAAGTT CACCAAGAAG AAGAACAAGA  3360
ACTACGACGA AGCACATATG CCATCAATTT CCGGATCTCA AGGAACTCTT GACAACATTG  3420
ATGTGATTGA GTTGAAGCAA GAGCTCAAAG AACGCGATAG TGCACTTTAC GAAGTCCGCC  3480
TTGACAATCT GGATCGTGCC CGCGAAGTTG ATGTTCTGAG GGAGACAGTG AACAAGTTGA  3540
AAACCGAGAA CAAGCAATTA AAGAAAGAAG TGGACAAACT CACCAACGGT CCAGCCACTC  3600
GTGCTTCTTC CCGCGCCTCA ATTCCAGTTA TCTACGACGA TGAGCATGTC TATGATGCAG  3660
CGTGTAGCAG TACATCAGCT AGTCAATCTT CGAAACGATC CTCTGGCTGC AACTCAATCA  3720
AGGTTACTGT AAACGTGGAC ATCGCTGGAG AAATCAGTTC GATCGTTAAC CCGGACAAAG  3780
```

FIG. 28 CONTINUED.

AGATAATCGT AGGATATCTT GCCATGTCAA CCAGTCAGTC ATGCTGGAAA GACATTGATG 3840

TTTCTATTCT AGGACTATTT GAAGTCTACC TATCCAGAAT TGATGTGGAG CATCAACTTG 3900

GAATCGATGC TCGTGATTCT ATCCTTGGCT ATCAAATTGG TGAACTTCGA CGCGTCATTG 3960

GAGACTCCAC AACCATGATA ACCAGCCATC CAACTGACAT TCTTACTTCC TCAACTACAA 4020

TCCGAATGTT CATGCACGGT GCCGCACAGA GTCGCGTAGA CAGTCTGGTC CTTGATATGC 4080

TTCTTCCAAA GCAAATGATT CTCCAACTCG TCAAGTCAAT TTTGACAGAG AGACGTCTGG 4140

TGTTAGCTGG AGCAACTGGA ATTGGAAAGA GCAAACTGGC GAAGACCCTG GCTGCTTATG 4200

TATCTATTCG AACAAATCAA TCCGAAGATA GTATTGTTAA TATCAGCATT CCTGAAAACA 4260

ATAAAGAAGA ATTGCTTCAA GTGGAACGAC GCCTGGAAAA GATCTTGAGA AGCAAAGAAT 4320

CATGCATCGT AATTCTAGAT AATATCCCAA AGAATCGAAT TGCATTTGTT GTATCCGTTT 4380

TTGCAAATGT CCCACTTCAA AACAACGAAG GTCCATTTGT AGTATGCACA GTCAACCGAT 4440

ATCAAATCCC TGAGCTTCAA ATTCACCACA ATTTCAAAAT GTCAGTAATG TCGAATCGTC 4500

TCGAAGGATT CATCCTACGT TACCTCCGAC GACGGGCGGT AGAGGATGAG TATCGTCTAA 4560

CTGTACAGAT GCCATCAGAG CTCTTCAAAA TCATTGACTT CTTCCCAATA GCTCTTCAGG 4620

CCGTCAATAA TTTTATTGAG AAAACGAATT CTGTTGATGT GACAGTTGGT CCAAGAGCAT 4680

GCTTGAACTG TCCTCTAACT GTCGATGGAT CCCGTGAATG GTTCATTCGA TTGTGGAATG 4740

AGAACTTCAT TCCATATTTG GAACGTGTTG CTAGAGATGG CAAAAAAACC TTCGGTCGCT 4800

GCACTTCCTT CGAGGATCCC ACCGACATCG TCTCTAAAAA ATGGCCGTGG TTCGATGGTG 4860

AAAACCCGGA GAATGTGCTC AAACGTCTTC AACTCCAAGA CCTCGTCCCG TCACCTGCCA 4920

ACTCATCCCG ACAACACTTC AATCCCCTCG AGTCGTTGAT CCAATTGCAT GCTACCAAGC 4980

ATCAGACCAT CGACAACATT TGAACAGAAG ACTCTAATCT TCTCTCGCCT CTCCCCCGCT 5040

TTCCTTATCT TCGTACCGGT ACCTGATGAT TCCCCATTTT CCCCCTTTTC CCCCCAATTT 5100

CCCAGAACCT CCTGTTCCCT TTGTTCCTAG TCCTCCCGGG TGCCGACGCC GAAGCGATTT 5160

AAAAACCTTT TTCTTTCCGA AACATTTCCC ATTGCTCATT AATAGTCAAA TTGAATAAAC 5220

AGTGTATGTA CTTAAAAAAA AAAAAAAAAA AACTCGAGGG GGGGCCCGGT ACCCAGCTTT 5280

TGTTCCCTTT AGTGAGGGTT AATTGCGCGC TTGGCGTAAT CATGGTCATA GCTGTTTCCT 5340

GTGTGAAATT GTTATCCGCT CACAATTCCA CACAACATAC GAGCCGGAAG CATAAAGTGT 5400

AAAGCCTGGG GTGCCTAATG AGTGAGCTAA CTCACATTAA TTGCGTTGCG CTCACTGCCC 5460

GCTTTCCAGT CGGGAAACCT GTCGTGCCAG CTGCATTAAT GAATCGGCCA ACGCGCGGGG 5520

AGAGGCGGTT TGCGTATTGG GCGCTCTTCC GCTTCCTCGC TCACTGACTC GCTGCGCTCG 5580

GTCGTTCGGC TGCGGCGAGC GGTATCAGCT CACTCAAAGG CGGTAATACG GTTATCCACA 5640

GAATCAGGGG ATAACGCAGG AAAGAACATG TGAGCAAAAG GCCAGCAAAA GGCCAGGAAC 5700

FIG. 28 CONTINUED.

```
CGTAAAAAGG CCGCGTTGCT GGCGTTTTTC CATAGGCTCC GCCCCCCTGA CGAGCATCAC   5760
AAAAATCGAC GCTCAAGTCA GAGGTGGCGA AACCCGACAG GACTATAAAG ATACCAGGCG   5820
TTTCCCCCTG GAAGCTCCCT CGTGCGCTCT CCTGTTCCGA CCCTGCCGCT TACCGGATAC   5880
CTGTCCGCCT TTCTCCCTTC GGGAAGCGTG GCGCTTTCTC ATAGCTCACG CTGTAGGTAT   5940
CTCAGTTCGG TGTAGGTCGT TCGCTCCAAG CTGGGCTGTG TGCACGAACC CCCCGTTCAG   6000
CCCGACCGCT GCGCCTTATC CGGTAACTAT CGTCTTGAGT CCAACCCGGT AAGACACGAC   6060
TTATCGCCAC TGGCAGCAGC CACTGGTAAC AGGATTAGCA GAGCGAGGTA TGTAGGCGGT   6120
GCTACAGAGT TCTTGAAGTG GTGGCCTAAC TACGGCTACA CTAGAAGGAC AGTATTTGGT   6180
ATCTGCGCTC TGCTGAAGCC AGTTACCTTC GGAAAAAGAG TTGGTAGCTC TTGATCCGGC   6240
AAACAAACCA CCGCTGGTAG CGGTGGTTTT TTTGTTTGCA AGCAGCAGAT TACGCGCAGA   6300
AAAAAAGGAT CTCAAGAAGA TCCTTTGATC TTTTCTACGG GGTCTGACGC TCAGTGGAAC   6360
GAAAACTCAC GTTAAGGGAT TTTGGTCATG AGATTATCAA AAAGGATCTT CACCTAGATC   6420
CTTTTAAATT AAAAATGAAG TTTTAAATCA ATCTAAAGTA TATATGAGTA AACTTGGTCT   6480
GACAGTTACC AATGCTTAAT CAGTGAGGCA CCTATCTCAG CGATCTGTCT ATTTCGTTCA   6540
TCCATAGTTG CCTGACTCCC CGTCGTGTAG ATAACTACGA TACGGGAGGG CTTACCATCT   6600
GGCCCCAGTG CTGCAATGAT ACCGCGAGAC CCACGCTCAC CGGCTCCAGA TTTATCAGCA   6660
ATAAACCAGC CAGCCGGAAG GGCCGAGCGC AGAAGTGGTC CTGCAACTTT ATCCGCCTCC   6720
ATCCAGTCTA TTAATTGTTG CCGGGAAGCT AGAGTAAGTA GTTCGCCAGT TAATAGTTTG   6780
CGCAACGTTG TTGCCATTGC TACAGGCATC GTGGTGTCAC GCTCGTCGTT TGGTATGGCT   6840
TCATTCAGCT CCGGTTCCCA ACGATCAAGG CGAGTTACAT GATCCCCCAT GTTGTGCAAA   6900
AAAGCGGTTA GCTCCTTCGG TCCTCCGATC GTTGTCAGAA GTAAGTTGGC CGCAGTGTTA   6960
TCACTCATGG TTATGGCAGC ACTGCATAAT TCTCTTACTG TCATGCCATC CGTAAGATGC   7020
TTTTCTGTGA CTGGTGAGTA CTCAACCAAG TCATTCTGAG AATAGTGTAT GCGGCGACCG   7080
AGTTGCTCTT GCCCGGCGTC AATACGGGAT AATACCGCGC CACATAGCAG AACTTTAAAA   7140
GTGCTCATCA TTGGAAAACG TTCTTCGGGG CGAAAACTCT CAAGGATCTT ACCGCTGTTG   7200
AGATCCAGTT CGATGTAACC CACTCGTGCA CCCAACTGAT CTTCAGCATC TTTTACTTTC   7260
ACCAGCGTTT CTGGGTGAGC AAAAACAGGA AGGCAAAATG CCGCAAAAAA GGGAATAAGG   7320
GCGACACGGA AATGTTGAAT ACTCATACTC TTCCTTTTTC AATATTATTG AAGCATTTAT   7380
CAGGGTTATT GTCTCATGAG CGGATACATA TTTGAATGTA TTTAGAAAAA TAAACAAATA   7440
GGGGTTCCGC GCACATTTCC CCGAAAAGTG CCAC                               7474
```

FIG. 29.


EcoNI
SacII
SplI
SgrAI
BbeI
Eco78
KasI
NarI
SpeI
Gal4b.d.
AflII
CYH2
12000
NgoMI
NaeI
DraIII
2000
unc53
F1 ori
pCB50
10000
x3414 bps
TRP1
4000
SouI
8000
6000
2micron
amp
Asp718
KpnI
StuI
XmaIII
NcoI
PstI

FIG. 30.

```
TATGACGACG TCAAATGTAG AATTGATACC ATTCTACACG GATTGGGCCA ATCGGCACCT      60
TTCGAAGGGC AGCTTATCAA AGTCGATTAG GGATATTTCC AATGATTTTC GCGACTATCG     120
ACTGGTTTCT CAGCTTATTA ATGTGATCGT TCCGATCAAC GAATTCTCGC CTGCATTCAC     180
GAAACGTTTG GCAAAAATCA CATCGAACCT GGATGGCCTC GAAACGTGTC TCGACTACCT     240
GAAAAATCTG GGTCTCGACT GCTCGAAACT CACCAAAACC GATATCGACA GCGGAAACTT     300
GGGTGCAGTT CTCCAGCTGC TCTTCCTGCT CTCCACCTAC AAGCAGAAGC TTCGGCAACT     360
GAAAAAAGAT CAGAAGAAAT TGGAGCAACT ACCCACATCC ATTATGCCAC CCGCGGTTTC     420
TAAATTACCC TCGCCACGTG TCGCCACGTC AGCAACCGCT TCAGCAACTA ACCCAAATTC     480
CAACTTTCCA CAAATGTCAA CATCCAGGCT TCAGACTCCA CAGTCAAGAA TATCGAAAAT     540
TGATTCATCA AAGATTGGTA TCAAGCCAAA GACGTCTGGA CTTAAACCAC CCTCATCATC     600
AACCACTTCA TCAAATAATA CAAATTCATT CCGTCCGTCG AGCCGTTCGA GTGGCAATAA     660
TAATGTTGGC TCGACGATAT CCACATCTGC GAAGAGCTTA GAATCATCAT CAACGTACAG     720
CTCTATTTCG AATCTAAACC GACCTACCTC CCAACTCCAA AAACCTTCTA GACCACAAAC     780
CCAGCTAGTT CGTGTTGCTA CAACTACAAA AATCGGAAGC TCAAAGCTAG CCGCTCCGAA     840
AGCCGTGAGC ACCCCAAAAC TTGCTTCTGT GAAGACTATT GGAGCAAAAC AAGAGCCCGA     900
TAACAGCGGT GGTGGTGGTG GTGGAATGCT GAAATTAAAG TTATTCAGTA GCAAAAACCC     960
ATCTTCCTCA TCGAATAGCC CACAACCTAC GAGAAAGGCG GCGGCGGTGC CTCAACAACA    1020
AACTTTGTCG AAAATCGCTG CCCCAGTGAA AAGTGGCCTG AAGCCGCCGA CCAGTAAGCT    1080
GGGAAGTGCC ACGTCTATGT CGAAGCTTTG TACGCCAAAA GTTTCCTACC GTAAAACGGA    1140
CGCCCCAATC ATATCTCAAC AAGACTCGAA ACGATGCTCA AAGAGCAGTG AAGAAGAGTC    1200
CGGATACGCT GGATTCAACA GCACGTCGCC AACGTCATCA TCGACGGAAG GTTCCCTAAG    1260
```

FIG. 30 CONTINUED. 66/99

```
CATGCATTCC ACATCTTCCA AGAGTTCAAC GTCAGACGAA AAGTCTCCGT CATCAGACGA  1320
TCTTACTCTT AACGCCTCCA TCGTGACAGC TATCAGACAG CCGATAGCCG CAACACCGGT  1380
TTCTCCAAAT ATTATCAACA AGCCTGTTGA GGAAAAACCA ACACTGGCAG TGAAAGGAGT  1440
GAAAAGCACA GCGAAAAAAG ATCCACCTCC AGCTGTTCCG CCACGTGACA CCCAGCCAAC  1500
AATCGGAGTT GTTAGTCCAA TTATGGCACA TAAGAAGTTG ACAAATGACC CCGTGATATC  1560
TGAAAAACCA GAACCTGAAA AGCTCCAATC AATGAGCATC GACACGACGG ACGTTCCACC  1620
GCTTCCACCT CTAAAATCAG TTGTTCCACT TAAAATGACT TCAATCCGAC AACCACCAAC  1680
GTACGATGTT CTTCTAAAAC AAGGAAAAAT CACATCGCCT GTCAAGTCGT TTGGATATGA  1740
GCAGTCGTCC GCGTCTGAAG ACTCCATTGT GGCTCATGCG TCGGCTCAGG TGACTCCGCC  1800
GACAAAAACT TCTGGTAATC ATTCGCTGGA GAGAAGGATG GGAAAGAATA AGACATCAGA  1860
ATCCAGCGGC TACACCTCTG ACGCCGGTGT TGCGATGTGC GCCAAAATGA GGGAGAAGCT  1920
GAAAGAATAC GATGACATGA CTCGTCGAGC ACAGAACGGC TATCCTGACA ACTTCGAAGA  1980
CAGTTCCTCC TTGTCGTCTG GAATATCCGA TAACAACGAG CTCGACGACA TATCCACGGA  2040
CGATTTGTCC GGAGTAGACA TGGCAACAGT CGCCTCCAAA CATAGCGACT ATTCCCACTT  2100
TGTTCGCCAT CCCACGTCTT CTTCCTCAAA GCCCCGAGTC CCCAGTCGGT CCTCCACATC  2160
AGTCGATTCT CGATCTCGAG CAGAACAGGA GAATGTGTAC AAACTTCTGT CCCAGTGCCG  2220
AACGAGCCAA CGTGGCGCCG CTGCCACCTC AACCTTCGGA CAACATTCGC TAAGATCCCC  2280
GGGATACTCA TCCTATTCTC CACACTTATC AGTGTCAGCT GATAAGGACA CAATGTCTAT  2340
GCACTCACAG ACTAGTCGAC GACCTTCTTC ACAAAAACCA AGCTATTCAG GCCAATTTCA  2400
TTCACTTGAT CGTAAATGCC ACCTTCAAGA GTTCACATCC ACCGAGCACA GAATGGCGGC  2460
TCTCTTGAGC CCGAGACGGG TGCCGAACTC GATGTCGAAA TATGATTCTT CAGGATCCTA  2520
CTCGGCGCGT TCCCGAGGTG GAAGCTCTAC TGGTATCTAT GGAGAGACGT TCCAACTGCA  2580
CAGACTATCC GATGAAAAAT CCCCCGCACA TTCTGCCAAA AGTGAGATGG GATCCCAACT  2640
ATCACTGGCT AGCACGACAG CATATGGATC TCTCAATGAG AAGTACGAAC ATGCTATTCG  2700
GGACATGGCA CGTGACTTGG AGTGTTACAA GAACACTGTC GACTCACTAA CCAAGAAACA  2760
GGAGAACTAT GGAGCATTGT TTGATCTTTT TGAGCAAAAG CTTAGAAAAC TCACTCAACA  2820
CATTGATCGA TCCAACTTGA AGCCTGAAGA GGCAATACGA TTCAGGCAGG ACATTGCTCA  2880
TTTGAGGGAT ATTAGCAATC ATCTTGCATC CAACTCAGCT CATGCTAACG AAGGCGCTGG  2940
TGAGCTTCTT CGTCAACCAT CTCTGGAATC AGTTGCATCC CATCGATCAT CGATGTCATC  3000
GTCGTCGAAA AGCAGCAAGC AGGAGAAGAT CAGCTTGAGC TCGTTTGGCA AGAACAAGAA  3060
GAGCTGGATC CGCTCCTCAC TCTCCAAGTT CACCAAGAAG AAGAACAAGA ACTACGACGA  3120
AGCACATATG CCATCAATTT CCGGATCTCA AGGAACTCTT GACAACATTG ATGTGATTGA  3180
```

FIG. 30 CONTINUED. 67/99

```
GTTGAAGCAA GAGCTCAAAG AACGCGATAG TGCACTTTAC GAAGTCCGCC TTGACAATCT   3240
GGATCGTGCC CGCGAAGTTG ATGTTCTGAG GGAGACAGTG AACAAGTTGA AAACCGAGAA   3300
CAAGCAATTA AAGAAAGAAG TGGACAAACT CACCAACGGT CCAGCCACTC GTGCTTCTTC   3360
CCGCGCCTCA ATTCCAGTTA TCTACGACGA TGAGCATGTC TATGATGCAG CGTGTAGCAG   3420
TACATCAGCT AGTCAATCTT CGAAACGATC CTCTGGCTGC AACTCAATCA AGGTTACTGT   3480
AAACGTGGAC ATCGCTGGAG AAATCAGTTC GATCGTTAAC CCGGACAAAG AGATAATCGT   3540
AGGATATCTT GCCATGTCAA CCAGTCAGTC ATGCTGGAAA GACATTGATG TTTCTATTCT   3600
AGGACTATTT GAAGTCTACC TATCCAGAAT TGATGTGGAG CATCAACTTG GAATCGATGC   3660
TCGTGATTCT ATCCTTGGCT ATCAAATTGG TGAACTTCGA CGCGTCATTG GAGACTCCAC   3720
AACCATGATA ACCAGCCATC CAACTGACAT TCTTACTTCC TCAACTACAA TCCGAATGTT   3780
CATGCACGGT GCCGCACAGA GTCGCGTAGA CAGTCTGGTC CTTGATATGC TTCTTCCAAA   3840
GCAAATGATT CTCCAACTCG TCAAGTCAAT TTTGACAGAG AGACGTCTGG TGTTAGCTGG   3900
AGCAACTGGA ATTGGAAAGA GCAAACTGGC GAAGACCCTG GCTGCTTATG TATCTATTCG   3960
AACAAATCAA TCCGAAGATA GTATTGTTAA TATCAGCATT CCTGAAAACA ATAAAGAAGA   4020
ATTGCTTCAA GTGGAACGAC GCCTGGAAAA GATCTTGAGA AGCAAAGAAT CATGCATCGT   4080
AATTCTAGAT AATATCCCAA AGAATCGAAT TGCATTTGTT GTATCCGTTT TTGCAAATGT   4140
CCCACTTCAA AACAACGAAG GTCCATTTGT AGTATGCACA GTCAACCGAT ATCAAATCCC   4200
TGAGCTTCAA ATTCACCACA ATTTCAAAAT GTCAGTAATG TCGAATCGTC TCGAAGGATT   4260
CATCCTACGT TACCTCCGAC GACGGGCGGT AGAGGATGAG TATCGTCTAA CTGTACAGAT   4320
GCCATCAGAG CTCTTCAAAA TCATTGACTT CTTCCCAATA GCTCTTCAGG CCGTCAATAA   4380
TTTTATTGAG AAAACGAATT CTGTTGATGT GACAGTTGGT CCAAGAGCAT GCTTGAACTG   4440
TCCTCTAACT GTCGATGGAT CCCGTGAATG GTTCATTCGA TTGTGGAATG AGAACTTCAT   4500
TCCATATTTG GAACGTGTTG CTAGAGATGG CAAAAAAACC TTCGGTCGCT GCACTTCCTT   4560
CGAGGATCCC ACCGACATCG TCTCTAAAAA ATGGCCGTGG TTCGATGGTG AAAACCCGGA   4620
GAATGTGCTC AAACGTCTTC AACTCCAAGA CCTCGTCCCG TCACCTGCCA ACTCATCCCG   4680
ACAACACTTC AATCCCCTCG AGTCGTTGAT CCAATTGCAT GCTACCAAGC ATCAGACCAT   4740
CGACAACATT TGAACAGAAG ACTCTAATCT TCTCTCGCCT CTCCCCCGCT TTCCTTATCT   4800
TCGTACCGGT ACCTGATGAT TCCCCATTTT CCCCCTTTTC CCCCCAATTT CCCAGAACCT   4860
CCTGTTCCCT TTGTTCCTAG TCCTCCCGGG TGCCGACGCC GAAGCGATTT AAAAACCTTT   4920
TTCTTTCCGA AACATTTCCC ATTGCTCATT AATAGTCAAA TTGAATAAAC AGTGTATGTA   4980
CTTAAAAAAA AAAAAAAAAA AAAAAAAAAA GGCCTATGCG GCCGGGCCAT GGAGGCCGAA   5040
TTCCCGGGGA TCCGTCGACC TGCAGCCAAG CTAATTCCGG GCGAATTTCT TATGATTTAT   5100
```

FIG. 30 CONTINUED.

```
GATTTTTATT ATTAAATAAG TTATAAAAAA AATAAGTGTA TACAAATTTT AAAGTGACTC  5160
TTAGGTTTTA AAACGAAAAT TCTTGTTCTT GAGTAACTCT TTCCTGTAGG TCAGGTTGCT  5220
TTCTCAGGTA TAGCATGAGG TCGCTCTTAT TGACCACACC TCTACCGGCA TGCAAGCTTG  5280
GCGTAATCAT GGTCATAGCT GTTTCCTGTG TGAAATTGTT ATCCGCTCAC AATTCCACAC  5340
AACATACGAG CCGGAAGCAT AAAGTGTAAA GCCTGGGGTG CCTAATGAGT GAGGTAACTC  5400
ACATTAATTG CGTTGCGCTC ACTGCCCGCT TTCCAGTCGG GAAACCTGTC GTGCCAGCTG  5460
GATTAATGAA TCGGCCAACG CGCGGGGAGA GGCGGTTTGC GTATTGGGCG CTCTTCCGCT  5520
TCCTCGCTCA CTGACTCGCT GCGCTCGGTC GTTCGGCTGC GGCGAGCGGT ATCAGCTCAC  5580
TCAAAGGCGG TAATACGGTT ATCCACAGAA TCAGGGGATA ACGCAGGAAA GAACATGTGA  5640
GCAAAAGGCC AGCAAAAGGC CAGGAACCGT AAAAAGGCCG CGTTGCTGGC GTTTTTCCAT  5700
AGGCTCCGCC CCCCTGACGA GCATCACAAA AATCGACGCT CAAGTCAGAG GTGGCGAAAC  5760
CCGACAGGAC TATAAAGATA CCAGGCGTTT CCCCCTGGAA GCTCCCTCGT GCGCTCTCCT  5820
GTTCCGACCC TGCCGCTTAC CGGATACCTG TCCGCCTTTC TCCCTTCGGG AAGCGTGGCG  5880
CTTTCTCATA GCTCACGCTG TAGGTATCTC AGTTCGGTGT AGGTCGTTCG CTCCAAGCTG  5940
GGCTGTGTGC ACGAACCCCC CGTTCAGCCC GACCGCTGCG CCTTATCCGG TAACTATCGT  6000
CTTGAGTCCA ACCCGGTAAG ACACGACTTA TCGCCACTGG CAGCAGCCAC TGGTAACAGG  6060
ATTAGCAGAG CGAGGTATGT AGGCGGTGCT ACAGAGTTCT TGAAGTGGTG GCCTAACTAC  6120
GGCTACACTA GAAGGACAGT ATTTGGTATC TGCGCTCTGC TGAAGCCAGT TACCTTCGGA  6180
AAAAGAGTTG GTAGCTCTTG ATCCGGCAAA CAAACCACCG CTGGTAGCGG TGGTTTTTTT  6240
GTTTGCAAGC AGCAGATTAC GCGCAGAAAA AAAGGATCTC AAGAAGATCC TTTGATCTTT  6300
TCTACGGGGT CTGACGCTCA GTGGAACGAA AACTCACGTT AAGGGATTTT GGTCATGAGA  6360
TTATCAAAAA GGATCTTCAC CTAGATCCTT TTAAATTAAA AATGAAGTTT TAAATCAATC  6420
TAAAGTATAT ATGAGTAAAC TTGGTCTGAC AGTTACCAAT GCTTAATCAG TGAGGCACCT  6480
ATCTCAGCGA TCTGTCTATT TCGTTCATCC ATAGTTGCCT GACTCCCCGT CGTGTAGATA  6540
ACTACGATAC GGGAGGGCTT ACCATCTGGC CCCAGTGCTG CAATGATACC GCGAGACCCA  6600
CGCTCACCGG CTCCAGATTT ATCAGCAATA AACCAGCCAG CCGGAAGGGC CGAGCGCAGA  6660
AGTGGTCCTG CAACTTTATC CGCCTCCATC CAGTCTATTA ATTGTTGCCG GGAAGCTAGA  6720
GTAAGTAGTT CGCCAGTTAA TAGTTTGCGC AACGTTGTTG CCATTGCTAC AGGCATCGTG  6780
GTGTCACGCT CGTCGTTTGG TATGGCTTCA TTCAGCTCCG GTTCCCAACG ATCAAGGCGA  6840
GTTACATGAT CCCCCATGTT GTGCAAAAAA GCGGTTAGCT CCTTCGGTCC TCCGATCGTT  6900
GTCAGAAGTA AGTTGGCCGC AGTGTTATCA CTCATGGTTA TGGCAGCACT GCATAATTCT  6960
CTTACTGTCA TGCCATCCGT AAGATGCTTT TCTGTGACTG GTGAGTACTC AACCAAGTCA  7020
```

FIG. 30 CONTINUED.

```
TTCTGAGAAT AGTGTATGCG GCGACCGAGT TGCTCTTGCC CGGCGTCAAT ACGGGATAAT   7080
ACCGCGCCAC ATAGCAGAAC TTTAAAAGTG CTCATCATTG GAAAACGTTC TTCGGGGCGA   7140
AAACTCTCAA GGATCTTACC GCTGTTGAGA TCCAGTTCGA TGTAACCCAC TCGTGCACCC   7200
AACTGATCTT CAGCATCTTT TACTTTCACC AGCGTTTCTG GGTGAGCAAA AACAGGAAGG   7260
CAAAATGCCG CAAAAAAGGG AATAAGGGCG ACACGGAAAT GTTGAATACT CATACTCTTC   7320
CTTTTTCAAT ATTATTGAAG CATTTATCAG GGTTATTGTC TCATGAGCGG ATACATATTT   7380
GAATGTATTT AGAAAAATAA ACAAATAGGG GTTCCGCGCA CATTTCCCCG AAAAGTGCCA   7440
CCTGAACGAA GCATCTGTGC TTCATTTTGT AGAACAAAAA TGCAACGCGA GAGCGCTAAT   7500
TTTTCAAACA AAGAATCTGA GCTGCATTTT TACAGAACAG AAATGCAACG CGAAAGCGCT   7560
ATTTTACCAA CGAAGAATCT GTGCTTCATT TTTGTAAAAC AAAAATGCAA CGCGAGAGCG   7620
CTAATTTTTC AAACAAAGAA TCTGAGCTGC ATTTTTACAG AACAGAAATG CAACGCGAGA   7680
GCGCTATTTT ACCAACAAAG AATCTATACT TCTTTTTTGT TCTACAAAAA TGCATCCCGA   7740
GAGCGCTATT TTTCTAACAA AGCATCTTAG ATTACTTTTT TTCTCCTTTG TGCGCTCTAT   7800
AATGCAGTCT CTTGATAACT TTTTGCACTG TAGGTCCGTT AAGGTTAGAA GAAGGCTACT   7860
TTGGTGTCTA TTTTCTCTTC CATAAAAAAA GCCTGACTCC ACTTCCCGCG TTTACTGATT   7920
ACTAGCGAAG CTGCGGGTGC ATTTTTTCAA GATAAAGGCA TCCCCGATTA TATTCTATAC   7980
CGATGTGGAT TGCGCATACT TTGTGAACAG AAAGTGATAG CGTTGATGAT TCTTCATTGG   8040
TCAGAAAATT ATGAACGGTT TCTTCTATTT TGTCTCTATA TACTACGTAT AGGAAATGTT   8100
TACATTTTCG TATTGTTTTC GATTCACTCT ATGAATAGTT CTTACTACAA TTTTTTTGTC   8160
TAAAGAGTAA TACTAGAGAT AAACATAAAA AATGTAGAGG TCGAGTTTAG ATGCAAGTTC   8220
AAGGAGCGAA AGGTGGATGG GTAGGTTATA TAGGGATATA GCACAGAGAT ATATAGCAAA   8280
GAGATACTTT TGAGCAATGT TTGTGGAAGC GGTATTCGCA ATATTTTAGT AGCTCGTTAC   8340
AGTCCGGTGC GTTTTTGGTT TTTTGAAAGT GCGTCTTCAG AGCGCTTTTG GTTTTCAAAA   8400
GCGCTCTGAA GTTCCTATAC TTTCTAGAGA ATAGGAACTT CGGAATAGGA ACTTCAAAGC   8460
GTTTCCGAAA ACGAGCGCTT CCGAAAATGC AACGCGAGCT GCGCACATAC AGCTCACTGT   8520
TCACGTCGCA CCTATATCTG CGTGTTGCCT GTATATATAT ATACATGAGA AGAACGGCAT   8580
AGTGCGTGTT TATGCTTAAA TGCGTACTTA TATGCGTCTA TTTATGTAGG ATGAAAGGTA   8640
GTCTAGTACC TCCTGTGATA TTATCCCATT CCATGCGGGG TATCGTATGC TTCCTTCAGC   8700
ACTACCCTTT AGCTGTTCTA TATGCTGCCA CTCCTCAATT GGATTAGTCT CATCCTTCAA   8760
TGCTATCATT TCCTTTGATA TTGGATCATA TTAAGAAACC ATTATTATCA TGACATTAAC   8820
CTATAAAAAT AGGCGTATCA CGAGGCCCTT TCGTCTCGCG CGTTTCGGTG ATGACGGTGA   8880
AAACCTCTGA CACATGCAGC TCCCGGAGAC GGTCACAGCT TGTCTGTAAG CGGATGCCGG   8940
```

FIG. 30 CONTINUED 70/99

GAGCAGACAA GCCCGTCAGG GCGCGTCAGC GGGTGTTGGC GGGTGTCGGG GCTGGCTTAA 9000

CTATGCGGCA TCAGAGCAGA TTGTACTGAG AGTGCACCAT AGATCAACGA CATTACTATA 9060

TATATAATAT AGGAAGCATT TAATAGACAG CATCGTAATA TATGTGTACT TTGCAGTTAT 9120

GACGCCAGAT GGCAGTAGTG GAAGATATTC TTTATTGAAA AATAGCTTGT CACCTTACGT 9180

ACAATCTTGA TCCGGAGCTT TTCTTTTTTT GCCGATTAAG AATTAATTCG GTCGAAAAAA 9240

GAAAAGGAGA GGGCCAAGAG GGAGGGCATT GGTGACTATT GAGCACGTGA GTATACGTGA 9300

TTAAGCACAC AAAGGCAGCT TGGAGTATGT CTGTTATTAA TTTCACAGGT AGTTCTGGTC 9360

CATTGGTGAA AGTTTGCGGC TTGCAGAGCA CAGAGGCCGC AGAATGTGCT CTAGATTCCG 9420

ATGCTGACTT GCTGGGTATT ATATGTGTGC CCAATAGAAA GAGAACAATT GACCCGGTTA 9480

TTGCAAGGAA AATTTCAAGT CTTGTAAAAG CATATAAAAA TAGTTCAGGC ACTCCGAAAT 9540

ACTTGGTTGG CGTGTTTCGT AATCAACCTA AGGAGGATGT TTTGGCTCTG GTCAATGATT 9600

ACGGCATTGA TATCGTCCAA CTGCATGGAG ATGAGTCGTG GCAAGAATAC CAAGAGTTCC 9660

TCGGTTTGCC AGTTATTAAA AGACTCGTAT TTCCAAAAGA CTGCAACATA CTACTCAGTG 9720

CAGCTTCACA GAAACCTCAT TCGTTTATTC CCTTGTTTGA TTCAGAAGCA GGTGGGACAG 9780

GTGAACTTTT GGATTGGAAC TCGATTTCTG ACTGGGTTGG AAGGCAAGAG AGCCCCGAAA 9840

GCTTACATTT TATGTTAGCT GGTGGACTGA CGCCAGAAAA TGTTGGTGAT GCGCTTAGAT 9900

TAAATGGCGT TATTGGTGTT GATGTAAGCG GAGGTGTGGA GACAAATGGT GTAAAAGACT 9960

CTAACAAAAT AGCAAATTTC GTCAAAAATG CTAAGAAATA GGTTATTACT GAGTAGTATT 10020

TATTTAAGTA TTGTTTGTGC ACTTGCCGAT CTATGCGGTG TGAAATACCG CACAGATGCG 10080

TAAGGAGAAA ATACCGCATC AGGAAATTGT AAACGTTAAT ATTTTGTTAA AATTCGCGTT 10140

AAATTTTTGT TAAATCAGCT CATTTTTTAA CCAATAGGCC GAAATCGGCA AAATCCCTTA 10200

TAAATCAAAA GAATAGACCG AGATAGGGTT GAGTGTTGTT CCAGTTTGGA ACAAGAGTCC 10260

ACTATTAAAG AACGTGGACT CCAACGTCAA AGGGCGAAAA ACCGTCTATC AGGGCGATGG 10320

CCCACTACGT GAACCATCAC CCTAATCAAG TTTTTTGGGG TCGAGGTGCC GTAAAGCACT 10380

AAATCGGAAC CCTAAAGGGA GCCCCCGATT TAGAGCTTGA CGGGGAAAGC CGGCGAACGT 10440

GGCGAGAAAG GAAGGGAAGA AAGCGAAAGG AGCGGGCGCT AGGGCGCTGG CAAGTGTAGC 10500

GGTCACGCTG CGCGTAACCA CCACACCCGC CGCGCTTAAT GCGCCGCTAC AGGGCGCGTC 10560

GCGCCATTCG CCATTCAGGC TGCGCAACTG TTGGGAAGGG CGATCGGTGC GGGCCTCTTC 10620

GCTATTACGC CAGCTGGCGA AAGGGGGATG TGCTGCAAGG CGATTAAGTT GGGTAACGCC 10680

AGGGTTTTCC CAGTCACGAC GTTGTAAAAC GACGGCCAGT CGTCCAAGCT TTCGCGAGCT 10740

CGAGATCCCG AGCTTTGCAA ATTAAAGCCT TCGAGCGTCC CAAAACCTTC TCAAGCAAGG 10800

TTTTCAGTAT AATGTTACAT GCGTACACGC GTCTGTACAG AAAAAAAAGA AAAATTTGAA 10860

FIG. 30 CONTINUED. 71/99

ATATAAATAA CGTTCTTAAT ACTAACATAA CTATAAAAAA ATAAATAGGG ACCTAGACTT 10920

CAGGTTGTCT AACTCCTTCC TTTTCGGTTA GAGCGGATGT GGGGGGAGGG CGTGAATGTA 10980

AGCGTGACAT AACTAATTAC ATGATATCGA CAAAGGAAAA GGGGCCTGTT TACTCACAGG 11040

CTTTTTTCAA GTAGGTAATT AAGTCGTTTC TGTCTTTTTC CTTCTTCAAC CCACCAAAGG 11100

CCATCTTGGT ACTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT 11160

TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTCATA GAAATAATAC 11220

AGAAGTAGAT GTTGAATTAG ATTAAACTGA AGATATATAA TTTATTGGAA AATACATAGA 11280

GCTTTTTGTT GATGCGCTTA AGCGATCAAT TCAACAACAC CACCAGCAGC TCTGATTTTT 11340

TCTTCAGCCA ACTTGGAGAC GAATCTAGCT TTGACGATAA CTGGAACATT TGGGATTCTA 11400

CCCTTACCCA AGATCTTACC GTAACCGGCT GCCAAAGTGT CAATAACTGG AGCAGTTTCC 11460

TTAGAAGCAG ATTTCAAGTA TTGGTCTCTC TTGTCTTCTG GGATCAATGT CCACAATTTG 11520

TCCAAGTTCA AGACTGGCTT CCAGAAATGA GCTTGTTGCT TGTGGAAGTA TCTCATACCA 11580

ANCCTTACCG AAATAACCTG GATGGTATTT ATCCATGTTA ATTCTGTGGT GATGTTGACC 11640

ACCGGCCATA CCTCTACCAC CGGGGTGCTT TCTGTGCTTA CCGATACGAC CTTTACCGGC 11700

TGAGACGTGA CCTCTGTGCT TTCTAGTCTT AGTGAATCTG GAAGGCATTC TTGATTAGTT 11760

GGATGATTGT TCTGGGATTT AATGCAAAAA AATCACTAAG AAGGAAAAAA ATCAACGGAG 11820

AAAGCAAACG CCATCTTAAA TATACGGGAT ACAGATGAAA GGTTTGAACC TATCTGGGAA 11880

AATACGCATT AAACAAGCGA AAAACTGCGA GGAAAATTGT TTGCGTCTCT GCGGGCTATT 11940

CACGCGCCAG AGGAAAATAG GAAAAATAAC AGGGCATTAG AAAAATAATT TTGATTTTGG 12000

TAATGTGTGG GTCCCTGGTG TACAGATGTT ACATTGGTTA CAGTACTCTT GTTTTTGCTG 12060

TGTTTTTCGA TGAATCTCCA AAATGGTTGT TAGCACATGG AAGAGTCACC GATGCTAAGT 12120

TATCTCTATG TAAGCTACGT GGCGTGACTT TTGATGAAGC CGCACAAGAG ATACAGGATT 12180

GGCAACTGCA AATAGAATCT GGGGATCTAG ATATCCTTTT GTTGTTTCCG GGTGTACAAT 12240

ATGGACTTCC TCTTTTCTGG CAACCAAACC CATACATCGG GATTCCTATA ATACCTTCGT 12300

TGGTCTCCCT AACATGTAGG TGGCGGAGGG GAGATATACA ATAGAACAGA TACCAGACAA 12360

GACATAATGG GCTAAACAAG ACTACACCAA TTACACTGCC TCATTGATGG TGGTACATAA 12420

CGAACTAATA CTGTAGCCCT AGACTTGATA GCCATCATCA TATCGAAGTT TCACTACCCT 12480

TTTTCCATTT GCCATCTATT GAAGTAATAA TAGGCGCATG CAACTTCTTT TCTTTTTTTT 12540

TCTTTTCTCT CTCCCCCGTT GTTGTCTCAC CATATCCGCA ATGACAAAAA AAATGATGGA 12600

AGACACTAAA GGAAAAAATT AACGACAAAG ACAGCACCAA CAGATGTCGT TGTTCCAGAG 12660

CTGATGAGGG GTATCTTCGA ACACACGAAA CTTTTTCCTT CCTTCATTCA CGCACACTAC 12720

TCTCTAATGA GCAACGGTAT ACGGCCTTCC TTCCAGTTAC TTGAATTTGA AATAAAAAAA 12780

FIG. 30 CONTINUED.

```
GTTTGCCGCT TTGCTATCAA GTATAAATAG ACCTGCAATT ATTAATCTTT TGTTTCCTCG   12840
TCATTGTTCT CGTTCCCTTT CTTCCTTGTT TCTTTTTCTG CACAATATTT CAAGCTATAC   12900
CAAGCATACA ATCAACTCCA AGCTTGAAGC AAGCCTCCTG AAAGATGAAG CTACTGTCTT   12960
CTATCGAACA AGCATGCGAT ATTTGCCGAC TTAAAAAGCT CAAGTGCTCC AAAGAAAAAC   13020
CGAAGTGCGC CAAGTGTCTG AAGAACAACT GGGAGTGTCG CTACTCTCCC AAAACCAAAA   13080
GGTCTCCGCT GACTAGGGCA CATCTGACAG AAGTGGAATC AAGGCTAGAA AGACTGGAAC   13140
AGCTATTTCT ACTGATTTTT CCTCGAGAAG ACCTTGACAT GATTTTGAAA ATGGATTCTT   13200
TACAGGATAT AAAAGCATTG TTAACAGGAT TATTTGTACA AGATAATGTG AATAAAGATG   13260
CCGTCACAGA TAGATTGGCT TCAGTGGAGA CTGATATGCC TCTAACATTG AGACAGCATA   13320
GAATAAGTGC GACATCATCA TCGGAAGAGA GTAGTAACAA AGGTCAAAGA CAGTTGACTG   13380
TATCGCCGGA ATTGCAATAC CCAGCTTTGA CTCA                               13414
```

FIG. 31.


NdeI
ClaI
AatII
AgeI
Asp718
KpnI
StuI
XmaIII
NcoI
SalI
PstI
Gal4b.d.
unc53 c-term
10000
CYH2
AflII
2000
6000
pCB51
10288 bps
NruI
f1 ori
AlwNI
NgoMI
NaeI
DraIII
4000
6000
TRP1
amp
2micron
BstXI
SauI
PmaCI

74/99

FIG. 32.

```
TATGCCATCA ATTTCCGGAT CTCAAGGAAC TCTTGACAAC ATTGATGTGA TTGAGTTGAA     60
GCAAGAGCTC AAAGAACGCG ATAGTGCACT TTACGAAGTC CGCCTTGACA ATCTGGATCG    120
TGCCCGCGAA GTTGATGTTC TGAGGGAGAC AGTGAACAAG TTGAAAACCG AGAACAAGCA    180
ATTAAAGAAA GAAGTGGACA AACTCACCAA CGGTCCAGCC ACTCGTGCTT CTTCCCGCGC    240
CTCAATTCCA GTTATCTACG ACGATGAGCA TGTCTATGAT GCAGCGTGTA GCAGTACATC    300
AGCTAGTCAA TCTTCGAAAC GATCCTCTGG CTGCAACTCA ATCAAGGTTA CTGTAAACGT    360
GGACATCGCT GGAGAAATCA GTTCGATCGT TAACCCGGAC AAAGAGATAA TCGTAGGATA    420
TCTTGCCATG TCAACCAGTC AGTCATGCTG GAAAGACATT GATGTTTCTA TTCTAGGACT    480
ATTTGAAGTC TACCTATCCA GAATTGATGT GGAGCATCAA CTTGGAATCG ATGCTCGTGA    540
```

FIG. 32 CONTINUED. 75/99

```
TTCTATCCTT GGCTATCAAA TTGGTGAACT TCGACGCGTC ATTGGAGACT CCACAACCAT    600
GATAACCAGC CATCCAACTG ACATTCTTAC TTCCTCAACT ACAATCCGAA TGTTCATGCA    660
CGGTGCCGCA CAGAGTCGCG TAGACAGTCT GGTCCTTGAT ATGCTTCTTC CAAAGCAAAT    720
GATTCTCCAA CTCGTCAAGT CAATTTTGAC AGAGAGACGT CTGGTGTTAG CTGGAGCAAC    780
TGGAATTGGA AAGAGCAAAC TGGCGAAGAC CCTGGCTGCT TATGTATCTA TTCGAACAAA    840
TCAATCCGAA GATAGTATTG TTAATATCAG CATTCCTGAA AACAATAAAG AAGAATTGCT    900
TCAAGTGGAA CGACGCCTGG AAAAGATCTT GAGAAGCAAA GAATCATGCA TCGTAATTCT    960
AGATAATATC CCAAAGAATC GAATTGCATT TGTTGTATCC GTTTTTGCAA ATGTCCCACT   1020
TCAAAACAAC GAAGGTCCAT TTGTAGTATG CACAGTCAAC CGATATCAAA TCCCTGAGCT   1080
TCAAATTCAC CACAATTTCA AAATGTCAGT AATGTCGAAT CGTCTCGAAG GATTCATCCT   1140
ACGTTACCTC CGACGACGGG CGGTAGAGGA TGAGTATCGT CTAACTGTAC AGATGCCATC   1200
AGAGCTCTTC AAAATCATTG ACTTCTTCCC AATAGCTCTT CAGGCCGTCA ATAATTTTAT   1260
TGAGAAAACG AATTCTGTTG ATGTGACAGT TGGTCCAAGA GCATGCTTGA ACTGTCCTCT   1320
AACTGTCGAT GGATCCCGTG AATGGTTCAT TCGATTGTGG AATGAGAACT TCATTCCATA   1380
TTTGGAACGT GTTGCTAGAG ATGGCAAAAA AACCTTCGGT CGCTGCACTT CCTTCGAGGA   1440
TCCCACCGAC ATCGTCTCTA AAAAATGGCC GTGGTTCGAT GGTGAAAACC CGGAGAATGT   1500
GCTCAAACGT CTTCAACTCC AAGACCTCGT CCCGTCACCT GCCAACTCAT CCCGACAACA   1560
CTTCAATCCC CTCGAGTCGT TGATCCAATT GCATGCTACC AAGCATCAGA CCATCGACAA   1620
CATTTGAACA GAAGACTCTA ATCTTCTCTC GCCTCTCCCC CGCTTTCCTT ATCTTCGTAC   1680
CGGTACCTGA TGATTCCCCA TTTTCCCCCT TTTCCCCCCA ATTTCCCAGA ACCTCCTGTT   1740
CCCTTTGTTC CTAGTCCTCC CGGGTGCCGA CGCCGAAGCG ATTTAAAAAC CTTTTTCTTT   1800
CCGAAACATT TCCCATTGCT CATTAATAGT CAAATTGAAT AAACAGTGTA TGTACTTAAA   1860
AAAAAAAAAA AAAAAAAAAA AAAAGGCCTA TGCGGCCGGG CCATGGAGGC CGAATTCCCG   1920
GGGATCCGTC GACCTGCAGC CAAGCTAATT CCGGGCGAAT TTCTTATGAT TTATGATTTT   1980
TATTATTAAA TAAGTTATAA AAAAAATAAG TGTATACAAA TTTTAAAGTG ACTCTTAGGT   2040
TTTAAAACGA AAATTCTTGT TCTTGAGTAA CTCTTTCCTG TAGGTCAGGT TGCTTTCTCA   2100
GGTATAGCAT GAGGTCGCTC TTATTGACCA CACCTCTACC GGCATGCAAG CTTGGCGTAA   2160
TCATGGTCAT AGCTGTTTCC TGTGTGAAAT TGTTATCCGC TCACAATTCC ACACAACATA   2220
CGAGCCGGAA GCATAAAGTG TAAAGCCTGG GGTGCCTAAT GAGTGAGGTA ACTCACATTA   2280
ATTGCGTTGC GCTCACTGCC CGCTTTCCAG TCGGGAAACC TGTCGTGCCA GCTGGATTAA   2340
TGAATCGGCC AACGCGCGGG GAGAGGCGGT TTGCGTATTG GGCGCTCTTC CGCTTCCTCG   2400
CTCACTGACT CGCTGCGCTC GGTCGTTCGG CTGCGGCGAG CGGTATCAGC TCACTCAAAG   2460
```

FIG. 32 CONTINUED. 76/99

GCGGTAATAC GGTTATCCAC AGAATCAGGG GATAACGCAG GAAAGAACAT GTGAGCAAAA 2520

GGCCAGCAAA AGGCCAGGAA CCGTAAAAAG GCCGCGTTGC TGGCGTTTTT CCATAGGCTC 2580

CGCCCCCCTG ACGAGCATCA CAAAAATCGA CGCTCAAGTC AGAGGTGGCG AAACCCGACA 2640

GGACTATAAA GATACCAGGC GTTTCCCCCT GGAAGCTCCC TCGTGCGCTC TCCTGTTCCG 2700

ACCCTGCCGC TTACCGGATA CCTGTCCGCC TTTCTCCCTT CGGGAAGCGT GGCGCTTTCT 2760

CATAGCTCAC GCTGTAGGTA TCTCAGTTCG GTGTAGGTCG TTCGCTCCAA GCTGGGCTGT 2820

GTGCACGAAC CCCCCGTTCA GCCCGACCGC TGCGCCTTAT CCGGTAACTA TCGTCTTGAG 2880

TCCAACCCGG TAAGACACGA CTTATCGCCA CTGGCAGCAG CCACTGGTAA CAGGATTAGC 2940

AGAGCGAGGT ATGTAGGCGG TGCTACAGAG TTCTTGAAGT GGTGGCCTAA CTACGGCTAC 3000

ACTAGAAGGA CAGTATTTGG TATCTGCGCT CTGCTGAAGC CAGTTACCTT CGGAAAAAGA 3060

GTTGGTAGCT CTTGATCCGG CAAACAAACC ACCGCTGGTA GCGGTGGTTT TTTTGTTTGC 3120

AAGCAGCAGA TTACGCGCAG AAAAAAAGGA TCTCAAGAAG ATCCTTTGAT CTTTTCTACG 3180

GGGTCTGACG CTCAGTGGAA CGAAAACTCA CGTTAAGGGA TTTTGGTCAT GAGATTATCA 3240

AAAAGGATCT TCACCTAGAT CCTTTTAAAT TAAAAATGAA GTTTTAAATC AATCTAAAGT 3300

ATATATGAGT AAACTTGGTC TGACAGTTAC CAATGCTTAA TCAGTGAGGC ACCTATCTCA 3360

GCGATCTGTC TATTTCGTTC ATCCATAGTT GCCTGACTCC CCGTCGTGTA GATAACTACG 3420

ATACGGGAGG GCTTACCATC TGGCCCCAGT GCTGCAATGA TACCGCGAGA CCCACGCTCA 3480

CCGGCTCCAG ATTTATCAGC AATAAACCAG CCAGCCGGAA GGGCCGAGCG CAGAAGTGGT 3540

CCTGCAACTT TATCCGCCTC CATCCAGTCT ATTAATTGTT GCCGGGAAGC TAGAGTAAGT 3600

AGTTCGCCAG TTAATAGTTT GCGCAACGTT GTTGCCATTG CTACAGGCAT CGTGGTGTCA 3660

CGCTCGTCGT TTGGTATGGC TTCATTCAGC TCCGGTTCCC AACGATCAAG GCGAGTTACA 3720

TGATCCCCCA TGTTGTGCAA AAAAGCGGTT AGCTCCTTCG GTCCTCCGAT CGTTGTCAGA 3780

AGTAAGTTGG CCGCAGTGTT ATCACTCATG GTTATGGCAG CACTGCATAA TTCTCTTACT 3840

GTCATGCCAT CCGTAAGATG CTTTTCTGTG ACTGGTGAGT ACTCAACCAA GTCATTCTGA 3900

GAATAGTGTA TGCGGCGACC GAGTTGCTCT TGCCCGGCGT CAATACGGGA TAATACCGCG 3960

CCACATAGCA GAACTTTAAA AGTGCTCATC ATTGGAAAAC GTTCTTCGGG GCGAAAACTC 4020

TCAAGGATCT TACCGCTGTT GAGATCCAGT TCGATGTAAC CCACTCGTGC ACCCAACTGA 4080

TCTTCAGCAT CTTTTACTTT CACCAGCGTT TCTGGGTGAG CAAAAACAGG AAGGCAAAAT 4140

GCCGCAAAAA AGGGAATAAG GGCGACACGG AAATGTTGAA TACTCATACT CTTCCTTTTT 4200

CAATATTATT GAAGCATTTA TCAGGGTTAT TGTCTCATGA GCGGATACAT ATTTGAATGT 4260

ATTTAGAAAA ATAAACAAAT AGGGGTTCCG CGCACATTTC CCCGAAAAGT GCCACCTGAA 4320

CGAAGCATCT GTGCTTCATT TTGTAGAACA AAAATGCAAC GCGAGAGCGC TAATTTTTCA 4380

FIG. 32 CONTINUED. 77/99

```
AACAAAGAAT CTGAGCTGCA TTTTTACAGA ACAGAAATGC AACGCGAAAG CGCTATTTTA   4440
CCAACGAAGA ATCTGTGCTT CATTTTTGTA AAACAAAAAT GCAACGCGAG AGCGCTAATT   4500
TTTCAAACAA AGAATCTGAG CTGCATTTTT ACAGAACAGA AATGCAACGC GAGAGCGCTA   4560
TTTTACCAAC AAAGAATCTA TACTTCTTTT TTGTTCTACA AAAATGCATC CCGAGAGCGC   4620
TATTTTTCTA ACAAAGCATC TTAGATTACT TTTTTTCTCC TTTGTGCGCT CTATAATGCA   4680
GTCTCTTGAT AACTTTTTGC ACTGTAGGTC CGTTAAGGTT AGAAGAAGGC TACTTTGGTG   4740
TCTATTTTCT CTTCCATAAA AAAAGCCTGA CTCCACTTCC CGCGTTTACT GATTACTAGC   4800
GAAGCTGCGG GTGCATTTTT TCAAGATAAA GGCATCCCCG ATTATATTCT ATACCGATGT   4860
GGATTGCGCA TACTTTGTGA ACAGAAAGTG ATAGCGTTGA TGATTCTTCA TTGGTCAGAA   4920
AATTATGAAC GGTTTCTTCT ATTTTGTCTC TATATACTAC GTATAGGAAA TGTTTACATT   4980
TTCGTATTGT TTTCGATTCA CTCTATGAAT AGTTCTTACT ACAATTTTTT TGTCTAAAGA   5040
GTAATACTAG AGATAAACAT AAAAAATGTA GAGGTCGAGT TTAGATGCAA GTTCAAGGAG   5100
CGAAAGGTGG ATGGGTAGGT TATATAGGGA TATAGCACAG AGATATATAG CAAAGAGATA   5160
CTTTTGAGCA ATGTTTGTGG AAGCGGTATT CGCAATATTT TAGTAGCTCG TTACAGTCCG   5220
GTGCGTTTTT GGTTTTTTGA AAGTGCGTCT TCAGAGCGCT TTTGGTTTTC AAAAGCGCTC   5280
TGAAGTTCCT ATACTTTCTA GAGAATAGGA ACTTCGGAAT AGGAACTTCA AAGCGTTTCC   5340
GAAAACGAGC GCTTCCGAAA ATGCAACGCG AGCTGCGCAC ATACAGCTCA CTGTTCACGT   5400
CGCACCTATA TCTGCGTGTT GCCTGTATAT ATATATACAT GAGAAGAACG GCATAGTGCG   5460
TGTTTATGCT TAAATGCGTA CTTATATGCG TCTATTTATG TAGGATGAAA GGTAGTCTAG   5520
TACCTCCTGT GATATTATCC CATTCCATGC GGGGTATCGT ATGCTTCCTT CAGCACTACC   5580
CTTTAGCTGT TCTATATGCT GCCACTCCTC AATTGGATTA GTCTCATCCT TCAATGCTAT   5640
CATTTCCTTT GATATTGGAT CATATTAAGA AACCATTATT ATCATGACAT TAACCTATAA   5700
AAATAGGCGT ATCACGAGGC CCTTTCGTCT CGCGCGTTTC GGTGATGACG GTGAAAACCT   5760
CTGACACATG CAGCTCCCGG AGACGGTCAC AGCTTGTCTG TAAGCGGATG CCGGGAGCAG   5820
ACAAGCCCGT CAGGGCGCGT CAGCGGGTGT TGGCGGGTGT CGGGGCTGGC TTAACTATGC   5880
GGCATCAGAG CAGATTGTAC TGAGAGTGCA CCATAGATCA ACGACATTAC TATATATATA   5940
ATATAGGAAG CATTTAATAG ACAGCATCGT AATATATGTG TACTTTGCAG TTATGACGCC   6000
AGATGGCAGT AGTGGAAGAT ATTCTTTATT GAAAAATAGC TTGTCACCTT ACGTACAATC   6060
TTGATCCGGA GCTTTTCTTT TTTTGCCGAT TAAGAATTAA TTCGGTCGAA AAAAGAAAAG   6120
GAGAGGGCCA AGAGGGAGGG CATTGGTGAC TATTGAGCAC GTGAGTATAC GTGATTAAGC   6180
ACACAAAGGC AGCTTGGAGT ATGTCTGTTA TTAATTTCAC AGGTAGTTCT GGTCCATTGG   6240
TGAAAGTTTG CGGCTTGCAG AGCACAGAGG CCGCAGAATG TGCTCTAGAT TCCGATGCTG   6300
```

FIG. 32 CONTINUED. 78/99

ACTTGCTGGG TATTATATGT GTGCCCAATA GAAAGAGAAC AATTGACCCG GTTATTGCAA 6360
GGAAAATTTC AAGTCTTGTA AAAGCATATA AAAATAGTTC AGGCACTCCG AAATACTTGG 6420
TTGGCGTGTT TCGTAATCAA CCTAAGGAGG ATGTTTTGGC TCTGGTCAAT GATTACGGCA 6480
TTGATATCGT CCAACTGCAT GGAGATGAGT CGTGGCAAGA ATACCAAGAG TTCCTCGGTT 6540
TGCCAGTTAT TAAAAGACTC GTATTTCCAA AAGACTGCAA CATACTACTC AGTGCAGCTT 6600
CACAGAAACC TCATTCGTTT ATTCCCTTGT TTGATTCAGA AGCAGGTGGG ACAGGTGAAC 6660
TTTTGGATTG GAACTCGATT TCTGACTGGG TTGGAAGGCA AGAGAGCCCC GAAAGCTTAC 6720
ATTTTATGTT AGCTGGTGGA CTGACGCCAG AAAATGTTGG TGATGCGCTT AGATTAAATG 6780
GCGTTATTGG TGTTGATGTA AGCGGAGGTG TGGAGACAAA TGGTGTAAAA GACTCTAACA 6840
AAATAGCAAA TTTCGTCAAA AATGCTAAGA AATAGGTTAT TACTGAGTAG TATTTATTTA 6900
AGTATTGTTT GTGCACTTGC CGATCTATGC GGTGTGAAAT ACCGCACAGA TGCGTAAGGA 6960
GAAAATACCG CATCAGGAAA TTGTAAACGT TAATATTTTG TTAAAATTCG CGTTAAATTT 7020
TTGTTAAATC AGCTCATTTT TTAACCAATA GGCCGAAATC GGCAAAATCC CTTATAAATC 7080
AAAAGAATAG ACCGAGATAG GGTTGAGTGT TGTTCCAGTT TGGAACAAGA GTCCACTATT 7140
AAAGAACGTG GACTCCAACG TCAAAGGGCG AAAAACCGTC TATCAGGGCG ATGGCCCACT 7200
ACGTGAACCA TCACCCTAAT CAAGTTTTTT GGGGTCGAGG TGCCGTAAAG CACTAAATCG 7260
GAACCCTAAA GGGAGCCCCC GATTTAGAGC TTGACGGGGA AAGCCGGCGA ACGTGGCGAG 7320
AAAGGAAGGG AAGAAAGCGA AAGGAGCGGG CGCTAGGGCG CTGGCAAGTG TAGCGGTCAC 7380
GCTGCGCGTA ACCACCACAC CCGCCGCGCT TAATGCGCCG CTACAGGGCG CGTCGCGCCA 7440
TTCGCCATTC AGGCTGCGCA ACTGTTGGGA AGGGCGATCG GTGCGGGCCT CTTCGCTATT 7500
ACGCCAGCTG GCGAAAGGGG GATGTGCTGC AAGGCGATTA AGTTGGGTAA CGCCAGGGTT 7560
TTCCCAGTCA CGACGTTGTA AAACGACGGC CAGTCGTCCA AGCTTTCGCG AGCTCGAGAT 7620
CCCGAGCTTT GCAAATTAAA GCCTTCGAGC GTCCCAAAAC CTTCTCAAGC AAGGTTTTCA 7680
GTATAATGTT ACATGCGTAC ACGCGTCTGT ACAGAAAAAA AAGAAAAATT TGAAATATAA 7740
ATAACGTTCT TAATACTAAC ATAACTATAA AAAAATAAAT AGGGACCTAG ACTTCAGGTT 7800
GTCTAACTCC TTCCTTTTCG GTTAGAGCGG ATGTGGGGGG AGGGCGTGAA TGTAAGCGTG 7860
ACATAACTAA TTACATGATA TCGACAAAGG AAAAGGGGCC TGTTTACTCA CAGGCTTTTT 7920
TCAAGTAGGT AATTAAGTCG TTTCTGTCTT TTTCCTTCTT CAACCCACCA AAGGCCATCT 7980
TGGTACTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT 8040
TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT CATAGAAATA ATACAGAAGT 8100
AGATGTTGAA TTAGATTAAA CTGAAGATAT ATAATTTATT GGAAAATACA TAGAGCTTTT 8160
TGTTGATGCG CTTAAGCGAT CAATTCAACA ACACCACCAG CAGCTCTGAT TTTTTCTTCA 8220

FIG. 32 CONTINUED. 79/99

GCCAACTTGG AGACGAATCT AGCTTTGACG ATAACTGGAA CATTTGGGAT TCTACCCTTA 8280

CCCAAGATCT TACCGTAACC GGCTGCCAAA GTGTCAATAA CTGGAGCAGT TTCCTTAGAA 8340

GCAGATTTCA AGTATTGGTC TCTCTTGTCT TCTGGGATCA ATGTCCACAA TTTGTCCAAG 8400

TTCAAGACTG GCTTCCAGAA ATGAGCTTGT TGCTTGTGGA AGTATCTCAT ACCAANCCTT 8460

ACCGAAATAA CCTGGATGGT ATTTATCCAT GTTAATTCTG TGGTGATGTT GACCACCGGC 8520

CATACCTCTA CCACCGGGGT GCTTTCTGTG CTTACCGATA CGACCTTTAC CGGCTGAGAC 8580

GTGACCTCTG TGCTTTCTAG TCTTAGTGAA TCTGGAAGGC ATTCTTGATT AGTTGGATGA 8640

TTGTTCTGGG ATTTAATGCA AAAAAATCAC TAAGAAGGAA AAAAATCAAC GGAGAAAGCA 8700

AACGCCATCT TAAATATACG GGATACAGAT GAAAGGTTTG AACCTATCTG GGAAAATACG 8760

CATTAAACAA GCGAAAAACT GCGAGGAAAA TTGTTTGCGT CTCTGCGGGC TATTCACGCG 8820

CCAGAGGAAA ATAGGAAAAA TAACAGGGCA TTAGAAAAAT AATTTTGATT TTGGTAATGT 8880

GTGGGTCCCT GGTGTACAGA TGTTACATTG GTTACAGTAC TCTTGTTTTT GCTGTGTTTT 8940

TCGATGAATC TCCAAAATGG TTGTTAGCAC ATGGAAGAGT CACCGATGCT AAGTTATCTC 9000

TATGTAAGCT ACGTGGCGTG ACTTTTGATG AAGCCGCACA AGAGATACAG GATTGGCAAC 9060

TGCAAATAGA ATCTGGGGAT CTAGATATCC TTTTGTTGTT TCCGGGTGTA CAATATGGAC 9120

TTCCTCTTTT CTGGCAACCA AACCCATACA TCGGGATTCC TATAATACCT TCGTTGGTCT 9180

CCCTAACATG TAGGTGGCGG AGGGGAGATA TACAATAGAA CAGATACCAG ACAAGACATA 9240

ATGGGCTAAA CAAGACTACA CCAATTACAC TGCCTCATTG ATGGTGGTAC ATAACGAACT 9300

AATACTGTAG CCCTAGACTT GATAGCCATC ATCATATCGA AGTTTCACTA CCCTTTTTCC 9360

ATTTGCCATC TATTGAAGTA ATAATAGGCG CATGCAACTT CTTTTCTTTT TTTTTCTTTT 9420

CTCTCTCCCC CGTTGTTGTC TCACCATATC CGCAATGACA AAAAAAATGA TGGAAGACAC 9480

TAAAGGAAAA AATTAACGAC AAAGACAGCA CCAACAGATG TCGTTGTTCC AGAGCTGATG 9540

AGGGGTATCT TCGAACACAC GAAACTTTTT CCTTCCTTCA TTCACGCACA CTACTCTCTA 9600

ATGAGCAACG GTATACGGCC TTCCTTCCAG TTACTTGAAT TTGAAATAAA AAAAGTTTGC 9660

CGCTTTGCTA TCAAGTATAA ATAGACCTGC AATTATTAAT CTTTTGTTTC CTCGTCATTG 9720

TTCTCGTTCC CTTTCTTCCT TGTTTCTTTT TCTGCACAAT ATTTCAAGCT ATACCAAGCA 9780

TACAATCAAC TCCAAGCTTG AAGCAAGCCT CCTGAAAGAT GAAGCTACTG TCTTCTATCG 9840

AACAAGCATG CGATATTTGC CGACTTAAAA AGCTCAAGTG CTCCAAAGAA AAACCGAAGT 9900

GCGCCAAGTG TCTGAAGAAC AACTGGGAGT GTCGCTACTC TCCCAAAACC AAAAGGTCTC 9960

CGCTGACTAG GGCACATCTG ACAGAAGTGG AATCAAGGCT AGAAAGACTG GAACAGCTAT 10020

TTCTACTGAT TTTTCCTCGA GAAGACCTTG ACATGATTTT GAAAATGGAT TCTTTACAGG 10080

ATATAAAAGC ATTGTTAACA GGATTATTTG TACAAGATAA TGTGAATAAA GATGCCGTCA 10140

FIG. 32 CONTINUED.

```
CAGATAGATT GGCTTCAGTG GAGACTGATA TGCCTCTAAC ATTGAGACAG CATAGAATAA   10200
GTGCGACATC ATCATCGGAA GAGAGTAGTA ACAAAGGTCA AAGACAGTTG ACTGTATCGC   10260
CGGAATTGCA ATACCCAGCT TTGACTCA                                      10288
```

FIG. 33.


Bsg I
Asp 718
Kpn I
Rsr II
Sac AI
EcoR I
Sma I
Xma I
Bam HI
Nde I
Bsp MII
Ban II
Sac I 136
Hpa I
BsmI
Bgl II
Bal I
Bsp 1407
Dsa I
AflII
Bst EII
Pf1 MI
Ppu MI
Sap I
Pvu II
AlwNI
Eam 1105
Eco 31
Bgl I
Sco I
Sna BI
Bsa AI
Ppu 10I
Nsi I
1000
2000
3000
4000
5000
6000
7000
pCB55
7625 bps
anc 53 frag

FIG. 34.

```
GCTTGCATGC AACTTCTTTT CTTTTTTTTT CTTTTCTCTC TCCCCCGTTG TTGTCTCACC      60
ATATCCGCAA TGACAAAAAA AATGATGGAA GACACTAAAG GAAAAAATTA ACGACAAAGA     120
CAGCACCAAC AGATGTCGTT GTTCCAGAGC TGATGAGGGG TATCTTCGAA CACACGAAAC     180
TTTTTCCTTC CTTCATTCAC GCACACTACT CTCTAATGAG CAACGGTATA CGGCCTTCCT     240
TCCAGTTACT TGAATTTGAA ATAAAAAAAG TTTGCCGCTT TGCTATCAAG TATAAATAGA     300
CCTGCAATTA TTAATCTTTT GTTTCCTCGT CATTGTTCTC GTTCCCTTTC TTCCTTGTTT     360
CTTTTTCTGC ACAATATTTC AAGCTATACC AAGCATACAA TCAACTCCAA GCTTTGCAAA     420
GATGGATAAA GCGGAATTAA TTCCCGAGCC TCCAAAAAAG AAGAGAAAGG TCGAATTGGG     480
TACCGCCGCC AATTTTAATC AAAGTGGGAA TATTGCTGAT AGCTCATTGT CCTTCACTTT     540
CACTAACAGT AGCAACGGTC CGAACCTCAT AACAACTCAA ACAAATTCTC AAGCGCTTTC     600
ACAACCAATT GCCTCCTCTA ACGTTCATGA TAACTTCATG AATAATGAAA TCACGGCTAG     660
TAAAATTGAT GATGGTAATA ATTCAAAACC ACTGTCACCT GGTTGGACGG ACCAAACTGC     720
GTATAACGCG TTTGGAATCA CTACAGGGAT GTTTAATACC ACTACAATGG ATGATGTATA     780
TAACTATCTA TTCGATGATG AAGATACCCC ACCAAACCCA AAAAAAGAGA TCGAATTCCC     840
GGGGATCCGC TCCTCACTCT CCAAGTTCAC CAAGAAGAAG AACAAGAACT ACGACGAAGC     900
ACATATGCCA TCAATTTCCG GATCTCAAGG AACTCTTGAC AACATTGATG TGATTGAGTT     960
GAAGCAAGAG CTCAAAGAAC GCGATAGTGC ACTTTACGAA GTCCGCCTTG ACAATCTGGA    1020
TCGTGCCCGC GAAGTTGATG TTCTGAGGGA GACAGTGAAC AAGTTGAAAA CCGAGAACAA    1080
GCAATTAAAG AAAGAAGTGG ACAAACTCAC CAACGGTCCA GCCACTCGTG CTTCTTCCCG    1140
CGCCTCAATT CCAGTTATCT ACGACGATGA GCATGTCTAT GATGCAGCGT GTAGCAGTAC    1200
```

FIG. 34 CONTINUED. 83/99

```
ATCAGCTAGT CAATCTTCGA AACGATCCTC TGGCTGCAAC TCAATCAAGG TTACTGTAAA   1260
CGTGGACATC GCTGGAGAAA TCAGTTCGAT CGTTAACCCG GACAAAGAGA TAATCGTAGG   1320
ATATCTTGCC ATGTCAACCA GTCAGTCATG CTGGAAAGAC ATTGATGTTT CTATTCTAGG   1380
ACTATTTGAA GTCTACCTAT CCAGAATTGA TGTGGAGCAT CAACTTGGAA TCGATGCTCG   1440
TGATTCTATC CTTGGCTATC AAATTGGTGA ACTTCGACGC GTCATTGGAG ACTCCACAAC   1500
CATGATAACC AGCCATCCAA CTGACATTCT TACTTCCTCA ACTACAATCC GAATGTTCAT   1560
GCACGGTGCC GCACAGAGTC GCGTAGACAG TCTGGTCCTT GATATGCTTC TTCCAAAGCA   1620
AATGATTCTC CAACTCGTCA AGTCAATTTT GACAGAGAGA CGTCTGGTGT TAGCTGGAGC   1680
AACTGGAATT GGAAAGAGCA AACTGGCGAA GACCCTGGCT GCTTATGTAT CTATTCGAAC   1740
AAATCAATCC GAAGATAGTA TTGTTAATAT CAGCATTCCT GAAAACAATA AAGAAGAATT   1800
GCTTCAAGTG GAACGACGCC TGGAAAAGAT CTATGAATCG TAGATACTGA AAAACCCCGC   1860
AAGTTCACTT CAACTGTGCA TCGTGCACCA TCTCAATTTC TTTCATTTAT ACATCGTTTT   1920
GCCTTCTTTT ATGTAACTAT ACTCCTCTAA GTTTCAATCT TGGCCATGTA ACCTCTGATC   1980
TATAGAATTT TTTAAATGAC TAGAATTAAT GCCCATCTTT TTTTTGGACC TAAATTCTTC   2040
ATGAAAATAT ATTACGAGGG CTTATTCAGA AGCTTTGGAC TTCTTCGCCA GAGGTTTGGT   2100
CAAGTCTCCA ATCAAGGTTG TCGGCTTGTC TACCTTGCCA GAAATTTACG AAAAGATGGA   2160
AAAGGGTCAA ATCGTTGGTA GATACGTTGT TGACACTTCT AAATAAGCGA ATTTCTTATG   2220
ATTTATGATT TTTATTATTA AATAAGTTAT AAAAAAAATA AGTGTATACA AATTTTAAAG   2280
TGACTCTTAG GTTTTAAAAC GAAAATTCTT GTTCTTGAGT AACTCTTTCC TGTAGGTCAG   2340
GTTGCTTTCT CAGGTATAGC ATGAGGTCGC TCTTATTGAC CACACCTCTA CCGGCATGCC   2400
CGAAATTCCC CTACCCTATG AACATATTCC ATTTTGTAAT TTCGTGTCGT TTCTATTATG   2460
AATTTCATTT ATAAAGTTTA TGTACAAATA TCATAAAAAA AGAGAATCTT TTTAAGCAAG   2520
GATTTTCTTA ACTTCTTCGG CGACAGCATC ACCGACTTCG GTGGTACTGT TGGAACCACC   2580
TAAATCACCA GTTCTGATAC CTGCATCCAA AACCTTTTTA ACTGCATCTT CAATGGCCTT   2640
ACCTTCTTCA GGCAAGTTCA ATGACAATTT CAACATCATT GCAGCAGACA AGATAGTGGC   2700
GATAGGGTCA ACCTTATTCT TTGGCAAATC TGGAGCAGAA CCGTGGCATG GTTCGTACAA   2760
ACCAAATGCG GTGTTCTTGT CTGGCAAAGA GGCCAAGGAC GCAGATGGCA ACAAACCCAA   2820
GGAACCTGGG ATAACGGAGG CTTCATCGGA GATGATATCA CCAAACATGT TGCTGGTGAT   2880
TATAATACCA TTTAGGTGGG TTGGGTTCTT AACTAGGATC ATGGCGGCAG AATCAATCAA   2940
TTGATGTTGA ACCTTCAATG TAGGAAATTC GTTCTTGATG GTTTCCTCCA CAGTTTTTCT   3000
CCATAATCTT GAAGAGGCCA AAACATTAGC TTTATCCAAG GACCAAATAG GCAATGGTGG   3060
CTCATGTTGT AGGGCCATGA AAGCGGCCAT TCTTGTGATT CTTTGCACTT CTGGAACGGT   3120
```

FIG. 34 CONTINUED. 84/99

GTATTGTTCA CTATCCCAAG CGACACCATC ACCATCGTCT TCCTTTCTCT TACCAAAGTA 3180

AATACCTCCC ACTAATTCTC TGACAACAAC GAAGTCAGTA CCTTTAGCAA ATTGTGGCTT 3240

GATTGGAGAT AAGTCTAAAA GAGAGTCGGA TGCAAAGTTA CATGGTCTTA AGTTGGCGTA 3300

CAATTGAAGT TCTTTACGGA TTTTTAGTAA ACCTTGTTCA GGTCTAACAC TACCTGTACC 3360

CCATTTAGGA CCACCCACAG CACCTAACAA AACGGCATCA ACCTTCTTGG AGGCTTCCAG 3420

CGCCTCATCT GGAAGTGGGA CACCTGTAGC ATCGATAGCA GCACCACCAA TTAAATGATT 3480

TTCGAAATCG AACTTGACAT TGGAACGAAC ATCAGAAATA GCTTTAAGAA CCTTAATGGC 3540

TTCGGCTGTG ATTTCTTGAC CAACGTGGTC ACCTGGCAAA ACGACGATCT TCTTAGGGGC 3600

AGACATTAGA ATGGTATATC CTTGAAATAT ATATATATAT TGCTGAAATG TAAAAGGTAA 3660

GAAAAGTTAG AAAGTAAGAC GATTGCTAAC CACCTATTGG AAAAAACAAT AGGTCCTTAA 3720

ATAATATTGT CAACTTCAAG TATTGTGATG CAAGCATTTA GTCATGAACG CTTCTCTATT 3780

CTATATGAAA AGCCGGTTCC GGCCTCTCAC CTTTCCTTTT TCTCCCAATT TTTCAGTTGA 3840

AAAAGGTATA TGCGTCAGGC GACCTCTGAA ATTAACAAAA AATTTCCAGT CATCGAATTT 3900

GATTCTGTGC GATAGCGCCC CTGTGTGTTC TCGTTATGTT GAGGAAAAAA ATAATGGTTG 3960

CTAAGAGATT CGAACTCTTG CATCTTACGA TACCTGAGTA TTCCCACAGT TGGGGATCTC 4020

GACTCTAGCT AGAGGATCAA TTCGTAATCA TGGTCATAGC TGTTTCCTGT GTGAAATTGT 4080

TATCCGCTCA CAATTCCACA CAACATACGA GCCGGAAGCA TAAAGTGTAA AGCCTGGGGT 4140

GCCTAATGAG TGAGGTAACT CACATTAATT GCGTTGCGCT CACTGCCCGC TTTCCAGTCG 4200

GGAAACCTGT CGTGCCAGCT GGATTAATGA ATCGGCCAAC GCGCGGGGAG AGGCGGTTTG 4260

CGTATTGGGC GCTCTTCCGC TTCCTCGCTC ACTGACTCGC TGCGCTCGGT CGTTCGGCTG 4320

CGGCGAGCGG TATCAGCTCA CTCAAAGGCG GTAATACGGT TATCCACAGA ATCAGGGGAT 4380

AACGCAGGAA AGAACATGTG AGCAAAAGGC CAGCAAAAGG CCAGGAACCG TAAAAAGGCC 4440

GCGTTGCTGG CGTTTTTCCA TAGGCTCCGC CCCCCTGACG AGCATCACAA AAATCGACGC 4500

TCAAGTCAGA GGTGGCGAAA CCCGACAGGA CTATAAAGAT ACCAGGCGTT TCCCCCTGGA 4560

AGCTCCCTCG TGCGCTCTCC TGTTCCGACC CTGCCGCTTA CCGGATACCT GTCCGCCTTT 4620

CTCCCTTCGG GAAGCGTGGC GCTTTCTCAT AGCTCACGCT GTAGGTATCT CAGTTCGGTG 4680

TAGGTCGTTC GCTCCAAGCT GGGCTGTGTG CACGAACCCC CCGTTCAGCC CGACCGCTGC 4740

GCCTTATCCG GTAACTATCG TCTTGAGTCC AACCCGGTAA GACACGACTT ATCGCCACTG 4800

GCAGCAGCCA CTGGTAACAG GATTAGCAGA GCGAGGTATG TAGGCGGTGC TACAGAGTTC 4860

TTGAAGTGGT GGCCTAACTA CGGCTACACT AGAAGGACAG TATTTGGTAT CTGCGCTCTG 4920

CTGAAGCCAG TTACCTTCGG AAAAAGAGTT GGTAGCTCTT GATCCGGCAA ACAAACCACC 4980

GCTGGTAGCG GTGGTTTTTT TGTTTGCAAG CAGCAGATTA CGCGCAGAAA AAAAGGATCT 5040

FIG. 34 CONTINUED. 85/99

```
CAAGAAGATC CTTTGATCTT TTCTACGGGG TCTGACGCTC AGTGGAACGA AAACTCACGT   5100
TAAGGGATTT TGGTCATGAG ATTATCAAAA AGGATCTTCA CCTAGATCCT TTTAAATTAA   5160
AAATGAAGTT TTAAATCAAT CTAAAGTATA TATGAGTAAA CTTGGTCTGA CAGTTACCAA   5220
TGCTTAATCA GTGAGGCACC TATCTCAGCG ATCTGTCTAT TTCGTTCATC CATAGTTGCC   5280
TGACTCCCCG TCGTGTAGAT AACTACGATA CGGGAGGGCT TACCATCTGG CCCCAGTGCT   5340
GCAATGATAC CGCGAGACCC ACGCTCACCG GCTCCAGATT TATCAGCAAT AAACCAGCCA   5400
GCCGGAAGGG CCGAGCGCAG AAGTGGTCCT GCAACTTTAT CCGCCTCCAT CCAGTCTATT   5460
AATTGTTGCC GGGAAGCTAG AGTAAGTAGT TCGCCAGTTA ATAGTTTGCG CAACGTTGTT   5520
GCCATTGCTA CAGGCATCGT GGTGTCACGC TCGTCGTTTG GTATGGCTTC ATTCAGCTCC   5580
GGTTCCCAAC GATCAAGGCG AGTTACATGA TCCCCCATGT TGTGCAAAAA AGCGGTTAGC   5640
TCCTTCGGTC CTCCGATCGT TGTCAGAAGT AAGTTGGCCG CAGTGTTATC ACTCATGGTT   5700
ATGGCAGCAC TGCATAATTC TCTTACTGTC ATGCCATCCG TAAGATGCTT TTCTGTGACT   5760
GGTGAGTACT CAACCAAGTC ATTCTGAGAA TAGTGTATGC GGCGACCGAG TTGCTCTTGC   5820
CCGGCGTCAA TACGGGATAA TACCGCGCCA CATAGCAGAA CTTTAAAAGT GCTCATCATT   5880
GGAAAACGTT CTTCGGGGCG AAAACTCTCA AGGATCTTAC CGCTGTTGAG ATCCAGTTCG   5940
ATGTAACCCA CTCGTGCACC CAACTGATCT TCAGCATCTT TTACTTTCAC CAGCGTTTCT   6000
GGGTGAGCAA AAACAGGAAG GCAAAATGCC GCAAAAAAGG GAATAAGGGC GACACGGAAA   6060
TGTTGAATAC TCATACTCTT CCTTTTTCAA TATTATTGAA GCATTTATCA GGGTTATTGT   6120
CTCATGAGCG GATACATATT TGAATGTATT TAGAAAAATA AACAAATAGG GGTTCCGCGC   6180
ACATTTCCCC GAAAAGTGCC ACCTGACGTC TAAGAAACCA TTATTATCAT GACATTAACC   6240
TATAAAAATA GGCGTATCAC GAGGCCCTTT CGTCTCGCGC GTTTCGGTGA TGACGGTGAA   6300
AACCTCTGAC ACATGCAGCT CCCGGAGACG GTCACAGCTT GTCTGTAAGC GGATGCCGGG   6360
AGCAGACAAG CCCGTCAGGG CGCGTCAGCG GGTGTTGGCG GGTGTCGGGG CTGGCTTAAC   6420
TATGCGGCAT CAGAGCAGAT TGTACTGAGA GTGCACCATA ACGCATTTAA GCATAAACAC   6480
GCACTATGCC GTTCTTCTCA TGTATATATA TATACAGGCA ACACGCAGAT ATAGGTGCGA   6540
CGTGAACAGT GAGCTGTATG TGCGCAGCTC GCGTTGCATT TTCGGAAGCG CTCGTTTTCG   6600
GAAACGCTTT GAAGTTCCTA TTCCGAAGTT CCTATTCTCT AGCTAGAAAG TATAGGAACT   6660
TCAGAGCGCT TTTGAAAACC AAAAGCGCTC TGAAGACGCA CTTTCAAAAA ACCAAAAACG   6720
CACCGGACTG TAACGAGCTA CTAAAATATT GCGAATACCG CTTCCACAAA CATTGCTCAA   6780
AAGTATCTCT TTGCTATATA TCTCTGTGCT ATATCCCTAT ATAACCTACC CATCCACCTT   6840
TCGCTCCTTG AACTTGCATC TAAACTCGAC CTCTACATTT TTTATGTTTA TCTCTAGTAT   6900
TACTCTTTAG ACAAAAAAAT TGTAGTAAGA ACTATTCATA GAGTGAATCG AAAACAATAC   6960
```

FIG. 34 CONTINUED.

GAAAATGTAA ACATTTCCTA TACGTAGTAT ATAGAGACAA AATAGAAGAA ACCGTTCATA 7020

ATTTTCTGAC CAATGAAGAA TCATCAACGC TATCACTTTC TGTTCACAAA GTATGCGCAA 7080

TCCACATCGG TATAGAATAT AATCGGGGAT GCCTTTATCT TGAAAAAATG CACCCGCAGC 7140

TTCGCTAGTA ATCAGTAAAC GCGGGAAGTG GAGTCAGGCT TTTTTTATGG AAGAGAAAAT 7200

AGACACCAAA GTAGCCTTCT TCTAACCTTA ACGGACCTAC AGTGCAAAAA GTTATCAAGA 7260

GACTGCATTA TAGAGCGCAC AAAGGAGAAA AAAAGTAATC TAAGATGCTT TGTTAGAAAA 7320

ATAGCGCTCT CGGGATGCAT TTTTGTAGAA CAAAAAAGAA GTATAGATTC TTTGTTGGTA 7380

AAATAGCGCT CTCGCGTTGC ATTTCTGTTC TGTAAAAATG CAGCTCAGAT TCTTTGTTTG 7440

AAAAATTAGC GCTCTCGCGT TGCATTTTTG TTTTACAAAA ATGAAGCACA GATTCTTCGT 7500

TGGTAAAATA GCGCTTTCGC GTTGCATTTC TGTTCTGTAA AAATGCAGCT CAGATTCTTT 7560

GTTTGAAAAA TTAGCGCTCT CGCGTTGCAT TTTTGTTCTA CAAAATGAAG CACAGATGCT 7620

TCGTT 7625


A
Soluble
35S labelled
protein
- G-actin
+ G-actin
start
polymerization
pellet
super-
natant
pellet
super-
natant
insoluble
protein
control
soluble
protein
control
F-actin +
binding
proteins
soluble
proteins
B
pTB72
µg/ml actin
0 100 250
S P S P S P
C
pTB73
(3e ATG)
+ actin
P S R
pTB72
(start at 1e ATG)
- actin + actin
R P S P S
212
170
116
76
53
actin

FIG. 35.

FIG. 36.


A
35S UNC-53
sepharose with GST
sepharose with GST-sem-5
sup
washes
bound
sup
washes
bound
B
+SDS -SDS
c ab c ab
C
GST-SEM-5
sup wash bound
1 2 3 4
GST
sup wash bound
1 2 3 4

FIG. 36 (CONTD.)

D



FIG. 37.



FIG. 38.


PstI
EcoNI
NruI
SacII
BstXI
SgrAI
BbeI
Eco78
KasI
NarI
NcoI
KpnI
Asp718
BspMI
AflII
BspTOI
ApaI
FspI
ScoI
8000
2000
6000
4000
ptb113
9642 bps
unc53

FIG. 39.

```
ATGACCATGA TTACGCCAAG CTTGTCTTCT TCTAAATTCC CATAAAATCC CGAAACTCCT     60
TCCCTCTATC TTCTTTTTCT TCTCGTTTTC AAATGTTTCT CTCTATCCCA TTCTCTCATC    120
AATTGAGTGG GATGAGGCTA TCTCTGCCTC TCTTCTGAAT CTCTGAACCA TCTTACATTA    180
CACTGTGGAT GACGAGCCCC ACAGGCTCCC TTGCATCAGA TACTGCCATT GGGGATGGCA    240
AAGAAGAGAG AAGGTATTGT GAGGATATAT TTTTCTAAGA AAAAACGTTT GAAGAAAAGA    300
AGATGAAGAA GATCTGCTTG ATTCATTGCA CAAGTTAGAA GTAACAGGGG TCTATATTTC    360
GAAGAACTTA AAGGGAATGC AACTGAACAT AAAATTAAAC AAAGGGATTG AATCCTGCAG    420
TGAGTATTTT CGGTTTTTCA CTGGTTCTCT GTAAAAAGAG TAATGCAAAG GGCAAGTTAA    480
CTTAGGTCGT AAATGTATTG AATTTGCTTA AAATCTGAAG ATCTAGTGGT GAACCGTGGA    540
AGATTATCAA GAGGAGGCTG AAGATCTGTT TAAGAACCAT TAATCAAACT GGTATTCTAT    600
TTTCACTGGT TGTATGTAAA CATTCTATCT TATTCCTTTT ATCACTGTTC TGCACTTTCC    660
```

FIG. 39 CONTINUED. 93/99

```
TATAAAAAAA GTTGACCGAC CGTACTCTCT GAATTCATTT TTCCCGATCT TACCAACTCC   720
CGATCTATCT CTATCCCTGG TTTTTTCTTC GTGCTCCAAT GGAATTCTTG AGACTTCCAC   780
TATCTTCTCT GGCACCCTCC ACTACGCGTA GGCGTCTCTC GCTTCGTGTA TTCCCGGGAA   840
GCCGGTTCCC GTCTCTCCCG CCGCTGCCGC TGCCGCACAC AGCTTTACAC CTCGTAGAAT   900
CCCCAAAGAG GGGCGTGGCT TGCGGGTGCC AACATCCTCC TGCCGAGGAA GAAGCAGGCA   960
CTCATCACTC GCATCATCAA CCTCGGGATT GGCCAAAGGA CCCAAAGGTA TGTTTCGAAT  1020
GATACTAACA TAACATAGAA CATTTTCAGG AGGACCCTTG GCTAGAACTA GTGGATCCGA  1080
GCTCTCCCAT ATGACGACGT CAAATGTAGA ATTGATACCA ATCTACACGG ATTGGGCCAA  1140
TCGGCACCTT TCGAAGGGCA GCTTATCAAA GTCGATTAGG GATATTTCCA ATGATTTTCG  1200
CGACTATCGA CTGGTTTCTC AGCTTATTAA TGTGATCGTT CCGATCAACG AATTCTCGCC  1260
TGCATTCACG AAACGTTTGG CAAAAATCAC ATCGAACCTG GATGGCCTCG AAACGTGTCT  1320
CGACTACCTG AAAAATCTGG GTCTCGACTG CTCGAAACTC ACCAAAACCG ATATCGACAG  1380
CGGAAACTTG GGTGCAGTTC TCCAGCTGCT CTTCCTGCTC TCCACCTACA AGCAGAAGCT  1440
TCGGCAACTG AAAAAAGATC AGAAGAAATT GGAGCAACTA CCCACATCCA TTATGCCACC  1500
CGCGGTTTCT AAATTACCCT CGCCACGTGT CGCCACGTCA GCAACCGCTT CAGCAACTAA  1560
CCCAAATTCC AACTTTCCAC AAATGTCAAC ATCCAGGCTT CAGACTCCAC AGTCAAGAAT  1620
ATCGAAAATT GATTCATCAA AGATTGGTAT CAAGCCAAAG ACGTCTGGAC TTAAACCACC  1680
CTCATCATCA ACCACTTCAT CAAATAATAC AAATTCATTC CGTCCGTCGA GCCGTTCGAG  1740
TGGCAATAAT AATGTTGGCT CGACGATATC CACATCTGCG AAGAGCTTAG AATCATCATC  1800
AACGTACAGC TCTATTTCGA ATCTAAACCG ACCTACCTCC CAACTCCAAA AACCTTCTAG  1860
ACCACAAACC CAGCTAGTTC GTGTTGCTAC AACTACAAAA ATCGGAAGCT CAAAGCTAGC  1920
CGCTCCGAAA GCCGTGAGCA CCCCAAAACT TGCTTCTGTG AAGACTATTG GAGCAAAACA  1980
AGAGCCCGAT AACAGCGGTG GTGGTGGTGG TGGAATGCTG AAATTAAAGT TATTCAGTAG  2040
CAAAAACCCA TCTTCCTCAT CGAATAGCCC ACAACCTACG AGAAAGGCGG CGGCGGTGCC  2100
TCAACAACAA ACTTTGTCGA AAATCGCTGC CCCAGTGAAA AGTGGCCTGA AGCCGCCGAC  2160
CAGTAAGCTG GGAAGTGCCA CGTCTATGTC GAAGCTTTGT ACGCCAAAAG TTTCCTACCG  2220
TAAAACGGAC GCCCCAATCA TATCTCAACA AGACTCGAAA CGATGCTCAA AGAGCAGTGA  2280
AGAAGAGTCC GGATACGCTG GATTCAACAG CACGTCGCCA ACGTCATCAT CGACGGAAGG  2340
TTCCCTAAGC ATGCATTCCA CATCTTCCAA GAGTTCAACG TCAGACGAAA AGTCTCCGTC  2400
ATCAGACGAT CTTACTCTTA ACGCCTCCAT CGTGACAGCT ATCAGACAGC CGATAGCCGC  2460
AACACCGGTT TCTCCAAATA TTATCAACAA GCCTGTTGAG GAAAAACCAA CACTGGCAGT  2520
GAAAGGAGTG AAAAGCACAG CGAAAAAAGA TCCACCTCCA GCTGTTCCGC CACGTGACAC  2580
```

FIG. 39 CONTINUED. 94/99

```
CCAGCCAACA ATCGGAGTTG TTAGTCCAAT TATGGCACAT AAGAAGTTGA CAAATGACCC  2640
CGTGATATCT GAAAAACCAG AACCTGAAAA GCTCCAATCA ATGAGCATCG ACACGACGGA  2700
CGTTCCACCG CTTCCACCTC TAAAATCAGT TGTTCCACTT AAAATGACTT CAATCCGACA  2760
ACCACCAACG TACGATGTTC TTCTAAAACA AGGAAAAATC ACATCGCCTG TCAAGTCGTT  2820
TGGATATGAG CAGTCGTCCG CGTCTGAAGA CTCCATTGTG GCTCATGCGT CGGCTCAGGT  2880
GACTCCGCCG ACAAAAACTT CTGGTAATCA TTCGCTGGAG AGAAGGATGG GAAAGAATAA  2940
GACATCAGAA TCCAGCGGCT ACACCTCTGA CGCCGGTGTT GCGATGTGCG CCAAAATGAG  3000
GGAGAAGCTG AAAGAATACG ATGACATGAC TCGTCGAGCA CAGAACGGCT ATCCTGACAA  3060
CTTCGAAGAC AGTTCCTCCT TGTCGTCTGG AATATCCGAT AACAACGAGC TCGACGACAT  3120
ATCCACGGAC GATTTGTCCG GAGTAGACAT GGCAACAGTC GCCTCCAAAC ATAGCGACTA  3180
TTCCCACTTT GTTCGCCATC CCACGTCTTC TTCCTCAAAG CCCCGAGTCC CCAGTCGGTC  3240
CTCCACATCA GTCGATTCTC GATCTCGAGC AGAACAGGAG AATGTGTACA AACTTCTGTC  3300
CCAGTGCCGA ACGAGCCAAC GTGGCGCCGC TGCCACCTCA ACCTTCGGAC AACATTCGCT  3360
AAGATCCCCG GGATACTCAT CCTATTCTCC ACACTTATCA GTGTCAGCTG ATAAGGACAC  3420
AATGTCTATG CACTCACAGA CTAGTCGACG ACCTTCTTCA CAAAAACCAA GCTATTCAGG  3480
CCAATTTCAT TCACTTGATC GTAAATGCCA CCTTCAAGAG TTCACATCCA CCGAGCACAG  3540
AATGGCGGCT CTCTTGAGCC CGAGACGGGT GCCGAACTCG ATGTCGAAAT ATGATTCTTC  3600
AGGATCCTAC TCGGCGCGTT CCCGAGGTGG AAGCTCTACT GGTATCTATG GAGAGACGTT  3660
CCAACTGCAC AGACTATCCG ATGAAAAATC CCCCGCACAT TCTGCCAAAA GTGAGATGGG  3720
ATCCCAACTA TCACTGGCTA GCACGACAGC ATATGGATCT CTCAATGAGA AGTACGAACA  3780
TGCTATTCGG GACATGGCAC GTGACTTGGA GTGTTACAAG AACACTGTCG ACTCACTAAC  3840
CAAGAAACAG GAGAACTATG GAGCATTGTT TGATCTTTTT GAGCAAAAGC TTAGAAAACT  3900
CACTCAACAC ATTGATCGAT CCAACTTGAA GCCTGAAGAG GCAATACGAT TCAGGCAGGA  3960
CATTGCTCAT TTGAGGGATA TTAGCAATCA TCTTGCATCC AACTCAGCTC ATGCTAACGA  4020
AGGCGCTGGT GAGCTTCTTC GTCAACCATC TCTGGAATCA GTTGCATCCC ATCGATCATC  4080
GATGTCATCG TCGTCGAAAA GCAGCAAGCA GGAGAAGATC AGCTTGAGCT CGTTTGGCAA  4140
GAACAAGAAG AGCTGGATCC GCTCCTCACT CTCCAAGTTC ACCAAGAAGA AGAACAAGAA  4200
CTACGACGAA GCACATATGC CATCAATTTC CGGATCTCAA GGAACTCTTG ACAACATTGA  4260
TGTGATTGAG TTGAAGCAAG AGCTCAAAGA ACGCGATAGT GCACTTTACG AAGTCCGCCT  4320
TGACAATCTG GATCGTGCCC GCGAAGTTGA TGTTCTGAGG GAGACAGTGA ACAAGTTGAA  4380
AACCGAGAAC AAGCAATTAA AGAAAGAAGT GGACAAACTC ACCAACGGTC CAGCCACTCG  4440
TGCTTCTTCC CGCGCCTCAA TTCCAGTTAT CTACGACGAT GAGCATGTCT ATGATGCAGC  4500
```

FIG. 39 CONTINUED. 95/99

```
GTGTAGCAGT ACATCAGCTA GTCAATCTTC GAAACGATCC TCTGGCTGCA ACTCAATCAA  4560
GGTTACTGTA AACGTGGACA TCGCTGGAGA AATCAGTTCG ATCGTTAACC CGGACAAAGA  4620
GATAATCGTA GGATATCTTG CCATGTCAAC CAGTCAGTCA TGCTGGAAAG ACATTGATGT  4680
TTCTATTCTA GGACTATTTG AAGTCTACCT ATCCAGAATT GATGTGGAGC ATCAACTTGG  4740
AATCGATGCT CGTGATTCTA TCCTTGGCTA TCAAATTGGT GAACTTCGAC GCGTCATTGG  4800
AGACTCCACA ACCATGATAA CCAGCCATCC AACTGACATT CTTACTTCCT CAACTACAAT  4860
CCGAATGTTC ATGCACGGTG CCGCACAGAG TCGCGTAGAC AGTCTGGTCC TTGATATGCT  4920
TCTTCCAAAG CAAATGATTC TCCAACTCGT CAAGTCAATT TTGACAGAGA GACGTCTGGT  4980
GTTAGCTGGA GCAACTGGAA TTGGAAAGAG CAAACTGGCG AAGACCCTGG CTGCTTATGT  5040
ATCTATTCGA ACAAATCAAT CCGAAGATAG TATTGTTAAT ATCAGCATTC CTGAAAACAA  5100
TAAAGAAGAA TTGCTTCAAG TGGAACGACG CCTGGAAAAG ATCTTGAGAA GCAAAGAATC  5160
ATGCATCGTA ATTCTAGATA ATATCCCAAA GAATCGAATT GCATTTGTTG TATCCGTTTT  5220
TGCAAATGTC CCACTTCAAA ACAACGAAGG TCCATTTGTA GTATGCACAG TCAACCGATA  5280
TCAAATCCCT GAGCTTCAAA TTCACCACAA TTTCAAAATG TCAGTAATGT CGAATCGTCT  5340
CGAAGGATTC ATCCTACGTT ACCTCCGACG ACGGGCGGTA GAGGATGAGT ATCGTCTAAC  5400
TGTACAGATG CCATCAGAGC TCTTCAAAAT CATTGACTTC TTCCCAATAG CTCTTCAGGC  5460
CGTCAATAAT TTTATTGAGA AAACGAATTC TGTTGATGTG ACAGTTGGTC CAAGAGCATG  5520
CTTGAACTGT CCTCTAACTG TCGATGGATC CCGTGAATGG TTCATTCGAT TGTGGAATGA  5580
GAACTTCATT CCATATTTGG AACGTGTTGC TAGAGATGGC AAAAAAACCT TCGGTCGCTG  5640
CACTTCCTTC GAGGATCCCA CCGACATCGT CTCTAAAAAA TGGCCGTGGT TCGATGGTGA  5700
AAACCCGGAG AATGTGCTCA AACGTCTTCA ACTCCAAGAC CTCGTCCCGT CACCTGCCAA  5760
CTCATCCCGA CAACACTTCA ATCCCCTCGA GTCGTTGATC CAATTGCATG CTACCAAGCA  5820
TCAGACCATC GACAACATTT GAACAGAAGA CTCTAATCTT CTCTCGCCTC TCCCCCGCTT  5880
TCCTTATCTT CGTACCGGTA CCATGGTATT GATATCTGAG CTCCGCATCG GCCGCTGTCA  5940
TCAGATCGCC ATCTCGCGCC CGTGCCTCTG ACTTCTAAGT CCAATTACTC TTCAACATCC  6000
CTACATGCTC TTTCTCCCTG TGCTCCCACC CCCTATTTTT GTTATTATCA AAAAAACTTC  6060
TTCTTAATTT CTTTGTTTTT TAGCTTCTTT TAAGTCACCT CTAACAATGA AATTGTGTAG  6120
ATTCAAAAAT AGAATTAATT CGTAATAAAA AGTCGAAAAA AATTGTGCTC CCTCCCCCCA  6180
TTAATAATAA TTCTATCCCA AAATCTACAC AATGTTCTGT GTACACTTCT TATGTTTTTT  6240
TTACTTCTGA TAAATTTTTT TTGAAACATC ATAGAAAAAA CCGCACACAA AATACCTTAT  6300
CATATGTTAC GTTTCAGTTT ATGACCGCAA TTTTTATTTC TTCGCACGTC TGGGCCTCTC  6360
ATGACGTCAA ATCATGCTCA TCGTGAAAAA GTTTTGGAGT ATTTTTGGAA TTTTTCAATC  6420
```

FIG 39 CONTINUED. 96/99

```
AAGTGAAAGT TTATGAAATT AATTTTCCTG CTTTTGCTTT TTGGGGGTTT CCCCTATTGT   6480
TTGTCAAGAG TTTCGAGGAC GGCGTTTTTC TTGCTAAAAT CACAAGTATT GATGAGCACG   6540
ATGCAAGAAA GATCGGAAGA AGGTTTGGGT TTGAGGCTCA GTGGAAGGTG AGTAGAAGTT   6600
GATAATTTGA AAGTGGAGTA GTGTCTATGG GGTTTTTGCC TTAAATGACA GAATACATTC   6660
CCAATATACC AAACATAACT GTTTAAAATT AAACATTTTT CTAAATTTTA TATGATTTCT   6720
TTTAAATTTG CAAAAATTAC TTAAATTTGA ATTCCCGCGC AAATGAGTGA CTTCATTTTC   6780
TGCATTATTG TGTTTTCCGG CTATATTAAT AGGTATTTGT TTGTGTTTTT CTTTATTTTA   6840
TGATTCGAAC TCCAATTTGT AAATTTTCGA ACATATTTCC CTAAAGAAAA AATATGATTA   6900
ATCTGGAAAA ATTGGAAAAT TATTTTTCAA ATAAAAAACA AAGAAAAAAA TGAAGAAAAA   6960
CCTATTAGTT TGGCCATAAA ACGCAAAAAT GTCGAAAATG ACGTCACTCA TCTGCGCGGG   7020
AAATCAAGAA TAATTCGGCC TTTTTTATTT TTTTGGAAAA TCGTAAAACA TTTAGAAAAA   7080
TTTTTTAATA GTTATAGTGG GACTGTATTC TGTCATTTAG GGCAAAAGCC AGAGACGCTA   7140
CTCCACCGTT GGGGGATCCA CTAGTCGGCC GTACGGGCCC TTTCGTCTCG CGCGTTTCGG   7200
TGATGACGGT GAAAACCTCT GACACATGCA GCTCCCGGAG ACGGTCACAG CTTGTCTGTA   7260
AGCGGATGCC GGGAGCAGAC AAGCCCGTCA GGGCGCGTCA GCGGGTGTTG GCGGGTGTCG   7320
GGGCTGGCTT AACTATGCGG CATCAGAGCA GATTGTACTG AGAGTGCACC ATATGCGGTG   7380
TGAAATACCG CACAGATGCG TAAGGAGAAA ATACCGCATC AGGCGGCCTT AAGGGCCTCG   7440
TGATACGCCT ATTTTTATAG GTTAATGTCA TGATAATAAT GGTTTCTTAG ACGTCAGGTG   7500
GCACTTTTCG GGGAAATGTG CGCGGAACCC CTATTTGTTT ATTTTTCTAA ATACATTCAA   7560
ATATGTATCC GCTCATGAGA CAATAACCCT GATAAATGCT TCAATAATAT TGAAAAAGGA   7620
AGAGTATGAG TATTCAACAT TTCCGTGTCG CCCTTATTCC CTTTTTTGCG GCATTTTGCC   7680
TTCCTGTTTT TGCTCACCCA GAAACGCTGG TGAAAGTAAA AGATGCTGAA GATCAGTTGG   7740
GTGCACGAGT GGGTTACATC GAACTGGATC TCAACAGCGG TAAGATCCTT GAGAGTTTTC   7800
GCCCCGAAGA ACGTTTTCCA ATGATGAGCA CTTTTAAAGT TCTGCTATGT GGCGCGGTAT   7860
TATCCCGTAT TGACGCCGGG CAAGAGCAAC TCGGTCGCCG CATACACTAT TCTCAGAATG   7920
ACTTGGTTGA GTACTCACCA GTCACAGAAA AGCATCTTAC GGATGGCATG ACAGTAAGAG   7980
AATTATGCAG TGCTGCCATA ACCATGAGTG ATAACACTGC GGCCAACTTA CTTCTGACAA   8040
CGATCGGAGG ACCGAAGGAG CTAACCGCTT TTTTGCACAA CATGGGGGAT CATGTAACTC   8100
GCCTTGATCG TTGGGAACCG GAGCTGAATG AAGCCATACC AAACGACGAG CGTGACACCA   8160
CGATGCCTGT AGCAATGGCA ACAACGTTGC GCAAACTATT AACTGGCGAA CTACTTACTC   8220
TAGCTTCCCG GCAACAATTA ATAGACTGGA TGGAGGCGGA TAAAGTTGCA GGACCACTTC   8280
TGCGCTCGGC CCTTCCGGCT GGCTGGTTTA TTGCTGATAA ATCTGGAGCC GGTGAGCGTG   8340
```

FIG. 39 CONTINUED.

```
GGTCTCGCGG TATCATTGCA GCACTGGGGC CAGATGGTAA GCCCTCCCGT ATCGTAGTTA   8400
TCTACACGAC GGGGAGTCAG GCAACTATGG ATGAACGAAA TAGACAGATC GCTGAGATAG   8460
GTGCCTCACT GATTAAGCAT TGGTAACTGT CAGACCAAGT TTACTCATAT ATACTTTAGA   8520
TTGATTTAAA ACTTCATTTT TAATTTAAAA GGATCTAGGT GAAGATCCTT TTTGATAATC   8580
TCATGACCAA AATCCCTTAA CGTGAGTTTT CGTTCCACTG AGCGTCAGAC CCCGTAGAAA   8640
AGATCAAAGG ATCTTCTTGA GATCCTTTTT TTCTGCGCGT AATCTGCTGC TTGCAAACAA   8700
AAAAACCACC GCTACCAGCG GTGGTTTGTT TGCCGGATCA AGAGCTACCA ACTCTTTTTC   8760
CGAAGGTAAC TGGCTTCAGC AGAGCGCAGA TACCAAATAC TGTCCTTCTA GTGTAGCCGT   8820
AGTTAGGCCA CCACTTCAAG AACTCTGTAG CACCGCCTAC ATACCTCGCT CTGCTAATCC   8880
TGTTACCAGT GGCTGCTGCC AGTGGCGATA AGTCGTGTCT TACCGGGTTG GACTCAAGAC   8940
GATAGTTACC GGATAAGGCG CAGCGGTCGG GCTGAACGGG GGGTTCGTGC ACACAGCCCA   9000
GCTTGGAGCG AACGACCTAC ACCGAACTGA GATACCTACA GCGTGAGCAT TGAGAAAGCG   9060
CCACGCTTCC CGAAGGGAGA AAGGCGGACA GGTATCCGGT AAGCGGCAGG GTCGGAACAG   9120
GAGAGCGCAC GAGGGAGCTT CCAGGGGGAA ACGCCTGGTA TCTTTATAGT CCTGTCGGGT   9180
TTCGCCACCT CTGACTTGAG CGTCGATTTT TGTGATGCTC GTCAGGGGGG CGGAGCCTAT   9240
GGAAAAACGC CAGCAACGCG GCCTTTTTAC GGTTCCTGGC CTTTTGCTGG CCTTTTGCTC   9300
ACATGTTCTT TCCTGCGTTA TCCCCTGATT CTGTGGATAA CCGTATTACC GCCTTTGAGT   9360
GAGCTGATAC CGCTCGCCGC AGCCGAACGA CCGAGCGCAG CGAGTCAGTG AGCGAGGAAG   9420
CGGAAGAGCG CCCAATACGC AAACCGCCTC TCCCCGCGCG TTGGCCGATT CATTAATGCA   9480
GCTGGCACGA CAGGTTTCCC GACTGGAAAG CGGGCAGTGA GCGCAACGCA ATTAATGTGA   9540
GTTAGCTCAC TCATTAGGCA CCCCAGGCTT TACACTTTAT GCTTCCGGCT CGTATGTTGT   9600
GTGGAATTGT GAGCGGATAA CAATTTCACA CAGGAAACAG CT                      9642
```

FIG. 40. 98/99


300
250
200
150
100
50
0
Rel. value
Fracpos
FreeLen
C0
C9
C0
C9
p-L-lysine coating
No coating

FIG. 41.



PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C12N 15/12, C07K 14/435, C12N 5/10, A01K 67/027, 67/033, A61K 38/17, A01H 5/00, C07K 16/18, C12N 5/26

A3

(11) International Publication Number: WO 96/38555

(43) International Publication Date: 5 December 1996 (05.12.96)

(21) International Application Number: PCT/EP96/02311

(22) International Filing Date: 31 May 1996 (31.05.96)

(30) Priority Data:
9510944.3 31 May 1995 (31.05.95) GB

(71)(72) Applicants and Inventors: BOGAERT, Thierry [BE/BE]; Voorstraat 36 bus 11, B-8500 Kortrijk (BE). STRINGHAM, Eve [CA/CA]; 9326-133 A Street, Surrey, British Columbia V3V 5R5 (CA). VANDEKERCKHOVE, Joel [BE/BE]; Rode Beukendreef 27, B-Loppem (BE).

(74) Agent: BALDOCK, Sharon, Claire; Boult Wade Tennant, 27 Furnival Street, London EC4A 1PQ (GB).

(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(88) Date of publication of the international search report:
30 January 1997 (30.01.97)

(54) Title: UNC-53 FROM C. ELEGANS AND ITS USES IN TESTING COMPOUNDS INVOLVED IN THE CONTROL OF CELL BEHAVIOUR AND PHARMACEUTICAL COMPOSITIONS

(57) Abstract

UNC-53 protein of C. elegans or its functional equivalent is identified as a signal transducer/integrator involved in controlling the rate and directionality of cell migration and/or cell shape. Nucleic acid sequences encoding UNC-53 protein or its functional equivalent, such as genomic or cDNA are used to transfect C. elegans or mammalian cell lines useful for identifying inhibitors or enhancers of the UNC-53 protein. Any of the inhibitors or enhancers identified or the UNC-53 protein itself or sequences encoding UNC-53 protein can be used in the preparation of medicament for treatment of neurological conditions such as Alzheimer's or Huntingdon's disease, peripheral neuropathies for inhibition of metastasis.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	**GB**	United Kingdom	**MW**	Malawi
AT	Austria	**GE**	Georgia	**MX**	Mexico
AU	Australia	**GN**	Guinea	**NE**	Niger
BB	Barbados	**GR**	Greece	**NL**	Netherlands
BE	Belgium	**HU**	Hungary	**NO**	Norway
BF	Burkina Faso	**IE**	Ireland	**NZ**	New Zealand
BG	Bulgaria	**IT**	Italy	**PL**	Poland
BJ	Benin	**JP**	Japan	**PT**	Portugal
BR	Brazil	**KE**	Kenya	**RO**	Romania
BY	Belarus	**KG**	Kyrgystan	**RU**	Russian Federation
CA	Canada	**KP**	Democratic People's Republic of Korea	**SD**	Sudan
CF	Central African Republic			**SE**	Sweden
CG	Congo	**KR**	Republic of Korea	**SG**	Singapore
CH	Switzerland	**KZ**	Kazakhstan	**SI**	Slovenia
CI	Côte d'Ivoire	**LI**	Liechtenstein	**SK**	Slovakia
CM	Cameroon	**LK**	Sri Lanka	**SN**	Senegal
CN	China	**LR**	Liberia	**SZ**	Swaziland
CS	Czechoslovakia	**LT**	Lithuania	**TD**	Chad
CZ	Czech Republic	**LU**	Luxembourg	**TG**	Togo
DE	Germany	**LV**	Latvia	**TJ**	Tajikistan
DK	Denmark	**MC**	Monaco	**TT**	Trinidad and Tobago
EE	Estonia	**MD**	Republic of Moldova	**UA**	Ukraine
ES	Spain	**MG**	Madagascar	**UG**	Uganda
FI	Finland	**ML**	Mali	**US**	United States of America
FR	France	**MN**	Mongolia	**UZ**	Uzbekistan
GA	Gabon	**MR**	Mauritania	**VN**	Viet Nam

INTERNATIONAL SEARCH REPORT

Inte onal Application No
PCT/EP 96/02311

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12N15/12 C07K14/435 C12N5/10 A01K67/027 A01K67/033
A01H5/00 A61K38/17 C07K16/18 C12N5/26

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07K C12N A01K A61K A01H

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X A	EMBL Database Entry CEF45E10 Accession number Z47810; 26 January 1995 XP002019188 & NATURE, vol. 368, no. 6466, 3 April 1994, LONDON GB, pages 32-38, R. WILSON ET AL.: "2.2 Mb of contiguous nucleotide sequence from chromosome III of C. elegans" see the whole document --- -/--	1-10

[X] Further documents are listed in the continuation of box C. [ ] Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

4

Date of the actual completion of the international search	Date of mailing of the international search report
4 December 1996	13. 12. 96

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+ 31-70) 340-3016	Montero Lopez, B

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

Int. onal Application No
PCT/EP 96/02311

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JOURNAL OF NEUROSCIENCE 13 (10). 1993. 4254-4271. ISSN: 0270-6474, XP000612286 HEKIMI S ET AL: "Axonal guidance defects in a Caenorhabditis elegans mutant reveal cell-extrinsic determinants of neuronal morphology."	19,43
A	see abstract see page 4255, left-hand column, paragraph 2 - paragraph 3 see page 4267, right-hand column, paragraph 2 - page 4271, left-hand column, paragraph 3 -----	1-18, 20-42, 44-88

4

Form PCT/ISA/210 (continuation of second sheet) (July 1992)